7T SWI for diagnosis of astrocytic and oligodendroglial tumors
Whole-body ultra-low-dose CT for ventriculoperitoneal shunt complications
Dual-energy CT for risk stratification of intracranial hemorrhage in stroke
MR imaging findings of carcinoma ex pleomorphic adenoma
Indications for Use:
The FRED™ X System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment of adult patients (22 years of age or older) with wide-necked (neck width 4 mm or dome-to-neck ratio < 2) saccular or fusiform intracranial aneurysms arising from a parent vessel with a diameter 2.0 mm and 5.0 mm.

Rx Only:
Federal (United States) law restricts this device to sale by or on the order of a physician. For Healthcare professionals intended use only.

MICROVENTION, FRED and HEADWAY are registered trademarks of MicroVention, Inc. in the United States and other jurisdictions. Stylized X is a trademark of MicroVention, Inc. © 2022 MicroVention, Inc. MM1222 US 03/22

* Data is derived from in vivo and ex vitro testing and may not be representative of clinical performance.

1. Data on file


The only FDA PMA approved portfolio with a 0.021” delivery system for smaller device sizes, and no distal lead wire.

The FRED™ X Flow Diverter features the same precise placement and immediate opening of the FRED™ Device, now with X Technology. X Technology is a covalently bonded, nanoscale surface treatment, designed to:

- **REDUCE MATERIAL THROMBOGENICITY**

- **MAINTAIN NATURAL VESSEL HEALING RESPONSE**

- **IMPROVE DEVICE DELIVERABILITY AND RESHEATHING**

For more information, contact your local MicroVention sales representative or visit our website. www.microvention.com
**INDICATIONS FOR USE:**
The WEB Aneurysm Embolization System is intended for the endovascular embolization of ruptured and unruptured intracranial aneurysms and other neurovascular abnormalities such as arteriovenous fistulas (AVF). The WEB Aneurysm Embolization System is also intended for vascular occlusion of blood vessels within the neurovascular system to permanently obstruct blood flow to an aneurysm or other vascular malformation.

**POTENTIAL COMPLICATIONS:**
Potential complications include but are not limited to the following: hematoma at the site of entry, aneurysm rupture, emboli, vessel perforation, parent artery occlusion, hemorrhage, ischemia, vasospasm, clot formation, device migration or misplacement, premature or difficult device detachment, non-detachment, incomplete aneurysm filling, neovascularization, post-embolization syndrome, and neurological deficits including stroke and death. For complete indications, potential complications, warnings, precautions, and instructions, see instructions for use (IFU provided with the device).

**VIA 21, 27, 33** - The VIA Microcatheter is intended for the introduction of interventional devices (such as the WEB device/stents/flow diverters) and infusion of diagnostic agents (such as contrast media) into the neuro, peripheral, and coronary vasculature.

**VIA 17,17 Preshaped** - The VIA Microcatheter is intended for the introduction of interventional devices (such as the WEB device/stents/flow diverters) and infusion of diagnostic agents (such as contrast media) into the neuro, peripheral, and coronary vasculature.

The VIA Microcatheter is contraindicated for use with liquid embolic materials, such as n-butyl 2-cyanoacrylate or ethylene vinyl alcohol & DMSO (dimethyl sulfoxide).

The device should only be used by physicians who have undergone training in all aspects of the WEB Aneurysm Embolization System procedure as prescribed by the manufacturer.

RX Only: Federal law restricts this device to sale by or on the order of a physician.

For healthcare professional intended use only.
What does seeing better with MultiHance® mean?1-4*

MultiHance® demonstrated superiority in both qualitative and quantitative enhancement of brain lesions compared with Dotarem® at 0.1 mmol/kg dose.11

- The 0.1 mmol/kg dose of MultiHance demonstrated consistently better visualization for all readers for all visualization endpoints vs non-contrast MRI.
- 3 blinded and independent readers reported superiority (P<0.002) of 0.1-mmol/kg MultiHance for all endpoints in Arm 1.
- 3 blinded independent readers also reported the mean percentage signal enhancement of lesions on the T1SE images was significantly (P<.0006) higher for MultiHance compared with Dotarem in patients given 0.1-mmol/kg doses of both agents. Similar results were obtained for determination of LBR. LBR findings on TIGRE images were similar.

The individuals who appear are for illustrative purposes. All persons depicted are models and not real patients.

Please see Brief Summary of Prescribing Information including Boxed Warning on adjacent page.

*MRI imaging of the CNS in adult and pediatric patients to visualize lesions with abnormal BBB or abnormal vascularity of the brain, spine and associated tissues or to evaluate adults with known or suspected renal or aorto-iliac-femoral occlusive vascular disease.

1Multicenter, multinational, double-blind randomized, intravascular crossover study design of 177 patients with known or suspected brain tumors. Each patient received 0.1-mmol/kg doses of MultiHance and Dotarem in two identical MR imaging examinations. For Arm 1, 1, the contrast agents for patients were administered by IV using manual bolus injection (n = 83) or power a power injector (n = 13). The agents were administered at 0.1 mmol/kg/body weight, corresponding to 0.2 mL/kg for MultiHance and for Dotarem. For Arm 2, Administration of agents were IV using manual bolus injection (n = 83) or power a power injector (n = 24). The agents were administered at 0.05, 0.1 mmol/kg/body weight, corresponding to 0.1 mL/kg for MultiHance and at 0.1 mmol/kg/body weight, corresponding to 0.2 mL/kg for Dotarem. All injections were followed by a saline flush of up to 30 mL. The interval between the 2 MRI imaging examinations was >46 hours to avoid carryover effects but <14 days to minimize the chance of disease progression. All images were evaluated by 3 blinded, independent experienced radiologists who were unaffiliated with the study centers. Each reader evaluated the patient images separately and independently. Images were evaluated qualitatively for diagnostic and quality and scored for: 1) lesion border delineation, 2) lesion extent, 3) visualization of lesion internal morphology, and 4) lesion contrast enhancement compared with surrounding normal tissue. All assessments used a 3-point scales from 1 (examination 1 better) through 0 (examinations equal) to 1 (examination 2 better).


MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL and MultiHance® Multipack™ (gadobenate dimeglumine) injection, 529 mg/mL

Indications and Usage:
MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL is a gadolinium-based contrast agent indicated for intravenous use in:
- Magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and pediatric patients (including term neonates) to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues and
- Magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-iliac-femoral occlusive vascular disease

IMPORTANT SAFETY INFORMATION:

CONTRAINDICATIONS
MultiHance is contraindicated in patients with known allergic or hypersensitivity reactions to gadolinium-based contrast agents.

WARNINGS AND PRECAUTIONS
Nephrogenic Systemic Fibrosis: NSF has occurred in patients with impaired elimination of GBCAs. Higher than recommended dosing or repeated dosing appears to increase risk.

Hypersensitivity Reactions: Anaphylactic and anaphylactoid reactions have been reported, involving cardiovascular, respiratory, and/or cutaneous manifestations. Some patients experienced circulatory collapse and died. In most cases, initial symptoms occurred within minutes of MultiHance administration and resolved with prompt emergency treatment. Consider the risk for hypersensitivity reactions, especially in patients with a history of hypersensitivity reactions of a history of asthma or other allergic disorders.

Gadolinium Retention: Gadolinium is retained for months or years in several organs. The highest concentrations have been identified in the bone, followed by brain, skin, kidney, liver, and spleen. At equivalent doses, retention varies among the linear agents. Retention is lowest and similar among the macrocyclic GBCAs. Consequences of gadolinium retention in the brain have not been established, but they have been established in the skin and other organs in patients with impaired renal function. Minimize repetitive GBCA imaging studies, particularly closely spaced studies when possible.

Acute Renal Failure: In patients with renal insufficiency, acute renal failure requiring dialysis or worsening renal function have occurred with the use of GBCAs. The risk of renal failure may increase with increasing dose of the contrast agent. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests.

Extravasation and Injection Site Reactions: Extravasation of MultiHance may lead to injection site reactions, characterized by local pain or burning sensation, swelling, blistering, and necrosis. Exercise caution to avoid local extravasation during intravenous administration of MultiHance.

Cardiac Arrhythmias: Cardiac arrhythmias have been observed in patients receiving MultiHance in clinical trials. Assess patients for underlying conditions

REFERENCE:

© 2022 Bracco Diagnostics Inc. All Rights Reserved. US-MH-2100020 04/22

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL is a gadolinium-based contrast agent for MRI of the brain, skin, kidney, liver, and spleen. It is used to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues in pediatric patients from birth, including term neonates, to less than 17 years of age. Adverse reactions in pediatric patients were similar to those reported in adults. No dose adjustment according to age is necessary in pediatric patients two years of age and older. For pediatric patients, less than 2 years of age, the recommended dosage range is 0.1 to 0.2 mL/kg. The safety of MultiHance has not been established in preterm neonates.

**Interference with Visualization of Certain Lesions:** Certain lesions seen on non-contrast images may not be seen on contrast images. Exercise caution when interpreting contrast MR images in the absence of companion non-contrast MR images.

**ADVERSE REACTIONS**
The most commonly reported adverse reactions are nausea (1.3%) and headache (1.2%).

**USE IN SPECIFIC POPULATIONS**
- **Pregnancy:** GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. Use only if imaging is essential during pregnancy and cannot be delayed.
- **Lactation:** There is no information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. However, limited literature reports that breastfeeding after MultiHance administration to the mother would result in the infant receiving an oral dose of 0.001%-0.04% of the maternal dose.
- **Pediatric Use:** MultiHance is approved for intravenous use for MRI of the CNS to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues in pediatric patients from birth, including term neonates, to less than 17 years of age. Adverse reactions in pediatric patients were similar to those reported in adults. No dose adjustment according to age is necessary in pediatric patients two years of age and older. For pediatric patients, less than 2 years of age, the recommended dosage range is 0.1 to 0.2 mL/kg. The safety of MultiHance has not been established in preterm neonates.

**You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.**


MultiHance is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH – 78224 Singen (Germany) and by Patheon Italia S.p.A., Ferentino, Italy. MultiHance is a registered trademark of Bracco International B.V. MultiHance Multipack is a trademark of Bracco International B.V. All other trademarks and registered trademarks are the property of their respective owners.

**References:**
MULTIHANCE (gadobenate dimeglumine)

MUltiple phase 1 and 2 Studies (5.1)

The following adverse reactions occurred in less than 0.5% of the 4967 adult subjects who received MultiHance in Clinical Trials in the U.S.: headache, pain, headache, pyrexia, nausea, migraine, chest pain, and vomiting. More frequent adverse events reported for MultiHance compared to the control substance in the clinical trials included: headache, pyrexia, nausea, vomiting, and vomiting.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in women ages 15-44 with a live birth is 2% (or 1 in 50 pregnancies). In one animal study, administration of gadobenate dimeglumine during organogenesis at doses up to three times the recommended human dose based on body surface area has shown increased intraductal babies in rabbits. There was no evidence of Multihance-induced teratogenic effects in rats or rabbits when given at doses up to 2 mg/kg based on body surface area, however, rat dams exhibited no systemic toxicity at this dose. The highest dose evaluated is 6 mg/kg in rats, based on a 100-fold safety margin. No evidence of lethality of the F1 generation at doses up to 2 mg/kg in a rat and postnatal lethality in the F2 generation was seen at 2 mg/kg, based on a 100-fold safety margin.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in women ages 15-44 with a live birth is 2% (or 1 in 50 pregnancies). In one animal study, administration of gadobenate dimeglumine during organogenesis at doses up to three times the recommended human dose based on body surface area has shown increased intraductal babies in rabbits. There was no evidence of Multihance-induced teratogenic effects in rats or rabbits when given at doses up to 2 mg/kg based on body surface area, however, rat dams exhibited no systemic toxicity at this dose. The highest dose evaluated is 6 mg/kg in rats, based on a 100-fold safety margin. No evidence of lethality of the F1 generation at doses up to 2 mg/kg in a rat and postnatal lethality in the F2 generation was seen at 2 mg/kg, based on a 100-fold safety margin.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in women ages 15-44 with a live birth is 2% (or 1 in 50 pregnancies). In one animal study, administration of gadobenate dimeglumine during organogenesis at doses up to three times the recommended human dose based on body surface area has shown increased intraductal babies in rabbits. There was no evidence of Multihance-induced teratogenic effects in rats or rabbits when given at doses up to 2 mg/kg based on body surface area, however, rat dams exhibited no systemic toxicity at this dose. The highest dose evaluated is 6 mg/kg in rats, based on a 100-fold safety margin. No evidence of lethality of the F1 generation at doses up to 2 mg/kg in a rat and postnatal lethality in the F2 generation was seen at 2 mg/kg, based on a 100-fold safety margin.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in women ages 15-44 with a live birth is 2% (or 1 in 50 pregnancies). In one animal study, administration of gadobenate dimeglumine during organogenesis at doses up to three times the recommended human dose based on body surface area has shown increased intraductal babies in rabbits. There was no evidence of Multihance-induced teratogenic effects in rats or rabbits when given at doses up to 2 mg/kg based on body surface area, however, rat dams exhibited no systemic toxicity at this dose. The highest dose evaluated is 6 mg/kg in rats, based on a 100-fold safety margin. No evidence of lethality of the F1 generation at doses up to 2 mg/kg in a rat and postnatal lethality in the F2 generation was seen at 2 mg/kg, based on a 100-fold safety margin.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in women ages 15-44 with a live birth is 2% (or 1 in 50 pregnancies). In one animal study, administration of gadobenate dimeglumine during organogenesis at doses up to three times the recommended human dose based on body surface area has shown increased intraductal babies in rabbits. There was no evidence of Multihance-induced teratogenic effects in rats or rabbits when given at doses up to 2 mg/kg based on body surface area, however, rat dams exhibited no systemic toxicity at this dose. The highest dose evaluated is 6 mg/kg in rats, based on a 100-fold safety margin. No evidence of lethality of the F1 generation at doses up to 2 mg/kg in a rat and postnatal lethality in the F2 generation was seen at 2 mg/kg, based on a 100-fold safety margin.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in women ages 15-44 with a live birth is 2% (or 1 in 50 pregnancies). In one animal study, administration of gadobenate dimeglumine during organogenesis at doses up to three times the recommended human dose based on body surface area has shown increased intraductal babies in rabbits. There was no evidence of Multihance-induced teratogenic effects in rats or rabbits when given at doses up to 2 mg/kg based on body surface area, however, rat dams exhibited no systemic toxicity at this dose. The highest dose evaluated is 6 mg/kg in rats, based on a 100-fold safety margin. No evidence of lethality of the F1 generation at doses up to 2 mg/kg in a rat and postnatal lethality in the F2 generation was seen at 2 mg/kg, based on a 100-fold safety margin.
ASNR and AJNR are pleased once again to join efforts with other imaging-related journals that have training programs on editorial aspects of publishing for trainees or junior staff (<5 years on staff), including Radiology (Olmsted fellowship), AJR (Figley and Rogers fellowships), JACR (Bruce J. Hillman fellowship), and Radiologia.

CALL FOR AJNR EDITORIAL FELLOWSHIP CANDIDATES

2023 Candidate Information and Requirements

GOALS
• Increase interest in editorial and publication-related activities in younger individuals.
• Increase understanding and participation in the AJNR review process.
• Incorporate into AJNR's Editorial Board younger individuals who have previous experience in the review and publication process.
• Fill a specific need in neuroradiology not offered by other similar fellowships.
• Increase the relationship between “new” generation of neuroradiologists and more established individuals.
• Increase visibility of AJNR among younger neuroradiologists.

ACTIVITIES OF THE FELLOWSHIP
• Serve as Editorial Fellow for one year. This individual will be listed on the masthead as such.
• Review at least one manuscript per month for 12 months. Evaluate all review articles submitted to AJNR.
• Learn how electronic manuscript review systems work.
• Be involved in the final decision of selected manuscripts together with the Editor-in-Chief.
• Participate in all monthly Senior Editor telephone conference calls.
• Participate in 2 virtual meetings of the Editorial Board.
• Evaluate progress and adjust program to specific needs in annual meeting or telephone conference with the Editor-in-Chief.
• Embark on an editorial scientific or bibliometric project that will lead to the submission of an article to AJNR or another appropriate journal as determined by the Editor-in-Chief. This project will be presented by the Editorial Fellow at the ASNR annual meeting. The Foundation of the ASNR will provide $2000 funding for this activity.
• Recruit trainees as reviewers as determined by the Editor-in-Chief.
• Serve as Guest Editor for an issue of AJNR's News Digest with a timely topic.

QUALIFICATIONS
• Be a fellow in neuroradiology from North America, including Canada (this may be extended to include other countries).
• Be a junior faculty neuroradiology member (<5 years) in either an academic or private environment.
• Be an “in-training” or member of ASNR in any other category.

APPLICATION
• Include a short letter of intent with statement of goals and desired research project. CV must be included.
• Include a letter of recommendation from the Division Chief or fellowship program director. A statement of protected time to perform the functions outlined is desirable.
• Applications will be evaluated by AJNR’s Senior Editors prior to the ASNR annual meeting. The name of the selected individual will be announced at the meeting.
• Applications should be received by March 1, 2023 and sent to Ms. Karen Halm, AJNR Managing Editor, electronically at khalms@asnr.org.
The next generation GBCA from Guerbet is here

To learn more, scan QR code or visit www.guerbet-us.com

GBCA = Gadolinium Based Contrast Agent
© Guerbet 2022 GU10220184
I am a global citizen.
I am patient-centered care.
I am committed to health equity.
I am a teacher.
I am a life-long learner.
I am determined.
I am curious.
I am a collaborative team player.
I am a volunteer.

I am ASNR.

Don’t miss out on the tools, resources and relationships you’ve come to rely on. Log in and renew your ASNR membership today! www.asnr.org
1549   PERSPECTIVES   M. Hauben

1550   REVIEW ARTICLE


1559   GENERAL CONTENTS


1567   Diffuse Large B-Cell Epstein-Barr Virus–Positive Primary CNS Lymphoma in Non-AIDS Patients: High Diagnostic Accuracy of DSC Perfusion Metrics   A. Pons-Escoda, et al.

1575   SWI by 7T MR Imaging for the Microscopic Imaging Diagnosis of Astrocytic and Oligodendrogial Tumors   M. Natsumeda, et al.

1582   The Value of Preoperative Phase-Contrast MRI in Predicting the Clinical Outcome of Moyamoya Disease after Encephalo-Duro-Arterial Synangiosis Surgery   S. Liu, et al.

1589   Quantitative Intracerebral Iodine Extravasation in Risk Stratification for Intracranial Hemorrhage in Patients with Acute Ischemic Stroke   C. Ma, et al.


1603   Schizencephaly in Hereditary Hemorrhagic Telangiectasia   J. Gaines, et al.


Correlation of Collateral Scores Derived from Whole-Brain Time-Resolved Flat Panel Detector Imaging in Acute Ischemic Stroke  
C.C. Kurmann, et al.

Successful Reperfusion is Associated with Favorable Functional Outcome despite Vessel Perforation during Thrombectomy: A Case Series and Systematic Review  
C. Ducroux, et al.

MR Imaging Findings of Carcinoma Ex Pleomorphic Adenoma Related to Extracapsular Invasion and Prognosis  
A. Akutsu, et al.

The Cochlea in Branchio-Oto-Renal Syndrome: An Objective Method for the Diagnosis of Offset Cochlear Turns  
A.F. Juliano, et al.

Accelerated Synthetic MRI with Deep Learning–Based Reconstruction for Pediatric Neuroimaging  
E. Kim, et al.

Distinctive Brain Malformations in Zhu-Tokita-Takenuchi-Kim Syndrome  
B.J. Halliday, et al.

Neuroimaging in Pediatric Patients with Juvenile Xanthogranuloma of the CNS  
B.L. Serrallach, et al.

Volumetric Brain MRI Study in Fetuses with Intrauterine Growth Restriction Using a Semiautomated Method  
R. Peretz, et al.

Peer Learning Program Metrics: A Pediatric Neuroradiology Example  
N. Kadom, et al.

35 YEARS AGO IN AJNR

Recalling the Usefulness of Conebeam CT in Temporal Bone Imaging: Higher Resolution with Lower Radiation Dose  
M. Quintas-Neves, et al.

Reply  
K. Rajendran, et al.


BOOK REVIEWS  R.M. Quencer, Section Editor

Please visit www.ajnrblog.org to read and comment on Book Reviews.
Title: Central Park Lake. With its ample supply of rowboats, rowers and their passive companions can tour the many sites bordering the 220 acres of water (all accessible to pedestrians as well) including the Central Park West skyline, which includes some of the most iconic New York City architecture. From this vantage point, which looks north-northwest, we are treated to 2 classically inspired New York City buildings designed by famed architect Emery Roth. First, on the left, is the San Remo (completed 1930), the city’s first twin tower, capped by circular colonnades inspired by the Choragic Monument of Lysicrates. Right of center is the massive but less lofty Beresford (completed 1929), with its 3 massive octagonal, copper-capped towers. As with much of the city’s skyline, zoning laws influenced design. The 1916 zoning law required setbacks for high rises to preserve sunlight and air flow at street level, and influenced the Beresford, while the Multiple Dwelling Law of 1929 only accommodated a massive and towering residential complex like the San Remo conditional on a split tower, for similar reasons. If one walks or sails slightly to the left, a third Emery Roth building, the El Dorado, comes into view to the north.

Manfred Hauben, MD, MPH, Pfizer Inc and NYU Langone Health, New York City
Radiologic Evaluation Criteria for Chronic Subdural Hematomas: Recommendations for Clinical Trials


ABSTRACT

SUMMARY: Embolization of the middle meningeal artery has gained substantial interest as a therapy for chronic subdural hematomas. For the results of the currently running chronic subdural hematoma trials to inform clinical practice, sufficient accuracy and matching definitions are necessary. We summarized the current practice in chronic subdural hematoma evaluation and derived suggestions on reporting standards using the (Nested) Knowledge AutoLit living review platform. On the basis of the most commonly reported data elements, we suggested a set of standardized image-based study end points for chronic subdural hematoma evaluation for future trials. The measurement methods and reporting standards as proposed in this article have been derived from published best practices and are endorsed by the European Society of Minimally Invasive Neurological Therapy’s research committee. The standardization of radiologic outcome measures and measurement techniques in chronic subdural hematoma embolization trials would increase the impact and implication of each trial as well as facilitate data pooling for increased statistical power and, therefore, translation to clinical practice.

ABBREVIATIONS: cSDH = chronic subdural hematoma; MLS = midline-shift; MLS-M = MLS versus midline or displacement perpendicular to the midline; MLS-T = MLS transverse; MMA = middle meningeal artery; NK = (Nested) Knowledge; SDH = subdural hematoma

Chronic subdural hematoma (cSDH) is a frequently occurring pathology in daily neurosurgical practice, with increasing frequency as the population ages. However, there is still a relative lack of high-quality evidence at many decision points in the treatment algorithm of the typical patient with cSDH, which is far from optimized. Despite numerous studies investigating the management of cSDH, questions about the choice of surgical technique, adjuvant therapies, and postoperative care remain unanswered. Many of the studies published in the literature report heterogeneous baseline data, using variable terminology and definitions of operative technique, and evaluate disparate outcome measures. Even cSDH lacks a universally accepted definition.

In recent years, middle meningeal artery (MMA) embolization has emerged as a new and promising therapy option for cSDH. Numerous clinical trials evaluating the safety and efficacy of this new treatment method have recently been initiated, and some have already published their results. A systematic review of 96 studies examining clinical outcomes in patients with cSDH revealed that 39% of the studies used a radiologic outcome measure generally based on a postoperative CT scan. However, these radiologic outcome measures were highly heterogeneous, as was the timing of the scans. Furthermore, there seems to be a lack of consensus on how to determine a specific radiologic outcome measure. For example, various techniques on how to measure subdural hematoma (SDH) thickness and volume or even midline shift (MLS) exist. These techniques pose a significant barrier to establishing an evidence-based approach for the management of cSDH, as stated in published meta-analyses that have sought to elucidate the optimal treatment options for cSDH. To overcome these barriers and enable cross-study evaluation of the efficacy of MMA embolization, and other cSDH treatments, the development of standardized outcome measures is needed, which should subsequently be reported by all clinical studies and trials concerning a specific disease state.

In this article, we describe and discuss the heterogeneity of radiologic outcome measures for clinical trials on MMA embolization for cSDH. To emphasize the relevance of a common definition and selection of radiographically defined parameters, we completed a review of radiologic outcomes and inclusion/exclusion...
criteria in active cSDH trials. Furthermore, we propose a potential standardized methodology for defining and measuring radiologic outcomes of cSDH, as well as how and when to report them. Because published research on the evaluation of the accuracy and reliability of specific radiologic outcome measures such as cSDH volume, width, and MLS specifically in cSDH is sparse, the measurement methods and reporting standards as proposed in this article have been derived from the best published practices and are endorsed by European Society of Minimally Invasive Neurological Therapy’s research committee.

**MATERIALS AND METHODS**

**Clinical Trials of cSDH Embolization**

We performed a literature search of ClinicalTrials.gov to identify currently active or complete and unpublished trials on MMA embolization in patients with cSDH. ClinicalTrials.gov was searched for the terms Chronic AND Subdural AND (hematoma OR haematoma OR hemorrhage OR haemorrhage OR bleeding) AND (embolization OR embolization) on August 7, 2021. The review of these clinical trials was then conducted through the AutoLit platform (Nested Knowledge [NK]; https://nested-knowledge.com).12

All interventions used and radiologic outcome data elements as well as image-based inclusion or exclusion criteria were tagged by using the AutoLit tagging feature. Included studies were scanned for the predetermined radiologic outcomes with the related definitions and follow-up time points, and a unique tag was created for each data element found on the basis of a full-protocol review, as relevant. All tagging was completed by 1 author and quality-controlled by an independent author.

Qualitative synthesis on the frequency of study design types and data elements was graphically presented in the form of a sun-burst diagram on the Synthesis feature (NK) after the completion of tagging different studies. Each section represented a tag that was applied across trials, and frequency could be determined by the platform on the basis of the number of studies that had that tag (Fig 1; for interactive version, see https://nested-knowledge.com/nest/qualitative/461). After quantitative summary data were extracted from the NK Qualitative Synthesis feature, the appropriate tables and figures were created using Microsoft-based data presentation software (Microsoft Excel and PowerPoint).

**RESULTS**

**Study Characteristics**

As of August 7, 2021, fifteen studies, of these 12 randomized controlled trials, relating to embolization of the MMA of cSDH had been identified on clinicaltrials.gov. All of these 15 studies used image-based measures as end points. The main imaging-based outcome data elements and inclusion/exclusion criteria were based on measures of the following: cSDH size, MLS, radiographic resolution, radiographic recurrence, and radiographic progression. The most frequent radiologic outcome measures identified were cSDH size (11/15, 73.3%) and cSDH recurrence (9/15, 60%).

Five of 15 (33.3%) trials also reported radiologic measurements as inclusion or exclusion criteria. The most frequently identified in-/exclusion criterion was cSDH width > 10 mm (in 4 of 5). However, some of these criteria may evolve as discussions among the trial investigators continue. Details on the radiologic measures are listed in the Online Supplemental Data.

In addition, the planned follow-up periods and intervals of the trials were highly heterogeneous: Periods of follow-up ranged from 6 weeks to 12 months, with intervals between visits ranging from 2 weeks to 6 months.

**SDH Width and Volume Measurement**

As in Online Supplemental Data the determination of cSDH width and volume is an essential factor for cSDH treatment monitoring and the definition of radiologic recurrence or progression. However, for both variables, a number of different measurement techniques have been published and compared. For cSDH volume estimation, manual computer-assisted volumetric analysis is considered the gold standard. To facilitate volume measurement in cSDH, a simple bedside estimation method, known as the ABC/2 method, was proposed and validated for use in the measurement of acute and cSDH volume.13-15 This method is based on the mathematic formula for the volume of an ellipsoid, \( V = \frac{4}{3} \pi \times (A/2) \times (B/2) \times (C/2) \), where \( A \), \( B \), and \( C \) represent the 3 diameters of the ellipsoid commonly measured on the axial plane. If \( \pi \) is estimated to be 3, the formula simplifies to ABC/2.16-18 To our knowledge, only 3 published studies explicitly evaluated this volumetric measurement technique specifically in patients with cSDH.14,15,19 In addition, the study by Gebel et al13 involved patients with acute subdural hematomas as well as chronic ones.

Overall, the assessed volume measurement techniques showed a high correlation with the criterion standard in patients with acute as well as cSDH.13-15 Sucu et al15 compared 5 different ABC/2-based volume measurement formulas to identify the formula that provided the most accurate estimation of hematoma volume compared with the criterion standard. Although all 5 formulas showed excellent correlation with the criterion standard, the ABC/2 method with the measurement of maximum width and length, which are not necessarily on the same section, achieved the highest correlation coefficient. Won et al14 found a correlation between ABC/2 and computer-assisted values with an \( R^2 \) of 0.93 when evaluating 100 cSDHs in 82 patients. This group used the section with the maximum length to determine maximum width (taken perpendicular to the length). For determination of hematoma depth, the number of slices with visible hematoma multiplied by section thickness was performed in all 3 studies.13-15

To elucidate some of the shortcomings and problems arising from the above-mentioned techniques, we applied some of these width-measurement methods to specific patients with unevenly shaped hematomas (Fig 2C). These cases illustrate that accurately following the given measurement techniques may lead to measurements that do not seem to correspond to hematoma width as we would define it according to the underlying formula of the radius of an ellipsoid-shaped body. As demonstrated in Fig 2, inaccurate width measurements are particularly likely to occur in hematomas that are close to the vertex and those that are irregularly (ie, not crescent) shaped. Indeed, the further removed the cSDH collection is from an ellipsoid shape, the less accurate the...
ABC/2 formula is. According to a study by Manickam et al that measured the proximity to an ellipsoid shape using 3D simulations, most cSDHs demonstrated highly irregular morphology, and only a very few (9%) remotely conformed to ellipsoid geometric morphology.

Above the superior temporal line, axial CT slices are no longer perpendicular to the cranium or cSDH (Fig 2C, patient 1); rather, they run obliquely because of the curvature of the cranial vault. Therefore, the width of the cSDH measured on a section close to vertex is greater than it actually is. Furthermore, because of their chronic nature and traction of developing membranes, cSDHs are not always symmetrically crescent-shaped; they may appear as asymmetric shapes, such as a comma, pear, or lens on axial CT slices (Fig 2C, patients 2 and 3). As a result, whenever possible, computer-assisted volumetric analysis should be applied, especially in studies in which longitudinal analyses are performed. Most CT scanners today can produce axial slices of 0.625-mm thickness, generating relatively isometric voxels of $0.625 \times 0.5 \times 0.5$ mm. These can be reconstructed in the coronal plane for improved accuracy of measurement.
Selection of radiologic measurement techniques requires both high accuracy and harmonization across studies to provide meaningful comparative data. Thus, even though most ABC/2 volume measurement techniques show a high correlation with the criterion standard,13-15 a designated standard measurement technique needs to be defined to ensure comparability among clinical studies.

Another problem lies in the lack of validation of certain methodologies with respect to specific situations. For example, the question of the cSDH width-measurement technique most suitable to reliably detect changes in cSDH size, especially after therapy, remains currently unanswered. However, if cSDH width is reported, details on the assessment technique should be described and measurements should be reported in combination with cSDH volume.

Only a few studies address problems regarding cSDH segmentation. Sucu et al,16 for example, excluded 6 of 28 patients with cSDH because it was not possible to differentiate the isodense hematoma from the brain parenchyma on CT scans. Certainly, the frequency of this problem may also be dependent on the image contrast/quality produced by a particular CT protocol on a particular model. Therefore, in such scenarios, signs of mass effect, such as MLS and local cortical flattening, can be evaluated to compare cSDH sizes. However, how to include these cases in trials or studies in which accurate measurements of hematoma size and volume are compared pre- and postoperatively remains unclear. Nevertheless, such scenarios should be reported and described.

**MLS**

Another frequent outcome measure in cSDH studies is MLS, a sign of a space-occupying effect. Besides cisternal compression and sulcal flattening, MLS is an important indicator of mass effect and can help determine the need for surgical intervention.9

Different measurement techniques for the estimation of MLS have been published.8,9,21 There are 2 possible measurement techniques (MLS transverse: displacement relative to the tabula interna in relation to the width of the intracranial space [MLS-T] and MLS versus midline or displacement perpendicular to ideal midline [MLS-M]) that can each be combined with either a specific predefined anatomic measurement location (which also indirectly defines the section and location of the measurement) or the identification of the location with the estimated largest MLS (which can be a different section and location in each patient). MLS estimation in cSDH according to these techniques can lead to very different measurements.21 Overall, the septum pellucidum seems to be the structure that is more sensitive to the space-occupying effect of intracranial masses. Variations, especially when longitudinal studies are analyzed, might also be dependent on section thickness and patient position or image reconstruction. Measurement of MLS-M might be a more reliable estimate and has shown high interobserver agreement.22 Moreover, determining the midline is easier than determining the width of the intracranial space, especially if the patient is not perfectly aligned during CT examination or if the skull is asymmetric, deformed, or has been removed by surgery or trauma, which is also of high relevance in studies including pre- and postoperative scans of patients with cSDH. So far, no study has systematically compared MLS estimations using the aforementioned measurement techniques in patients with cSDH and their specific intrarater and interrater variability.

On the basis of the currently available information, we propose the following MLS measurements in future cSDH therapy studies:

- As MLS-M, ie, perpendicular to the midline joining the most anterior and posterior visible points on the falx, especially in studies including patients undergoing an operation (to increase pre- and postoperative comparability and decrease the effects of asymmetry of the skull)
- If available, measurements should be conducted on axial and coronal slices
- On axial slices, measurements of the maximum at the level and location of the foramen of Monro and as the maximum displacement of the septum pellucidum relative to the midline should be taken (to increase sensitivity for hematomas located at the convexity)
- On coronal slices, measurements of the maximum MLS of the septum pellucidum at the level of the highest point of the septum should be taken (to decrease the effects of slice thickness and patient position or image reconstruction)
• Overall, MLS should then be determined as the mean of these 3 measurements (or 2 in cases in which coronal reconstructions are missing).

Examples of the described MLS measurements are shown in Fig 3.

Patient presentation may also impact the level to which MLS indicates cSDH size and mass effect. Most notably, bilateral cSDH is common. When it occurs, the midline is pushed back to its normal position, making the MLS less useful in such patients. Atrophy is another factor influencing the degree of MLS. Therefore, other imaging features and clinical information must be taken into account to adequately evaluate the mass effect.10

Measuring postoperative MLS alone probably plays a smaller role in cSDH because clinical improvement can be achieved with partial evacuation, which could result in residual cSDH and MLS.10,23 Therefore, the MLS should always be assessed in conjunction with other parameters such as clinical information and cSDH volume. Nonetheless, we strongly encourage authors to provide a detailed description of the algorithms/measurement techniques used when reporting cSDH width, volume, MLS, or other quantitative radiologic measures. A summary of expert suggestions for measurement performance in cSDH is provided in Table 1.

Follow-up Image Evaluation
Postoperative image findings and characteristics differ from those of preoperative examinations. Intracranial air collections, removal or deformation of the skull, and changes in hematoma shape and composition represent some of the issues that can complicate comparison of pre- and postoperative radiologic measurements.

Embolization of the meningeal artery is currently performed either as a primary therapeutic option in patients with cSDH or as a secondary measure when persistent or recurrent hematoma occurs following an operation. Therefore, these differences may also be relevant for a number of radiologic features obtained in the current embolization trials7 and should be carefully addressed, particularly with respect to longitudinal observations and treatment monitoring. Most studies include radiologic hematoma recurrence or progression as their primary or secondary end points (Table 1).

Hence, strict definitions and standardization of image analyses should be mandatory. However, to our knowledge, there are currently no studies specifically evaluating the applicability and accuracy of the above-mentioned measurement techniques in patients with cSDH after an operation, when early postoperative changes are still visible and the brain has not yet recovered and unfolded to its full extent. Therefore, in such cases, authors should provide detailed reports on whether air collections were included in volumetric measurements or how they obtained measurements if the skull had been removed or deformed.

**Follow-up Period and Intervals for cSDH Embolization Studies**
Standardization of follow-up periods and intervals of the cSDH embolization trials would be advantageous in that it would increase the overall value, validity, and significance of each individual clinical trial and enable joint analyses.

---

**FIG 3.** Proposed MLS measurement as the mean of maximum at the level and location of the foramen of Monro (MLS-MI), the maximum displacement of the septum pellucidum relative to the midline (MLS-M2), and the maximum MLS of the septum pellucidum at the level of the highest point of the septum on coronal slices (MLS-C). Overall MLS is determined as the mean of these 3 measurements (or 2 in cases in which coronal reconstructions are missing). MLS-M indicates axial MLS perpendicular to the midline; MLS-C, coronal MLS perpendicular to the midline.
After surgical evacuation, routine follow-up CTs do not seem to provide any benefit over CTs performed only in patients with clinical deterioration or persisting neurologic deficits with respect to good clinical outcome. Furthermore, patients who were followed clinically without routine follow-up CT had fewer repeat surgeries—and this link may be causative, meaning that differential radiologic follow-up strategies are, in fact, influencing the data on reoperation and rendering studies yet more noncomparable in methods and outcomes. Thus, in cSDH embolization studies, possible complications may occur during the postoperative period, such as infarction or new intracranial hemorrhage, for which the window of occurrence is not well-defined. In addition, radiologic progression is often stated as a primary or secondary outcome measure, and dictates whether additional surgical evacuation is performed. Furthermore, cSDH embolization might also be performed in combination with surgical evacuation therapy and is sometimes even performed in asymptomatic patients. Therefore, only performing posttreatment follow-up in case of clinical deterioration would be ineffective. However, currently, there are no studies explicitly evaluating the benefit of repeat and early follow-up CTs and the use of radiologic progression as the outcome parameter in cSDH embolization studies.

We, therefore, suggest a common imaging and clinical evaluation protocol for the application in cSDH embolization trials with a follow-up of 180 days (6 months).

To detect possible treatment-related complications such as ischemic infarction or new intracranial hemorrhage and to provide a postoperative reference for further comparisons, we suggest an early follow-up scan after 24 hours (1 day).

In addition, we suggest performing 2 additional CT scans because in contrast to surgical evacuation, embolization therapy does not result in an immediate reduction of hematoma size. Furthermore, repeat scans might allow the identification of possible early predictors of successful cSDH volume reduction or resolution after 6 months.

To monitor treatment effect and hematoma evolution across time, 2 more scans at 14–28 days (2–4 weeks) and 60–90 days (2–3 months) are also suggested.

### Parameters of Radiographic Progression

It is unclear which radiographic parameter is the most relevant for the definition of progression; a postoperative increase in cSDH volume might not necessarily correspond to a progression in MLS or SDH width due to brain atrophy. However, a progression in MLS will more likely correspond to an increase in cSDH volume. In contrast, cSDH width might increase on the basis of hematoma organization and shape alterations, but the overall volume could remain the same. The application of different thresholds for each of these parameters to define progression also affects the sensitivity and specificity across these radiologic measures.

It is, therefore, vital that the reproducibility and comparability of longitudinal measurements be taken into account for each parameter. Volume changes corresponding to a few voxels that might have been segmented differently at the edge of the hematoma might already lead to an increase or decrease in volume. Here, automatic artificial intelligence–based segmentation algorithms are likely more accurate and could increase reproducibility, but further development and diagnostic accuracy studies are needed to confirm this possibility. Neural networks can be used to automatically segment cSDH to obtain more accurate volume measurements closer to the criterion standard. However, to our knowledge, only 1 study has applied this automatic segmentation technique specifically to patients with cSDH so far. In their study, Kellogg et al used a convolutional neural network to segment cSDH on CT scans, achieving an average DICE score of 0.806. However, this technique might be limited when it comes to the segmentation of isodense cSDH, and so far, there is no broader availability of this technique.

Furthermore, width measurements in longitudinal studies might be dependent on hematoma-shape changes and, therefore, are not directly comparable. However, any form of measurable recurrence might indicate a later progression with concurrent clinical symptoms. Therefore, radiographic parameters should always be evaluated and reported in the context of clinical information and, as much as possible, at similar time points with similar sets of related outcome measures.

Advantages and disadvantages of all parameters to indicate radiographic progression are shown in Table 2.
Recurrence and Progression as Study End Points in cSDH Embolization Trials

Recurrence and progression are frequently included as either primary or secondary end points in the cSDH embolization trials. However, as shown in the Online Supplemental Data, there is no official standardized definition of radiographic hematoma recurrence or progression.

Furthermore, the application of thresholds and various definitions of primary and secondary radiologic end points also leads to altered sensitivities and specificities for the detection of recurrence and progression. Using radiographic progression as a study end point, therefore, poses some challenges, especially when considering the individual clinical relevance. However, due to the nature of the Onyx embolization agent (Covidien), we believe that a combination of both clinical and radiologic outcome measures is vital to the integrity of the trials and their ability to potentially change clinical practice. First, the addition of micronized tantalum powder to Onyx results in it being radiopaque. This means that a surgeon viewing the posttreatment CT or angiography scans cannot be blinded to the assignment of the patient to the control or treatment arm, which could lead to substantial bias with regard to further decision-making.

Furthermore, while clinical outcomes are generally of more value due to the above-provided reasons, no validated clinical measurement tool for cSDH exists, leaving room for imprecision and further bias. For example, it is difficult to say whether a patient with dementia who presented with mild headache and confusion and is now less confused following treatment constitutes a clinical improvement. This is in contrast to stroke trials, in which the National Institutes of Health Stroke Scale and modified Rankin Scale allow consistent, validated reporting of clinical outcomes. As a result, a trial that reports differing rates of recurrence requiring repeat surgery between the 2 arms on the basis of clinical assessment (a “soft” measure) would need to corroborate this outcome with concurrent radiographic evidence of cSDH volume reduction (a “hard” measure). It is critical, therefore, that the volumetric measurements are as accurate as possible. Due to the previously mentioned variations in hematoma size, morphology, density, and location, the only way to consistently achieve this accuracy is to perform section-by-section computer-assisted delineation of volumes followed by summation (ie, the criterion standard). The commonly applied ABC/2 methodology and its derivations are subject to too much variation and are, thus, insufficient as an outcome measure.

### Table 2. Advantages and disadvantages of singular and combinations of radiographic measurements to evaluate cSDH progression

<table>
<thead>
<tr>
<th>Advantage</th>
<th>Disadvantage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Width</td>
<td>Simple, practical, good external applicability, sensitivity easy to adjust (2 vs 5 mm, and so forth)</td>
</tr>
<tr>
<td>Volume</td>
<td>Intuitively the right choice, presumably most accurate</td>
</tr>
<tr>
<td>Volume + width</td>
<td>Raises the bar for specificity</td>
</tr>
<tr>
<td>Volume + width + MLS</td>
<td>Raises the bar for specificity even further</td>
</tr>
<tr>
<td>Too dependent on measurement technique and location, sensitivity might be low</td>
<td>Labor intensive, unlikely to be used in day-to-day practice</td>
</tr>
<tr>
<td>More challenging to interpret, 2 thresholds to define</td>
<td>Less sensitive</td>
</tr>
<tr>
<td>Even more challenging to interpret, definition issues, 2 df (&gt;2 mm and &gt; 2 mm and &gt; 20 mL)</td>
<td>Low sensitivity</td>
</tr>
</tbody>
</table>

DISCUSSION

Recommendations for Standardizing Outcome Reporting

On the basis of these factors, we propose the standardized reporting of a clinical outcome (ie, rate of recurrence requiring surgery) and radiographic change as measured by manual computer-assisted volumetric analysis as outcome measures for the cSDH embolization trials. While such a measurement may seem cumbersome for the clinical routine, it provides the greatest potential to gain quality evidence. If the trial results should prove positive, adjustment for increased ease of implementation could be addressed at a later time point in conjunction with ongoing communication about the most clinically meaningful radiologic measures and best practices for using them (eg, manual versus automated) to maximize specificity, sensitivity, and replicability.

In addition, following completion of the trials, the standardization of the measurement technique, as well as the follow-up intervals, would facilitate meta-analysis of the results, boosting the quality of evidence for otherwise underrepresented subgroups, and provide more concrete guidance to the study design in future trials. Also, while there are likely to be differences in techniques and software when implementing a standard methodology, every center will have, for example, a standard axial CT scan of 5 mm. This would be particularly important if the trials were to report conflicting results or if results of a few are not positive. To this end, it will be critical to demonstrate that the radiographic outcome is in line with the clinical outcome, be it symptomatic improvement or reduction of necessary repeat interventions.

Because radiologic parameters seem to play a minor role when it comes to the definition of in- or exclusion criteria for clinical trials and because the selection of in- or exclusion criteria is very dependent on the scope and design of the trial, providing recommendations is outside the scope of this article. However, when radiologic criteria are applied, we suggest the same methods as we defined for radiologic outcome parameters and strongly encourage detailed documentation of methodology, while also emphasizing the need for the homogenization of measurement techniques.

Acceptable Variations

After initial training on the specific study standards, a constant quality control is required to guarantee a low interobserver variability, both for imaging core lab readers and for the core lab readers with the radiologists at the clinical sites. On the basis of
our own unpublished observations, the deviation of MLS in individual patients among core lab readers and between local readings and the core lab should be <2 mm in at least 80% of the cases. The deviation of cSDH thickness measurements in individual patients should be <2 mm among core lab readers and <3 mm between local readings and those of the core lab (in at least 80% of the cases).

Limitations

Our common-data-elements review of existing cSDH trials has several limitations: First and most important, we based our analysis on reported protocols for collection of end points based on clinicaltrials.gov and other public-facing documentation of these studies and, therefore, may not have captured all study practices. However, this issue is yet another important part of study reporting—full and transparent outcome reporting from the stage of protocol drafting through to publication is necessary for replicable and transparent research. As we described throughout this article, there are very few published studies addressing the methodologic validity of imaging-based outcome measures specifically in cSDH. The here-proposed radiologic outcome parameters and measurement techniques are, therefore, based on current practice, practicability, and basic knowledge endorsed by the European Society of Minimally Invasive Neurological Therapy consortium. Furthermore, our recommendations reflect the research and experience of a limited group of experts, and further open dialogue is necessary to confirm the appropriateness of our recommended outcome set for cSDH trials. In addition, we would like to emphasize the need for further research addressing the reliability of measurement techniques defining radiologic outcome parameters in clinical trials of cSDH embolization. However, with this work, we aimed to highlight the need for homogenization and clear definition of outcome measures and hope to initiate further discussion and elucidate research concerning this topic.

CONCLUSIONS

Moving toward the standardization of radiologic outcome measures and measurement techniques in cSDH would increase the impact and significance of each embolization trial. Many open questions remain, especially with regard to the evaluation of the applicability and validity of radiologic outcome measures such as volume, width, and MLS in postoperative scans and as treatment-monitoring options. Currently, it seems as though manual computer-assisted measurements of cSDH volume represent the only viable option for sufficient accuracy. Furthermore, the definition of the optimal trial end point remains unclear and is highly dependent on the hypothesis to be tested. However, in order for the results of the currently running cSDH embolization trials to change clinical practice, we believe a combination of radiologic and clinical outcome measures is necessary. It is possible and reasonable that once the role of embolization for cSDH is well-established, a more simplified user-friendly version of hematoma measurement that has been adequately validated against the criterion standard of manual computer-assisted volume measurements may be used in day-to-day practice. However, the major findings here—that radiologic outcome reporting in currently active cSDH trials is highly heterogeneous and noncomparable—require open, rapid, and ongoing communication about study design among neurointerventionalists to ensure that these trials contribute to larger-scale, comparable outcomes research in support of evidence-based practice.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES

15. Suci HK, Gokmen M, Gelal F. The value of XYZ/2 technique compared with computer-assisted volumetric analysis to estimate the
Cluster Analysis of DSC MRI, Dynamic Contrast-Enhanced MRI, and DWI Parameters Associated with Prognosis in Patients with Glioblastoma after Removal of the Contrast-Enhancing Component: A Preliminary Study


ABSTRACT

BACKGROUND AND PURPOSE: No report has been published on the use of DSC MR imaging, DCE MR imaging, and DWI parameters in combination to create a prognostic prediction model in glioblastoma patients. The aim of this study was to develop a machine learning-based model to find preoperative multiparametric MR imaging parameters associated with prognosis in patients with glioblastoma. Normalized CBV, volume transfer constant, and ADC of the nonenhancing T2 high-signal-intensity lesions were evaluated using K-means clustering.

MATERIALS AND METHODS: A total of 142 patients with glioblastoma who underwent preoperative MR imaging and total resection were included in this retrospective study. From the normalized CBV, volume transfer constant, and ADC maps, the parametric data were sorted using the K-means clustering method. Patients were divided into training and test sets (ratio, 1:1), and the optimal number of clusters was determined using receiver operating characteristic analysis. Kaplan-Meier survival analysis and log-rank tests were performed to identify potential parametric predictors. A multivariate Cox proportional hazard model was conducted to adjust for clinical predictors.

RESULTS: The nonenhancing T2 high-signal-intensity lesions were divided into 6 clusters. The cluster (class 4) with the relatively low normalized CBV and volume transfer constant value and the lowest ADC values was most associated with predicting glioblastoma prognosis. The optimal cutoff of the class 4 volume fraction of nonenhancing T2 high-signal-intensity lesions predicting 1-year progression-free survival was 9.70%, below which the cutoff was associated with longer progression-free survival. Two Kaplan-Meier curves based on the cutoff value showed a statistically significant difference (P = .037). When we adjusted for all clinical predictors, the cluster with the relatively low normalized CBV and volume transfer constant values and the lowest ADC value was an independent prognostic marker (hazard ratio, 3.04; P = .048). The multivariate Cox proportional hazard model showed a concordance index of 0.699 for progression-free survival.

CONCLUSIONS: Our model showed that nonenhancing T2 high-signal-intensity lesions with the relatively low normalized CBV, low volume transfer constant values, and the lowest ADC values could serve as useful prognostic imaging markers for predicting survival outcomes in patients with glioblastoma.

ABBREVIATIONS: CE = contrast-enhancing; CEL = contrast-enhancing lesion; DCE = dynamic contrast-enhanced; GBM = glioblastoma; GTR = gross total resection; k\text{trans} = volume transfer constant; MGMT = O6-methylguanine-DNA methyltransferase; ML = machine learning; nCBV = normalized CBV; NE-T2HSIL = nonenhancing T2 high-signal-intensity lesion; PFS = progression-free survival

Glioblastoma (GBM) is the most common and most aggressive malignant tumor of the CNS.1-3 Because the gross total resection (GTR) of the contrast-enhancing lesion (CEL) component of GBM is associated with longer survival,4 the current standard treatment of GBM consists of a maximally safe GTR of the CEL, followed by adjuvant concurrent chemoradiation...
therapy. However, GBM frequently recurs as tumor cells infiltrate beyond the CEL components, leading to a dismal prognosis with an average overall survival rate of approximately 16 months. Tumor cells that infiltrate past the CEL margin are visualized as hyperintense lesions on T2WI and are known as nonenhancing T2 high-signal-intensity lesions (NE-T2HSILs). It is known that the preoperative T2-hyperintensity lesions that surround the CEL components of GBM are mainly composed of NE-T2HSILs and vasogenic edema. The importance of the residual NE-T2HSIL has recently been recognized, and studies have found that NE-T2HSIL affects the prognosis of patients with GBM. The preoperative prognosis of GBM in terms of the NE-T2HSIL, therefore, enables more aggressive management of the tumor if necessary, which could lead to survival benefits.

Advanced MR imaging detects various aspects of tumor pathophysiology and enables noninvasive visualization of the tumor. Because the survival and proliferation of tumor cells are highly related to angiogenesis and an increase in vascular permeability, perfusion and diffusion imaging is expected to provide additional useful information about the NE-T2HSILs of GBM. Dynamic contrast-enhanced (DCE) MR imaging is a standard technique used to assess the integrity of the BBB on the basis of T1 enhancement. An important perfusion-related parameter measured in DCE MR imaging studies is the volume transfer constant (Ktrans). Ktrans is defined as the rate at which the contrast agent leaks into the extravascular extracellular space per volume of tissue. DSC MR imaging, another perfusion-weighted MR imaging technique, measures capillary perfusion on the basis of the susceptibility effect in T2*-weighted images. Normalized CBV (nCBV), the most common perfusion parameter used in DSC MR imaging studies, reflects the presence of blood vessels in each individual voxel. Last, DWI evaluates the random motion of water molecules. Quantitative analysis of the DWI enables the calculation of the ADC, which is known to have an inverse correlation with tissue cellularity.

Extracting and combining MR imaging features from multiple modalities is labor-intensive, and achieving satisfactory diagnostic accuracy remains a major challenge. With recent developments in artificial intelligence, machine learning (ML) techniques have been steadily applied in glioma imaging studies and are revealing ways to solve these problems. ML techniques can efficiently process complex imaging data, identify meaningful disease patterns, and thus help radiologists make precise predictions about the progression of the disease. Therefore, the application of ML techniques in imaging analysis will enable the effective integration of complementary imaging information obtained from using multiple MR imaging modalities.

Although previous studies have been conducted to combine several MR imaging modalities for the improvement of the prognosis of GBM, no report has been published on the use of DSC MR imaging, DCE MR imaging, and DWI parameters in combination to create a prognostic model. Our study specifically focused on the NE-T2HSILs of GBM because of their importance as a site of recurrence and their relationship to prognosis, especially in patients with GBM who underwent GTR of the contrast-enhancing (CE) components. Our aim was, therefore, to find nCBV, Ktrans, and ADC parameters associated with prognosis in NE-T2HSIL on T2-FLAIR after GTR of the contrast-enhancing components in patients with GBM using ML-based cluster analysis.

**MATERIALS AND METHODS**

**Patients**

This retrospective study was approved by the institutional review board of the Seoul National University Hospital (IRB No. 1811–164–992), and the requirement for informed consent was waived. In this study, a total of 273 patients who were diagnosed with GBM from April 2010 to December 2019 were initially reviewed. Among the 273 patients, patients were selected according to the selection criteria outlined below.

The inclusion criteria were as follows: 1) patients older than 18 years of age, 2) diagnosed with GBM according to the 2016 World Health Organization Classification of Tumors of the Central Nervous System, who had preoperative conventional MR imaging including 3D CE-T1WI and T2-weighted FLAIR imaging, 4) who had preoperative advanced MR imaging, including DCE MR imaging, DSC MR imaging, and DWI, and 5) who underwent standard treatment, which includes GTR followed by concurrent chemoradiation therapy with 6 cycles of adjuvant temozolomide. The exclusion criteria were as follows: 1) patients with loss of raw data (n = 22), 2) lost to follow-up (n = 41), 3) who had undergone partial resection (n = 12), 4) who had undergone biopsy only (n = 14), 5) who did not complete standard treatment (n = 12), 6) who had unreadable data (n = 28), and 7) a loss of clinical information (n = 2). Under these inclusion and exclusion criteria, a total of 142 patients (85 men and 57 women; age range, 22–84 years) were ultimately enrolled in this study (Online Supplemental Data).

All included patients were divided into the progression group (n = 113) or the nonprogression group (n = 29) 1 year after the operation. The patients periodically underwent clinicoradiologic follow-up after completion of the standard treatment and were diagnosed with disease progression if they met at least 1 criterion of the Response Assessment in Neuro-Oncology (RANO) criteria. The RANO criteria are as follows: 1) ≥25% increase in the sum of the products of perpendicular diameters of enhancing lesions with the smallest tumor measurement, 2) any new lesion, 3) clear clinical deterioration not attributable to cause other than the tumor, and 4) clear progression of nonmeasurable disease.

**Mask Segmentation and Advanced Image Processing**

The 3D CE-T1WIs of all patients were registered and resliced into isometric voxels of $1 \times 1 \times 1$ mm$^3$ to achieve spatial alignment and correct motion artifacts across consecutive images. The T2 FLAIR, nCBV, Ktrans, and ADC maps were then coregistered and resliced to the isovoxel CE-T1WI using rigid transformations with 6 df in the SPM package (Version 12; www.fil.ion.ucl.ac.uk/spm/).

A 3D U-Net-based deep learning model was created using the open data set and images from several organizations, and the tumor segmentation masks were generated on the basis of 3D CE-T1WI and FLAIR images. Using the tumor masks, we analyzed nCBV, Ktrans, and ADC values in the NE-T2HSILs, and the segmentation
of the NE-T2HSIL was validated by an experienced neuroradiologist (with 19 years of experience in neuro-oncologic imaging). The process of mask segmentation and image processing is shown in the Online Supplemental Data.

**K-Means Clustering Analysis and Optimization of the Number of Clusters**

Using the tumor-segmentation masks, we performed voxelwise K-means clustering in the NE-T2HSILs based on nCBV, $K_{trans}$, and ADC maps. The K-means clustering module in the scikit-learn Python package (https://scikit-learn.org/stable/index.html) was used. K-means clustering is an iterative analysis that partitions a data set into K clusters, optimizing the similarities among data in a group while maintaining the greatest possible separation between different groups. K initial means are randomly selected, and each time new data are added to the program, they are assigned to the cluster with the closest mean. In the next step, the mean of the selected cluster is recalculated, and this process is repeated until all the data have been added to the program. All voxels from all segmented masks in the training set were first combined and then divided into multiple clusters based on the similarities across data points in the same cluster and the differences across data points in different clusters. To determine the optimal number of clusters, we ran the program several times from 3 to 6 clusters. Finally, the best cluster number was chosen, which best discriminates the 1-year progression-free survival (PFS) in the training set on the basis of a univariate analysis.

**Patient Population: Training and Test Sets**

We randomly assigned all patients to a training or test set to prevent overfitting in the K-means clustering analysis. We divided the training set and test set at a ratio of 1:1. Each training set consisted of 71 patients, and the test set consisted of 71 patients. The patients in the training and the test sets were equally balanced with respect to the 2 prognosis groups. Next, the K-means clustering performance was evaluated using the parametric data of all patients in the test set.

**Clinical Predictors and Outcome Definition**

Clinical predictors were obtained from all patients’ medical records, including sex, age, isocitrate dehydrogenase isozyme 1 ($IDH1$) mutation status, and $O^6$-methylguanine-DNA methyltransferase (MGMT) promoter methylation status. The primary end point of this study was PFS. For those patients who were diagnosed with tumor progression according to the RANO criteria, PFS was calculated from the day of the operation until the day of progression. For those patients who showed no progression during the follow-up period, PFS was monitored at the time of the last follow-up MR imaging examination, and PFS was estimated by survival analysis.

**Variable Selection**

The selection of variables that are significantly relevant to the patient’s survival outcome is extremely important in developing a prognostic model. The variables we analyzed in this study included the volume fractions of each parametric cluster in the NE-T2HSIL and several clinical predictors, including sex, age, $IDH1$ mutation status, and MGMT promoter methylation status. We first applied these variables in the univariate analysis and then included the variables that were found to be statistically significant in the multivariate analysis.

MR imaging protocol, imaging processing, and statistical analysis are summarized in the Online Supplemental Data.

**RESULTS**

**Demographic Data of the Study Population**

A total of 142 patients who were diagnosed with GBM were enrolled in our study. The demographic data of all enrolled patients are summarized in Table 1. During the follow-up period, 113 (79.6%) patients experienced progression, and 29 (20.4%) patients did not experience progression 1 year after the operation. Patient demographics in the training and test sets are summarized in the Online Supplemental Data.

**Optimization of the Number of Clusters Using the Training and Test Sets**

To determine the optimal number of clusters, we randomly divided all enrolled patients into a training set and a test set at a ratio of 1:1. The initial K-means clustering was performed on the parametric data of all patients in the training set. All voxels from the segmented NE-T2HSIL masks were divided into clusters on the basis of the nCBV, $K_{trans}$, and ADC maps. A range of cluster numbers was entered, and finally, the cluster number of 6 ($k = 6$) was chosen because it best discriminated the 1-year PFS in the training set on the basis of univariate analysis (Online Supplemental Data). Receiver operating characteristic analysis was performed for both the training and test sets, and the areas under the curve were 0.69 and 0.67, respectively. The area under the curve values suggest that the division into 6 clusters is an acceptable distinction (Online Supplemental Data).

**Class 4r Correlated with PFS in All Patients**

After we validated the number of clusters, the training and test sets were combined for survival analysis. The 2D clustering plots based on the nCBV, $K_{trans}$, and ADC values are demonstrated in the Online Supplemental Data. The average percentages of voxels in each of the 6 clusters were 4.99%, 18.42%, 8.41%, 27.34%, 29.24%, and 19.60% in numeric order. The parametric information for each cluster is shown in the Online Supplemental Data. Among the 6 clusters, “class 4r” was the cluster with the relatively low nCBV and $K_{trans}$ values and the lowest ADC values in the segmented NE-T2HSIL mask. We found that a higher class 4

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Mean (SD) or No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>56.0 (13.2)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>85 (59.9%)</td>
</tr>
<tr>
<td>Female</td>
<td>57 (40.1%)</td>
</tr>
<tr>
<td>$IDH1$</td>
<td></td>
</tr>
<tr>
<td>Wild-type</td>
<td>133 (93.4%)</td>
</tr>
<tr>
<td>Mutant</td>
<td>9 (6.3%)</td>
</tr>
<tr>
<td>MGMT promoter</td>
<td></td>
</tr>
<tr>
<td>Unmethylated</td>
<td>68 (47.9%)</td>
</tr>
<tr>
<td>Methylated</td>
<td>74 (52.1%)</td>
</tr>
</tbody>
</table>
Volume fraction was associated with a shorter PFS in patients with GBM. We defined the term "class 4r" as the volume fraction of cluster 4 in the total NE-T2HSIL of each patient. A video clip with a 3D clustering plot can be accessed in the Online Supplemental Data.

Stratification Based on Class 4r and Survival Analysis in All Patients

Our study suggested that class 4r in the NE-T2HSIL was associated with 1-year PFS prediction in GBM. The optimal cutoff of class 4r for stratifying the shorter and longer PFS groups was 9.70% of the NE-T2HSIL volume fraction. The cutoff value distinguished the 2 PFS groups with a significant difference in the log-rank test ($P = .037$). Thus, our results showed that patients with GBM with a class 4r of $\geq 9.7\%$ had a significantly longer PFS time than patients with a class 4r of $< 9.7\%$. The Kaplan-Meier survival curves and a table with the "numbers at risk" are shown in Fig 1.

Univariate and Multivariate Analysis in All Patients

The univariate Cox proportional hazard analysis showed that clinical variables such as age, IDH1 mutation status, and MGMT promoter methylation status were independent predictors of 1-year PFS in patients with GBM. In addition, among the MR imaging parametric variables, only an increase in class 4r was identified as an adverse predictor of PFS (Table 2).

In the multivariate Cox proportional hazard analysis, a statistically significant difference in PFS between patients with low and high class 4r values (hazard ratio, 3.04; 95% CI, 1.00–9.10; $P$ value $= .048$) was observed, which was independent of prognostic genetic factors, including IDH1 mutation status and MGMT promoter methylation status (Table 3). The concordance index value for PFS was 0.699 (standard error, 0.025), indicating that the volume fraction of regions with the relatively low nCBV and $K^{trans}$ values and the lowest ADC value is a moderately good

---

Table 2: Univariate Cox proportional hazard analysis of the potential prognostic factors for 1-year PFS

<table>
<thead>
<tr>
<th>Variables</th>
<th>Hazard Ratio</th>
<th>Wald</th>
<th>$P$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.02</td>
<td>3.90</td>
<td>.047</td>
</tr>
<tr>
<td>Sex</td>
<td>Female</td>
<td>0.70</td>
<td>3.40</td>
</tr>
<tr>
<td>Preoperative KPS</td>
<td>0.98</td>
<td>3.74</td>
<td>.054</td>
</tr>
<tr>
<td>IDH1 mutation</td>
<td>Mutant</td>
<td>0.21</td>
<td>7.10</td>
</tr>
<tr>
<td>MGMT promoter Methylated</td>
<td>0.31</td>
<td>35</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>NE-T2HSIL volume</td>
<td>Class 1</td>
<td>1.00</td>
<td>0.08</td>
</tr>
<tr>
<td>Class 2</td>
<td>1.00</td>
<td>0.32</td>
<td>.57</td>
</tr>
<tr>
<td>Class 3</td>
<td>1.00</td>
<td>0.00</td>
<td>.98</td>
</tr>
<tr>
<td>Class 4</td>
<td>1.00</td>
<td>2.30</td>
<td>.13</td>
</tr>
<tr>
<td>Class 5</td>
<td>1.00</td>
<td>0.01</td>
<td>.92</td>
</tr>
<tr>
<td>Class 6</td>
<td>1.00</td>
<td>0.59</td>
<td>.44</td>
</tr>
<tr>
<td>NE-T2HSIL VF</td>
<td>Class 1r</td>
<td>0.84</td>
<td>0.02</td>
</tr>
<tr>
<td>Class 2r</td>
<td>0.66</td>
<td>0.46</td>
<td>.50</td>
</tr>
<tr>
<td>Class 3r</td>
<td>2.69</td>
<td>0.02</td>
<td>.90</td>
</tr>
<tr>
<td>Class 4r</td>
<td>3.04</td>
<td>3.90</td>
<td>.048</td>
</tr>
<tr>
<td>Class 5r</td>
<td>0.59</td>
<td>0.51</td>
<td>.47</td>
</tr>
<tr>
<td>Class 6r</td>
<td>0.64</td>
<td>0.46</td>
<td>.50</td>
</tr>
</tbody>
</table>

Note: KPS, Karnofsky performance status; VF, volume fraction.
DISCUSSION

In this study, we developed a multiparametric prognostic model for patients with GBM who received GTR of the CEL mass. We found that a higher volume fraction of voxels with relatively low nCBV and $K_{\text{trans}}$ values and the lowest ADC value in NE-T2HSIL showed a significant association with worse GBM prognosis: A low $K_{\text{trans}}$ value indicates preserved vascular permeability due to subtle BBB damage,19 a low nCBV value implies a lack of tumor angiogenesis,20 and a low ADC value reflects an increase in tumor cellularity.13 Thus, regions of relatively low nCBV and $K_{\text{trans}}$ values and the lowest ADC value represent the hypoxic hypercellular regions within the NE-T2HSIL. We believe that a high content of these regions in the NE-T2HSIL can be a significant prognostic factor in predicting the survival outcomes of GBM.

Few studies have used DSC MR imaging, DCE MR imaging, or DWI to evaluate MR imaging-derived parameters in the NE-T2HSIL to predict the prognosis of GBM. Derived from DWI, a low ADC value can be used as a marker indicating regions with a high content of microscopic tumor cells.13 On T2WI, however, these microscopic tumor cells are in a mixture of vasogenic edema, where high ADC values are present.21,22 Hence, the low ADC level helps locate the regions with high microscopic tumor cell content from the vasogenic edema mixture.21,22 Consistent with our finding, Lee et al21 also suggested that the minimum ADC value of NE-T2HSIL may indicate the infiltration of neoplastic cells in peritumoral edema.

Derived from DCE and DSC MR imaging, $K_{\text{trans}}$ and nCBV values reflect the extent of perfusion and tissue vascularity. Our finding of low $K_{\text{trans}}$ and low nCBV levels can be interpreted as hypoxic tumor regions, which are key to the highly infiltrative

Table 3: Multivariate Cox proportional hazard analysis to analyze significant independent predictors of 1-year PFS

<table>
<thead>
<tr>
<th>Variables</th>
<th>Hazard Ratio</th>
<th>95% CI</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>NE-T2HSIL VF Class 4</td>
<td>3.36</td>
<td>1.17–9.63</td>
<td>.024</td>
</tr>
<tr>
<td>Age</td>
<td>1.02</td>
<td>1.00–1.04</td>
<td>.014</td>
</tr>
<tr>
<td>IDH1</td>
<td>0.44</td>
<td>0.13–1.45</td>
<td>.178</td>
</tr>
<tr>
<td>MGMT promoter</td>
<td>0.27</td>
<td>0.17–0.41</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

Note: VF indicates volume fraction.
Local hypoxic tumor conditions prompt the activation of hypoxia-inducible factor 1, leading to vascular endothelial growth factor production. The vascular endothelial growth factor then promotes angiogenesis and invasion of the normal brain parenchyma, which ultimately lead to tumor progression. However, our results contradict those of previous studies. For example, Kim et al recently suggested the potential of a high $K_{\text{trans}}$ value within the NE-T2HSIL in predicting the prognosis of GBM. According to that study, patients with GBM with higher $K_{\text{trans}}$ values in the 99th percentile had a worse prognosis. With respect to rCBV, Jain et al reported that higher mean rCBV values in NE-T2HSIL are associated with a worse prognosis in GBM. The reason for the discrepancies between our current data and these 2 previous studies is that these 2 reports did not include the ADC parameter, a tissue cellularity imaging marker. We believe that in the NE-T2HSIL, a low ADC value resulting from hypercellularity is more important than hypervascularity or hyperpermeability for the prognosis; additionally, hypoxic hypercellular areas seem to have an aggressive potential.

Despite the discrepancy between our results and previous studies, we suggest that regions with low parametric values within the NE-T2HSILs may relate to the early stages of pseudopalisade development. Pseudopalisades are unique pathologic features that differentiate GBM from low-grade gliomas. Although the detailed mechanism for the formation of pseudopalisades remains unclear, a new model proposed by Rong et al may provide...
insight into our results. According to this model, the high incidence of intravascular thrombosis in patients with GBM can directly trigger or spread hypoxia within the tumor. After vascular insult, however, the BBB and vascular structure remain intact to some extent. This feature keeps permeability relatively low until pseudopalisading cells migrate away from the vascular occlusion site, secrete proangiogenic factors, and develop central necrosis. Therefore, tumor voxels with relatively low nCBV and Ktrans values and the lowest ADC value could represent NE-T2HSILs with large numbers of pseudopalisading cells in the early stages of development.

Our study has several limitations. First, it is based on a retrospective design that is inevitably prone to selection bias. However, we tried to minimize the selection bias by collecting most of the data from April 2010 to December 2019 in the Seoul National University Hospital. Second, all patient data were collected from a single medical center. Future studies with multicenter data could help validate and generalize our results. Third, the size of our study population was relatively small, especially the number of samples from April 2010 to December 2019 in the Seoul National University Hospital. We tried to minimize the selection bias by collecting most of the data from April 2010 to December 2019 in the Seoul National University Hospital. Second, all patient data were collected from a single medical center. Future studies with multicenter data could help validate and generalize our results. Third, the size of our study population was relatively small, especially the number of samples in the nonprogression groups, so a future study is warranted in a large population for the validation of our results. Last, although we have suggested a plausible correlation between pathologic features and imaging features, this study lacks pathologic validation because the NE-T2HSILs are not the usual target of GBM.

CONCLUSIONS

The multiparametric model showed that the NE-T2HSILs with the relatively low nCBV and Ktrans values and the lowest ADC value could serve as useful imaging markers in predicting survival outcomes in patients with GBM. Our investigation could help radiologists locate hypoxic, hypercellular regions of the NE-T2HSIL, consider more aggressive treatment to prevent early tumor recurrence, and ultimately improve the overall survival of patients with GBM.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


Diffuse Large B-Cell Epstein-Barr Virus–Positive Primary CNS Lymphoma in Non-AIDS Patients: High Diagnostic Accuracy of DSC Perfusion Metrics


ABSTRACT

BACKGROUND AND PURPOSE: Immunodeficiency-associated CNS lymphoma may occur in different clinical scenarios beyond AIDS. This subtype of CNS lymphoma is diffuse large B-cell and Epstein-Barr virus–positive. Its accurate presurgical diagnosis is often unfeasible because it appears as ring-enhancing lesions mimicking glioblastoma or metastasis. In this article, we describe clinicoradiologic features and test the performance of DSC-PWI metrics for presurgical identification.

MATERIALS AND METHODS: Patients without AIDS with histologically confirmed diffuse large B-cell Epstein-Barr virus–positive primary CNS lymphoma (December 2010 to January 2022) and diagnostic MR imaging without onco-specific treatment were retrospectively studied. Clinical, demographic, and conventional imaging data were reviewed. Previously published DSC-PWI time-intensity curve analysis methodology, to presurgically identify primary CNS lymphoma, was used in this particular lymphoma subtype and compared with a prior cohort of 33 patients with Epstein-Barr virus–negative CNS lymphoma, 35 with glioblastoma, and 36 with metastasis data. Normalized curves were analyzed and compared on a point-by-point basis, and previously published classifiers were tested. The standard percentage of signal recovery and CBV values were also evaluated.

RESULTS: Seven patients with Epstein-Barr virus–positive primary CNS lymphoma were included in the study. DSC-PWI normalized time-intensity curve analysis performed the best for presurgical identification of Epstein-Barr virus–positive CNS lymphoma (area under the receiver operating characteristic curve of 0.984 for glioblastoma and 0.898 for metastasis), followed by the percentage of signal recovery (0.833 and 0.873) and CBV (0.855 and 0.687).

CONCLUSIONS: When a necrotic tumor is found in a potentially immunocompromised host, neuroradiologists should consider Epstein-Barr virus–positive CNS lymphoma. DSC-PWI could be very useful for presurgical characterization, with especially strong performance of normalized time-intensity curves.

ABBREVIATIONS: AUC = area under the receiving operating characteristic curve; CE = contrast-enhanced; DLBCL = diffuse large B-cell; EBV = Epstein-Barr virus; GE = gradient-echo; nTIC = normalized time-intensity curve; PCNSL = primary CNS lymphoma; PSR = percentage of signal recovery; rCBV = relative CBV; TIC = time-intensity curve; WHO = World Health Organization

Presurgical suspicion of CNS lymphoma is crucial for patient management. When it is suspected, initial corticosteroids should be avoided, and biopsy instead of surgical resection is recommended.1,2

Conventional imaging features of CNS lymphoma are widely described,3–7 but they mainly refer to primary CNS lymphoma.

This work was partially supported by a grant from the Instituto de Salud Carlos III (PI10/00360) to Carles Majós and Albert Pons-Escoda. Francesco Grussu has received funding from the postdoctoral fellowship program Beatriz de Pinós (2020 BP 00117), funded by the Secretary of Universities and Research (Government of Catalonia). Raquel Perez-Lopez is supported by a Prostate Cancer Foundation Young Investigator Award, CRIS Foundation Talent Award (TALENT-05), Fero Foundation, and the Instituto de Salud Carlos III.

Please address correspondence to Albert Pons-Escoda, MD, Radiology Department, Institut de Diagnòstic per la Imatge (IDI), Hospital Universitari de Bellvitge, C/Ferri Llarga SN, L’Hospitalet de Llobregat, 08907 Barcelona, Spain; e-mail: albert.pons.idi @gencat.cat; @PonsEscoda

Indicates article with online supplemental data.

http://dx.doi.org/10.3174/ajnr.A7668
(PCNSL), which specifically is Epstein-Barr virus (EBV)-negative and occurs in immunocompetent patients. However, less frequent subtypes of CNS lymphoma do not follow this imaging pattern. This is the case of immunodeficiency-associated CNS lymphoma, which usually appears as ring-enhancing lesions with central necrosis complicating accurate presurgical diagnosis.

The World Health Organization (WHO) Classification of Tumors of the CNS includes B-cell and EBV-positivity as essential criteria for immunodeficiency-associated CNS lymphoma. Diffuse large B-cell (DLBC) EBV positive lymphoma is considered a distinct immunobiologic entity and represents nearly 10% of all CNS lymphomas. In the scientific literature, DLBC EBV-positive CNS lymphoma is mainly described in the context of AIDS. However, while the AIDS incidence is decreasing, other causes of immunodeficiency are increasing. This is the case for iatrogenesis (treatment-induced immunosuppression) in the context of post-transplantation or for other causes such as autoimmune diseases, or even for other situations such as immunosenescence and chronic inflammation.

DSC-PWI is a quantitative MR imaging technique that has shown promising results for presurgical identification of PCNSL. This tumor shows a characteristic time-intensity curve (TIC), which can be precisely evaluated with a new methodology that renders normalized TICs (nTICs) as well as by a lower relative CBV (rCBV) and a higher percentage of signal recovery (PSR) than glioblastoma or metastasis. However, to the best of our knowledge, there is very little literature regarding DSC-PWI features specific to DLBC EBV-positive CNS lymphoma.

In summary, DLBC EBV-positive CNS lymphoma constitutes a unique clinical immunobiologic entity with particular imaging features that challenge its presurgical diagnosis. Conventional imaging is usually misleading, and comprehensive analysis of the full potential of DSC-PWI in this scenario is lacking.

In this article, the clinical and radiologic features of a homogeneous data set of patients with DLBC EBV-positive CNS lymphoma without AIDS are comprehensively described. The main objective of the study was to test the performance of DSC-PWI metrics (nTIC, PSR, CBV) for the presurgical differentiation of this entity from glioblastoma and metastasis.

**MATERIALS AND METHODS**

The research ethics committee of the Hospital Universitari de Bellvitge tertiary center approved this retrospective study and issued a waiver for a specific informed consent. Patient data were protected and anonymized in accordance with European Union General Data Protection Regulation legislation.

**Patients**

Records of patients with confirmed primary DLBC EBV-positive CNS lymphoma (December 2010 to January 2022) were retrieved from our center’s database. Inclusion criteria were the following: 1) confirmed tumor diagnosis by histology (2016 WHO lymphoid neoplasm and 2021 WHO CNS tumor classification); 2) extension study without evidence of systemic lymphoma; and 3) available diagnostic MR imaging examination without onco-specific treatment.

Relevant clinical and demographic data were retrieved from the hospital records, including age, sex, underlying conditions, radiologic diagnosis, histopathologic diagnosis, and initial diagnostic-therapeutic patient management.

For comparison of the obtained perfusion metrics, we retrieved DSC-PWI data from previously published cases of EBV-negative PCNSL, glioblastoma, and metastasis, which are balanced by technique and demographic characteristics, as well as quality-filtered.

**Imaging**

The MR images included in the study were acquired in a single center with 1 of 2 scanners, either an Ingenia 1.5T or an Intera 1.5T (Philips Healthcare), both using a 16-channel head coil. MR imaging examinations included T1WI, contrast-enhanced (CE) T1WI, TSE-T2WI, gradient-echo (GE) T2*WI, DWI, and DSC-PWI.

**Conventional Imaging**

Two experienced neuroradiologists from our tertiary reference center neuro-oncology unit, A.P.-E. and C.M., with >8 and 25 years of experience in neuro-oncologic radiology, respectively, visually assessed T1WI, CE-T1WI, TSE-T2WI, GE-T2*WI, and DWI sequences. The assessment was done independently and included the number of lesions, location, ring enhancement, TSE-T2WI signal intensity, GE-T2*WI hemorrhagic components, and diffusion restriction. Discrepancies were resolved by consensus.

**Perfusion Imaging Acquisition**

Two GE DSC-PWI sequences were used. The first (2 cases) included 40 dynamic volumes with a temporal resolution of 1.9 seconds with the following parameters: flip angle $\approx 7^\circ$, $TE = 25–30$ ms, $TR = 16–20$ ms, in-plane resolution $= 1.72$ mm, and section-thickness $= 1.5$ mm. The second (5 cases) included 60 dynamic volumes with a temporal resolution of 1.6 seconds with flip angle $= 75^\circ$, $TE = 40$ ms, $TR = 1522–1771$ ms, pixel spacing $= 1.75$ mm, and section thickness $= 5$ mm. The intravenous contrast was gadobutrol, 1 mmol/mL, 0.1 mmol/kg. No contrast preload administered. Baseline acquisition was on the order of 10 points. The start of the automatic injection (4–5 mL/s) was by a manual setting.

**Postprocessing**

The segmentations of enhancing tumor and contralateral normal-appearing WM were performed on CE-T1WI semi-automatically (histogram intensity thresholding) and coregistered with DSC-PWI. Necrosis was not included in the segmentations. Segmentations were performed on 3D Slicer, Version 4.10 (http://www.slicer.org), and coregistration was with the BRAINSFit module (3D Slicer). TICs were preprocessed using the method proposed by Pons-Escoda et al., which renders nTICs: Signal-intensity values of the enhancing tumor TIC were normalized by dividing by the maximal signal intensity drop of the normal-appearing WM, and time values were normalized as relative to the period of the descending curve on normal-appearing WM. The resultant nTICs are time- and intensity-normalized, making them comparable among patients. The TICs were processed using Python 3.6 software (https://www.python.org/downloads/release/python-360/).

Visual evaluation of the average curves and point-by-point statistical comparison (Mann-Whitney $U$ test) were performed.
Two previously published classifiers to differentiate PCNSL from glioblastoma and metastasis through nTICs were used to assess the performance in the particular group of DLBC EBV-positive CNS lymphomas. Also, we assessed the performance of mean rCBV and PSR. rCBV was obtained after leakage correction and normalized to the contralateral normal-appearing WM with 3D Slicer, Version 4.10, and PSR was obtained as described by Cha et al.

**RESULTS**

**Patients**

Seven patients fulfilled the inclusion criteria and were included in the study (4 men; mean age, 70 years; range, 62–78 years). The underlying conditions were the following: 3 iatrogenic in the context of posttransplant, 2 iatrogenic in the context of autoimmune disease, 1 chronic inflammation, and 1, elderly, related to immunosenescence. The original radiologic diagnosis was metastasis or glioblastoma in all patients. Initial biopsy was recommended in 4 cases, while the remaining patients were candidates for initial maximal safe resection. Patient characteristics are specified in Table 1. Four patients with DLBC EBV-positive CNS lymphoma were on corticosteroids at the time of MR imaging.

**Imaging**

Conventional Imaging. Conventional imaging findings are shown in Table 2. The most relevant findings on MR imaging were the following: single lesions and peripheral cortico-subcortical location; necrotic lesions with ring enhancement and different degrees of hemorrhage; and heterogeneous signal on DWI (Table 2 and Fig 1). An unexpected TSE-T2 heterogeneously iso-/hypointense signal of the central nonenhancing content of lesions was also described.
Perfusion Imaging. Figure 2 overlays the average nTIC for DLBC EBV-positive CNS lymphoma, PCNSL (EBV-negative), metastasis, and glioblastoma. Few differences were detected between DLBC EBV-positive CNS lymphoma and PCNSL. The most relevant visual differences with metastasis or glioblastoma were seen around the maximal-signal-intensity drop and signal-recovery segments of the curves. The Mann-Whitney U test found significant differences between DLBC EBV-positive CNS lymphoma and glioblastoma at almost all time points of the curve, with the greatest level around the maximal-signal-intensity drop and signal-recovery segments, reinforcing the visual assessment.

Results of the 2 previously published classifier algorithms, along with the classification potential of PSR and rCBV, can be found in Table 3, Fig 3, and the Online Supplemental Data. The 2 nTIC algorithms showed the most significant differences (P < .001 for glioblastoma and metastasis) and the best classification results. For glioblastoma, they yielded an area under the receiver operating curve (AUC) of 0.984, accuracy of 0.93, sensitivity of 1.0, and specificity of 0.91, while for metastasis, they yielded an AUC of 0.898, accuracy of 0.82, sensitivity of 1.0, and specificity of 0.78. Additionally, PSR was also significant for both comparisons, albeit slightly less so (P < .01 for both, AUC = 0.833 and 0.873). Finally, rCBV yielded significant differences for DLBC EBV-positive CNS lymphoma against glioblastoma (P = .003, AUC = 0.855), but not against metastasis (P = .122, AUC = 0.687).

Furthermore, when we compared DLBC EBV-positive CNS lymphoma and PCNSL, visual assessment of average nTICs showed very similar morphology, and statistical comparison confirmed no significant differences between them in the Mann-Whitney U test. Moreover, no significant differences were found in PSR, while rCBV showed a barely significant difference (P = .05). All results are summarized in Table 3, Fig 3, and the Online Supplemental Data.

Last, the 1-way adapted classifier results can be found in the Online Supplemental Data. The nTIC algorithm (Online Supplemental Data) discriminated between DLBC EBV-positive CNS lymphoma and glioblastoma/metastasis as a whole, with AUC = 0.90, while the AUC was 0.85 for PSR and 0.77 for rCBV.

No significant differences were found in all time points of nTICs, CBV, or PSR values among the different DSC-PWI techniques (Mann-Whitney U test, P values = .245–1), neither among patients with nor without corticosteroids at the time of MR imaging (Mann-Whitney U test, P values = .157–.724).

DISCUSSION

In this study, we present a unique cohort of 7 patients with DLBC EBV-positive CNS lymphoma without AIDS in whom DSC-PWI was performed and compare them with those with PCNSL (EBV-negative), glioblastoma, and metastasis. While conventional imaging was misleading due to the strong similarity between DLBC EBV-positive CNS lymphoma and glioblastoma or metastasis, DSC-PWI metrics provided promising results, the best determined by nTIC analysis. Moreover, this is the first study to describe and...
analyze DLBC EBV-positive CNS lymphoma nTIC features and PSR values, to the best of our knowledge.

Currently, it is recognized that DLBC EBV-positive CNS lymphoma is a specific subtype of CNS lymphoma associated with immunodeficiency.\(^8,15,16\) AIDS-related CNS lymphoma appeared to become one of the most frequent brain tumors in the 1990s due to the explosion of the AIDS pandemic.\(^33\) However, with the advent of antiretroviral therapies, AIDS-related CNS lymphoma has gradually decreased in the 2000s.\(^34,35\) Inherent to medical advances, other non-AIDS immunodeficiencies such as iatrogenic (posttransplantation and others), immunosenescence, and chronic inflammation have increased and probably overtaken AIDS as a cause of immunodeficiency-related CNS lymphoma.\(^17-21,36\) Also, due to the differing underlying physiopathologies of these conditions, strict monitoring of patients, and the improvement in imaging techniques, necrotic tumors have become the main radiologic differentials.\(^14,37-39\)

In the authors’ opinion, radiology literature regarding DLBC EBV-positive CNS lymphoma without AIDS is scarce, probably due to the constantly evolving epidemiologic scenario and the relative rarity of the disease, making it difficult to pool these patients accurately.\(^14,15,21,33-35,37-39\) However, DLBC EBV-positive CNS lymphoma without AIDS is a clear and specific clinical immunobiologic entity that is challenging to diagnose because of the uncommon signatures for the much more frequent PCNSL and its great similarity to glioblastoma and metastasis on conventional imaging.\(^14,37-39\) Last, its identification before any surgical approach is crucial for optimal management because prompt biopsy without corticosteroids is the best choice, while surgical resection is not recommended.\(^1\)

In reference to the role of DSC-PWI, our literature search identified only 1 article that specifically assessed DSC-PWI of patients with DLBC EBV-positive CNS lymphoma without AIDS.\(^10\) Another article\(^14\) analyzed a subgroup of CNS lymphomas under the term “atypical PCNSL” in patients without AIDS. Lee et al\(^10\) specifically assessed rCBV values of patients with DLBC EBV-positive CNS lymphoma and compared them with those in patients who were EBV-negative. They did not find differences between EBV-positive and EBV-negative CNS lymphomas, while we found a slightly significant difference. On the other hand, Suh et al\(^14\) reported relevant differences in rCBV values between their patients with atypical PCNSL and glioblastoma, congruent with our results. Nevertheless, in both articles the DSC-PWI analysis remained limited to rCBV, and the absence of AIDS is considered enough to rule out immunodeficiency, which raises the question of whether CNS lymphomas included in these articles could actually be “other

\[\text{FIG 2. Average nTIC of DLBC EBV-positive CNS lymphoma, PCNSL (EBV-negative), metastasis, and glioblastoma. Few differences may be seen between DLBC EBV-positive CNS lymphoma and PCNSL. The most relevant visual differences between DLBC EBV-positive CNS lymphoma and metastasis or glioblastoma are seen around the maximal-signal-intensity drop and the signal-recovery segments of the curves.}\]

<table>
<thead>
<tr>
<th>Table 3: Summary of results</th>
</tr>
</thead>
<tbody>
<tr>
<td>P*</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>nTIC algorithms vs glioblastoma</td>
</tr>
<tr>
<td>vs metastasis</td>
</tr>
<tr>
<td>PSR vs glioblastoma</td>
</tr>
<tr>
<td>vs metastasis</td>
</tr>
<tr>
<td>rCBV vs glioblastoma</td>
</tr>
<tr>
<td>vs metastasis</td>
</tr>
</tbody>
</table>

\(a\) Statistical significance, Mann-Whitney U test.
immunodeficiency-associated,” such as ours. Finally, the mere comparison of EBV-positive and EBV-negative CNS lymphoma\textsuperscript{10} and the noninclusion of metastasis in the differential\textsuperscript{14} may condition the lack of clinically relevant information from our point of view and experience. To overcome these issues, we present a unique cohort with comprehensive clinical and demographic information and pathologic diagnosis according to the 2016 WHO lymphoid neoplasm\textsuperscript{15} and the 2021 WHO CNS tumor\textsuperscript{8} classifications, and we systematically describe conventional imaging and analyze the full potential of DSC-PWI to presurgically identify DLBC EBV-positive CNS lymphoma.

In this study, standard DSC-PWI metrics of PSR and rCBV achieved good or acceptable results in pair-wise discrimination of DLBC EBV-positive CNS lymphoma and glioblastoma or metastasis. Nonetheless, the application of previously reported nTICs analysis methodology\textsuperscript{22} yielded improved diagnostic performance. We mainly applied the previously published PCNSL presurgical classifier algorithms\textsuperscript{22} to our data set; but as a secondary analysis, we generated a dedicated algorithm to differentiate PCNSL and glioblastoma/metastasis as a whole group, also obtaining excellent results. Additionally, the curve-normalization process allows overlaying the averaged nTICs of relevant differential diagnoses (Fig 2), which offers radiologist-friendly visual evaluation of curve differences. An additional advantage of the nTIC classifier results is the high-sensitivity levels provided, which is ideal in this scenario in which the most relevant goal is to raise suspicion of CNS lymphoma to avoid prebiopsy corticosteroids and potentially harmful tumor resection.\textsuperscript{2}

DSC-PWI pulse-sequence parameters are known to influence CBV and PSR values, often paradoxically (ie, those sequences optimized for CBV calculations may be suboptimal for PSR and vice versa).\textsuperscript{40} In this respect, we believe that the use of nTICs could be an alternative, especially in heterogeneous samples with nonstandardized technical acquisitions, which could be the situation among many neuroradiology departments worldwide such as ours because in this scenario, the evaluation of the whole normalized curve could surpass standard approaches such as CBV and PSR calculations.\textsuperscript{22,23}

On the other hand, in our experience, conventional imaging findings were insufficient to raise suspicion of CNS lymphoma because these tumors appear almost consistently as ring-enhancing necrotic lesions, with differing amounts of hemorrhage, mimicking glioblastoma or metastasis.\textsuperscript{9,14} We noted a prevalent heterogeneous low TSE-T2 signal from the central nonenhancing content of lesions,

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure3.png}
\caption{Boxplots depicting the results of the nTIC algorithms to differentiate PCNSL versus glioblastoma (upper left) and PCNSL versus metastasis (upper right) for each tumor subtype. Lower row: Boxplots depicting PSR and rCBV values for each tumor subtype.}
\end{figure}
not attributable to hemorrhage or calcification and, to the best of our knowledge, not usually seen in glioblastoma or metastasis. Several considerations should be taken into account concerning this study. The single-site and retrospective character of the study may affect reproducibility. Nevertheless, they may also have conferred useful homogeneity to the study. Also, the limited number of cases of DLBC EBV-positive CNS lymphoma included may raise objections. However, this is a rare condition that needs to be detected presurgically, and the DSC-PWI characteristics have hardly been evaluated in the literature. At any rate, the data suffices for a proof-of-concept demonstration, and our results warrant further multicentric prospective studies for validation. Furthermore, heterogeneous DSC-PWI technique acquisition parameters may compromise the generalizability of our concrete results. However, nTIC methodology is applicable elsewhere, and thresholds could be adapted in technically different cohorts.

Moreover, in our data set, no significant differences were found in nTICs among different DSC-PWI techniques, and indeed the nTIC method was created itself to hypothetically attenuate the impact of technical and physiologic variability on isolated parameter evaluation. Some of the data used in this investigation were part of previously published studies, but the aims of the study were clearly differentiated, and prior data were used for comparisons and differential diagnoses. Moreover, the use of previously published algorithms conferred a certain robustness on the study. Additionally, the reliability of data is ensured because they are available, well-balanced, curated, and filtered for prior publication. Finally, the absence of infection and brain abscess in the differential is a limitation. However, in our clinical experience with this data set of patients, glioblastoma and metastasis were the main differential diagnoses considered.

CONCLUSIONS
DSC-PWI could be very useful to presurgically differentiate DLBC EBV-positive CNS lymphoma and glioblastoma or metastasis. Among DSC-PWI metrics, nTIC curvology assessment could surpass the performance of standard PSR and rCBV measures. Neuroradiologists should be aware of any risk factors for immunodeficiency when facing a necrotic tumor in the brain. In the event of potential immunodeficiency, careful assessment of DSC-PWI may raise the suspicion of DLBC EBV-positive CNS lymphoma, which would drastically alter patient management.

ACKNOWLEDGMENTS
We thank CERCA Programme/Generalitat de Catalunya for institutional support.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


SWI by 7T MR Imaging for the Microscopic Imaging Diagnosis of Astrocytic and Oligodendroglial Tumors


ABSTRACT

BACKGROUND AND PURPOSE: Despite advances in molecular imaging, preoperative diagnosis of astrocytomas and oligodendrogliomas can be challenging. In the present study, we assessed whether 7T SWI can be used to distinguish astrocytomas and oligodendrogliomas and whether malignant grading of gliomas is possible.

MATERIALS AND METHODS: 7T SWI was performed on 21 patients with gliomas before surgery with optimization for sharp visualization of the corticomedullary junction. Scoring for cortical thickening and displacement of medullary vessels, characteristic of oligodendrogliomas, and cortical tapering, characteristic of astrocytic tumors, was performed. Additionally, characteristics of malignancy, including thickening of the medullary veins, the presence of microbleeds, and/or necrosis were scored.

RESULTS: Scoring for oligodendroglial (highest possible score, +3) and astrocytic (lowest score possible, −3) characteristics yielded a significant difference between astrocytomas and oligodendrogliomas (mean, −1.93 versus +1.71; P < .01). Scoring for malignancy was significantly different among the World Health Organization grade II (n = 10), grade III (n = 4), and grade IV (n = 7) tumors (mean, 0.20 versus 1.38 versus 2.79). Cortical thickening was observed significantly more frequently in oligodendrogliomas (P < .02), with a sensitivity of 71.4% and specificity of 85.7%; observation of tapering of the cortex was higher in astrocytomas (P < .01) with a sensitivity of 85.7% and specificity of 100%.

CONCLUSIONS: Visualization of the corticomedullary junction by 7T SWI was useful in distinguishing astrocytomas and oligodendrogliomas. Observation of tapering of the cortex was most sensitive and specific for diagnosing astrocytomas. Reliably predicting malignant grade was also possible by 7T SWI.

ABBREVIATIONS: GRE = gradient recalled-echo; LIV = local image variance; WHO = World Health Organization; IDH = isocitrate dehydrogenase

Recent molecular analyses have greatly advanced our ability to pathologically diagnose gliomas. Isocitrate dehydrogenase (IDH) mutation in the absence of 1p/19q codeletion is diagnostic for astrocytomas, and IDH mutation with 1p/19q codeletion, for oligodendrogliomas.1

However, radiographically distinguishing astrocytomas and oligodendrogliomas remains challenging by conventional MR imaging. Features such as calcification and lower homogeneous signal on T2WI are characteristic for 1p/19q-codeleted oligodendrogliomas, whereas the presence of T2 FLAIR mismatch and subventricular zone invasion is characteristic of 1p/19q noncodeleted, IDH-mutant astrocytomas.2,3 MR perfusion studies have suggested that higher maximum relative CBV4 and lower extravascular extracellular distribution volume (Ve) values, especially in conjunction with calcification and high cortical involvement, are suggestive of oligodendroglioma.5 MR spectroscopy studies revealed that the metabolites mlns-to-Cr ratio was significantly higher in astrocytomas compared with oligodendrogliomas.6 Furthermore, MR imaging texture analysis7 and radiomics8 were applied to reliably distinguish astrocytomas and oligodendrogliomas. Molecular imaging of gliomas has also entered the era of clinical application. The detection of the oncometabolite 2-hydroxyglutarate by MR spectroscopy has made accurate, presurgical diagnosis of IDH-mutant gliomas possible.9–11 A recent MR spectroscopy study suggested that cystathionine is a marker for oligodendrogliomas with 1p/19q codeletion,12 though more robust methods are desired.
Marked improvements in the contrast-to-noise ratio by 7T MR imaging has enabled visualization of high-resolution images. Seminal work by Duyn et al\(^\text{13}\) used gradient recalled-echo (GRE) MR imaging and a multichannel detector to achieve a nominal voxel size of \(0.24 \times 0.24 \times 1.0 \text{ mm}^3\) (58 N.L.). We have previously described the microscopic application of 7T MR imaging by post-processing of \(T2^*\) GRE images to depict senile plaquelike structures in Alzheimer disease.\(^\text{14}\) By means of this method, visualization of the corticomedullary junction,\(^\text{15}\) medullary vessels, and microbleeds was possible, aiding in the diagnosis of gliomas. Especially, the visualization of the corticomedullary junction and fine medullary vessels is not possible by 3T MR imaging. Here, we report for the first time, the usefulness of 7T SWI for the preoperative diagnosis of astrocytomas and oligodendrogliomas, as well as malignant grading.

**MATERIALS AND METHODS**

**Patients**

Twenty-one adult patients with World Health Organization (WHO) grade II–IV gliomas, including 13 (61.9%) patients with relatively small (diameter of <3 cm) gliomas localized to the cortical and/or subcortical area, undergoing 7T MR imaging evaluation at the Center for Integrated Brain Science, Niigata University before surgical treatment at the Department of Neurosurgery, Niigata University between April 2009 and December 2015 were included in the study. Written informed consent was obtained from all participants in accordance with the human research guidelines of the internal review board of Niigata University (approval # H16-263).

**7T MR Imaging**

SWI studies were performed using a 7T Signa Horizon LX (GE Healthcare) MR imaging system. Details of the clinical microscopic imaging techniques were previously described.\(^\text{16-18}\)

High-resolution T2*-weighted 2D GRE images were obtained with \(TR = 220 \text{ ms}, TE = 21.4 \text{ ms}, \text{flip angle} = 20^\circ, \text{FOV} = 80 \times 80 \text{ mm}, \text{and matrix size} = 512 \times 512 \text{ with 3-mm thickness} \times 0.156 \times 0.156 \times 3 \text{ mm in spatial resolution} \) (Online Supplemental Data). SWIs were obtained by postprocessing of T2*-weighted 2D GRE images, adhering to methods originally introduced by Reichenbach et al\(^\text{19}\) using in-house software written in MATLAB (MathWorks) on a Windows-based computer (Online Supplemental Data).\(^\text{20}\)

To determine the optimal postprocessing parameters for assessment of gliomas, we altered the kernel size of the filter sequentially from 4 to 255 (Online Supplemental Data) and the number of phase mask multiplications from 0 to 54 (Online Supplemental Data). A kernel size filter of 64 was determined to be optimal for phase unwrapping (Online Supplemental Data) and the number of phase mask multiplications to optimize the contrast-to-noise ratio 9 times (Online Supplemental Data) for the visualization of veins running inside the tumor. Thus, the optimal parameters to visualize gliomas were the same as those previously reported for microscopic imaging of senile plaquelike structures in patients with Alzheimer disease.\(^\text{14}\)

**Pathologic Diagnosis**

Surgical specimens were independently analyzed by 2 pathologists (R.G. and A.K.) and diagnosed according to the WHO 2016 classification.\(^\text{21}\) Differences in diagnosis (mainly judgments between WHO grades II and III) in a couple of cases were resolved by deliberation. IDH1 R132H (H09 clone, Dianova, 1:100), ATRX (polyclonal, SIGMA-Aldrich; 1:1000), and P53 (clone DO-7; Dako Omnis; 1:50) immunohistochemical analysis was performed in formalin-fixed, paraffin-embedded sections using the avidin-biotin-peroxide method (Vectorlabs) with diaminobenzidin as the chromogen and counterstained with hematoxylin.\(^\text{22}\)

For cases showing negative staining for IDH1 R132H, DNA sequencing for IDH1 and IDH2 was analyzed. Methods for sequencing are specified in the Online Supplemental Data.

**Assessment of lp/19q Codeletion**

Methods for assessment of lp/19q codeletion are detailed in the Online Supplemental Data.

**Assessment of 7T Imaging**

One experienced neuroradiologist (K.O.) and a neurosurgeon (M.N.) independently assessed 7T SWIs, blinded to the clinical information. Thickening of the cortex, assessed by an increase of the distance from the cortical surface to the corticomedullary junction by ≥50% (scored +1 present/−1 absent) and displacement of medullary vessels (scored +1 present/−1 absent) were considered characteristic of astrocytomas. The tapering or thinning of the corticomedullary junction was considered characteristic of oligodendrogliomas. Therefore, a minimum score of −3 (astrocytoma-like) and maximum score of +3 (oligodendroglioma-like) were assessed. Findings for malignancy were also scored. The thickening of the medullary veins and the presence of microbleeds and/or necrosis were each scored as +1 when present, zero when absent. Thus, a minimum score of zero and a maximum score of +3 were possible. Scores were presented as means (SD). To calculate the sensitivity and specificity of specific categories, the 2 scorers resolved interobserver variability by thorough discussion.

**Statistical Analyses**

Differences between 2 groups were assessed by an unpaired \(t\) test, differences among 3 groups were assessed by the 1-way ANOVA test with the post hoc Tukey multiple comparison test, and contingency tables were assessed by the Fisher exact test using GraphPad Prism 9 software (GraphPad Software). Error bars represent standard error of the mean unless otherwise specified. \(P < .05\) was considered statistically significant.

**RESULTS**

**Optimization of SWI**

After optimization, the visualization of the corticomedullary junction, seen as a hypointense band (triangles), and elongation of the medullary vessels running perpendicular to the cortical surface (brackets) were clearly depicted by 7T SWI (Fig 1A). This detail cannot be achieved by SWI (Fig 1B), T1-weighted (Fig 1C), or FLAIR imaging (Fig 1D) using a conventional 3T machine. Additionally, 7T SWIs appeared to show higher resolution than 3T SWIs (Online Supplemental Data), though specific parameters differed.
Pathologic Diagnosis

Demographics, pathologic diagnoses, and molecular profiles of the 21 patients with gliomas are summarized in the Online Supplemental Data. The age of patients ranged from 29 to 81 years (median, 50 years); 10 female patients and 11 male patients were recruited. Tumors in 7 of 21 (33%) patients were pathologically diagnosed as WHO grade IV; 4 (19%), as WHO grade III; and 10 (48%), as grade II. The IDH1 R132H mutation was detected in 12 (57%) tumors; IDH2 R172W, in 1 (5%) tumor; and the rest (38%) were IDH1/2 wild-type. The 1p/19q codeletion was detected by fluorescence in situ hybridization in 7 (33%) cases and thus these were diagnosed as oligodendroglioma. In 1 diffuse astrocytoma, an IDH1-mutant case, 1p was intact but 19q loss was detected (Online Supplemental Data).

**Scoring for Astrocytic and Oligodendrogial Characteristics**

A representative astrocytic tumor (Fig 2A) showed predominant WM invasion and focal obscuring of the corticomedullary junction (arrow) without displacing medullary vessels and other normal structures on 7T SWI (B). An oligodendroglioma (WHO grade II) with classic perinuclear halos and chicken wire-like vessels (C) shows thickening of the cortex (triangles), elongation not thickening of the medullary vessels of the cortex, and expansive growth, displacing the medullary vessels on 7T-SWI (D). Scoring yielded a significant difference between astrocytomas and oligodendrogliomas (mean −1.93 versus +1.71, P < .001) (E). In a case of anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted, diffuse thickening of the cortex without tapering, thickening of medullary vessels, and microbleeds were observed (F). Scale bars = 50 μm.

DA/AA/GBM indicates diffuse astrocytoma/anaplastic astrocytoma/glioblastoma; OD/AOD, oligodendroglioma/anaplastic oligodendroglioma.

**FIG 1.** Comparison of 7T SWI and 3T MR imaging. Displacement of the corticomedullary junction, seen as a hypointense band (triangles), and elongation of medullary veins running perpendicular to the cortical surface (brackets) can be observed on 7T SWI (spatial resolution, 0.156 × 0.156 × 3 mm; total scan time, 3 minutes and 48 seconds; number of slices, 5) (A), which cannot be appreciated on 3T SWI (0.653 × 0.653 × 2 mm; 4 minutes and 12 seconds; 64 slices) (B). 3T T1-weighted images (C), or 3T FLAIR images (D) obtained on a 3T clinical scanner. Apparent cortical thickening was observed in this diffuse astrocytoma, giving the impression of an oligodendroglioma. However, on close inspection, tapering of the cortex is observed at the edges of the lesion (A, arrows).

**FIG 2.** 7T SWI characteristics of astrocytic and oligodendroglial lesions. Astrocytic lesions (A) were predominantly located in the WM and displayed infiltrative growth and focal obscuring of the corticomedullary junction (arrow) without displacing medullary vessels and other normal structures on 7T SWI (B). An oligodendroglioma (WHO grade II) with classic perinuclear halos and chicken wire-like vessels (C) shows thickening of the cortex (triangles), elongation not thickening of the medullary vessels of the cortex, and expansive growth, displacing the medullary vessels on 7T-SWI (D). Scoring yielded a significant difference between astrocytomas and oligodendrogliomas (mean −1.93 versus +1.71, P < .001) (E). In a case of anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted, diffuse thickening of the cortex without tapering, thickening of medullary vessels, and microbleeds were observed (F). Scale bars = 50 μm.

DA/AA/GBM indicates diffuse astrocytoma/anaplastic astrocytoma/glioblastoma; OD/AOD, oligodendroglioma/anaplastic oligodendroglioma.

**Pathologic Diagnosis**

Demographics, pathologic diagnoses, and molecular profiles of the 21 patients with gliomas are summarized in the Online Supplemental Data. The age of patients ranged from 29 to 81 years (median, 50 years); 10 female patients and 11 male patients were recruited. Tumors in 7 of 21 (33%) patients were pathologically diagnosed as WHO grade IV; 4 (19%), as WHO grade III; and 10 (48%), as grade II. The IDH1 R132H mutation was detected in 12 (57%) tumors; IDH2 R172W, in 1 (5%) tumor; and the rest (38%) were IDH1/2 wild-type. The 1p/19q codeletion was detected by fluorescence in situ hybridization in 7 (33%) cases and thus these were diagnosed as oligodendroglioma. In 1 diffuse astrocytoma, an IDH1-mutant case, 1p was intact but 19q loss was detected (Online Supplemental Data).

**Scoring for Astrocytic and Oligodendrogial Characteristics**

A representative astrocytic tumor (Fig 2A) showed predominant WM invasion without massive cortical involvement and focal disappearance of the corticomedullary junction (arrow). Hypointensities reflecting normal vascular structures were not displaced and/or became less obvious, reflecting the invasive nature of astrocytomas. Oligodendrogliomas (Fig 2C), on the other hand, showed cortical involvement with likely cortical thickening, elongation of cortical medullary vessels, and displacement of vascular structures, evidence of expansive growth (Fig 2D). Scoring for these characteristics yielded a significant difference between astrocytomas and oligodendrogliomas (mean −1.93 [SD, 0.10] versus +1.71 [SD, 0.20], P < .001, Fig 2E).

We next looked at the sensitivity and specificity of each characteristic to diagnose oligodendrogliomas and astrocytomas. Cortical thickening was found in 5 of 7 (71.4%) oligodendrogliomas, whereas only 2 of 14 (14.3%) astrocytomas showed this feature (P < .02). Therefore, observation of cortical thickening yielded a sensitivity of 71.4% and specificity of 85.7% for diagnosing oligodendrogliomas. Likewise, displacement of medullary vessels was found in 4 of 7 (57.1%) oligodendrogliomas but in only 3 of 14 (21.4%) astrocytomas (P = .16), thus yielding a sensitivity of 57.1% and specificity of 78.6% for diagnosing oligodendrogliomas. Finally, observation of tapering of the cortex, suggesting invasion of the tumor from the WM into the cortex, was found in 12 of 14
astrocytomas, but in none of the 7 (0%) oligodendrogliomas (P, .01) that showed diffuse thickening of the cortex. Therefore, this observation yielded a sensitivity of 85.7% and specificity of 100% in diagnosing astrocytomas. In a case of a relatively small cortical-subcortical tumor, elongation of medullary vessels in the cortex and distinct borders were observed, giving the impression of an oligodendroglioma (A). Morphologically, the tumor displayed predominantly oligodendroglioma-like pathology (B). Fluorescence in situ hybridization (FISH) revealed 1p-intact (C), 19q-loss (D). ATRX staining was lost in tumor cells (E), and P53 was immunopositive (>10% positive) (F), suggesting astrocytic lineage. Scale bars = 100 μm. Circles indicate individual tumor cells.

**Diffuse Astrocytoma Displaying Radiographic and Pathologic Features of Oligodendroglioma**

One astrocytoma had radiographic characteristics of cortical thickening without tapering and displacement of medullary vessels, characteristic of oligodendrogliomas (Fig 4A). Hence, the scoring was +3. Close pathologic examination revealed that the tumor itself had predominant, morphologic characteristics of oligodendroglioma (Fig 4B). The 1p/19q analysis revealed 19q loss, but 1p was intact (Fig 4C, -D). Most interesting, ATRX immunostaining was lost (Fig 4E) and P53 staining was positive (Fig 4F) in tumor cells, suggestive of IDH-mutant astrocytoma.

**DISCUSSION**

In the present report, we show, for the first time, that 7T SWI is useful in distinguishing astrocytic and oligodendroglial tumors.
Very fine details such as thickening and displacement of medullary vessels and disruption and displacement of the corticomedullary junction, which are not readily detected by 3T SWI, were observed by 7T MR microscopy. This method was especially useful in the diagnosis of small gliomas located in cortical/subcortical areas. We found that thickening of the cortex and elongation of corticomedullary vessels and displacement of medullary vessels and other normal structures were suggestive of oligodendrogliomas, with a few exceptions. On the other hand, tapering of the cortex and latency of medullary vessels were characteristic of astrocytomas.

**Astrocytomas with Oligodendroglia-like Characteristics**

We found 1 case showing cortical involvement and expansive growth on 7T SWI (Fig 4A) and displaying a predominant oligodendroglia-like morphology (Fig 4B). However, surrogate markers including ATRX loss and P53 immunopositivity suggested astrocytic tumor, and 1p/19q fluorescence in site hybridization indicated that 1p was intact, though 19q was lost. Otani et al.23 reported 7 cases of IDH-mutant and 1p-intact/19q-loss anaplastic astrocytomas, containing areas of oligodendroglia-like morphology with longer survival compared with 19q-intact anaplastic astrocytomas. Radiographic features of these tumors were not mentioned in the report. The presence of such cases that would be diagnosed as IDH-mutant, 1p/19q-noncodeleted astrocytomas but possessing oligodendroglia-like features may confound the radiographic diagnosis of astrocytic-versus-oligodendrogial tumors.

**7T SWI for Determination of Malignant Grade.** Furthermore, we found that detection of microbleeds, thickened medullary vessels, and/or necrosis was suggestive of malignant tumors. Massive necrosis can often be observed by 1.5 or 3T MR imaging, but microbleeds can be difficult to distinguish from blood vessels or small necrosis, and medullary vessels cannot readily be observed even on postcontrast images. Medullary vessels were clearly depicted on 7T SWI without the use of contrast media. Most interesting, all 4 WHO grade II oligodendroglia had a malignancy score of zero, whereas none of the 3 WHO grade III anaplastic oligodendroglia had a malignancy score of zero. Notably, thickening of the medullary vessels was observed in all WHO grade III oligodendroglia, whereas none of the WHO grade II oligodendroglia showed thickening (P < .03). A recent article suggests the difficulty of differentiating WHO grade II and III oligodendroglia by conventional T1 contrast-enhanced and FLAIR images.24 Di Ciantis et al.25 showed that in 6 of 21 (29%) patients with intractable epilepsy with conventional MRIs with unrevealing findings, structural lesions were found by 7T 2D GRE. Further investigation is needed, but 7T SWI may detect vessel changes and small microbleeds not observed on conventional MR imaging.

**Interpreting the Findings on 7T SWI in Gliomas**

In the present report, we found 7T SWI to be useful in distinguishing oligodendroglia and astrocytomas and high susceptibility correlated with malignancy. Susceptibility is most likely affected by venous structures within the tumor, microbleeds, as well as iron and calcium deposition. When one pathologically diagnoses gliomas, not much attention is given to venous structures within the tumor. Detailed assessment of venous structures within gliomas may lead to a better understanding of the intensities found on 7T SWI microscopy.

**Application of 7T SWI in Assessment of Brain Tumors and Other Diseases**

Reports of 7T SWI for radiographic assessment of brain tumors have largely been restricted to small reports.26 An important study by Grabner et al27 showed that local image variance (LIV) or quantification of hypointensities on 7T SWI was higher in 21 high-grade gliomas compared with 9 low-grade gliomas and that significantly higher values were found in IDH1-R132H-negative gliomas compared with IDH1-R132H-positive ones. Evidently, the results of LIV SWI correspond with malignancy scores in the present article, being higher in higher-grade gliomas. Correlation of LIV SWI and IDH mutation can be interpreted as follows: A high percentage of lower-grade gliomas exist in IDH-mutant cases, whereas IDH wild-type gliomas are likely to be glioblastomas. Di Ieva et al.28 reported the usefulness of fact-based quantification as a robust method of assessing signal heterogeneity on 7T SWI to analyze tumor grade in gliomas, in agreement with results of the malignancy score in the present study.

Other 7T SWI reports exist of visualization of vascular anomalies such as cavernous malformations with associated developmental venous anomalies,29,30 radiation-induced microbleeds,31-33 iron deposition in multiple sclerosis lesions,34-36 substantia nigra in Parkinson disease,37 other degenerative diseases,38 and senile plaquelike lesions in patients with Alzheimer disease.14 In the present study, we found that the same postprocessing methods were optimal for visualization of the corticomedullary junction and the small vasculature of gliomas.

**Limitations**

Study limitations include the small sample size, selection bias restricting eligible patients to those demonstrating mild or no symptoms to eliminate motion artifacts during long imaging times, lack of direct comparison between 7T SWI and 3T SWI in this series, the use of a semiquantitative scoring system that requires subjective judgment, difficulty of generalizing to clinical practice because of limited accessibility to 7T scanners, the use of a deliberately tailored protocol using 7T SWI with limited brain coverage, and the unavailability of multiparametric 7T data such as enhancement and diffusion restriction due to time constraints.

**CONCLUSIONS**

Despite recent advances, the preoperative diagnosis of gliomas remains challenging. In the present report, we performed 7T SWI in a series of 21 patients with gliomas and found a close correlation between findings of cortical thickening and displacement of medullary vessels on 7T SWI with oligodendrogliomas, whereas cortical tapering and infiltrative expansion in the WM was found in astrocytomas. Tapering of the cortex was associated with the highest sensitivity and specificity in distinguishing astrocytomas from oligodendrogliomas. Additionally, observations of thickening of medullary vessels, microbleeds, and necrosis were associated with a higher WHO grade. 7T SWI is a useful tool to distinguish
astrogliomas and oligodendrogliomas and to determine malignancy in these tumors.

ACKNOWLEDGMENTS

Professor Tsutomu Nakada died on July 1, 2018, before the acceptance of this manuscript. We acknowledge his many contributions to this research and manuscript including, but not limited to, acquisition of funding, conceptualization of study, optimization of imaging, and study supervision. The authors would also like to acknowledge all those who helped with imaging of patients, Dr Kenichi Yamada for providing 3T SWIs, Mr Hiroaki Saito for clinical 3T SWI, and Mr Shingo Nigorikawa for help with genetic analyses.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


The Value of Preoperative Phase-Contrast MRI in Predicting the Clinical Outcome of Moyamoya Disease after Encephalo-Duro-Arterial Synangiosis Surgery

S. Liu, M. Lu, C. Han, F. Hao, F. Sheng, Y. Liu, L. Zhang, D. Liu, R. Xie, H. Zhang, and J. Cai

ABSTRACT

BACKGROUND AND PURPOSE: In patients with Moyamoya disease, the relationship between preoperative hemodynamic status and prognosis after encephalo-duro-arterial synangiosis (EDAS) surgery was unclear. We aimed to explore the value of the preoperative hemodynamic status acquired by cine phase-contrast MR imaging in predicting collateral formation and clinical outcomes after EDAS surgery in patients with Moyamoya disease.

MATERIALS AND METHODS: Participants with Moyamoya disease were prospectively recruited and underwent preoperative phase-contrast MR imaging. All participants were classified into good and poor groups according to the collateral formation after EDAS surgery. On the basis of the change in the mRS system, participants were classified into the improved mRS group and the poor response group. Hemodynamic status including mean velocity, peak velocity, and blood volume flow of the superficial temporal artery was compared between groups. Logistic regression was performed to relate the phase-contrast MR imaging parameters to collateral formation and clinical outcomes.

RESULTS: A total of 45 patients with Moyamoya disease with unilateral EDAS surgery were finally included. Mean velocity, peak velocity, and blood volume flow of the ipsilateral superficial temporal artery were significantly greater in patients with good collateral formation compared with those with poor collateral formation (P = .011, .004, and .013, respectively). The mean velocity, peak velocity, and blood volume flow were independently associated with postoperative collateral formation after adjusting for confounding factors. Furthermore, the peak velocity of the ipsilateral superficial temporal artery was also significantly associated with improvement of the mRS score.

CONCLUSIONS: Good hemodynamic status of the ipsilateral superficial temporal artery as a donor artery evaluated by phase-contrast MR imaging was significantly associated with better collateral formation and improved mRS after EDAS surgery in patients with Moyamoya disease.

ABBREVIATIONS: BVF = blood volume flow; EDAS = encephalo-duro-arterial synangiosis; MMA = middle meningeal artery; MMD = Moyamoya disease; PC-MRI = phase-contrast MRI; rCBF = relative CBF; rCBV = relative CBV; rTTP = relative TTP; STA = superficial temporal artery; Vmean = mean velocity; Vpeak = peak velocity

Moyamoya disease (MMD) is a type of cerebrovascular disease characterized by progressive stenosis and even occlusive changes in the bilateral terminal part of the ICA and the middle and anterior cerebral arteries. Encephalo-duro-arterial synangiosis (EDAS) is one of the most commonly used indirect surgical procedures. It reroutes a branch of the external carotid artery to the surface of the brain and relies on neovascularization via angiogenic mechanisms from pedicle-based grafts. Generally, the superficial temporal artery (STA) and its branches are the donor arteries. Therefore, identification of information about the STA as a donor artery may be beneficial in the prediction of surgical prognosis.

Please address correspondence to Jianming Cai, MD, Department of Radiology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, 100083, China; e-mail: beil12345@sina.cn

ORIGINAL RESEARCH
ADULT BRAIN

Liu Nov 2022 www.ajnr.org
Previous studies proved that an increased caliber of the STA was associated with good prognosis of EDAS surgery.\textsuperscript{6,7} However, morphologic features of the STA could provide only indirect information. Functional characteristics, in particular the hemodynamic status, might provide more direct information about the role of the STA as the donor artery. To date, the relationship between the preoperative hemodynamic status of the STA and clinical outcome after surgery was unknown.

Phase-contrast MR imaging (PC-MR imaging) is a nonradioactive detection method for quantitatively analyzing the hemodynamic status of targeted vessels. The reliability and reproducibility of PC-MR imaging have been validated by several studies.\textsuperscript{8,9} PC-MR imaging has been performed in patients with MMD in several studies and could provide similar quantitative data of the targeted vessels.\textsuperscript{10-12} Therefore, we hypothesized that the preoperative hemodynamic status of the STA is closely related to the development of collateral vasculature and the change of symptoms after the operation, aiming to explore the relationship between the hemodynamic status of the STA and postoperative outcomes in patients with MMD using PC-MR imaging.

**MATERIALS AND METHODS**

**Study Population**
This prospective study was approved by the institutional review board of Chinese PLA General Hospital. All participants provided written informed consent to participate in the study. From October 2020 to November 2021, consecutive participants who underwent their first EDAS surgery were recruited. Previously, PC-MR imaging examinations were performed in participants within 1 week before the operation. From the 59 participants, 14 were excluded for the following reasons: 1) poor image quality of the postoperative DSA or PC-MR imaging (n = 3); and 2) unavailable postoperative DSA (n = 11). Finally, 45 participants were recruited.

**MR Imaging Examination**
All participants underwent MR imaging examinations using a 3T whole-body MR imaging scanner (Magnetom Skyra; Siemens) with a head-neck coil. All participants were instructed to remain still during the examination.

The parameters of PC-MR images were as follows: TR = 20.36 ms; TE = 2.8 ms; section thickness = 5 mm; number of slices = 20; FOV = 233 × 340 mm; matrix = 176 × 256; flip angle = 20°; number of acquisitions = 3. Reconstructed MIP images of TOF, obtained previously, were used to position the PC-MR imaging sequence. The scan planes were placed where the targeted vessels were straight and perpendicular to the vessels on the basis of the coronal and sagittal projection images. Because the velocity of the vessels varied from one patient to another, prescans were performed to acquire the best velocity-encoding (the brightest sequence without any regurgitation). The prescan velocity-encoding of the STA was 15–45 cm/s.

The parameters of DSC images were as follows: TR = 1360 ms; TE = 30 ms; section thickness = 5 mm; number of slices = 20; FOV read = 229 mm; matrix = 144 × 144; flip angle = 90°; number of acquisitions = 60. Gadolinium contrast medium (Magnevist; Bayer Healthcare Pharmaceuticals) was intravenously injected using a high-pressure injector (Medrad Spectris Solaris EP MR injection system; Bayer Healthcare) at the fifth acquisition (0.2 mL/kg, 4.5–5 mL/s) and followed immediately by a 30-mL physiologic saline flush.

**Surgical Treatment**
There is a standard procedure for the EDAS in our institution that is similar to that described previously in the literature.\textsuperscript{13} Generally, the STA and accompanying cuff of the galea connective tissue were exposed and then covered and sutured onto the surface of brain.

**Angiography**
All participants underwent DSA (Allura Xper FD20 angio system; Philips Healthcare) >3 months after the operation because the development of donor arteries was observed 3 months after indirect surgery.\textsuperscript{14} As selective catheterization and intra-arterial injection of nonionic monomeric iodine contrast medium were performed, anterior-posterior and lateral projection images of the bilateral ICAs, external carotid arteries, and dominant-side vertebral artery were obtained.

**Data Analysis**
**MR Imaging Examination.** Images of PC-MR imaging and DSC were transmitted to the syngo via (Siemens) postprocessing workstation. Hemodynamic information acquired by PC-MR imaging was obtained by drawing ROIs on the phase images, which contained the lumen of the vessel as much as possible without exceeding the vessel contour. To determine the boundary of the STA, the window width of magnitude images could be narrowed and the junction of hyperintensity (signal of blood flow) and isointensity (signal of soft tissue) was the boundary of the STA. Measurements of mean velocity (Vmean), peak velocity (Vpeak), and blood volume flow (BVF) of the bilateral STA were performed and documented by 2 of the authors (H. Zhang and S. Liu), who had >5 years’ experience and were blinded to the clinical symptoms.

DSC data were analyzed by MR perfusion software. Maps of DSC were generated using the local arterial input function mode. ROIs were manually drawn at the lateral MCA territories and cerebellum. The great cerebral vessels and ischemic or hemorrhage lesions were avoided. Relative TTP (rTTP) was calculated by subtracting the value of the MCA territories from the value of the cerebellum. Relative CBF (rCBF) and CBV (rCBV) were calculated by dividing the value of the MCA territories by the value of the cerebellum.\textsuperscript{15}

**DSA Examination.** DSA data were independently evaluated by 2 neuroradiologists (H. Zhang and S. Liu) who were blinded to the radiologic findings. We modified the classification proposed by Matsushima et al.\textsuperscript{16} and collateral formation after surgery was divided into 4 grades, which included grade III, in which the area supplied by the surgical bypass covered more than two-thirds of the MCA distribution; grade II, in which between two-thirds and one-third of the MCA distribution was covered; grade I, in which less than one-third of the cortical branch of the MCA was covered; and grade 0, in which no collateral circulation was covered. Grades II and III were regarded as good collateral formation, and the others were poor collateral formation. In addition, morphologic...
features of the ipsilateral STA, which included straightness of the bilateral STA and location of the bifurcation, were also evaluated. The STA with no more than 3 turns was regarded as straight. The high bifurcation position defined as the STA trunk accounted for more than half of the full length of the STA. Furthermore, the diameters of the bilateral middle meningeal artery (MMA) after EDAS surgery were measured on DSA images.

Clinical Follow-up. On the basis of the mRS system, preoperative and postoperative symptoms of patients were evaluated. Postoperative mRS was evaluated at the time of DSA examination, which were performed at least 3 months after the operation. Participants were assigned to the improved group if their mRS scores improved by at least 1 grade. Patients with no change or worsening of symptoms after EDAS surgery were classified in the poor response group.

Statistical Analysis
Continuous variables were documented as mean (SD). Categoric variables were presented as frequencies. The independent Student t test was used if the continuous data adhered to a normal distribution and variance homogeneity. The Mann-Whitney U test was used if the continuous data adhered to a normal distribution and variance homogeneity. The chi-squared test was used if the continuous data were compared using the chi-squared test. The sensitivity, specificity, and cutoff values were calculated, respectively. Univariate and multivariable logistic regression models were used to calculate the OR and the corresponding 95% CI of PC-MR imaging in discriminating the collateral foundation and mRS. Interreader and intrareader reliability were determined via intraclass correlation coefficients and 95% CIs or k values. Results with P < .05 were regarded as statistically significant. SPSS 23.0 software (Version 23.0; IBM) was used for statistical analysis.

RESULTS
Patient Characteristics
Among the 45 participants (23 women and 22 men; mean age, 33.89 [SD, 18.04] years, 17 had hypertension (38%), 20 had hyperlipidemia (44%), 5 had diabetes (11%), and 1 (2%) had coronary heart disease. Three (7%) participants had a history of smoking, and the posterior cerebral arteries in 6 (13%) participants were involved. The average time interval from EDAS surgery to the postoperative DSA examination was 7.41 (SD, 1.81) months. The number of participants in Suzuki stages I–II, III–IV, and V–VI was 6 (13%), 30 (67%), and 9 (20%), respectively.

On the basis of the neoangiogenesis after revascularization, 23 participants (grade II revascularization, n = 22; grade III, n = 1) were observed to have good collateral formation on DSA during follow-up and 22 (grade 0, n = 3; grade I, n = 19) had poor collateral formation. Preoperative perfusion status including Vmean, rCBF, and rCBV in the ipsilateral hemispheres with good collateral formation was significantly worse than that in those with poor collateral formation (all, P value < .05; Table 1). No statistically significant difference was found in other clinical features between the participants with good and poor collateral formation (Tables 1 and 2; Figs 1 and 2).

Association of Hemodynamic Features of STA and Postoperative Collateral Formation
The Vmean (6.69 [SD, 2.02] cm/s versus 5.30 [SD, 1.41] cm/s, P = .011), mean Vpeak (22.62 [SD, 5.79] cm/s versus 17.00 [SD, 6.62] cm/s, P = .004), and mean BVF (0.70 [SD, 0.32] mL/s versus 0.50 [SD, 0.17] mL/s, P = .013) of the ipsilateral STA in participants with good collateral formation were significantly greater compared with those with poor collateral formation (Table 2 and Fig 3A).

Table 1: Demographic and clinical characteristics

<table>
<thead>
<tr>
<th>Patients with MMD, Mean (SD) or No. (%)</th>
<th>Good Collateral Formation (n = 23)</th>
<th>Poor Collateral Formation (n = 22)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, male</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (yr)</td>
<td>30.87 (SD, 18.36)</td>
<td>37.05 (SD, 17.57)</td>
<td>.256</td>
</tr>
<tr>
<td>Hypertension</td>
<td>8 (35%)</td>
<td>9 (41%)</td>
<td>.672</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>9 (39%)</td>
<td>11 (50%)</td>
<td>.463</td>
</tr>
<tr>
<td>CHD</td>
<td>1 (4%)</td>
<td>0 (0%)</td>
<td>1.000</td>
</tr>
<tr>
<td>Diabetes</td>
<td>3 (13%)</td>
<td>2 (10%)</td>
<td>.001</td>
</tr>
<tr>
<td>Smoking</td>
<td>0 (0%)</td>
<td>3 (14%)</td>
<td>.217</td>
</tr>
<tr>
<td>DSA interval (mo)</td>
<td>7.11 (SD, 1.69)</td>
<td>7.73 (SD, 1.91)</td>
<td>.256</td>
</tr>
<tr>
<td>PCA involvement</td>
<td>4 (77%)</td>
<td>2 (9%)</td>
<td>.704</td>
</tr>
<tr>
<td>Diameter of MMA (mm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ipsilateral</td>
<td>2.49 (SD, 0.51)</td>
<td>2.42 (SD, 0.4)</td>
<td>.674</td>
</tr>
<tr>
<td>Contralateral</td>
<td>2.30 (SD, 0.45)</td>
<td>2.19 (SD, 0.46)</td>
<td>.471</td>
</tr>
<tr>
<td>Preoperative DSC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ipsilateral rTTP (sec)</td>
<td>3.36 (SD, 2.07)</td>
<td>1.40 (SD, 1.57)</td>
<td>.002</td>
</tr>
<tr>
<td>Contralateral rTTP (sec)</td>
<td>1.72 (SD, 2.10)</td>
<td>1.07 (SD, 2.38)</td>
<td>.353</td>
</tr>
<tr>
<td>Ipsilateral CBF (mL/100 g/min)</td>
<td>1.04 (SD, 0.31)</td>
<td>1.31 (SD, 0.44)</td>
<td>.021</td>
</tr>
<tr>
<td>Contralateral CBF (mL/100 g/min)</td>
<td>1.18 (SD, 0.34)</td>
<td>1.24 (SD, 0.31)</td>
<td>.540</td>
</tr>
<tr>
<td>Ipsilateral CBV (mL/100 g)</td>
<td>1.77 (SD, 0.62)</td>
<td>2.23 (SD, 0.65)</td>
<td>.019</td>
</tr>
<tr>
<td>Contralateral CBV (mL/100 g)</td>
<td>1.89 (SD, 0.48)</td>
<td>2.12 (SD, 0.54)</td>
<td>.138</td>
</tr>
<tr>
<td>Suzuki stage</td>
<td></td>
<td></td>
<td>.775</td>
</tr>
<tr>
<td>I–II</td>
<td>4</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>III–IV</td>
<td>13</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>V–VI</td>
<td>6</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

Note: CHD indicates coronary heart disease; DSA interval, interval from surgery to DSA examination; PCA, posterior cerebral artery.
When the $V_{\text{mean}} = 6.020 \text{ cm/s}$ was taken as the cutoff value, the sensitivity and specificity of $V_{\text{mean}}$ in predicting good collateral formation were 0.696 and 0.727, respectively. The sensitivity and specificity of $V_{\text{peak}}$ in predicting good collateral formation were 0.826 and 0.591, respectively, when $V_{\text{peak}} = 18.315 \text{ cm/s}$ was taken as the cutoff value. Moreover, the cutoff value of BVF was 0.585 mL/s with a sensitivity of 0.652 and specificity of 0.818.

Univariate logistic analysis showed that greater $V_{\text{mean}}$ (OR = 1.66; 95% CI, 1.08–2.53; $P = .020$), $V_{\text{peak}}$ (OR = 1.16; 95% CI, 1.04–1.30; $P = .009$), and BVF (OR = 1.04; 95% CI, 1.01–1.07; $P = .024$) of the ipsilateral STA were significantly associated with good collateral formation. Multivariate logistic analysis showed that the association of greater $V_{\text{mean}}$ (OR = 2.28; 95% CI, 1.23–4.25; $P = .009$), $V_{\text{peak}}$ (OR = 1.18; 95% CI, 1.04–
Table 2: Comparison of measurements of the STA between participants with good and poor collateral formation

<table>
<thead>
<tr>
<th>Patients with MMD, Mean (SD) or No. (%)</th>
<th>Good Collateral Formation (n = 23)</th>
<th>Poor Collateral Formation (n = 22)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphologic features of ipsilateral STA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cross-sectional area (mm²)</td>
<td>0.10 (SD, 0.03)</td>
<td>0.09 (SD, 0.02)</td>
<td>.258</td>
</tr>
<tr>
<td>Straightness</td>
<td>11 (48%)</td>
<td>13 (59%)</td>
<td>.449</td>
</tr>
<tr>
<td>High bifurcation position</td>
<td>10 (43%)</td>
<td>10 (46%)</td>
<td>.894</td>
</tr>
<tr>
<td>Morphologic features of contralateral STA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cross-sectional area (mm²)</td>
<td>0.11 (SD, 0.02)</td>
<td>0.12 (SD, 0.04)</td>
<td>.095</td>
</tr>
<tr>
<td>Straightness</td>
<td>12 (52%)</td>
<td>2 (55%)</td>
<td>.873</td>
</tr>
<tr>
<td>High bifurcation position</td>
<td>14 (61%)</td>
<td>9 (41%)</td>
<td>.181</td>
</tr>
<tr>
<td>PC-MR imaging of ipsilateral STA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vmean (cm/s)</td>
<td>6.69 (SD, 2.02)</td>
<td>5.30 (SD, 1.41)</td>
<td>.011</td>
</tr>
<tr>
<td>Vpeak (cm/s)</td>
<td>22.62 (SD, 5.79)</td>
<td>17.00 (SD, 6.62)</td>
<td>.004</td>
</tr>
<tr>
<td>BVF (mL/s)</td>
<td>0.70 (SD, 0.32)</td>
<td>0.50 (SD, 0.17)</td>
<td>.013</td>
</tr>
<tr>
<td>PC-MR imaging of contralateral STA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vmean (cm/s)</td>
<td>7.08 (SD, 2.92)</td>
<td>6.03 (SD, 1.53)</td>
<td>.141</td>
</tr>
<tr>
<td>Vpeak (cm/s)</td>
<td>23.06 (SD, 6.37)</td>
<td>18.75 (SD, 6.07)</td>
<td>.025</td>
</tr>
<tr>
<td>BVF (mL/s)</td>
<td>0.74 (SD, 0.35)</td>
<td>0.61 (SD, 0.26)</td>
<td>.166</td>
</tr>
</tbody>
</table>

Note: Ipsilateral STA indicates superficial temporal artery on the operative side; Contralateral STA, superficial temporal artery on the nonoperative side.

FIG 3. Comparison of PC-MR imaging parameters between patients with good and poor collateral formation (A) and between patients with improved mRS and poor response (B). The asterisk indicates P < .05.

1.34; P = .010), and BVF (OR = 1.73; 95% CI, 1.02–2.94; P = .043) of the ipsilateral STA and good collateral formation remained statistically significant after adjustment of patients’ clinical characteristics (age, sex, hypertension, hyperlipidemia, diabetes, smoking, and the interval from the operation to the latest DSA examination), morphologic features of the ipsilateral STA (cross-sectional area, straightness, and high bifurcation position of STA), preoperative perfusion status (rCBV), and diameter of the ipsilateral MMA after EDAS (Table 3).

Association of Hemodynamic Information and Change of mRS

The mean Vpeak (22.13 [SD, 6.59] cm/s versus 17.30 [SD, 6.13] cm/s, P = .015) of the ipsilateral STA in participants with an improved mRS was significantly greater compared with those with a poor response (Table 4 and Fig 3B).

Univariate logistic analysis showed that greater Vpeak (OR = 1.13; 95% CI, 1.02–1.26; P = .022) of the ipsilateral STA was significantly associated with improved mRS scores. Multivariate logistic analysis showed that the association of greater Vpeak (OR = 1.18; 95% CI, 1.03–1.34; P = .014) of the ipsilateral STA and improved mRS remained statistically significant after adjustment of participants’ clinical characteristics (age, sex, hypertension, hyperlipidemia, diabetes, smoking, and the interval from the operation to latest DSA examination), morphologic features of ipsilateral STA (cross-sectional area, straightness, and high bifurcation position of the STA), preoperative rCBV, and diameter of the ipsilateral MMA.

1586 Liu Nov 2022 www.ajnr.org
**Interaction of Age, Sex, and Preoperative rCBV**

In predicting the collateral formation, no interactive effect was found between age and sex or between age and preoperative rCBV or between sex and preoperative rCBV (Table 5).

**Reproducibility**

κ values for the intrareader agreement in measurement of Vmean, Vpeak, and BVF were 0.83, 0.92 and 0.85, respectively. For interreader agreement, the κ values were 0.80, 0.91, and 0.77 in the measurement of Vmean, Vpeak, and BVF. The intrareader agreement in evaluating collateral formation was 0.82.

**DISCUSSION**

To our knowledge, this is the first study investigating the relationship between the preoperative hemodynamic status of the ipsilateral STA as a donor artery and the postoperative outcomes of patients with MMD using PC-MR imaging. We found that patients with greater Vmean, Vpeak, and BVF of the ipsilateral STA were more likely to have better postoperative collateral formation. Furthermore, Vpeak of the ipsilateral STA was associated with improvement of symptoms. Our results suggest that good hemodynamic status of ipsilateral STA may serve as a predictor of favorable outcome in patients with MMD after EDAS surgery.

The PC-MR imaging technique has been widely used in quantitatively analyzing vascular diseases and evaluating hemodynamic status. The hemodynamic characteristics of intracranial vessels in patients with MMD have been evaluated in previous studies using PC-MR imaging, and most of them explored the hemodynamic change of the anterior and posterior circulation before and after the operation. However, few studies focused on the hemodynamic status of the STA. EDAS, as one of the most commonly used indirect surgical procedures in MMD, mostly adopted STA and its branches as donor arteries. Therefore, the hemodynamic features of the STA before the operation may be more significantly associated with the postoperative outcomes compared with those of the ICA and the posterior cerebral artery. In the present study, we used PC-MR imaging to assess the velocity and BVF of the STA and found an excellent reliability in the measurements of these hemodynamic parameters.

EDAS surgery reroutes branches of the external carotid artery such as the STA to the surface of the brain. With the development of collateral circulation, blood flow is diverted from the external carotid artery to the blood supply area of the ICA. Therefore, abundant blood flow in the STA enables the formation of collateral circulation after EDAS surgery. The mechanism by which the good hemodynamic status of the STA may promote the development of collateral circulation may be as follows: 1) The greater blood volume flow of the STA may provide sufficient blood supply for collateral formation, and 2) the higher flow velocity of the STA may indicate better vasoreactivity and function status as a donor artery, which can enable richer neovascularization after EDAS. In this study, we found that there were no significant differences in the morphologic features of the ipsilateral STA, which included caliber, straightness, and high bifurcation position, between patients with good and poor collateral formation. This finding may be because morphologic information about the STA could not directly reflect the hemodynamic status. Therefore, morphologic features of the ipsilateral STA alone could not be used to predict the prognosis of EDAS surgery.

In the present study, we found that the greater Vmean, Vpeak, and BVF of the ipsilateral STA were significantly associated with good collateral formation after EDAS surgery. The cutoff values of Vmean, Vpeak, and BVF were 6.020 cm/s, 18.315 cm/s, and 0.585 mL/s, respectively. Furthermore, no statistically interactive effect was found among clinical factors (age, sex and preoperative rCBV) in predicting collateral formation. A previous study showed that the blood flow velocity of the STA as the bypass artery could be used to predict the postoperative outcomes in the direct revascularization surgery using sonography. Similar to the conclusion of the sonographic study, we found that good hemodynamic status was also associated with a favorable outcome after EDAS surgery, which is an indirect revascularization surgery mostly using the STA as a donor artery. Thus, we recommend that for patients with MMD, PC-MR imaging could be regarded as a supplementary examination to predict collateral formation after EDAS surgery.

Our results showed that greater Vpeak of the ipsilateral STA closely related to the improved mRS scores after the operation, suggesting that better hemodynamic status of the ipsilateral STA may serve as a predictor of clinical outcomes in patients with MMD. As discussed above, the ipsilateral STA with better hemodynamic status correlated with more abundant collateral circulation formation, which could provide sufficient blood flow. Therefore, this result ameliorated the ischemic status of the hemispheres, and better mRS scores were obtained. In

**Table 3: Association of hemodynamic status of the ipsilateral STA and collateral formation using logistic regression analysis**

<table>
<thead>
<tr>
<th></th>
<th>Univariate Regression</th>
<th>Multivariate Regression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95% CI</td>
</tr>
<tr>
<td>Vmean</td>
<td>1.66</td>
<td>1.08–2.53</td>
</tr>
<tr>
<td>Vpeak</td>
<td>1.16</td>
<td>1.04–1.30</td>
</tr>
<tr>
<td>BVF</td>
<td>1.04</td>
<td>1.01–1.07</td>
</tr>
</tbody>
</table>

Multivariate regression was adjusted for age, sex, hypertension, hyperlipidemia, diabetes, smoking, interval from the operation to the latest DSA examination, cross-sectional area, straightness and high bifurcation position of the STA, preoperative rCBV, and the diameter of the MMA after EDAS.

**Table 4: Comparison of PC-MR imaging of STA between participants with improved mRS and those with poor response**

<table>
<thead>
<tr>
<th>Patients with MMD, Mean (SD) or No. (%)</th>
<th>Improved mRS (n = 24)</th>
<th>Poor Response mRS (n = 21)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC-MR imaging of ipsilateral STA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vmean (cm/s)</td>
<td>6.43 (SD, 1.91)</td>
<td>5.53 (SD, 1.73)</td>
<td>.106</td>
</tr>
<tr>
<td>Vpeak (cm/s)</td>
<td>22.13 (SD, 6.59)</td>
<td>17.30 (SD, 6.13)</td>
<td>.015</td>
</tr>
<tr>
<td>BVF (mL/s)</td>
<td>0.65 (SD, 0.30)</td>
<td>0.55 (SD, 0.24)</td>
<td>.268</td>
</tr>
<tr>
<td>PC-MR imaging of contralateral STA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vmean (cm/s)</td>
<td>6.92 (SD, 2.37)</td>
<td>6.15 (SD, 2.50)</td>
<td>.295</td>
</tr>
<tr>
<td>Vpeak (cm/s)</td>
<td>21.97 (SD, 6.60)</td>
<td>19.79 (SD, 6.22)</td>
<td>.263</td>
</tr>
<tr>
<td>BVF (mL/s)</td>
<td>0.71 (SD, 0.28)</td>
<td>0.64 (SD, 0.34)</td>
<td>.453</td>
</tr>
</tbody>
</table>
addition, Gao et al\textsuperscript{12} found that patients with poor hemodynamic status of the ipsilateral STA were more likely to develop cerebral hyperfusion syndrome, which could result in lower mRS scores. This study had several limitations. First, the sample size of the study is limited, and further investigations with larger sample sizes are warranted. Second, in the present study, 2D-PC-MR imaging was used to assess the hemodynamic features. Recently, 3D-PC-MR imaging has been increasingly used in the evaluation of vascular diseases, which could be more time-saving and provide more information. Third, the present study included only patients with MMD who had undergone unilateral EDAS surgery; therefore, the prognosis of those who underwent bilateral surgery should be further investigated using PC-MR imaging. Fourth, the hemodynamic status of the MMA and the accessory meningeal artery before and after EDAS surgery was not included.

**CONCLUSIONS**

The good hemodynamic status of the ipsilateral STA as a donor artery evaluated by PC-MR imaging was significantly associated with better collateral formation and improved mRS after EDAS surgery in patients with MMD. Our results suggest that PC-MR imaging could provide valuable information on the prediction of clinical outcomes in patients with MMD after EDAS surgery.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

**REFERENCES**

ABSTRACT

BACKGROUND AND PURPOSE: Intracerebral hemorrhage poses a severe threat to the outcomes in patients with postthrombectomy acute stroke. We aimed to compare the absolute intracerebral iodine concentration and normalized iodine concentration ratio in predicting intracerebral hemorrhage in patients postthrombectomy.

MATERIALS AND METHODS: Patients with acute anterior circulation large-vessel occlusion who underwent mechanical thrombectomy and had successful recanalization were retrospectively included in the study. Dual-energy CT was performed within 1 hour after mechanical thrombectomy. Postprocessing was performed to measure the absolute intracerebral iodine concentration and the normalized iodine concentration ratio. The correlation between the absolute intracerebral iodine concentration and the normalized iodine concentration ratio was analyzed using the Spearman rank correlation coefficient. We compared the area under the receiver operating characteristic curve of the absolute intracerebral iodine concentration and the normalized iodine concentration ratio using the DeLong test.

RESULTS: We included 138 patients with successful recanalization. Of 43 patients who did not have parenchymal contrast staining on postthrombectomy dual-energy CT, 5 (11.6%) developed intracerebral hemorrhage. Among patients (95/138, 68.8%) with parenchymal contrast staining, 37 (38.9%, 37/95) developed intracerebral hemorrhage. The absolute intracerebral iodine concentration was significantly correlated with the normalized iodine concentration ratio ($r = 0.807$; 95% CI, 0.718–0.867; $P < .001$). The cutoffs of the normalized iodine concentration ratio and absolute intracerebral iodine concentration for identifying patients with intracerebral hemorrhage development were 222.8%, with a sensitivity of 67.6% and specificity of 76.4%, and 2.7 mg I/mL, with a sensitivity of 75.7% and specificity of 65.5%, respectively. No significant difference was found between the areas under the receiver operating characteristic curve for the absolute intracerebral iodine concentration and the normalized iodine concentration ratio (0.753 versus 0.738; $P = .694$).

CONCLUSIONS: The hemorrhagic transformation predictive power of the normalized iodine concentration ratio is similar to that of the absolute intracerebral iodine concentration in patients with successful recanalization.

ABBREVIATIONS: AIIC = absolute intracerebral iodine concentration; AUC = area under the receiver operating characteristic curve; DECT = dual-energy CT; ICH = intracerebral hemorrhage; IQR = interquartile range; MT = mechanical thrombectomy; NICR = normalized iodine concentration ratio; SSS = superior sagittal sinus

Endovascular mechanical thrombectomy (MT) has become the management choice for acute ischemic anterior circulation large-vessel stroke and is implemented within up to 24 hours after stroke onset. Although advances have been made in patient selection for endovascular recanalization, clinical outcomes vary after thrombectomy. Intracerebral hemorrhage (ICH) poses a severe potential threat to outcomes in patients postthrombectomy.

Hyperattenuation commonly appears on NCCT after the MT procedure. Both iodine contrast agent extravasation and hemorrhage can be seen as high attenuation on NCCT. Differentiating contrast staining from hemorrhage is challenging in conventional single-energy CT. In dual-energy CT (DECT), remarkable progress has been made in material separation through the use of material-specific methods; consequently, it is easy to identify whether such high attenuation is due to hemorrhage or iodine contrast staining. At the same time, DECT parameters can be used to quantify iodine contrast staining. A recent study by Bonatti et al
suggested that quantitative iodine contrast staining plays an essential role in predicting hemorrhagic transformation in patients after MT. Byrne et al.\(^\text{13}\) hypothesized that systematic differences, namely the timing/volume of contrast agent administration, procedural technique, and patient-related factors, might lead to variability in iodine quantification. They used the relative ratio of the maximum iodine concentration in the brain parenchyma to the iodine concentration in the superior sagittal sinus (SSS) on DECT after MT to reduce the variability and improve the prediction of hemorrhagic transformation on follow-up CT.

This study included patients with small infarct cores and good recanalization. It was concluded that compared with the absolute intracerebral iodine concentration (AIIC) measured in the parenchymal hyperattenuating area, the relative ratio of the maximum iodine concentration to the iodine concentration in the SSS (normalized iodine concentration ratio [NICR]) was a better predictor of ICH development than the absolute values.

In our clinical practice, we had observed that a higher AIIC was strongly correlated with late development of ICH in patients postthrombectomy with good reperfusion. Therefore, we aimed to investigate a homogeneous cohort of patients, similar to the study by Byrne et al.\(^\text{13}\) with ASPECTS of \(\geq 7\) and good endovascular reperfusion, to compare the capability of the AIIC and NICR in predicting ICH development in patients postthrombectomy.

**MATERIALS AND METHODS**

**Study Population**

The local institutional research ethics review board approved this retrospective study and waived the need for written consent from patients. From June 2017 to August 2021, consecutive patients who underwent MT for acute anterior circulation large-vessel ischemic stroke were enrolled in this study. The inclusion criteria were as follows: MT performed for anterior circulation large-vessel occlusion within 6 hours. The exclusion criteria included no imaging data or missing imaging data, ASPECTS \(< 6\), unsuccessful endovascular recanalization (TICI score, \(< 2b\)), proximal ICA occlusion, and nonqualified CT image quality (Fig 1).

**Imaging Protocol**

NCCT scans were performed at admission and at the 24- to 8-hour follow-up time point using a single-source CT scanner (Somatom Emotion 16; Siemens). Noncontrast DECT was performed to assess patients within 1 hour after MT in the dual-energy mode (Somatom Definition Force; Siemens). The scanning parameters used in NCCT and noncontrast DECT are shown in Table 1.

**Clinical-Radiologic Data Collection**

We collected the following patient data from our medical database: sex, age, ASPECTS, NIHSS score at admission, site of occlusion, thrombectomy devices, history of hypertension, history of diabetes mellitus, history of atrial fibrillation, number of attempts at aspiration or stent retriever placement, procedural duration, onset time to puncture, thrombolytic therapy, and other treatments during hospitalization. The mRS scores were used to quantify the clinical outcomes 90 days after onset.

---

**Table 1: Scanning parameters of the noncontrast CT and noncontrast DECT**

<table>
<thead>
<tr>
<th></th>
<th>Single-Source CT</th>
<th>Dual-Energy CT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scanner</td>
<td>Somatom Emotion 16</td>
<td>Somatom FORCE</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>Siemens</td>
<td>Siemens</td>
</tr>
<tr>
<td>Scanning mode</td>
<td>Spiral</td>
<td>Spiral</td>
</tr>
<tr>
<td>Scanning direction</td>
<td>Caudal-cranial</td>
<td>Caudal-cranial</td>
</tr>
<tr>
<td>kV(p) (kV)</td>
<td>110</td>
<td>80/Sn 150</td>
</tr>
<tr>
<td>Reference mAs</td>
<td>240</td>
<td>310/207</td>
</tr>
<tr>
<td>Collimation (mm)</td>
<td>16 × 0.6</td>
<td>192 × 0.6</td>
</tr>
<tr>
<td>Section thickness (mm)</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Rotation time (sec)</td>
<td>0.6</td>
<td>1</td>
</tr>
<tr>
<td>Pitch</td>
<td>0.65</td>
<td>0.7</td>
</tr>
<tr>
<td>CARE Dose 4D(^4)</td>
<td>On</td>
<td>On</td>
</tr>
<tr>
<td>Reconstruction (A + B)</td>
<td>H41s medium+</td>
<td>HR40</td>
</tr>
<tr>
<td>Kernel</td>
<td>NA</td>
<td>ADMIRE 2</td>
</tr>
<tr>
<td>Iterative algorithm</td>
<td>NA</td>
<td>ADMIRE 2</td>
</tr>
</tbody>
</table>

Note:—ADMIRE indicates advanced modeled iterative reconstruction; NA, not applicable. \(^4\)Siemens.
Image Analysis

Two neuroradiologists (X.G. and C.M., with >5 years of neuroradiology experience) jointly evaluated the head NCCT and CTA images and recorded ASPECTS and regional leptomeningeal collateral scores at admission.14 Two interventional neuroradiologists (M.P. and H.C., with ≥16 years of interventional neuroradiology experience) performed the thrombectomy procedure and recorded the modified TICI score in each case.

X.G. and C.M. evaluated the DECT images using a commercially available software application (syngo.via, DECT brain hemorrhage application, Version VA30A; Siemens). Simulated 120-kV images (nonlinear blending images), virtual noncontrast images, and iodine overlay maps were generated using a 3-material decomposition algorithm.

Three mutually perpendicular ROIs (0.1–0.3 cm²) were subjectively placed at the site of maximum apparent contrast staining in the axial, coronal, and sagittal images (Fig 2). The iodine concentration was obtained by averaging these 3 values. To normalize the contrast concentration, we placed an ROI on the SSS while the NICR mode was selected. The NICR was calculated as follows: NICR = I_{staining}/I_{ss} × 100%, where I_{staining} and I_{ss} represent the absolute iodine concentrations of the contrast staining and SSS, respectively.13 We used the average of the values recorded by the 2 neuroradiologists in the statistical analysis. Two reviewers analyzed the virtual noncontrast images and iodine overlay maps to distinguish hemorrhage from iodinated contrast extravasation and reached an agreement. High attenuation present on the iodine overlay map that was not present on the virtual noncontrast map was classified as contrast staining. High attenuation on the virtual noncontrast map was classified as hemorrhage. The 2 radiologists jointly analyzed the follow-up CT images, and a consensus was reached on the diagnosis of hemorrhagic transformation. The locations of the contrast staining and hemorrhage were recorded (parenchymal, subarachnoid, or intraventricular). The occurrence of fresh high-attenuation or high-attenuation incongruous with that of postoperative DECT was classified as hemorrhage on the basis of the neurologic status of the patients. According to the European Cooperative Acute Stroke Study classification, the development of hemorrhagic transformation was evaluated in follow-up NCCT images.15 We divided these patients into subgroups on the basis of DECT and follow-up examinations. The present study focused only on the 2 groups with iodine staining with and without ICH. We divided the 2 groups into subgroups (groups with ASPECTS of ≤8 and >8).

Statistics Analysis

Continuous variables were summarized using mean (SD) and median and interquartile range (IQR) as appropriate, after assessing normality using the Shapiro-Wilk test. To compare subgroups, we used a Student t test for continuous variables with normal distribution, the Mann-Whitney U test for continuous variables with non-normal distribution, or the Pearson \( \chi^2 \)/Fisher exact test for categoric data. The intraclass correlation coefficient was calculated to determine the interrater reliability: <0.50, poor; 0.5–0.75, moderate; 0.75–0.90, good; and >0.90, excellent. The Spearman rank

**FIG 3.** A 75-year-old woman with an ASPECTS of 7 on preprocedural CT (A). B, C, and D, Left M2 middle trunk occlusion with modified TICI 3 re-canulization. E, Simulated conventional 120 kV(peak) images show hyperattenuation involving the left basal ganglia and temporal, frontal, and parietal lobes. F, Iodine overlay maps show contrast staining, with the AIC (2.4 mg I/mL) and NICR (151.9%), respectively. G, Virtual noncontrast CT reveals no hemorrhage signs. H, Contrast staining resolved on 36-hour follow-up CT. Her 90-day mRS score was 4.
correlation coefficient was used to analyze the correlation between the AIIC and NICR. We compared the AIIC and NICR parameters in terms of ICH development on follow-up CT. We compared the area under the receiver operating characteristic curve (AUC) of the AIIC and NICR using the DeLong test. Statistical analyses were performed using SPSS 22.0 (Version 22.0; IBM), GraphPad Prism (GraphPad Software), and MedCalc (MedCalc Software). A 2-sided \( P < .05 \) was considered a significant difference.

RESULTS

Patient Population
Among 223 consecutive patients with acute anterior circulation stroke who underwent thrombectomy, 138 were included in our study. The median age was 69 years (IQR, 62–77 years), and 72 patients were male (52.2%).

The mean baseline NIHSS score was 16.8 (SD, 6.8) in patients who met the inclusion criteria. The mean ASPECTS at admission was 9 (IQR, 8–9). Aspiration was performed in 27 patients, and 88 patients were treated with only a stent retriever. Twenty-three patients underwent aspiration followed by stent retriever placement during the thrombectomy procedure. The median number of attempts at aspiration or stent retriever placement was 1 (IQR, 1–2).

Quantitative Analyses
ICH Development. No contrast staining was seen in the initial DECT scan after thrombectomy in 43 of 138 patients (43/138, 31.2%), among these patients, 2 (2/43, 4.7%) developed parenchymal hematoma type 1, as seen on follow-up NCCT at 48 hours. Three patients (3/43, 7.0%) developed hemorrhagic infarction type 1. In all patients (95/138, 68.8%) with intracranial contrast staining, contrast staining was observed only at the brain parenchyma. On the basis of virtual noncontrast images and iodine overlay maps, contrast staining combined with hemorrhage was seen in only 2 patients (2/138, 1.4%). Follow-up NCCT revealed that 2 patients developed parenchymal hematoma type 2. Of the remaining 93 patients with contrast staining, follow-up NCCT showed that 35 patients (35/93, 37.6%) had hemorrhagic transformation (Online Supplemental Data). Figures 3 and 4 illustrate the development of varied outcomes in patients with contrast staining.

Among the 95 patients with contrast staining, patients (37/95, 38.9%) with ICH development had no significant difference in baseline ASPECTS compared with those (58/95, 61.1%) without ICH development (\( P = .348 \)). Patients with ICH development had lower regional leptomeningeal collateral scores (9.4 ± 4.6) than those without ICH development (11.8 [SD, 4.3]; \( P = .01 \)). Apart from the difference in the presence of diabetes mellitus, no significant differences were found in the clinical characteristics of the cohorts, including sex, age, hypertension, atrial fibrillation, baseline NIHSS score, MT duration, time of symptom onset to puncture, platelet count, hypersensitive C-reactive protein level, occlusion site, thrombectomy devices, attempts at aspiration or stent retriever placement, and treatment during
hospitalization ($P = .016$). Table 2 presents the baseline clinical data of the cohorts with and without ICH. Patients with diabetes had a higher incidence of ICH (17/30, 56.7%) than those without diabetes mellitus (20/65, 30.8%) ($P = .016$).

Imaging Analyses. The median AIIc was 2.0 mg I/mL (IQR, 1.7–4.5 mg I/mL; range, 0.4–18.3 mg I/mL) in 58 patients with contrast staining without ICH development and 5.9 mg I/mL (IQR, 2.7–11.4 mg I/mL; range, 1.0–25.2 mg I/mL) in 37 patients who developed ICH, as seen on follow-up images. The 2 groups showed a significant difference ($P < .001$). The median NICR was significantly different between the cohorts: 144.5% (IQR, 105.8%–221.0%) in patients without ICH development versus 330.6% (IQR, 181.8%–703.3%) in patients with ICH development ($P < .001$). Of the 96 patients without ICH development among the total of 138 patients, 30.2% (29/96) had a 90-day mRS score of 4–6, which was significantly different from that in 57.1% of patients (24/42) with ICH development ($P = .003$) (Table 3). The AIIc was significantly correlated with the NICR ($r = 0.807$; 95% CI, 0.718–0.867) (Fig 5). The AUCs of the AIIc and NICR were 0.753 (95% CI, 0.652–0.837; $P < .001$) and 0.738 (95% CI, 0.638–0.823; $P < .001$), respectively, in identifying patients with ICH development. The DeLong test for analyzing the AUCs of the AIIc and NICR showed no significant differences between the subgroups ($Z = 0.394$, 95% CI, −0.006–0.09; $P = .69$). For identifying patients with ICH development, the cutoff NICR was 222.8% with a sensitivity of 67.6% and specificity of 76.4% (likelihood ratio, 2.355), and the cutoff AIIc was 2.7 mg I/mL with a sensitivity of 75.7% and specificity of 65.5% (likelihood ratio, 2.693). There was excellent agreement between the iodine concentrations obtained by the 2 readers. The intraclass correlation coefficient of the AIIc was 0.932 ($P < .001$) and that of the NICR was 0.942 ($P < .001$).

Subgroups Analyses. Of the 95 patients with contrast staining, there were 52 (52/95, 54.7%) patients with AIIcs of ≤8 and 43 (43/95, 45.3%) patients with AIIcs of >8. Among patients with AIIcs of ≤8, twenty-two patients (22/52, 42.3%) developed ICH. No ICH transformation was observed in the remaining 30 patients (30/52, 57.7%). In patients with AIIcs > 8, there were 15 (15/43, 34.9%) patients with ICH development and 28 (28/43, 65.1%) patients without ICH development.

### Table 2: Univariate analysis of patients’ baseline characteristics in cohorts with iodine staining without and with ICH ($n = 95$)

<table>
<thead>
<tr>
<th>Patient Characteristics</th>
<th>No Hemorrhage ($n = 58$)</th>
<th>Hemorrhage ($n = 37$)</th>
<th>$P$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean) (SD) (yr)</td>
<td>68 (12.1)</td>
<td>67.7 (11.6)</td>
<td>.897a</td>
</tr>
<tr>
<td>Male sex (No.) (%)</td>
<td>28 (48.3%)</td>
<td>19 (51.3%)</td>
<td>.770b</td>
</tr>
<tr>
<td>History of hypertension (No.) (%)</td>
<td>28 (48.3%)</td>
<td>18 (48.6%)</td>
<td>.972b</td>
</tr>
<tr>
<td>History of diabetes mellitus (No.) (%)</td>
<td>13 (22.4%)</td>
<td>17 (45.9%)</td>
<td>.016b</td>
</tr>
<tr>
<td>History of atrial fibrillation (No.) (%)</td>
<td>28 (48.3%)</td>
<td>12 (32.4%)</td>
<td>.105b</td>
</tr>
<tr>
<td>MT duration (median) (IQR) (min)</td>
<td>70 (55–95)</td>
<td>60 (46–90)</td>
<td>.310c</td>
</tr>
<tr>
<td>Time of symptom onset to puncture (median) (IQR) (min)</td>
<td>200 (144–315)</td>
<td>230 (178–343)</td>
<td>.369c</td>
</tr>
<tr>
<td>Note: rLMC indicates regional leptomeningeal collateral score; hs-CRP, hypersensitive c-reactive protein.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 3: DECT parameters in groups without and with subsequent ICH

<table>
<thead>
<tr>
<th>DECT Parameters</th>
<th>Follow-up CT</th>
</tr>
</thead>
<tbody>
<tr>
<td>No ICH</td>
<td>ICH</td>
</tr>
<tr>
<td>AIIc (median) (IQR) (mg I/mL)</td>
<td>2.0 (1.7–4.5)</td>
</tr>
<tr>
<td>NICR (median) (IQR) (%)</td>
<td>144.5 (105.8–221.0)</td>
</tr>
<tr>
<td>90-Day mRS (4–6) (%)</td>
<td>30.2 (29/96)</td>
</tr>
</tbody>
</table>

Subgroups Analyses. Of the 95 patients with contrast staining, there were 52 (52/95, 54.7%) patients with AIIcs of ≤8 and 43 (43/95, 45.3%) patients with AIIcs of >8. Among patients with AIIcs of ≤8, twenty-two patients (22/52, 42.3%) developed ICH. No ICH transformation was observed in the remaining 30 patients (30/52, 57.7%). In patients with AIIcs > 8, there were 15 (15/43, 34.9%) patients with ICH development and 28 (28/43, 65.1%) patients without ICH development.

AIIC and NICR were significantly different in patients (AIIcs ≤ 8) without ICH and in those (AIIcs ≤ 8) with ICH ($P = .008$ and $P = .018$, respectively). AIIC and NICR were lower in patients (AIIcs > 8) without ICH than that in patients (AIIcs > 8) with ICH ($P = .005$ and $P = .002$, respectively). No significant differences were found in AIIC and NICR between the subgroups (AIIcs >8 and AIIcs ≤8) without ICH ($P = .17$ and $P = .134$, respectively). The same results were found in AIIC and NICR between the subgroups (AIIcs > 8 and AIIcs ≤ 8) with ICH ($P = .225$ and $P = .28$, respectively) (Online Supplemental Data).
No significant differences were seen in the AIIC and NICR between patients with hemorrhagic infarction type 1 and parenchymal hematoma. The AIIC was higher in patients with parenchymal hematoma type 2 development than in those with hemorrhagic infarction type 1 and parenchymal hematoma type 1 development (Table 4).

DISCUSSION
In this study, we examined patients with small infarct areas at admission who underwent successful MT. Our findings suggest that the AIIC can be used to identify patients with ICH development. Similarly, the NICR could be used to reliably identify patients with hemorrhagic transformation in the same cohort. A significant correlation was observed between the AIIC and NICR ($r = 0.807$; 95% CI, 0.718–0.867; $P < .001$) without a significant difference in the AUCs in identifying patients with ICH development ($P = .69$). Patients who developed ICH, as seen on follow-up CT, had worse long-term outcomes than those without hemorrhagic transformation.

Our study demonstrates the capability of the AIIC in predicting ICH development. In vitro experiments have demonstrated that DECT could be used to quantify the iodine concentration through the iodine-based material decomposition algorithm. Quantitative iodine parameters, including stroke, trauma, metastases, tumors, and perfusion, have been widely used in clinical practice. Bonatti et al examined patients with acute ischemic stroke undergoing MT with DECT and reported an absolute iodine concentration of $>1.35$ mg I/mL in the maximum apparent attenuation area, thereby achieving a sensitivity of 100% and specificity of 67.5% in predicting ICH development. Our study also showed a significant difference in iodine concentration in postprocedural DECT between the 2 groups with and without ICH development, with a cutoff value of $2.7$ mg I/mL. There was only a difference in the cutoff values for the two studies, which could be attributed to the different inclusion criteria between the 2 study samples. Our study included only patients with anterior circulation acute ischemic stroke with smaller infarct cores (ASPECTS $\geq 7$) as well as patients with good recanalization. By contrast, the study by Bonatti et al included all patients with anterior and posterior circulation stroke without the ASPECTS criteria, and 18.8% (16/85) of the patients were unsuccessfully recanalized. These inclusion criteria might result in a difference in the cutoff value for predicting ICH development. Furthermore, the differences in the spectral separation in the scanners potentially played a role in the differences in cutoff values.

According to our study, both the AIIC and NICR could aid in postthrombectomy risk stratification in the case of hemorrhage, differing from the findings of the study by Byrne et al. To minimize the variability related to systematic differences in patients, we introduced the NICR to improve the sensitivity of quantifying the iodine contrast of lesions. Patel et al reported that normalized iodine quantification of the aorta was more helpful in differentiating renal vascular lesions from nonvascular lesions. Byrne et al investigated postprocedural patients with acute ischemic stroke using DECT. They reported that the NICR could be a reliable predictor of hemorrhagic transformation. This study suggested that an NICR cutoff value of $>100\%$ might be a better predictor of ICH development than the AIIC. According to our study results, patients with ICH had a higher NICR than those without hemorrhagic transformation. This result was consistent with that of the study by Byrne et al. However, regarding the difference in the AIIC among the cohorts, our conclusion was completely different from that of the previous study. Our findings indicated a notable difference in the AIIC between the cohorts with and without ICH development. The AIIC calculated in our study had a significant positive correlation with the NICR ($r = 0.807$). This result indicated that both the AIIC and NICR could be used to predict ICH development in risk stratification for postthrombectomy management. Furthermore, patients with parenchymal hematoma type 2 development had a higher AIIC than those with parenchymal hematoma type 1 and hemorrhagic infarction type 1 development, whereas no significant difference was observed in the NICR between the 2 groups.

The DECT examination performed within 1 hour after the procedure made the results relevant to neurologic outcomes. Endovascularly administered iodine contrast media circulated within the body and reached a balanced state of distribution throughout the body before the DECT examination. Ischemic and reperfusion injuries lead to endothelial dysfunction, resulting in iodine extravasation in the tissues of acute ischemic stroke after successful recanalization. This time interval between the iodine contrast injection and DECT examination may make iodine extravasation directly proportional to the severity of the BBB disruption, and
iodine extravasation is not predominantly affected by systemic factors. This hypothesis sheds light on our findings, indicating that both the NICR and AIC are related to the severity of BBB disruption, which results in ICH development after successful reperfusion.

According to the subgroup analyses of this study, the AIC differed significantly between the groups (with the same ASPECTS) with and without ICH but did not differ between subgroups (ASPECTS of ≤8 and >8). Thus, the AIC had a great impact on the development of ICH. The median AIC in patients who did and did not develop ICH in this study (5.9 mg I/mL and 2.0 mg I/mL) was higher than that in the study by Byrne et al53 (1.2 mg/mL and 0.9 mg/mL), though similar patient inclusion criteria were applied (patients with baseline ASPECTS ≥ 7 and modified TICI scores of 2b or 3 after the procedure). Potential reasons may be the larger patient cohort examined in this study, different populations, and differences in spectral separation in the scanners. The use of 3 mutually perpendicular plane images to measure the AIC in this study may have had the advantage of reducing the measurement bias.

The 90-day mRS scores of 4–6 were observed to be significantly different between patients with and without ICH development. This result was consistent with those of previous studies,24,25 indicating that hemorrhagic transformation seriously threatens the patients’ neurologic outcomes. Therefore, early identification of patients with a high risk of hemorrhagic transformation is essential for improving the prognosis of patients undergoing successful thrombectomy. Our study also found that the collateral status was significantly worse in patients with ICH than in those without ICH, similar to the results of previous studies.26

Our study has a few limitations. First, the sample size was small owing to the strict inclusion and exclusion criteria, leading to a potential source of bias. A multicenter study with a large sample size is needed to improve the level and quality of evidence. Additionally, ROIs were drawn subjectively within the areas of maximum apparent contrast staining, which might have resulted in measurement errors. However, averaging the values calculated from the 3 planes can resolve this issue. A high concordance was achieved among the readers. Finally, a follow-up examination was performed using NCCT within 48 hours. Contrast staining usually resolves within 24 hours after endovascular therapy.27 Unfortunately, persistent contrast staining may be seen beyond 48 hours in some cases.28 Follow-up DECT should be performed to avoid classifying persistent contrast staining as hemorrhagic transformation.

CONCLUSIONS

We examined DECT quantitative parameters as imaging markers for identifying patients with acute ischemic stroke with hemorrhagic transformation after successful recanalization. The power of the NICR in predicting hemorrhagic transformation was similar to that of the AIC. Quantitative DECT parameters within 1 hour after successful MT may also help predict poor outcomes in patients. After successful MT, early risk stratification for ICH development can facilitate informed clinical decision-making and aid in predicting prognosis.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


Diagnostic Performance of Whole-Body Ultra-Low-Dose CT for Detection of Mechanical Ventriculoperitoneal Shunt Complications: A Retrospective Analysis


ABSTRACT

BACKGROUND AND PURPOSE: Radiographic shunt series are still the imaging technique of choice for radiologic evaluation of VP-shunt complications. Radiographic shunt series are associated with high radiation exposure and have a low diagnostic performance. Our aim was to investigate the diagnostic performance of whole-body ultra-low-dose CT for detecting mechanical ventriculoperitoneal shunt complications.

MATERIALS AND METHODS: This retrospective study included 186 patients (mean age, 54.8 years) who underwent whole-body ultra-low-dose CT (100 kV[peak]; reference, 10 mAs). Two radiologists reviewed the images for the presence of ventriculoperitoneal shunt complications, image quality, and diagnostic confidence. On a 5-point Likert scale, readers scored image quality and diagnostic confidence (1 = very low, 5 = very high). Sensitivity, specificity, positive predictive value, and negative predictive value were calculated. Radiation dose estimation of whole-body ultra-low-dose CT was calculated and compared with the radiation dose of a radiographic shunt series.

RESULTS: 34 patients positive for VP-shunt complications were correctly identified on whole-body ultra-low-dose CT by both readers. No false-positive or -negative cases were recorded by any of the readers, yielding a sensitivity of 100% (95% CI, 87.3%–100%), a specificity of 100% (95% CI, 96.9%–100%), and perfect agreement (κ = 1). Positive and negative predictive values were high at 100%. Shunt-specific image quality and diagnostic confidence were very high (median score, 5; range, 5–5). Interobserver agreement was substantial for image quality (κ = 0.73) and diagnostic confidence (κ = 0.78). The mean radiation dose of whole-body ultra-low-dose CT was significantly lower than the radiation dose of a conventional radiographic shunt series (0.67 [SD, 0.4] mSv versus 1.57 [SD, 0.6] mSv; 95% CI, 0.79–1.0 mSv; P < .001).

CONCLUSIONS: Whole-body ultra-low-dose CT allows detection of ventriculoperitoneal shunt complications with excellent diagnostic accuracy and diagnostic confidence. With concomitant radiation dose reduction on contemporary CT scanners, whole-body ultra-low-dose CT should be considered an alternative to the radiographic shunt series.

ABBREVIATIONS: IQR = interquartile range; VP-shunt = ventriculoperitoneal shunt; WB-ULD-CT = whole-body ultra-low-dose CT

Hydrocephalus is a common, surgically treatable disorder, defined as a pathologic accumulation of CSF resulting in a serious expansion of the brain ventricles. Ventriculoperitoneal shunt (VP-shunt) is an effective treatment for hydrocephalus. VP-shunts drain the excess CSF into the peritoneum, where it can be absorbed. However, VP-shunts have a high complication rate of 20%–40% within the first year of placement. The clinical symptoms of VP-shunt complications can vary and are often not specific. Errors in diagnosis can have serious consequences for patients. Thus, imaging is the primary method to detect VP-shunt complications.

Radiographic shunt series are still the imaging technique of choice for radiologic evaluation of VP-shunt complications. Shunt series cover the whole course of VP-shunts from the head to abdomen and usually consist of frontal skull, lateral skull, frontal chest, frontal abdomen, and lateral abdomen radiographs. However, recent studies on the diagnostic performance of radiographic shunt series reported remarkably low sensitivities (between 8.3% and 31%)
to detect mechanical VP-shunt complications. Radiographic shunt series often do not provide precise information about the abdominal catheter position. This leads to repeat x-ray examinations or even an additional (full-dose) CT. Furthermore, radiographic shunt series are associated with high radiation exposure. Due to the low sensitivity and high radiation exposure, better imaging alternatives are necessary. CT is usually associated with considerably higher radiation doses than radiographs. However, the radiation dose of CT protocols can be adapted to the clinical question. For example, in case of VP-shunts, the radiation dose can be remarkably reduced while the hyperdense shunt catheters can easily be visualized despite high image noise. Recent animal studies have shown that whole-body ultra-low-dose CT (WB-ULD-CT) with radiation doses lower than those in the radiographic shunt series visualizes the VP-shunt properly and enables detection of VP-shunt complications with higher accuracy than radiographic images.

Nonetheless, human studies are necessary to evaluate these promising findings. On the basis of experimental findings, ULD-CT protocols for VP-shunt imaging have been implemented into the clinical routine at various centers. Pala et al compared WB-ULD-CT with radiography and showed that ULD-CT allows significantly better visualization of the distal catheter using a lower radiation dose than a radiographic shunt series. We hypothesize that WB-ULD-CT for assessment of VP-shunt complications in humans is feasible and can be attained with high diagnostic accuracy and lower radiation doses than a radiographic shunt series. In the present study, we aimed to evaluate the diagnostic accuracy of WB-ULD-CT, focusing on the detection of mechanical VP-shunt malfunctions with an even lower radiation dose.

**MATERIALS AND METHODS**

Our local institutional ethics committee of the University of Aachen, Germany, approved this retrospective study and waived informed patient consent (registration number: EK 219/19).

**Study Population**

As a consequence of encouraging animal model results, we replaced the conventional radiographic shunt series with WB-ULD-CT for VP-shunt imaging in our institution by June 2016. As in many neurosurgical departments, VP-shunt imaging is performed routinely within 24 hours after implantation to ensure and precisely document the correct placement and verify the postprocedural course of the VP-shunt catheter. VP-shunt imaging is also performed when complications are suspected.

The inclusion period of this retrospective analysis was between June 2016 and November 2018. A total of 222 patients with VP-shunts underwent WB-ULD-CT during the inclusion period. The inclusion criteria for our study were the following: 1) 18 years of age or older, 2) WB-ULD-CT (within 24 hours after implantation of a VP-shunt or when VP-shunt failure was suspected), 3) VP-shunt, 4) complete clinical evaluation of the VP-shunt (including operative assessment if necessary), and 5) men and nonpregnant women. Patients with incomplete imaging of the course of the VP-shunt were excluded. The final sample size consisted of 186 patients; a Standards for Reporting of Diagnostic Accuracy flow chart of patient inclusion is shown in Fig 1.

Age, sex, etiology of hydrocephalus, history of a previous VP-shunt complication, the presence of symptoms, and operative/clinical results were recorded.

**Imaging Technique and CT Image Reconstruction**

All patients underwent WB-ULD-CT on a 40-section CT scanner (Somatom Definition AS; Siemens). The x-ray tube was operated at a tube voltage of 100 kV(peak) and a reference tube current of 10 mAs (collimation = 40 × 0.6 mm, pitch = 1.5). Automatic attenuation-based tube-current modulation (CARE Dose4D; Siemens) was activated. All reconstructions were acquired using a kernel (B45) with 5-mm (3-mm increment) section thickness and 1-mm (1-mm increment) in the axial, coronal, and sagittal planes. Images were generated using iterative reconstruction (Sinogram Affirmed Iterative Reconstruction Strength 3).

Moreover, 3D reconstructions using a volume-rendering technique were created.

**Reference Standard**

A neurosurgeon (H.A.H.) with 10 years of experience evaluated all patients’ clinical data, including symptoms, clinical examinations, intraoperative findings, and recorded readmissions and VP-shunt revisions for a 3-month period after WB-ULD-CT imaging. Patients were classified as negative when clinical and operative work-up revealed no VP-shunt complications and
when no VP-shunt-related readmissions were recorded within the 3-month period after imaging. Patients were classified as positive when mechanical VP-shunt complications were identified in the clinical examination and intraoperatively.

**Image Evaluation**

Image evaluation was performed on a standard PACS workstation. After the definition of the reference standard, 2 radiologists (A.E.O. with 8 years of experience; S.A. with 6 years of experience) who were blinded to all clinical data, independently evaluated WB-ULD-CT reconstructions regarding shunt-specific overall image quality and diagnostic confidence using 5-point Likert scales (1, very low; 5, excellent). The same readers assessed the WB-ULD-CT images regarding the presence/absence and type of mechanical shunt complication.

**Radiation Dose Estimation**

The dose-length product was obtained and used to estimate the effective radiation dose for all patients. The effective dose was estimated by multiplying the dose-length product by 0.015 mSv × mGy⁻¹ × cm⁻¹ (conversion factor). The same readers assessed the WB-ULD-CT images regarding the presence/absence and type of mechanical shunt complication.

**Statistical Analysis**

Statistical analyses were performed using SPSS Statistics for Windows 25 (IBM). The mean accounted effective dose for WB-ULD-CT was then compared with the reported cumulative radiation exposure by Shuaib et al of 1.57 (SD, 0.6) mSv per shunt series by calculating the difference between the 2 means, the significance value (P value), and the 95% CI. The Cohen κ coefficient was calculated for interrater agreement. A P value was considered significant at P < .05.
RESULTS

Patient Characteristics
The study cohort consisted of 186 patients (mean age, 54.8 years; range, 18–88 years), including 85 men (45.7%; mean age, 58.5 years; range, 19–87 years) and 101 women (54.3%; mean age, 51.6 years; range, 18–88 years); 54.8% of the WB-ULD-CT studies were within 24 hours after implantation of a new VP-shunt; and 45.2% of the WB-ULD-CT studies were performed when shunt failure was suspected. Further patient characteristics are given in Table 1.

Diagnostic Evaluation
Of the 186 patients, 152 patients (81.7%) were negative for mechanical complications. Thirty-four patients (18.3%) had VP-shunt complications. Seven patients (3.8%) had a breakage/disconnection of the subcutaneous shunt catheter, 1 patient had an abdominal pseudocyst (0.5%) (Fig 2) at the tip of the catheter, 2 patients (1.1%) had kinking of the catheter (Fig 3), and 24 patients (12.9%) (Fig 4) had a dislocation of the distal/peritoneal VP-shunt catheter (Table 2).

Both readers detected all 34 complications (18.3%) of 186 patients with a perfect agreement ($\kappa = 1$). There were no patients with false-negative or false-positive findings, resulting in a sensitivity of 100% (95% CI, 87.3%–100%) and a specificity of 100% (95% CI, 96.9%–100%). WB-ULD-CT showed a high positive predictive value of 100% (95% CI, 87.3%–100%) and a high negative predictive value of 100% (95% CI, 96.9%–100%).

Overall Image Quality and Diagnostic Confidence
The overall shunt-specific image quality was rated very high by both readers, with a mean score of 5 (IQR, 25%–75%; range, 5–5) and substantial interrater agreement ($\kappa \geq 0.73$). The diagnostic confidence of both readers was rated very high with a median score of 5 (IQR, 25%–75%; range, 5–5), and a substantial interrater agreement ($\kappa \geq 0.78$).

Radiation Dose Estimation
The mean dose-length product of WB-ULD-CTs was 45.04 (SD, 26.91) mGy × cm.

FIG 3. A 33-year-old woman presented with progressive headache, nausea, and vomiting, indicating a shunt dysfunction. Several shunt revisions were needed during infancy. The 3D reconstruction of the current WD-ULD-CT (right) depicts kinking of the shunt tube at the right clavicle (white arrow) as well as a short distal catheter in relation to an adult body size. However, the distal catheter passed through the peritoneum (transparent arrows on axial and coronal reconstructions on the left) and ends intraperitoneally.

FIG 4. A 26-year-old woman with obesity (body mass index, 35.3 kg/m²) with idiopathic intracranial hypertension received a VP-shunt after the failure of conservative therapy. After the implantation of a VP-shunt, the correct intraperitoneal position of the distal catheter was verified by WB-ULD-CT. Two weeks later she was admitted due to progressive abdominal pain. WB-ULD-CT (lateral view on 3D reconstruction on the left and axial reconstruction on the right) shows an extraperitoneal shunt dislocation.
mechanical complications (sensitivity poor sensitivity of a radiographic shunt series for the detection of on a radiographic shunt series, is easy to detect on CT images. Especially, extraperitoneal dislocation, which can easily be missed went WB-ULD-CT.

detection of mechanical VP-shunt complications, and this study is mostly confirmed on the basis of the combination of imaging find-
diagnostics. In daily practice, suspicion of VP-shunt complications is patients with suspected VP-shunt complications or in postprocedural

DISCUSSION

Imaging plays an essential role in the clinical work-up of adult patients with suspected VP-shunt complications or in postprocedural diagnostics. In daily practice, suspicion of VP-shunt complications is mostly confirmed on the basis of the combination of imaging find-
gings and clinical work-up. In the present work, we evaluated radiation exposure and diagnostic performance of WB-ULD-CT for the detection of mechanical VP-shunt complications, and this study is currently the largest cohort of patients with VP-shunts who under-
went WB-ULD-CT.

Our findings indicate that WB-ULD-CT has a high diagnostic accuracy for the detection of mechanical VP-shunt complications with a lower radiation dose than in radiographic shunt series.

Despite the restricted radiation dose of WB-ULD-CT, VP-shunt catheters could be appropriately visualized with sufficient image quality and diagnostic confidence. The readers were able to detect all 34 VP-shunt complications correctly without producing false-positive or false-negative findings.

Other studies, such as the one by Lehnert et al,12 showed a poor sensitivity of a radiographic shunt series for the detection of mechanical complications (sensitivity = 4%), which resulted in no significant impact on patient outcome regarding surgical shunt revision (OR, 0.9; 95% CI, 0.7–1.2; P = .74). A further study also reported the poor sensitivity of a radiographic shunt series for the detection of VP-shunt complications (sensitivity = 31%).11

On the other hand, animal studies have shown that WB-
ULD-CT is remarkably superior to a radiographic shunt series as the new criterion standard.

The observed high diagnostic accuracy of WB-ULD-CT for the detection of VP-shunt complications in our study emphasizes the potential role of WB-ULD-CT as an alternative to plain radiographs for VP-shunt imaging.

In a retrospective study by Pala et al,18 the low-dose CT had a lower radiation exposure than the x-ray series. However, the mean radiation exposure was higher than in our study (0.67 mSv versus 1.9 mSv). Also, another strength of our study is the size of the cohort, which is larger than the cohort of Pala et al.

We believe that WB-ULD-CT is more applicable for routine clinical practice because it is a time-saving, one-stop-shop method with high diagnostic accuracy and a reduced radiation dose compared with a radiographic series.14 Patients are not repositioned several times as is the case with x-ray examinations when several regions of the body must be examined. Instead, they are placed on the CT table only once, and the examination is performed from the entire shunt course. This approach is of great importance, especially postoperatively or in patients requiring intensive care.

We believe that the radiation dose could even be further reduced and image quality improved by using new technologies like advanced new iterative reconstruction, new filtering techniques, dual-energy CT, modern radiography hardware, and artificial intelligence–based reconstruction techniques.23–24

The retrospective single-center design of this study is a limitation. A multicenter approach with a larger cohort is required to reconfirm the results of our study. Due to the retrospective nature of the study, it was not possible to perform an interpatient comparison of performance and radiation dose between WB-ULD-CT and a conventional radiographic shunt series.

CONCLUSIONS

Our retrospective study indicates that WB-ULD-CT yields a high diagnostic accuracy for the detection of VP-shunt complications. Therefore, we believe that WB-ULD-CT is the first stage in the further development of the WB-ULD-CT protocol to replace radiologic shunt series as the new criterion standard.

Ethics Approval

Institutional Review Board approval was obtained from the University of Aachen before the initiation of this study.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org

REFERENCES

1. Little AS, Zabramski JM, Peterson M, et al. Ventriculoperitoneal shunt-
ning after aneurysmal subarachnoid hemorrhage: analysis of the indi-
ations, complications, and outcome with a focus on patients with border-
618–27 CrossRef Medline
placement for hydrocephalus with clipping versus coiling for ruptured
and unruptured cerebral aneurysms in the Nationwide Inpatient
CrossRef Medline


Table 2: Overview of detected shunt complications in WB-LD-CT by 2 readers (A.E.O. and S.A.)

<table>
<thead>
<tr>
<th>Complication Type</th>
<th>Reader A</th>
<th>Reader B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disconnection</td>
<td>7/7 (100%)</td>
<td>7/7 (100%)</td>
</tr>
<tr>
<td>Dislocation</td>
<td>24/24 (100%)</td>
<td>24/24 (100%)</td>
</tr>
<tr>
<td>Kinking</td>
<td>2/2 (100%)</td>
<td>2/2 (100%)</td>
</tr>
<tr>
<td>Pseudocyst</td>
<td>1/1 (100%)</td>
<td>1/1 (100%)</td>
</tr>
<tr>
<td>Total</td>
<td>34/34 (100%)</td>
<td>34/34 (100%)</td>
</tr>
</tbody>
</table>


Schizencephaly in Hereditary Hemorrhagic Telangiectasia

J.J. Gaines, B.C. Gilbert, J.R. Gossage, W. Parker, A. Reddy, and S.E. Forseen

ABSTRACT

BACKGROUND AND PURPOSE: The presence of malformations of cortical development in patients with hereditary hemorrhagic telangiectasia has been reported on previous occasions. We evaluated a sample of adults with hereditary hemorrhagic telangiectasia for the presence of malformations of cortical development, spatial coincidence of malformations of cortical development and AVMs, and the coincidence of brain and pulmonary AVMs.

MATERIALS AND METHODS: A total of 141 patients 18 years of age or older who were referred to the Augusta University hereditary hemorrhagic telangiectasia clinic and underwent brain MR imaging between January 19, 2018, and December 3, 2020, were identified. MR imaging examinations were reviewed retrospectively by 2 experienced neuroradiologists, and the presence of malformations of cortical development and AVMs was confirmed by consensus. Demographic and clinical information was collected for each case, including age, sex, hereditary hemorrhagic telangiectasia status by the Curacao Criteria, mutation type, presence of malformations of cortical development, presence of brain AVMs, presence of pulmonary AVMs, and a history of seizures or learning disabilities.

RESULTS: Five of 141 (3.5%) patients with hereditary hemorrhagic telangiectasia had malformations of cortical development. Two of the 5 patients with polymicrogyria also had closed-lip schizencephaly. One of the patients had a porencephalic cavity partially lined with heterotopic GM. The incidence of spatially coincident polymicrogyria and brain AVMs was 40% (2/5 cases). Of the patients with hereditary hemorrhagic telangiectasia and malformations of cortical development, 4/5 (80%) had pulmonary AVMs and 2/5 (40%) had brain AVMs.

CONCLUSIONS: To our knowledge, we are the first group to report the presence of schizencephaly in patients with hereditary hemorrhagic telangiectasia. The presence of schizencephaly and porencephaly lends support to the hypothesis of regional in utero cerebral hypoxic events as the etiology of malformations of cortical development in hereditary hemorrhagic telangiectasia.

ABBREVIATIONS: HHT = hereditary hemorrhagic telangiectasia; MCD = malformation of cortical development
migration, and postmigrational cortical organization, caused by environmental or genetic factors, can result in MCDs. The exact mechanisms of MCD formation are largely unknown. The clinical presentation of MCDs is highly variable and ranges from asymptomatic to intellectual disabilities and epilepsy. Pathologic findings are equally heterogeneous and may include excessive cortical folding, abnormal cell arrangement, and fusion of gyral surfaces.

The presence of MCDs in patients with HHT has been reported on 3 previous occasions, once in a pediatric sample and twice in adult samples. The prevalence of MCDs in HHT in these studies ranged between 5% and 12%. To date, nearly all of the MCDs reported in patients with HHT have been poligmicrogyrias. Unlike poligmicrogyrias in general, polymicrogyrias in patients with HHT are largely unilateral, more focal, and rarely associated with symptoms.

Klostranec et al reported a sample of patients with HHT with MCDs that were spatially coincident with AVMs and proposed a mechanism by which endoglin impairment leads to regional hypoperfusion which, in turn, leads to impairment in neuronal migration and cortical organization. Palagallo et al reported spatially coincident MCDs and AVMs in one-quarter of their sample. They also found that patients with HHT and MCDs were statistically more likely to have pulmonary and brain AVMs than patients with HHT without MCDs.

In the current study, we evaluated a sample of adults with HHT for the presence of MCDs, spatial coincidence of MCDs and AVMs, and the coincidence of brain and pulmonary AVMs.

**MATERIALS AND METHODS**

Consent requirements were waived by the internal review board for this retrospective chart review study. A total of 141 patients 18 years of age or older who were referred to the Augusta University HHT clinic and who underwent brain MR imaging between January 19, 2018, and December 3, 2020, were identified. All MR imaging examinations were performed using a 3T field strength and included pre- and postcontrast 3D T1-weighted FSPGR images. MR imaging examinations were reviewed retrospectively by 2 board-certified radiologists who hold Certificates of Added Qualification in Neuroradiology (B.C.G. and S.E.F.) with 7 and 10 years of experience, respectively.

The presence of MCDs and AVMs was confirmed by consensus. MCDs were defined in accordance with Severino et al. AVMs were defined as a network of dilated vessels (ie, nidus) with dilated feeding arteries and dilated draining veins. The Curacao Criteria were used to diagnose HHT and included the following: 1) spontaneous and recurrent epistaxis, 2) mucocutaneous telangiectasias, 3) visceral AVMs, and 4) HHT diagnosis in a first-degree relative. The diagnosis of HHT was considered "definite" if 3 or 4 of these criteria were met, "possible" if 2 criteria were met, and "unlikely" if <2 criteria were met.

Demographic and clinical information was collected from the medical record for each case, including age, sex, HHT status by the Curacao Criteria, mutation type, presence of MCDs, presence of brain AVMs, presence of pulmonary AVMs (including the presence of macroscopic pulmonary AVMs or a delayed right-to-left shunt on contrast echocardiography), and a history of seizures or learning disabilities.

**Summary of 141 patients**

<table>
<thead>
<tr>
<th>Summary</th>
<th>Demographics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>36.9%</td>
</tr>
<tr>
<td>Male</td>
<td>63.1%</td>
</tr>
<tr>
<td>Age (mean) (yr)</td>
<td>45.3</td>
</tr>
<tr>
<td>MCD</td>
<td>5</td>
</tr>
<tr>
<td>Yes</td>
<td>136</td>
</tr>
<tr>
<td>HHT mutation</td>
<td>35.4%</td>
</tr>
<tr>
<td>Endoglin</td>
<td>27.7%</td>
</tr>
<tr>
<td>SMAD4*</td>
<td>2.8%</td>
</tr>
<tr>
<td>RASA1</td>
<td>0.7%</td>
</tr>
<tr>
<td>Negative x 5</td>
<td>15.6%</td>
</tr>
<tr>
<td>Unknown/not tested</td>
<td>17.7%</td>
</tr>
<tr>
<td>AVMs</td>
<td>12.0%</td>
</tr>
<tr>
<td>Brain AVM</td>
<td>2.8%</td>
</tr>
<tr>
<td>Brain AVM (possible)</td>
<td>43.3%</td>
</tr>
<tr>
<td>Pulmonary AVM (microscopic)b</td>
<td>32.6%</td>
</tr>
<tr>
<td>Spinal AVM</td>
<td>0.7%</td>
</tr>
<tr>
<td>Brain vascular malformations</td>
<td>14.9%</td>
</tr>
<tr>
<td>Developmental venous anomaly</td>
<td>14.9%</td>
</tr>
<tr>
<td>Capillary vascular malformation, definite</td>
<td>4.3%</td>
</tr>
<tr>
<td>Curacao category</td>
<td>79.4%</td>
</tr>
<tr>
<td>Definite HHT</td>
<td>12.1%</td>
</tr>
<tr>
<td>Possible or suspected HHT</td>
<td>4.3%</td>
</tr>
<tr>
<td>Probable</td>
<td>4.3%</td>
</tr>
</tbody>
</table>

*aALK1 includes 2 variants of unknown significance; SMAD4 includes 1 variant of unknown significance.

*bPulmonary AVMs were defined as macroscopic if they were definitely visible on a CT scan and microscopic if contrast echocardiography showed a Grade 1 or greater delayed shunt and the CT findings were negative.

**FIG 1.** A 26-year-old woman with HHT. Sagittal 3D fast-spoiled gradient recalled imaging demonstrates poligmicrogyria involving the right posterior cingulate gyrus (A, yellow arrow). There is an abnormal GM-lined cleft between the calcarine sulcus and the occipital horn of the right lateral ventricle consistent with schizencephaly (A, red arrow). Coronal T1 image shows poligmicrogyria (B, yellow arrow) and schizencephaly (B, red arrow).
RESULTS

Patient demographic data are summarized in the Table. Five of 141 (3.5%) patients with HHT had MCDs. Of the 5 patients with HHT with MCDs, all 5 had polymicrogyria. All 4 patients with HHTs with polymicrogyria in whom testing was performed had endoglin mutations. Two of the 5 patients with polymicrogyria also had CSF-containing clefts lined with polymicrogyria (ie, schizencephaly), both of which were of the closed-lip variety (Figs 1 and 2). One of the patients had a porencephalic cavity partially lined with heterotopic GM (Fig 3). The other 2 cases of polymicrogyria included an 18-year-old man (Fig 4) and a 28-year-old man (Fig 5).

The incidence of spatially coincident polymicrogyria and brain AVMs in this sample was 40% (2/5 cases; Figs 3 and 4). Neither of the patients with schizencephaly had a spatially coincident brain AVM. Of the patients with HHT and MCDs, 4/5 (80%) had pulmonary AVMs and 2/5 (40%) had brain AVMs. Summary data for patients with HHT and polymicrogyria are seen in the Online Supplemental Data.

Patients with MCDs were not more likely to have coincident brain AVMs than patients without MCDs. Two of 5 (40%) patients with MCDs had brain AVMs, compared with 17/136 (13%) patients without MCDs (P = .11). Patients with MCDs were not more likely to have coincident pulmonary AVMs than patients without MCDs. Four of 5 (80%) patients with MCDs had pulmonary AVMs versus 103/136 (76%) patients without MCDs (P = 1.0).

Three of the patients with MCDs reported a history of migraine headaches. Two of the patients with MCDs were asymptomatic. One of the patients with polymicrogyria reported right-handed contracture and weakness. Both patients with schizencephaly reported a history of migraine headaches. None of the patients with MCDs had a history of seizures or learning disabilities.

DISCUSSION

Five of 141 (3.5%) patients in our sample of patients with HHT had MCDs, in the general range of prevalence observed by other authors examining adult patients with HHT. Polymicrogyria was present in all 5 of these patients. A novel finding in our sample was the presence of 2 patients with schizencephaly. To our knowledge, we are the first group to report the presence of schizencephaly in patients with HHT. The clefts were unilateral, lined with polymicrogyria, and closed-lip in morphology. Both patients with schizencephaly had a history of migraine headaches. Neither of these patients had a history of seizures or cognitive disabilities. Schizencephaly is now added to the growing list of MCDs reported in HHT, including polymicrogyria, nodular GM heterotopia, and focal cortical dysplasia.
Polymicrogyria is thought to arise from a brain insult occurring in the late migration to early cortical organizational stages of corticogenesis. All patients with HHT with polymicrogyria reported to date, including our sample, have shown focal polymicrogyria, the pattern most commonly associated with hypoxic events and infections. Generalized polymicrogyria is most commonly associated with congenital cytomegalovirus infection and peroxisomal disorders. Overall, polymicrogyria is most commonly perisylvian in location and bilateral. All reported cases of polymicrogyria in HHT to date, including our cases, are unilateral and not strictly perisylvian in location.

Schizencephaly is widely believed to be the result of a destructive lesion, particularly prenatal ischemic injuries. Porencephaly and schizencephaly are both considered to result from destructive lesions that occur within different developmental timeframes. If the destructive lesion occurs within 4–6 months’ gestation, neuronal migration is possible and polymicrogyria or GM heterotopia along the margins of the cavity will result. After 6 months’ gestation, the involved brain parenchyma is resorbed. Because neuronal migration is no longer possible, the cavity is not lined with polymicrogyria or GM heterotopia. The presence of patients with MCDs partially outlining porencephalic cavities in the current sample and in a previous report may indicate that the ischemic events in these patients occurred at the transition between the late migrational and early cortical organizational stages of corticogenesis. We were not able to replicate an earlier finding of the high rate of spatially coincident MCDs and brain AVMs. Spatial coincidence of brain AVMs and MCDs has been described by multiple groups. Only 2 of our patients had an AVM spatially related to an MCD. Palagallo et al reported spatial coincidence of MCDs and AVMs in only 3 of 12 patients. There are many possible explanations for these discrepant findings. First, it is possible that MCDs or AVMs were present but below current MR imaging resolution. Second, although suggestive imaging findings were not present, it is possible that spatially coincident AVMs were present and had spontaneously resolved. Third, spatially coincident AVMs may have not yet developed at the time of imaging. Finally, it is possible that spatial coincidence is an inconstant finding.

Patients with HHT with MCDs in our sample were not more likely to have pulmonary AVMs than patients with HHT without MCDs. As in previous studies, all patients with HHT with MCDs in our sample who were tested had HHT1 and did not have clinically evident seizures or developmental or cognitive disabilities.

Our study has a number of limitations, first and foremost being the retrospective nature of this study. Another limitation is the small sample of patients obtained with this rare disease. Although up-to-date MR imaging protocols for HHT were used throughout the study period, it is possible that additional MCDs and AVMs may not have been detected due to limitations in current MR imaging protocols.

CONCLUSIONS

Our study replicates many of the findings of previous studies showing an association between HHT and MCDs. To our knowledge, we are the first group to report the presence of schizencephaly in patients with HHT. The presence of schizencephaly and porencephaly lends support to the hypothesis of regional in utero cerebral hypoxic events as the etiology of MCDs in HHT.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES

Delayed CTP-Derived Deep Venous Outflow: A Novel Predictor of Striatocapsular Infarction after M1 Thrombectomy

S. Peretz, K. Pardo, J. Naftali, M. Findler, G. Raphaeli, R. Barnea, V. Khasminsky, and E. Auriel

ABSTRACT

BACKGROUND AND PURPOSE: Isolated striatocapsular infarction occurs commonly in patients with ischemic stroke following M1 thrombectomy. We aimed to explore the correlation between CTP-derived parameters of deep venous outflow at presentation and subsequent striatocapsular infarction in a retrospective cohort of such patients.

MATERIALS AND METHODS: TTP and peak enhancement were measured on CTP-derived time-attenuation curves of the internal cerebral and thalamostriate veins bilaterally. The difference in TTP (DTTP) and the relative decrease in venous enhancement between the ischemic and normal sides were calculated. NCCT performed 24 (SD, 12) hours postthrombectomy was used to determine tissue fate in the caudate head, caudate body, lentiform nucleus, and internal capsule. Striatocapsular ischemia (striatocapsular infarction–positive) was defined as infarction and striatocapsular injury as either infarction, contrast enhancement, or hemorrhagic transformation in ≥1 of these regions. A striatocapsular ischemia score was calculated (0 = no ischemic region, 1 = 1 ischemic region, 2 = ≥2 ischemic regions).

RESULTS: One hundred sixteen patients were included in the analysis. Sixty-one patients had striatocapsular infarction (striatocapsular infarction–positive). The mean thalamostriate DTTP was 1.95 (SD, 1.9) seconds for patients positive for striatocapsular infarction and 0.79 (SD, 2.1) for patients negative for it (P = .010). Results were similar for striatocapsular injury. The mean thalamostriate DTTP was 0.79 (SD, 2.1), 1.68 (SD, 1.4), and 2.05 (SD, 2) for striatocapsular infarction scores of 0, 1, and 2, respectively (P = .030).

CONCLUSIONS: CTP-derived thalamostriate DTTP is an excellent surrogate marker for striatocapsular infarction in patients post-M1 thrombectomy. The novel approach of extracting venous outflow parameters from CTP has numerous potential applications and should be further explored.

ABBREVIATIONS: DT = distance from the carotid T to the thrombus; ICC = intraclass correlation coefficient; IVT = intravenous thrombolytic; LSAs = lenticulostriate arteries; SCAs+ = ASPECTS-based striatocapsular involvement; SCI = striatocapsular infarction; SCInj = striatocapsular injury; SCIs = striatocapsular ischemia score

The lenticulostriate arteries (LSAs) are a collection of small, deep perforating arteries arising most commonly from the M1 and supplying the basal ganglia and superior part of the internal capsule. They are commonly considered as end arteries without reliable anastomoses or collateral supply.1–3

Isolated striatocapsular infarction (SCI), resulting from simultaneous occlusion of the ostia of multiple LSAs, is a common occurrence in patients who have had successful endovascular reperfusion of the target M1 segment occlusion.4–6 In these patients, a rich leptomeningeal collateral supply maintains cortical and subcortical WM viability, while the deeper striatocapsular territory has infarction. Postulated mechanisms are the lack of striatocapsular collateral supply, lack of reperfusion to occluded perforators during clot retrieval, and a low ischemic threshold of basal ganglionic gray matter. Individual vascular anatomic variants have also been shown to determine the fate of striatocapsular tissue.7 The exact site of M1 occlusion as measured by the distance from the carotid T to the thrombus (DT) independently predicts the involvement of the LSAs and subsequent SCI as recently reported.8

Venous outflow of the striatocapsular region relies mainly on paired thalamostriate veins, which drain into the straight sinus through paired internal cerebral veins and the great cerebral vein...
of Galen (Fig 1). Measuring flow parameters within these deep venous channels may be useful for tissue prognostication in patients with stroke and an M1 occlusion.

CTP is used extensively to determine the eligibility of patients with anterior circulation acute ischemic stroke for mechanical thrombectomy worldwide. Currently, CTP postprocessing algorithms focus on the voxel-based analysis of cerebral parenchymal perfusion data to produce maps of the infarct core and penumbra. However, data on flow within the cerebral veins may also be extracted from the CTP images. Analysis of these widely available data enables direct, dynamic assessment of cerebral venous flow.

In this study, we aimed to explore the correlation between CTP-derived parameters of venous outflow in the deep cerebral veins and SCI in a cohort of patients with stroke following acute M1 thrombectomy.

**MATERIALS AND METHODS**

**Study Subjects**

We retrospectively reviewed all patients who had undergone mechanical thrombectomy for acute ischemic stroke with M1 occlusion and had CTP performed in the acute phase from January 2018 to December 2021 in the Rabin Medical Center. We retrieved demographics and relevant clinical data including age, sex, vascular risk factors, NIHSS at admission, intravenous thrombolytic (IVT) treatment, procedural complications, mRS score, and mortality at 90 days.

Imaging data included NCCT, CTA, and CTP from admission and NCCT that was performed 24 (SD, 12) hours postthrombectomy.

**Imaging Acquisition**

All study images were acquired using the same multidetector row scanner (Brilliance iCT 256 Slice CT Scanner; Philips Healthcare) including NCCT, CTA, and CTP. CTP was acquired as a 60-second cine series beginning immediately after a power injection of 40 mL of contrast at 5.2 mL/s. The scan was performed in non-Jog mode with a scan slab of 8 cm. The lower edge of the FOV was positioned at the sella turcica. The scan consisted of 30 cycles with an intercycle delay of 2 seconds. Imaging parameters included 80 kV(peak), 100 mAs, and an 0.4-second rotation time.

**Imaging Analysis**

Admission NCCT images were reviewed by an experienced stroke neurologist (S.P.) who determined the ASPECTS for each patient. Involvement of at least 1 striatocapsular region (caudate head, lentiform nucleus, or internal capsule) on the ASPECTS score (SCAs+) was recorded.

CTA images were reviewed by a trained neuroradiologist (M.F.) who verified M1 occlusion and assessed the cerebral collateral status using the Tan collateral score.9 He additionally reviewed postthrombectomy DSA images and recorded the modified TICI score. Successful reperfusion was defined as a modified TICI score of ≥2b. The DT on the coronal MIP (section thickness, 10 mm) was also measured for each patient.

CTP data were postprocessed with the Brain Perfusion application of the IntelliSpace Portal (Philips Healthcare). All CTP scans underwent automated 3D correction for head movement during the CTP acquisition before they were analyzed. Suboptimal scans due to either excessive motion or inadequate contrast injection were excluded. Total penumbra and core volumes were automatically calculated by the application. Mean relative CBF and relative CBV of the lentiform nucleus and caudate head were measured using a manually drawn ROI. Venous outflow parameters were extracted from the CTP data by a trained neurologist (K.P.), blinded to postadmission imaging. After the bilateral internal cerebral and thalamostriate veins were visually identified on axial images of the time MIP CTP images, a circular ROI was manually placed over these veins. The software automatically detects the voxel with highest peak enhancement within this user-defined ROI and presents the time-attenuation curve and other parameters for the voxel. Measurements of TTP in seconds and peak enhancement in Hounsfield units were recorded (Fig 2). For each patient, the difference in TTP (ΔTTP = TTP ischemic hemisphere–TTP normal hemisphere) and the relative decrease in venous enhancement (enhancement ischemic hemisphere–enhancement normal hemisphere/enhancement normal hemisphere) were calculated for both internal cerebral and thalamostriate veins.
Images of NCCT performed 24 (SD, 12) hours postthrombectomy were reviewed by a second trained neurologist (J.N.) at a window width of W:40; L:40 to determine tissue fate within the 4 striatocapsular regions drained by the internal cerebral and thalamostriate veins, including the caudate head, caudate body, lentiform nucleus, and internal capsule. Caudate and lentiform nuclei infarction was evaluated on axial NCCT images. The internal capsule was evaluated shortly before the fiber tracts passed through the GM bridges between the caudate and the lentiform nucleus on coronal-reformatted NCCT images.10 Each of these regions was classified as normal, infarcted, contrast-enhanced, or with hemorrhagic transformation. A region was labeled as infarcted or contrast-enhanced when >10% of that region was involved; otherwise, it was labeled as normal (Fig 3). When available, a repeat NCCT performed from 48 hours to 7 days postthrombectomy was additionally reviewed to better define the tissue status on the 24-hour NCCT. Hemorrhagic transformation was defined as an enhanced lesion with significant mass effect, a rim of hypodensity, and/or when significant hyperattenuation was still evident on a repeat NCCT performed 48–72 hours postthrombectomy.11 Ischemic damage was recorded separately for each of the above 4 striatocapsular regions (0 = normal, 1 = ischemic). Striatocapsular infarction-positive (SCI+) was defined as isolated infarction in at least 1 of these regions. Striatocapsular injury-positive (SCInj+) was defined more broadly as either infarction, contrast enhancement, or hemorrhagic transformation in at least 1 of these regions. A striatocapsular ischemia score (SCIs) was also calculated for each patient (0 = no ischemic region, 1 = 1 ischemic region, 2 = 2 ischemic regions).

Thirty CTP scans and 50 NCCT scans were independently reviewed by a third experienced stroke neurologist (S.P.) to assess interrater reliability.

**Statistical Analysis**

Statistical analyses were performed using SPSS Statistics for Windows, Version 25.0 (IBM). Qualitative data were represented as frequencies and percentages; the Pearson $\chi^2$ test was used for comparison of baseline characteristics, treatment (IVT), and clinical outcomes (mortality, intracerebral hemorrhage); the $t$ test was used for comparison of treatment (arrival times) and clinical outcomes (mRS); 1-way ANOVA analysis was used for comparing intergroup differences of CTP parameters; and ORs were calculated by binary univariant logistic regression analysis to
quantify the association between CTP-derived venous outflow parameters and SCI as well as between DT and SCI. Normality distribution of CTP parameters was assessed using the Kolmogorov-Smirnov test. A secondary multivariable logistic regression analysis for SCI was performed to adjust for confounders. Results were considered significant at a level of $P < 0.05$. Interrater reliability was calculated with intraclass correlation coefficients (ICCs) from 2-way ANOVA analyses that were derived to compare readers.

**RESULTS**

A total of 123 patients were reviewed. Two patients were excluded from the analysis due to simultaneous acute ischemia involving the contralateral hemisphere, and 1 patient was excluded due to lack of 24-hour postthrombectomy NCCT. Four additional patients were excluded due to excessive motion or inadequate contrast injection. A total of 116 patients were included in the analysis. A repeat NCCT from 48 hours to 7 days postthrombectomy was available in 43/116 (37%) patients. The internal cerebral veins were clearly demonstrated bilaterally on CTP images in all study patients. In 7/116 (6%) patients, the thalamostriate veins were not demonstrated in a sufficient quality to extract venous flow data due to variant anatomy and gross section thickness of the time MIP CTP images; for those patients, only the internal cerebral vein data were analyzed.

Demographic, clinical, and procedural data of the 116 patients included in the analysis are presented in the Online Supplemental Data. The median age was 79 years (interquartile range, 68–86 years); 49 patients were women (54.4%). There was no significant difference between patients with SCI and those without in either age, sex, vascular risk factors, NIHSS, IVT treatment, procedural complications, mRS score, or mortality at 90 days. Baseline imaging characteristics at admission are presented in the Online Supplemental Data. The total ASPECTS was not significantly different among groups, but a higher proportion of SCAs+ was found in the SCI+ and SCInj+ groups, 24 (39.3%) and 37 (43%), respectively, compared with 4 (13.8%) in the SCI− (SCI−) group ($P = 0.014$). The CTA TAP collateral score was similar among the groups.

Additional CTP parameters are presented in the Online Supplemental Data. The CTP-derived core volume was higher in the SCI+ group (18.8 [SD, 24] cm$^3$) compared with the SCI− group (7.3 [SD, 8.2] cm$^3$, $P = 0.018$). Relative CBV in the lentiform nucleus and caudate head was decreased in the SCI+ group compared with SCI− group; relative CBV was significantly decreased in the lentiform nucleus of the SCI+ group compared with SCI− group, but not in the caudate head nucleus.

**Correlation between Venous Outflow Parameters and SCI**

Of 116 patients included in the analysis, 61 patients were found to have isolated striatocapsular ischemia in ≥1 of the striatocapsular regions (SCI+), and 29 patients had no SCI at all (SCI−). Patients from these 2 groups were included in the main SCI analysis.

Twenty-six additional patients had striatocapsular regions with either contrast enhancement or hemorrhagic transformation. These patients together with the patients with SCI+ were defined as the SCInj+ group and analyzed separately.

The delay in venous outflow in the thalamostriate vein, ipsilateral to the occluded MCA, was significantly higher in patients with SCI+ than in patients in the SCI− group. The mean $\Delta$TTP$_{SCI+}$ was 1.95 (SD, 1.9) seconds compared with ATTP$_{SCI−}$ of 0.79 (SD, 2.1) seconds ($P = 0.014$). A trend toward higher mean $\Delta$TTP in the internal cerebral vein in the SCI+ compared with SCI− group could also be seen, but statistical significance was not reached. No significant difference was found between the groups in relative enhancement (relative peak enhancement in the ischemic hemisphere) of either the thalamostriate or internal cerebral veins.

Analysis of patients with SCInj+ showed similar results with a mean $\Delta$TTP in the thalamostriate vein of 1.95 (SD, 2.2) seconds compared with 0.79 (SD, 2.1) seconds in patients without any SCInj ($P = 0.014$).

A higher $\Delta$TTP in the thalamostriate vein was significantly correlated with SCI (OR, 1.412; 95% CI, 1.072–1.86; $P = 0.014$) and SCInj (OR, 1.345; 95% CI, 1.052–1.719; $P = 0.018$). These results are presented in Tables 1 and 2. As previously reported, the DT was significantly correlated with SCI+ in our cohort (OR, 1.138; 95% CI, 1.058–1.223; $P = 0.001$), but the OR was lower than for ATTP.

Analysis of the SCIs as an ordinal score between 0 and 2, presented in Table 3, showed a direct correlation between $\Delta$TTP and the SCIs, with mean $\Delta$TTPs of 0.79 (SD, 2.1) seconds, 1.68 (SD, 1.4) seconds, and 2.05 (SD, 2) seconds for a SCIs of 0, 1, and 2, respectively ($P = 0.030$).

We also analyzed the correlation between venous outflow parameters and infarction of each of the 4 striatocapsular regions separately. The correlation between higher ATTP and infarction was statistically significant for the caudate body and lentiform nucleus, whereas the caudate head and internal capsule showed only a trend. Results are presented in the Online Supplemental Data.

**Interrater Reliability**

The ICCs for the reviewed imaging parameters were 0.81 (95% CI, 0.57–0.92) for SCI on NCCT, 0.95 (95% CI, 0.91–0.98) for internal cerebral TTP, 0.95 (95% CI, 0.90–0.98) for thalamostriate TTP, 0.90 (95% CI, 0.82–0.95) for internal cerebral enhancement, and 0.93 (95% CI, 0.85–0.97) for DT on CTA. These high values represent either good ($\geq 0.75$) or excellent ($\geq 0.9$) agreement between readers for these parameters. The ICC was only 0.39 (95% CI, 0.05–0.65) for thalamostriate enhancement, indicating a low reliability for this parameter in our analysis.

**Control of Potential Confounding Factors**

Results of multivariable logistic regression analysis for SCI adjusted for age, sex, admission ASPECTS-based striatocapsular involvement, successful reperfusion, collateral score, and IVT are presented in the Online Supplementary Data. Higher thalamostriate ATTP remained significantly correlated with SCI (OR, 1.511; 95% CI, 1.102–2.072; $P = 0.01$). SCAs+ was a potential confounding factor and correlated with SCI (OR, 2.895; 95% CI 0.97–8.644; $P = 0.057$). However, in a secondary univariate analysis including only patients without striatocapsular involvement (SCAs−, $n = 62$), ATTP remained significantly correlated with
Phenomenon possibly modulates ischemic stroke evolution and clinical outcomes. Formation of anastomoses between deep cortical veins on axial images of the CTP scan to quantify deep venous outflow as a surrogate marker for SCI has been reported. Favorable cortical venous outflow parameters have been associated with distal vessel occlusion, good baseline collateral, successful reperfusion, decreased infarct edema, and good clinical outcome. Administration of IVT was strongly associated with the presence of favorable venous outflow profiles in patients before endovascular thrombectomy. However, these neuroimaging markers have focused on the superficial cerebral venous system, which drains only cortical and juxta-cortical structures. The impact of deep venous outflow on striatocapsular tissue survival has not yet been explored.

Here we present a novel approach that uses widely available CTP data to quantify deep venous outflow as a surrogate marker for SCI. In our cohort of patients having undergone M1 thrombectomy, a higher delay in the TTP of the time-attenuation curve in the thalamostriate vein ipsilateral to an M1 occlusion (thalamostriate ΔTTP) was significantly correlated with infarction of the caudate body and lentiform nucleus separately and the striatocapsular region as a whole. Moreover, a higher thalamostriate ΔTTP was directly correlated with a larger extent of striatocapsular ischemia represented by the striatocapsular ischemia score. These results indicate that delayed thalamostriate venous flow is an excellent surrogate marker for striatocapsular ischemia. The ORs for the correlation of thalamostriate ΔTTP with SCI was higher than that of the recently reported DT in our cohort of patients, indicating that thalamostriate ΔTTP may be more accurate than DT as a surrogate marker for SCI.

Sparing of the lateral LSAs according to preprocedural digital DSA and asymmetric dilation of LSAs following successful thrombectomy on MRA have also been shown to predict favorable outcome following M1 thrombectomy. However, thalamostriate ΔTTP derived from CTP may be a superior surrogate marker for SCI because it provides equivalent information in a noninvasive manner and at an earlier preprocedural stage.

In our study, 2 independent raters visually identified and manually marked the bilateral internal cerebral and thalamostriate veins on axial images of the CTP scan to produce measurements of TTP and peak enhancement. These veins were easily detectable on CTP images of most of our patients. Interrater agreement was excellent for both thalamostriate and internal cerebral TTP (ICC = 0.95) and for internal cerebral enhancement (ICC = 0.899). This finding supports the strength and reliability of our novel approach to extract venous outflow parameters from CTP raw data. Indeed, interrater agreement for thalamostriate enhancement was poor, making this approach less practical.

### Table 1: CTP-derived venous outflow parameters in SCI and injury

<table>
<thead>
<tr>
<th>SCI (n = 90)</th>
<th>Striatocapsular Fate</th>
<th>Mean (SD)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ΔTTP (sec)</td>
<td>Thalamostriate vein</td>
<td>Viable</td>
<td>0.786 (2.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Infarcted</td>
<td>1.954 (1.8)</td>
</tr>
<tr>
<td></td>
<td>Internal cerebral vein</td>
<td>Viable</td>
<td>0.853 (1.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Infarcted</td>
<td>1.12 (1.1)</td>
</tr>
<tr>
<td>Relative enhancement</td>
<td>Thalamostriate vein</td>
<td>Viable</td>
<td>–0.1 (0.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Infarcted</td>
<td>–0.04 (0.5)</td>
</tr>
<tr>
<td></td>
<td>Internal cerebral vein</td>
<td>Viable</td>
<td>0.13 (0.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Infarcted</td>
<td>0.17 (0.3)</td>
</tr>
</tbody>
</table>

ΔTTPsci (n = 116)

<table>
<thead>
<tr>
<th>SCI</th>
<th>Striatocapsular Fate</th>
<th>Mean (SD)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ΔTTP</td>
<td>Thalamostriate vein</td>
<td>Viable</td>
<td>0.786 (2.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Injured</td>
<td>1.953 (2.2)</td>
</tr>
<tr>
<td></td>
<td>Internal cerebral vein</td>
<td>Viable</td>
<td>0.853 (1.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Injured</td>
<td>1.101 (1)</td>
</tr>
<tr>
<td>Relative enhancement</td>
<td>Thalamostriate vein</td>
<td>Viable</td>
<td>–0.1 (0.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Injured</td>
<td>–0.5 (0.13)</td>
</tr>
<tr>
<td></td>
<td>Internal cerebral vein</td>
<td>Viable</td>
<td>0.13 (0.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Injured</td>
<td>0.17 (0.3)</td>
</tr>
</tbody>
</table>

### Table 2: Correlation between delayed TTP and SCI or injury

<table>
<thead>
<tr>
<th>SCI</th>
<th>OR (95% CI) Infarct</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delayed TTP</td>
<td>Thalamostriate vein</td>
<td>1.412 (1.072–1.86)</td>
</tr>
<tr>
<td></td>
<td>Internal cerebral vein</td>
<td>1.212 (0.827–1.776)</td>
</tr>
<tr>
<td>SCInj Delayed TTP</td>
<td>Thalamostriate vein</td>
<td>1.345 (1.052–1.779)</td>
</tr>
<tr>
<td></td>
<td>Internal cerebral vein</td>
<td>1.217 (0.831–1.783)</td>
</tr>
</tbody>
</table>

### Table 3: Thalamostriate ΔTTP and SCIs

<table>
<thead>
<tr>
<th>SCIs</th>
<th>Mean (SD)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.786 (2.1)</td>
<td>.030</td>
</tr>
<tr>
<td>1</td>
<td>1.676 (1.4)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>2.053 (2.0)</td>
<td></td>
</tr>
</tbody>
</table>

SCI, with a mean ΔTTPsci+ of 1.91 (SD, 2.07) seconds compared with ΔTTPsci− of 0.89 (SD, 1.86) seconds (P = .048).

### DISCUSSION

Our study establishes a significant association between delay in deep venous outflow in the acute phase of MCA ischemic stroke and subsequent SCI after M1 thrombectomy. Accumulating evidence suggests that venous outflow may be an independent modulator of stroke evolution and clinical outcomes. Formation of microthrombi in venules distal to a cerebral arterial occlusion and a "venous steal" phenomenon possibly modulate ischemic cerebral tissue fate and may explain the failure of reperfusion despite successful recanalization. Incorporating venous outflow into collateral status assessment in patients having undergone thrombectomy has recently been shown to improve the prediction of clinical and radiologic outcomes.

The evaluation of cortical venous outflow patterns in acute ischemic stroke through neuroimaging surrogate markers such as opacification of cortical veins on monophasic or multiphase CTA or delayed cortical vein filling on dynamic CTA has been recently reported. Favorable cortical venous outflow patterns have been associated with distal vessel occlusion, good baseline collateral, successful reperfusion, decreased infarct edema, and good clinical outcome. Administration of IVT was strongly associated with the presence of favorable venous outflow profiles in patients before endovascular thrombectomy. However, these neuroimaging markers have focused on the superficial cerebral venous system, which drains only cortical and juxta-cortical structures. The impact of deep venous outflow on striatocapsular tissue survival has not yet been explored.

Here we present a novel approach that uses widely available CTP data to quantify deep venous outflow as a surrogate marker for SCI. In our cohort of patients having undergone M1 thrombectomy, a higher delay in the TTP of the time-attenuation curve in the thalamostriate vein ipsilateral to an M1 occlusion (thalamostriate ΔTTP) was significantly correlated with infarction of the caudate body and lentiform nucleus separately and the striatocapsular region as a whole. Moreover, a higher thalamostriate ΔTTP was directly correlated with a larger extent of striatocapsular ischemia represented by the striatocapsular ischemia score. These results indicate that delayed thalamostriate venous flow is an excellent surrogate marker for striatocapsular ischemia. The ORs for the correlation of thalamostriate ΔTTP with SCI was higher than that of the recently reported DT in our cohort of patients, indicating that thalamostriate ΔTTP may be more accurate than DT as a surrogate marker for SCI.

Sparing of the lateral LSAs according to preprocedural digital DSA and asymmetric dilation of LSAs following successful thrombectomy on MRA have also been shown to predict favorable outcome following M1 thrombectomy. However, thalamostriate ΔTTP derived from CTP may be a superior surrogate marker for SCI because it provides equivalent information in a noninvasive manner and at an earlier preprocedural stage.

In our study, 2 independent raters visually identified and manually marked the bilateral internal cerebral and thalamostriate veins on axial images of the CTP scan to produce measurements of TTP and peak enhancement. These veins were easily detectable on CTP images of most of our patients. Interrater agreement was excellent for both thalamostriate and internal cerebral TTP (ICC = 0.95) and for internal cerebral enhancement (ICC = 0.899). This finding supports the strength and reliability of our novel approach to extract venous outflow parameters from CTP raw data. Indeed, interrater agreement for thalamostriate enhancement was poor, making this approach less practical.
parameter unreliable for the analysis of deep venous outflow. This issue is probably due to the smaller diameter and high tortuosity of this vein combined with measurement of absolute peak enhancement on CTP images being highly angle-dependent. Subsequently, patient positioning may also affect this parameter.

Our results indicate that internal cerebral venous outflow is less accurate than thalamostriate outflow as a surrogate marker for SCI. While the thalamostriate veins drain the striatocapsular region exclusively, the internal cerebral veins receive several other major tributaries including the anterior septal veins, lateral direct veins, medial atrial veins,27 and choroidal veins, which drain extra-striatocapsular cerebral tissue. This process probably dampens the effect of striatocapsular ischemia on the time-attenuation curve of the internal cerebral veins. Most interesting, thalamostriate ΔTTP was highly associated with infarction of the caudate body and lentiform nucleus but less associated with caudate head infarction. This association is probably because the caudate head is drained separately by the anterior caudate vein, which enters the thalamostriate vein beyond the point where the time-attenuation curve was measured (Figs 1 and 2). Association of internal capsule infarction with thalamostriate ATTP also did not reach statistical significance. We hypothesize that this finding may be due to the challenge in assessing internal capsule infarction using NCCT, resulting in limited reliability. Of note, despite high anatomic variance of the thalamostriate vein tributaries, the thalamostriate vein itself is reportedly present bilaterally in >92% of patients and consistently drains most of the striatocapsular territory.28 This finding further supports the role of the thalamostriate vein as a robust imaging marker of striatocapsular drainage.

These intriguing interactions point to the enormous potential of this novel approach to extract dynamic cerebral venous outflow data with high temporal resolution from CTP images. Using the same technique, one may explore venous outflow parameters not only in acute ischemic stroke but also in healthy subjects and in patients with other acute or chronic cerebrovascular disease states. Further research may allow semi- or even fully-automated analysis of deep venous outflow patterns in these situations.

Currently used multiphase CTA provides dynamic, high-spatial-resolution images of the cerebral vasculature. However, imaging acquisition is performed at only 3 different time points after contrast injection, and time-resolved assessment of cerebral blood flow is limited. In contrast, CTP raw data provide low spatial resolution but contain multiple time points (usually >15) and allow thorough analysis of flow parameters from the time-enhancement curve. Because our study was primarily a proof-of-concept study, we measured only TTP and peak enhancement. These parameters were the most intuitive, reproducible, and simple to extract. Additional parameters such as arrival time, wash-in time, or ascending slope may add more information and should be the subject of future analyses.

The clinical impact of SCI in the setting of successful M1 thrombectomy is uncertain. While previous studies reported pre-treatment SCI to be associated with higher rates of hemorrhagic transformation, worse dysfunction and disability at discharge, and longer hospitalization,26 more recent studies have reported that it does not have a significant impact on clinical outcome.30,31 In our cohort, functional status indices at 90 days including mean mRS and the proportion of patients with good functional outcome (mRS ≤ 2) were not significantly different between patients with SCI+ and SCI− (Online Supplemental Data). This result possibly indicates that isolated SCI is not an important determinant of clinical long-term prognosis and should not directly affect the decision on thrombectomy in such patients. Nevertheless, our results are highly relevant as a proof-of-concept for the use of CTP-derived venous outflow parameters for tissue prognostication. Further studies using the same concept to explore both superficial and deep venous drainage in larger-territory MCA infarctions would most likely lead to a more significant clinical correlation.

Our study has several limitations. The patient cohort was relatively small, including only 116 patients. Data were collected retrospectively, which may introduce bias. The use of a single CT scanner type and postprocessing software may limit the generalizability of our findings. Deep cerebral veins were visually identified and manually rather than automatically marked on CTP images. Tissue fate in the striatocapsular region was determined by NCCT rather than MR imaging, due to low availability of this technique in our institution. SCAs+ on admission NCCT was common in our study and correlated with eventual SCI, raising the possibility that delayed venous outflow on CTP represents the result of early infarction rather than the cause of it. However, in a multivariable analysis that controlled for admission SCAs+ and in a secondary analysis that excluded patients with SCAs+ altogether, the correlation between thalamostriate ΔTTP and SCI+ remained significant, excluding this possibility. Finally, the use of ATTP as a single tissue-prognostication tool is limited by a significant overlap in ATTP distributions between the SCI− and SCI+ groups. However, we present a simple technique with excellent interrater reliability, and the statistical power of our findings is high. These support the high reproducibility and generalizability of our results.

CONCLUSIONS

CTP-derived thalamostriate ΔTTP is an excellent surrogate marker for SCI in patients post-M1 thrombectomy. The novel approach of extracting venous outflow parameters from CTP has numerous potential applications and should be further explored.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES

Learning Curve for Flow Diversion of Posterior Circulation Aneurysms: A Long-Term International Multicenter Cohort Study

ABSTRACT

BACKGROUND AND PURPOSE: Flow diversion has gradually become a standard treatment for intracranial aneurysms of the anterior circulation. Recently, the off-label use of the flow diverters to treat posterior circulation aneurysms has also increased despite initial concerns of rupture and the suboptimal results. This study aimed to explore the change in complication rates and treatment outcomes across time for posterior circulation aneurysms treated using flow diversion and to further evaluate the mechanisms and variables that could potentially explain the change and outcomes.

MATERIALS AND METHODS: A retrospective review using a standardized data set at multiple international academic institutions was performed to identify patients with ruptured and unruptured posterior circulation aneurysms treated with flow diversion during a decade spanning January 2011 to January 2020. This period was then categorized into 4 intervals.

RESULTS: A total of 378 procedures were performed during the study period. Across time, there was an increasing tendency to treat more vertebral artery and fewer large vertebrobasilar aneurysms (P = .05). Moreover, interventionalists have been increasingly using fewer overlapping flow diverters per aneurysm (P = .07). There was a trend toward a decrease in the rate of thromboembolic complications from 15.8% in 2011–13 to 8.9% in 2018–19 (P = .34).

CONCLUSIONS: This multicenter experience revealed a trend toward treating fewer basilar aneurysms, smaller aneurysms, and increased usage of a single flow diverter, leading to a decrease in the rate of thromboembolic and hemorrhagic complications.

Flow diversion has become an established treatment for intracranial aneurysms. The initial FDA approval for the Pipeline Embolization Device (PED; Covidien) was to treat large and giant wide-neck intracranial aneurysms in the ICA, from the petrous to the superior hypophyseal segments. This indication was expanded to include wide-neck ICA aneurysms up to the carotid
terminus of all sizes in February 2019. In December 2019, the Flow Redirection Endoluminal Device (FRED; MicroVention) was approved by the FDA with indications similar to those of the PED.

Despite the remarkable advancements in technology, flow diverters were being used reluctantly to treat posterior circulation aneurysms. However, due to the challenging nature of posterior circulation aneurysms, including their high risk of rupture and the suboptimal results associated with the use of standard techniques, the off-label use of flow diverters in the treatment of these aneurysms has gradually increased, with several studies attempting to evaluate the risks and benefits. In a propensity-matched comparison between the PED and FRED for the treatment of posterior circulation aneurysms, Griessenauer et al reported no significant differences in aneurysm occlusion or neurologic complications between the devices.

A recent multicenter study investigated the change in complication rates across time for anterior circulation aneurysms treated by the PED. A significant decline in complications was noted, which was attributed to the continuous improvement in clinical practice and experience with the PED, including the increased use of platelet function testing before the procedures. In this study, we aimed to examine changes in complication rates and outcomes with time for posterior circulation aneurysms treated by the PED and FRED, given that both devices had no significant difference in treatment outcomes. We further sought to evaluate the mechanisms and covariates that could explain these changes.

MATERIALS AND METHODS

Patient Population

A retrospective review of prospectively maintained databases at multiple academic institutions in the United States, Canada, Europe, and Asia was performed to identify patients with posterior circulation aneurysms treated with flow diversion using the PED or FRED during a decade spanning January 2011 to January 2020. Inclusion criteria consisted of adult patients (18 years of age or older) with the pathology and treatment mentioned above. Both ruptured and unruptured aneurysms with all morphologies (ie, saccular and fusiform) were included. All consecutive patients who fit the inclusion criteria at the participating center were included. Then, these patients were categorized on the basis of the treatment year to four 2-year intervals, except for the first 3 years due to low case numbers: 2011–2013, 2014–2015, 2016–2017, and 2018–2019. We collected the following information retrospectively: patient demographics, aneurysm characteristics, antiplatelet regimen, procedural details, complications, and angiographic and functional outcomes. Institutional review board approval was obtained at all centers. Patient consent was not required for this study, given that it was a retrospective analysis of de-identified data.

Complications and Outcomes

Thromboembolic complications occurring from the date of the procedure to the last follow-up were included. Intraprocedural thromboembolic complications were identified on DSA as either thrombus formation, slow filling of a previously normal-filling vessel, or complete vessel occlusion. Intraprocedural thromboembolism was treated at the discretion of the interventionalist performing the procedure. Postprocedural thromboembolic complications were identified using a combination of clinical and radiographic findings. Postprocedural imaging was performed at the discretion of the individual institutions. Routine screening for clinically silent ischemic stroke was not performed in all centers. Postprocedural imaging performed to detect an ischemic stroke could include any combination of a noncontrast CT, CTA, or MR imaging. Only ischemic strokes in the territory of the treated vessel were included. An ischemic complication was considered symptomatic if the patient reported symptoms attributable to thromboembolism or demonstrated signs attributable to thromboembolism, including both transient and permanent signs and symptoms. Hemorrhagic complications were identified intraoperatively as contrast extravasation on DSA or on postprocedural imaging. Hemorrhagic complications occurring from the time of the procedure until the last follow-up were included. Hemorrhages were counted as symptomatic if the patient reported symptoms or demonstrated signs attributable to hemorrhage. In contrast to ischemic complications, all vascular territories were included. Minor complications were defined as intraprocedural technical complications and vascular-access complications, which did not result in permanent deficits.

The angiographic outcome was assessed using DSA, MRA, or CTA. Aneurysm occlusion was categorized as complete occlusion (100%), near-complete occlusion (90%–100%), and partial occlusion (< 90%). Functional outcome was assessed using the mRS at the last follow-up. An mRS of 0–2 was considered a favorable outcome.

Statistical Analysis

Statistical analysis was conducted using R statistical and computing software (Version 4.0.2; http://www.r-project.org/). Numeric variables were compared using the Mann-Whitney U test or the Kruskal-Wallis test, depending on the number of groups, while categoric variables were compared using the χ² test. Univariable and multivariable logistic regression analyses were performed to identify predictors of good outcome (mRS 0–2) and thromboembolic and hemorrhagic complications. The examined covariates included age, sex, smoking, pretreatment mRS, multiple aneurysms, aneurysm location, aneurysm shape, aneurysm size, previous SAH, prior treatment, number of devices, antiplatelet regimen changed, and adjunctive coiling. Covariates that had a P value ≤ 0.1 in the univariable analysis were included in the multivariable analysis. A P value <.05 was considered statistically significant.
or near-complete occlusion (retreatment decreased with time from 12.2% in 2011 during 9 years of flow-diversion experience. However, the rate of aneurysms. There was no significant change in the occlusion rate the years, from 16% in 2011 in 2018–2018 – 2018. 

Thromboembolic complications occurred in 13% of procedures (Online Supplemental Data).

Across time, there was an increasing tendency to treat vertebral artery, posterior cerebral artery, and PICA aneurysms, with a lower rate of treating large vertebralbasilar fusiform aneurysms and superior cerebellar artery aneurysms (P = .05). Also, there was a tendency to treat smaller aneurysms across time, but this tendency was not found to be statistically significant (P = .27) (Online Supplemental Data).

**Treatment Outcome**

There was an increasing rate of using a single device for aneurysm treatment across time, from 72.4% in 2011–13 to 87.8% in 2018–19 (P = .07). At a mean follow-up of 13 months, complete or near-complete occlusion (>90%) was achieved in 84.5% of aneurysms. There was no significant change in the occlusion rate during 9 years of flow-diversion experience. However, the rate of retreatment decreased with time from 12.2% in 2011–13 to 3.5% in 2018–19 (P = .99). Similarly, the percentage of patients with reported worsening of their clinical outcome had declined across the years, from 16% in 2011–13 to 11.4% in 2018–19 (P = .03).

Thromboembolic complications occurred in 13% of procedures, of which 8.7% were symptomatic. There was a trend toward a decrease in the rate of thromboembolic complications from 15.8% in 2011–13 to 8.9% in 2018–19 (P = .3). There was also a nonsignificant decline in the rate of hemorrhagic complications (P = .78) and mortality (P = .88) (Table 1 and Figure).

**RESULTS**

**Patient and Aneurysm Characteristics**

A total of 378 procedures using either the PED or FRED were performed to treat posterior circulation aneurysms during the study period. The median age of the patients was 57 years, with an observed female/male ratio of 1:1. There was no significant difference in patient characteristics among the different periods as seen in the Online Supplemental Data.

Across time, there was an increasing tendency to treat vertebrobasilar aneurysms (as opposed to the basilar artery) (OR, 0.41; 95% CI, 0.18–0.87; P = .017). Similarly, the percentage of patients with reported worsening of their clinical outcome had declined across the years, from 16% in 2011–13 to 11.4% in 2018–19 (P = .03).

Thromboembolic complications occurred in 13% of procedures, of which 8.7% were symptomatic. There was a trend toward a decrease in the rate of thromboembolic complications from 15.8% in 2011–13 to 8.9% in 2018–19 (P = .3). There was also a nonsignificant decline in the rate of hemorrhagic complications (P = .78) and mortality (P = .88) (Table 1 and Figure).

**Factors Associated with Complication Rates**

Univariable analyses for determinants of thromboembolic complications are shown in Table 2. In a multivariable analysis, having a pretreatment mRS of 3–5 (adjusted OR, 3.00; 95% CI, 1.30–6.68; P = .008) and multiple aneurysms (adjusted OR, 2.55; 95% CI, 1.16–5.42; P = .017) was significantly associated with a higher risk of thromboembolic complications. On the other hand, vertebrobasilar aneurysms (as opposed to the basilar artery) (OR, 0.41; 95% CI, 0.18–0.87; P = .025) and saccular shape (as opposed to fusiform aneurysms) (OR, 0.43; 95% CI, 0.18–0.95; P = .045) were significantly associated with a lower risk of thromboembolic complications.

Univariable and multivariable logistic regression analyses for predictors of hemorrhagic complications are shown in the Online Supplemental Data. In a multivariable analysis, only a pretreatment mRS of 3–5 (OR, 10.15; 95% CI, 3.51–30.71; P < .001) was found to be associated with a higher risk of hemorrhagic complications (Online Supplemental Data).

**DISCUSSION**

This study reports a multicenter experience with flow diversion of posterior circulation aneurysms and the learning curve built on that experience. During the study period, there was a significant increase in the tendency to treat vertebrobasilar artery, posterior cerebral artery, and PICA aneurysms. Conversely, there was a lower tendency to treat large vertebrobasilar aneurysms. Moreover, interventionalists

---

**Table 1: Change in treatment outcome with time**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Last follow-up imaging (lapsed time (months))</td>
<td>14.0 [28.8]</td>
<td>24.0 [24.0]</td>
<td>14.0 [16.5]</td>
<td>6.80 [5.00]</td>
<td>&lt; .001</td>
<td>13.0 [20.6]</td>
</tr>
<tr>
<td>Last follow-up clinical time from treatment (months)</td>
<td>22.5 [40.5]</td>
<td>29.0 [29.0]</td>
<td>17.0 [17.3]</td>
<td>6.50 [6.00]</td>
<td>&lt; .001</td>
<td>13.0 [24.0]</td>
</tr>
<tr>
<td>Follow-up occlusion rate</td>
<td>Complete occlusion (100%)</td>
<td>47 (66.2%)</td>
<td>75 (68.9%)</td>
<td>69 (77.5%)</td>
<td>46 (67.7%)</td>
<td>.727</td>
</tr>
<tr>
<td>Incomplete occlusion (&lt;90%)</td>
<td>15 (21.1%)</td>
<td>14 (12.8%)</td>
<td>7 (7.9%)</td>
<td>12 (17.6%)</td>
<td>48 (41.2%)</td>
<td></td>
</tr>
<tr>
<td>Near-complete occlusion (90%–99%)</td>
<td>9 (12.7%)</td>
<td>20 (18.3%)</td>
<td>13 (14.6%)</td>
<td>10 (14.7%)</td>
<td>52 (15.4%)</td>
<td></td>
</tr>
<tr>
<td>Retreatment</td>
<td>6 (8.7%)</td>
<td>13 (11.2%)</td>
<td>5 (5.4%)</td>
<td>3 (3.5%)</td>
<td>.092</td>
<td>30 (8.2%)</td>
</tr>
<tr>
<td>mRS on last follow-up</td>
<td>0–2</td>
<td>66 (88.0%)</td>
<td>96 (84.2%)</td>
<td>82 (87.2%)</td>
<td>78 (88.6%)</td>
<td>.793</td>
</tr>
<tr>
<td></td>
<td>3–6</td>
<td>9 (12.0%)</td>
<td>18 (15.8%)</td>
<td>12 (12.8%)</td>
<td>10 (11.4%)</td>
<td>49 (13.2%)</td>
</tr>
<tr>
<td>Follow-up mRS</td>
<td>Improved</td>
<td>23 (30.7%)</td>
<td>28 (24.6%)</td>
<td>21 (22.3%)</td>
<td>10 (11.4%)</td>
<td>.034</td>
</tr>
<tr>
<td></td>
<td>No change</td>
<td>40 (53.3%)</td>
<td>65 (57.0%)</td>
<td>58 (61.7%)</td>
<td>68 (77.2%)</td>
<td>231 (62.3%)</td>
</tr>
<tr>
<td></td>
<td>Worsened</td>
<td>12 (16.0%)</td>
<td>21 (18.4%)</td>
<td>15 (16.0%)</td>
<td>10 (11.4%)</td>
<td>58 (15.6%)</td>
</tr>
<tr>
<td>Neurologic complications</td>
<td>Thromboembolic</td>
<td>12 (15.8%)</td>
<td>19 (16.1%)</td>
<td>10 (10.6%)</td>
<td>8 (8.9%)</td>
<td>.342</td>
</tr>
<tr>
<td></td>
<td>Thromboembolic (symptomatic)</td>
<td>9 (11.8%)</td>
<td>14 (11.9%)</td>
<td>3 (3.2%)</td>
<td>7 (7.8%)</td>
<td>.107</td>
</tr>
<tr>
<td></td>
<td>Hemorrhagic</td>
<td>5 (6.6%)</td>
<td>5 (4.2%)</td>
<td>4 (3.3%)</td>
<td>3 (3.3%)</td>
<td>.781</td>
</tr>
<tr>
<td></td>
<td>Hemorrhagic (symptomatic)</td>
<td>3 (3.9%)</td>
<td>4 (3.4%)</td>
<td>3 (3.2%)</td>
<td>3 (3.3%)</td>
<td>.994</td>
</tr>
<tr>
<td></td>
<td>Other procedural related complications</td>
<td>7 (9.2%)</td>
<td>9 (7.6%)</td>
<td>4 (3.3%)</td>
<td>5 (5.6%)</td>
<td>.57</td>
</tr>
<tr>
<td></td>
<td>Mortality</td>
<td>6 (8.0%)</td>
<td>9 (7.9%)</td>
<td>5 (5.3%)</td>
<td>6 (6.8%)</td>
<td>.881</td>
</tr>
</tbody>
</table>

---

Note: Continuous variables are presented as median [IQR]. Otherwise, data are No. (%). Data missing for 46 patients. Data missing for 56 patients. Data missing for 41 patients. Data missing for 10 patients. Data missing for 7 patients.
have increasingly used fewer overlapping flow diverters per aneurysm, which could also be related to treating smaller aneurysms. There was also a decline in the rate of symptomatic thromboembolic complications and retreatment rates across time. This was significantly correlated with treating saccular aneurysms and smaller aneurysms and the increased use of a single flow diverter.

To evaluate the performance of flow diversion for the treatment of posterior circulation aneurysms, Griessenauer et al.\textsuperscript{18} reported the largest cohort of posterior circulation aneurysms treated with the PED. A total of 129 consecutive patients (median age, 58 years; male/female ratio of 1:1.7) underwent 129 procedures to treat 131 aneurysms. Complete or near-complete occlusion (\(>90\%\)) was achieved in 79\% of cases. Major (\(\geq 2\) points of mRS change) and minor complications (\(< 2\) of mRS change), including thromboembolic and hemorrhagic strokes, occurred in 8.5\% and 16.3\% of patients, respectively.\textsuperscript{18} The same group also performed a propensity-matched comparison between the PED and FRED for the treatment of posterior circulation aneurysms and reported no significant differences in aneurysm occlusion or neurologic complications.\textsuperscript{15}

As for the concern about the fate of posterior circulation branches following flow diversion, Adeeb et al.\textsuperscript{19} found that major branching arteries in the posterior circulation including the PICA, anterior inferior cerebellar artery, and superior cerebellar artery had a low incidence of branch occlusion after coverage with flow diverters. However, occlusion of these terminal branches may carry a risk of ischemic complications, particularly when the anterior inferior cerebellar artery is affected. On the other hand, the vertebral and the posterior cerebral arteries had relatively higher incidences of occlusions, 35\% and 24\%, respectively, which were attributed to the rich collateral supply. Neither branch occlusion nor ischemic complications were associated with aneurysm morphology. There was also no significant effect of the number of flow-diverting devices on branch occlusion.\textsuperscript{19}

### Changes in Practice to Reduce Complications

Flow diverters are designed to divert the blood flow away from the aneurysm, therefore allowing intra-aneurysmal thrombus formation followed by neointimal growth across the neck of the aneurysm. This mechanism theoretically presents an ideal treatment for large, partially thrombosed fusiform vertebrobasilar aneurysms.\textsuperscript{20} In the multicenter study by Griessenauer et al,\textsuperscript{17} the rate of major complications (\(\geq 2\) points in mRS score change) in fusiform aneurysms was 11.5\%. However, a study by Natarajan et al.\textsuperscript{10} showed decreased morbidity (14\%–8.3\%) and mortality rates (57\%–0\%) following treatment of those subtypes of aneurysms in their practice across time. One of the proposed reasons behind this decline in complication rates is related to moving away from the treatment of holobasilar aneurysms that are partially thrombosed because these aneurysms have a higher risk of occluding critical perforators that may only be supplied through tenuous channels crossing the thrombus. Other proposed reasons included careful attention to antiplatelet therapy, limiting the number of PEDs, and use of adjunctive coiling.\textsuperscript{10}

![FIGURE. The rates of thromboembolic and hemorrhagic complications during the study years.](image-url)
In a meta-analysis of posterior nonsaccular aneurysms treated with flow diversion, Kiyofuji et al added that treatment of aneurysms of <10 mm was associated with fewer complications compared with those larger than 10 mm (18% versus 29%). They also found that aneurysms located within the vertebral artery (83%) had a better outcome compared with the vertebrobasilar junction and proximal basilar artery (33%), mid-/distal basilar artery, and holobasilar artery (18%). This finding is potentially related to the abundance of perforators along the basilar artery and proximal basilar artery (33%), mid-/distal basilar artery, and holobasilar artery (18%).

The holobasilar fusiform dolichoectatic aneurysm is the product of the unique and poorly understood pathophysiology distinct from other aneurysms. In our study, we have noticed significant changes across the years that align with these recommendations. Additionally, basilar artery aneurysms and fusiform shape were independent predictors of thromboembolic complications compared with their vertebral artery aneurysms and saccular counterparts. Thus, interventionalists transitioned to treating more vertebral artery aneurysms and fewer large vertebrobasilar aneurysms across the years, particularly asymptomatic ones. Also, the median size of aneurysms treated declined from 9 mm in 2011–13 to 7.7 mm in 2018–19. Despite the significant change in the size and location of aneurysms treated, there was no significant change in the rate of fusiform aneurysms treated, per se, across time.

One of the other factors suggested by Natarajan et al to reduce complications was limiting the number of overlapping flow diverters, because more devices were associated with an increased risk of perforator occlusion due to greater metal coverage. In our study, there was a significant shift to using only 1 device across time, from 72.4% of procedures in 2011 to 87.8% in 2018–19.

Moreover, as implied in the previous study on anterior circulation aneurysms, careful monitoring of platelet testing before procedures and switching to appropriate antiplatelet regimens in cases of clopidogrel nonresponders may have played a role in the drop of thromboembolic complications. The rate of platelet function testing in this study (72.9%) was lower than the ones reported by previous PED studies (96.1% and 88.5%).

Poor clinical status (mRS 3–5) at presentation was an independent predictor of treatment complications. These patients were more likely to present with a ruptured aneurysm (70.2%) compared with patients with an mRS of 0–2 (19.3%, P < .001). Patients with poor clinical status and ruptured aneurysms were more prone to complications related to brain injury and delayed cerebral ischemia. Those patients were also more likely to
present with fusiform aneurysms (76.6%) than patients with an mRS of 0–2 (64.5%, P = .07). Moreover, 17% of these patients had large or giant aneurysms (>20 mm) compared with 11.7% of patients with an mRS of 0–2 (P = .2). All these factors might have contributed to the increased rate of complications in this subgroup of patients.

**Limitations**

The primary limitations of the current study include its retrospective design and variability in the management of patients across centers. Retrospective studies are subject to incomplete data sets, selection bias, and unidentified confounders. The inclusion of multiple institutions improves the generalizability of the findings but introduces variability in patient management. This also introduces variation in aneurysm measurement and the device compaction rate. However, the use of a standardized datasheet among all centers and the large number of cases included should improve the generalization of the results. Although the study addresses improvement in patient and aneurysm selection, it does not account for improvement in the catheters and implants across the years. Screening of silent ischemic complications postoperatively was not routinely performed, which might underestimate the true thromboembolic rate. Moreover, the variability in the follow-up imaging protocol, especially with the use of noninvasive modalities (i.e., CTA and MRA), introduces another bias, given that those modalities are less reliable in assessing endoleaks in fusiform aneurysms.

**CONCLUSIONS**

This is the largest study that evaluates the real-world practice trends in the treatment of posterior circulation aneurysms using flow diversion. Across the years, fewer basilar and vertebrobasilar junction aneurysms were treated, but more aneurysms of the vertebral artery. The average diameter of treated aneurysms has also decreased. In the treatment of posterior circulation aneurysms using flow diverters, the fate of covered branch vessels. J Neurointerv Surg 2016:8:1041–47 CrossRef Medline


Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.
Effective Dose Measurements of the Latest-Generation Angiographic System in Patients with Acute Stroke: A Comparison with the Newest Multidetector CT Generation

A. Brehm, K.A.T. Nguyen, K.A. Blackham, and M.-N. Psychogios

ABSTRACT

BACKGROUND AND PURPOSE: Patients with acute ischemic stroke are increasingly triaged with one-stop management approaches, resulting in baseline imaging with a flat detector CT scanner. This study aimed to estimate the effective dose to a patient of a novel cervical and intracranial flat detector CT angiography and a flat detector CT perfusion protocol and to compare it with the effective dose of analogous multidetector row CT protocols.

MATERIALS AND METHODS: We estimated the effective dose to the patient according to the International Commission on Radiological Protection 103 using an anthropomorphic phantom with metal oxide semiconductor field effect transistor dosimeters. Placement was according to the organ map provided by the phantom manufacturer. We used 100 measurement points within the phantom, and 18 metal oxide semiconductor field effect transistor dosimeters were placed on the surface of the phantom. All protocols followed the manufacturer’s specifications, and patient positioning and collimation were performed as in routine clinical practice. Measurements were obtained on the latest-generation angiography and multidetector row CT systems with identical placement of the metal oxide semiconductor field effect transistor dosimeters.

RESULTS: The estimated effective doses of the investigated perfusion protocols were 4.52 mSv (flat detector CT perfusion without collimation), 2.88 mSv (flat detector CT perfusion with collimation), and 2.17 mSv (multidetector row CT perfusion). A novel protocol called portrait flat detector CT angiography that has a z-axis coverage area comparable with that of multidetector row CT angiography had an estimated effective dose of 0.91 mSv, while the dose from multidetector row CT was 1.35 mSv.

CONCLUSIONS: The estimated effective dose to the patient for flat detector CT perfusion and angiography on a modern biplane angiography system does not deviate substantially from that of analogous multidetector row CT protocols.

ABBREVIATIONS: AIS = acute ischemic stroke; FDCT = flat detector CT; FDCT-A = flat detector CT angiography; FDCT-P = flat detector CT perfusion; ICRP = International Commission on Radiological Protection; MDCT = multidetector CT; MDCT-A = multidetector CT angiography; MDCT-P = multidetector CT perfusion; MOSFET = metal oxide semiconductor field effect transistor

Implementing a one-stop management workflow can substantially shorten door-to-groin and door-to-reperfusion times.\(^1\)\(^2\) It can, furthermore, lead to improved patient outcomes according to a recently published randomized controlled trial.\(^3\) The one-stop management workflow combines diagnostic imaging and interventional therapy of patients with acute ischemic stroke (AIS) in 1 room—the angiography suite. Flat detector CT (FDCT) is used for the initial diagnostic imaging rather than the traditional approach in which the patient must first be transported to the multidetector CT (MDCT) room for diagnostic imaging and then subsequently to the angiography suite for treatment.\(^1\) One possible disadvantage of FDCT compared with MDCT is the limited coverage of FDCT angiography (FDCT-A), because it is impossible to simultaneously visualize the intracranial vessels, the extracranial vessels, and the aortic arch. This limitation was recently partially resolved by the introduction of a new portrait FDCT-A prototype in which the detector is rotated by 90° for an increased FOV. Furthermore, a recent publication showed a strong correlation between FDCT-perfusion (FDCT-P) and multidetector row perfusion (MDCT-P) for the automated measurements of ischemic core and ischemic penumbra volumes in patients with AIS, suggesting that FDCT-P can be used as effectively and reliably as MDCT-P.\(^4\) Despite the growing use of these protocols, the effective dose to the patient and, more specifically, the dose to the lens of the eye were not systematically compared with analogous MDCT protocols.
In the present study, we used a phantom to measure the effective dose to the patient and the eye lens dose of FDCT-P and portrait FDCT-A and to compare the results obtained with those obtained from analogous MDCT protocols.

**MATERIALS AND METHODS**

**Phantom**
We used an adult male ATOM phantom 701-C (Computerized Imaging Reference Systems) to measure the effective dose (Fig 1); the phantom represents the body of a male human with a height of 173 cm and a body weight of 73 kg. The phantom consists of averaged materials for soft, bone, lung, and brain tissues. The phantom is equipped with 39 slices of 2.5-cm thickness, all of them having cavities for detector placement in a 1.5 x 1.5 cm grid with a 0.5-cm diameter.

**Dosimeters**
For assessing the organ dose, we used metal oxide semiconductor field effect transistor (MOSFET) TN 1002RD-H dosimeters used with the MobileMOSFET system, model TN-RD-70-W (Best Medical Canada). The MobileMOSFET system consists of a remote monitoring dose-verification software, a Bluetooth wireless transceiver, and a reader module that acts as a channel between the MOSFET dosimeters and software. Up to 5 MOSFET dosimeters can be connected to 1 reader. In this study, 8 readers and 40 MOSFET dosimeters were used for simultaneous measurements. Before the measurements, all MOSFET dosimeters were calibrated. For calibration purposes, each of the MOSFET dosimeters was irradiated with a specified dose. The dose was then measured with an ionization chamber (PM500-CII 52.8210; Capintec) connected to the Unidos dosimeter (PTW Freiburg) as described before.5

**C-Arm Angiography and CT Systems**
We performed the measurements on an Artis icono biplane angiography system (Siemens Healthineers AG) with a Neuro Tabletop and Mattress (https://www.sgmattress.sg/) and on a Somatom Force CT scanner (Siemens Healthineers AG) with syngo CT VB20 software. For measurements on the Artis icono system, the A-plane C-arm was placed in the anterior-posterior position and the FOV for 3D imaging was set in the head region of the phantom. The perfusion measurements on the Artis icono system were performed with and without collimation of the x-ray field (Fig 2). The craniocaudal collimation and positioning of the phantom was applied according to the procedure-specific settings used in the clinical workflow at
the University Hospital Basel. The scan z-coverage in the collimated setup was 15 cm, derived from averaging the scan z-coverage of all scans obtained at the University Hospital Basel. The protocol is described in detail elsewhere. For perfusion measurements on the Somatom Force CT scanner, we used the standard acquisition protocol from the manufacturer. The scan z-coverage for perfusion measurements on the Somatom Force system is 11.4 cm.

In addition, we investigated the 3D imaging protocols for visualization of the carotid and intracranial arteries. The acquisition protocols for both systems were used as in clinical practice. For measurements on the Artis icono system, the detector was used in portrait mode without collimation (Fig 3). The imaging protocol with the detector in portrait mode (ie, rotated by 90°) is the latest 3D imaging prototype on the Artis icono. For 3D imaging of the carotid arteries on the Somatom Force CT scanner, the CARE Dose 4D and CARE kV technologies (Siemens) were applied. To ensure comparable results, we used the same z-coverage area for the FDCT-A and MDCT angiography (MDCT-A), excluding the aortic arch. We summarized the technical parameters of the 3D acquisition protocols for both systems in Tables 1 and 2.

**Estimation of Effective Dose**

To estimate the organ dose, we placed the MOSFET dosimeters in 118 measurement points in the ATOM phantom and on the phantom surface. The locations of the measurement points within the phantom were defined according to the organ map provided by the phantom manufacturer. These locations represent the anatomic positions of different organs (brain, eye lenses, salivary glands, thyroid, esophagus, bone surface, lung, liver, stomach, pancreas, adrenal gland, small intestine, spleen, kidney, red bone marrow, bladder, gonads, and so forth). To fit the MOSFET dosimeters within the phantom holes, we placed each dosimeter into the tissue-equivalent holder. The skin dose was measured by 18 dosimeters positioned on the surface of the phantom at slices 4, 10, 17, 28, and 38. We used

![Figure 3](image-url)

**FIG 3.** The position of the investigated head area of the phantom for carotid measurement on the Artis icono in frontal (left) and lateral (middle) views and on the Somatom Force in the lateral view (right).

| Table 1: Technical parameters of investigated 3D imaging protocols (brain perfusion, portrait angiography with head and neck angiography), measured eye lens dose (for left, right eye and mean), and effective dose for the anthropomorphic ATOM male phantom on Artis icono |
|---|---|---|
| **3D Imaging Protocol Parameters** | **60s DCT Head Perfusion** (10 Rotations) | **4s DCT Head Portrait** (1 Rotation) |
| Reconstructed volume size (diameter × height) (cm) | 24 × 18.5 (uncollimated) | 24 × 15” |
| Tube voltage (nominal) (kV) | 70 | 70 |
| Dose/frame (nominal) (nGy/f) | 360 | 360 |
| Rotation range | 200° | 200° |
| Angulation step (df) | 0.8 | 0.8 |
| Eye lens dose (mean) (mGy) | 65 and 69 (SD, 67) | 54 and 58 (SD, 56) |
| Estimated effective dose (mSv) | 4.52 | 2.88 |

**Note:**—60s DCT indicates 60s Dyna-CT; 4s DCT, 4s Dyna CT.

| Table 2: Technical parameters of investigated protocols (brain perfusion and head and neck angiography), measured eye lens dose (for left, right eye and mean), and effective dose for the anthropomorphic ATOM male phantom on Somatom Force |
|---|---|---|
| **3D Imaging Protocol Parameters** | **NeuroVPCT_Prolonged,** DynMulti4D | **NeuroVPCT_Prolonged,** Head Angio |
| Scan coverage (cm) | 11.4 | 24 |
| Tube voltage (kV) | 70 | 90 |
| Scan duration (sec) | 60 | NA |
| Number of cycles @ 1.5 seconds cycle time | 30 | NA |
| CTDIvol (mGy) | 144.2 | 19.9 |
| DLP (mGy × cm) | 2169.5 | 550 |
| Eye lens dose (mean) (mGy) | 119 and 125 (SD, 122) | 11.8 and 11.7 (SD, 11.8) |
| Estimated effective dose (mSv) | 2.17 | 1.35 |

**Note:**—CTDIvol indicates volume CT dose index; DLP, dose-length product; NA, not applicable.
The estimated effective dose to a patient of the FDCT-P protocol was 4.52 mSv without collimation and 2.88 mSv with collimation. The collimated dose of FDCT-P was 33% higher than the measured dose on MDCT (2.17 mSv). Eye lens doses of the perfusion protocols were 2-fold higher on MDCT (122 mGy) compared with uncollimated FDCT (67 mGy) and collimated FDCT (56 mGy).

The estimated effective dose to a patient of the portrait FDCT-A (0.91 mSv) was 48% lower than the effective dose of the corresponding MDCT-A protocol (1.35 mSv). The eye lens dose was also lower at 8 mGy compared with 11.8 mGy.

In all measurements, at least 95% of the radiation was recorded in the brain, red bone marrow, salivary glands, lung, esophagus, and thyroid. The remaining organs received <5% of the radiation, rendering them relatively clinically unimportant. A detailed overview of the dose distribution can be found in the Tables 3 and 4.

**RESULTS**

We summarized the estimated effective dose to the patient values for the investigated FDCT protocols in Table 1 and the investigated MDCT protocols in Table 2.

The estimated effective dose to a patient of the FDCT-P protocol was 4.52 mSv without collimation and 2.88 mSv with collimation. The collimated dose of FDCT-P was 33% higher than the measured dose on MDCT (2.17 mSv). Eye lens doses of the perfusion protocols were 2-fold higher on MDCT (122 mGy) compared with uncollimated FDCT (67 mGy) and collimated FDCT (56 mGy).

The estimated effective dose to a patient of the portrait FDCT-A (0.91 mSv) was 48% lower than the effective dose of the corresponding MDCT-A protocol (1.35 mSv). The eye lens dose was also lower at 8 mGy compared with 11.8 mGy.

In all measurements, at least 95% of the radiation was recorded in the brain, red bone marrow, salivary glands, lung, esophagus, and thyroid. The remaining organs received <5% of the radiation, rendering them relatively clinically unimportant. A detailed overview of the dose distribution can be found in the Tables 3 and 4.

**DISCUSSION**

Our study has the following main findings: 1) Collimation has a powerful impact on the estimated effective dose to the patient because it can reduce the dose by almost 50%, 2) the estimated effective dose to the patient of the collimated FDCT-P and of the portrait FDCT-A does not deviate substantially from analogous MDCT protocols, and 3) the eye lens dose appears to be similar on FDCT and MDCT.

Two prior publications estimating the effective dose to a patient of FDCT-P on predecessor systems (Artis Q and Artis Axiom; Siemens Healthineers AG) reported higher doses with 5.9 and 5.1 mSv, respectively. However, these measurements must be compared with our uncollimated dose results (4.52 mSv) because no use of collimation was reported in either publication. In this case, a 12% difference in the measurements of Struffert et al is well within the margin of error; however, the 30% difference compared with our prior publication is outside this margin. This difference could partly be explained by a different phantom and fewer measurement points. Furthermore, the directly and indirectly irradiated tissues were not analyzed separately in our previous publication, possibly leading to an overestimation of the organ doses, especially red bone marrow.

From a clinical standpoint, the collimated dose of FDCT-P is more important because the z-coverage can easily be reduced to parallel the parameters of MDCT-P.

Even more relevant is our result that the effective dose estimated for the collimated FDCT-P is only slightly higher than that with MDCT-P (33%), despite the considerably larger z-axis coverage area of 15 cm compared with the MDCT-P coverage of 11.4 cm (Fig 2 for reference). Nevertheless, MDCT-P for the triage
of patients with late-window stroke has been validated in 2 randomized controlled trials,\textsuperscript{11,12} while the technical equivalence of FDCT perfusion has yet to be established. A recent pilot trial of 13 patients showed promising results with high correlation for both ischemic core volume measurements on FDCT-P and MDCT-P and for follow-up infarct volumes.\textsuperscript{4} We presuppose that our current results will contribute to the effort to reproduce such clinically meaningful results in larger patient collectives.

While it is widely accepted that FDCT offers higher spatial resolution for high-contrast structures (eg, vessels and bones), an essential shortcoming of FDCT-A is the limited z-coverage area.\textsuperscript{13} This problem is largely solved by the development of a portrait FDCT-A protocol, which has a z-coverage area large enough to simultaneously visualize the circle of Willis and the intra- and extracranial carotid arteries down to their origins (Fig 4). This information is vital for planning interventions because the aortic arch configuration can influence the optimal vascular access site (eg, radial versus femoral) and for determining which catheters should be used for navigation to the intracranial vessels.\textsuperscript{14,15} Another difference between FDCT-A and MDCT-A is that the timing of the acquisition after the injection of the contrast media bolus is operator-dependent. In contrast to MDCT-A, in which an automated Hounsfield unit threshold trigger is typically used for the start of the scan (by placing an ROI in the ascending aorta), the scan start has to be executed manually in FDCT-A.\textsuperscript{16} To address this difference, we developed a “bolus-watching” protocol in which DSA is used to monitor the visible influx of contrast media into the common carotid arteries (following a 10-second delay after intravenous contrast injection) to manually initiate the 3D angiography.\textsuperscript{16} According to previous measurements, this protocol adds only a minor radiation dose.\textsuperscript{6}

The overall dose for perfusion and angiography on FDCT is, at 3.79 mSv, only slightly higher (8%) compared with MDCT. This difference is well below the accuracy threshold for the effective dose for patient measurements and, therefore, could be neglected. Both protocols (perfusion and angiography) are often used, even in the early time window of thrombolysis because it is more commonly recognized that perfusion plays an important role in the detection of medium and distal vessel occlusions,\textsuperscript{17,18} ie, as potential targets for mechanical thrombectomy.\textsuperscript{19} Recent measurements have shown an effective dose of 2 mSv for noncontrast FDCT parenchymal imaging, which is comparable with that of MDCT.\textsuperscript{20,21} Because the cumulative dose of commonly used protocols in one-stop management of acute ischemic stroke does not differ substantially from routine MDCT, we anticipate that our findings will mitigate dose considerations in the triage decisions of patients with AIS.

The lower dose to the lens of the eye from FDCT-P compared with MDCT-P is explained by the reduced range of rotation of the flat detector, which is between 200° and 220° for most protocols with the radiation source being, importantly, below the patient.\textsuperscript{22} However, the eye lens doses for the perfusion protocols have to be interpreted with caution because we were not able to incline the head of the phantom. Flexing the head toward the chin, as is performed for MDCT-P at our institution, might reduce the direct irradiation of the lens and, therefore, might reduce the dose substantially.\textsuperscript{23} With regard to the standard MDCT-A protocol, the effect of inclining the head should not have a relevant proportional impact due to the large z-coverage area. However, there is an alternative protocol (HeadAngio\_Xcare; Siemens Healthineers AG) using an organ-based tube-current modulation, which can reduce the eye lens dose. In this protocol, the direct x-ray exposure to the eye lens is reduced by lowering the x-ray tube current for a certain range of projection angles when the eye lenses are facing toward the x-ray tube. This protocol was not evaluated in this article. Overall, the certainty for the magnitude of the reduction of the lens dose is low because we were not able to incorporate all influencing factors.

One major strength of our study is that we used an anthropomorphic phantom with an identical measurement setup for both systems. This feature allows a reproducible comparison between different x-ray imaging modalities, acquisition protocols, and studies. This approach is superior to other measurement approaches, such as simulations or CT dose index–based approaches because the modern C-arm devices typically use a 210° rotation compared with MDCT, which has a 360° rotation. In the case of FDCT, this difference leads to a nonuniform dose distribution with the peak dose occurring in the central plane, on the side of the phantom closest to the radiation source.\textsuperscript{24} Furthermore, the larger x-coverage of FDCT compared with MDCT renders the traditional, weighted CT dose index approaches impractical.\textsuperscript{22} Another strength of our study is that we measured analogous protocols on both systems, enabling us to directly compare the effective dose to the patient from modern stroke imaging protocols.

However, our study has some limitations as well. The ATOM phantom is constructed to represent a broad cohort of different patients. Therefore, the actual dose to a patient might differ from the dose measured with the ATOM phantom. Because the ICRP...
103 does not define the distribution and number of measurement points within the phantom, the investigator typically chooses these parameters. This situation can lead to differences in the estimated effective dose, depending on the number and position of measurement points within an anthropomorphic phantom. In addition, Roser et al. showed that the organ-equivalent dose values calculated from discrete measurements might underestimate the simulated organ dose that was calculated on the basis of a continuous dose distribution by up to 50%. In the clinical routine, variance to our phantom study could occur not only with the collimation of the x-ray field but also the with the ROI, through normal practitioner and patient differences. However, because these parameters can be largely standardized in stroke protocols and because the coverage areas of the FDCT were at least as large as on the MDCT, our collimated results should be generalizable to clinical routine.

CONCLUSIONS

The estimated effective dose to the patient for FDCT-P and FDCT-A protocols on a modern biplane angiography system does not deviate substantially from analogous MDCT protocols.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the technical support and assistance with phantom experiments from Stepina Elizaveta, PhD, and Brehm Marcus, PhD, from Siemens Healthineers, Forchheim, Germany.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES

Correlation of Collateral Scores Derived from Whole-Brain Time-Resolved Flat Panel Detector Imaging in Acute Ischemic Stroke


ABSTRACT

BACKGROUND AND PURPOSE: Flat panel detector CT imaging allows simultaneous acquisition of multiphase flat panel CTA and flat panel CTP imaging directly in the angio suite. We compared collateral assessment derived from multiphase flat panel CTA and flat panel CTP with collateral assessment derived from DSA as the gold-standard.

MATERIALS AND METHODS: We performed a retrospective analysis of patients with occlusion of the first or second segment of the MCA who underwent pre-interventional flat panel detector CT. The hypoperfusion intensity ratio as a correlate of collateral status was calculated from flat panel CTP (time-to-maximum > 10 seconds volume/time-to-maximum > 6 seconds volume). Intraclass correlation coefficients were calculated for interrater reliability for the Calgary/Menon score for multiphase flat panel CTA and for the American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) score for DSA collateral scores. Correlations of the hypoperfusion intensity ratio, multiphase flat panel CTA score, and the ASITN/SIR score were calculated using the Spearman correlation.

RESULTS: From November 2019 to February 2020, thirty patients were included. Moderate interrater reliability was achieved for the ASITN/SIR DSA score (0.68; 95% CI, 0.50–0.82) as well as for the Calgary/Menon multiphase flat panel CTA score (0.53; 95% CI, 0.29–0.72). We found a strong correlation between the ASITN/SIR DSA and Calgary/Menon multiphase flat panel CTA score (ρ = 0.54, P = .002) and between the hypoperfusion intensity ratio and the Calgary/Menon multiphase flat panel CTA score (ρ = −0.57, P < .001). The correlation was moderate between the hypoperfusion intensity ratio and the ASITN/SIR DSA score (ρ = −0.49, P = .006). The infarct core volume correlated strongly with the Calgary/Menon multiphase flat panel CTA score (ρ = −0.66, P < .001) and the hypoperfusion intensity ratio (ρ = −0.76, P < .001) and correlated moderately with the ASITN/SIR DSA score (ρ = −0.46, P = .01).

CONCLUSIONS: The Calgary/Menon multiphase flat panel CTA score and the hypoperfusion intensity ratio correlated with each other and with the ASITN/SIR DSA score as the gold-standard. In our cohort, the collateral scoring derived from flat panel detector CT was clinically reliable.

ABBREVIATIONS: ASITN/SIR = American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology; FDCT = flat panel detector CT; FDCTP = flat panel detector CTP; HIR = hypoperfusion intensity ratio; ICC = intraclass correlation coefficient; mCTA = multiphase CTA; mFDCTA = multiphase flat panel detector CTA; rCBF = relative CBF; Tmax = time to maximum

In acute ischemic stroke, sufficient and effective collaterals are important, correlate with favorable outcome, and may be used for patient selection.1-3 The gold-standard American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) score for DSA4 is the most commonly used scale for visual collateral scoring.5 Two alternative collateral scores are the Calgary/Menon score for multiphase CTA (based on visual inspection)6 and the hypoperfusion intensity ratio (HIR) as a quantitative and thus objective estimation of the collateral supply. The HIR can be derived from perfusion imaging and is defined as the ratio of the volume of tissue with time to maximum (Tmax) > 10 seconds to the volume of tissue with Tmax > 6 seconds.7

The recently introduced whole-brain multiphase flat panel detector CT (FDCT) imaging allows acquisition of time-resolved whole-brain perfusion imaging directly in the angio suite by 10...
rotational sweeps. On the basis of flat panel detector CTP (FDCTP) source images, multiphase flat panel detector CTA (mFDCTA) and perfusion maps can be reconstructed. This technology enables direct transport of patients to the angio suite (“direct-to-the angio” approach), which, in turn, can improve in-hospital workflows, reduce the time to treatment, and may ultimately increase the chances of good clinical outcome.

While collateral scores are well-validated in conventional multiphase CTA (mCTA)/CTP, data on the evaluation of the collateral status derived from FDCTP imaging is scarce. FDCTP offers the unique possibility of validating and comparing cross-sectional collateral surrogates with the conventional DSA gold-standard, acquired at almost the same time.

The purpose of this study was to evaluate collateral imaging derived from FDCT as a cornerstone in its possible future use as a first-line stroke imaging technique (direct-to-the angio approach). We assessed interrater reliability and correlation of collateral scores derived from FDCTP (Calgary/Menon mFDCTA score, HIR) and from DSA (ASITN/SIR DSA score). Furthermore, we assessed the correlation of collateral scores with the size of infarct cores.

MATERIALS AND METHODS

The study protocol was approved by the Kantonale Ethikkommission Bern (reference ID 2018-02023). Informed consent was waived owing to the retrospective nature of the study. The data that support the findings of this study are available from the corresponding author on reasonable request.

Population

We included patients from November 2019 to February 2021 with M1 and M2 occlusions who underwent mechanical thrombectomy at our institution and pre-interventional FDCTP. Exclusion criteria were low-quality (qualitative and quantitative features not interpretable, eg, due to delayed contrast bolus arrival) FDCTP scans. Clinical data were extracted from the institutional stroke database or from the Clinical Information System.

Imaging Protocol

After neurologic examination on arrival at the emergency department, patients underwent either CT imaging (noncontrast CT, CTA, CTP) or MR imaging (DWI, FLAIR, SWI, MRA, MR Perfusion) and were subsequently transferred to the angio suite if the eligibility criteria for mechanical thrombectomy were fulfilled. The decision as to whether to perform pre-interventional FDCT imaging was at the discretion of the treating physician based on clinical reasoning. FDCT imaging provided additional information about the penumbra and infarct core volumes and collateral status, which allowed adjusting the treatment strategy accordingly.

FDCT imaging was performed with the patient under general anesthesia. Whole-brain imaging data were acquired using a biplane flat panel detector angiographic system (Artis icono; Siemens) by 10 rotational sweeps (each during 5 seconds) of the angiographic C-arm system around the patient. The first 2 sweeps served as mask runs, and the following 8 rotations recorded in-/outflow of contrast agent (60 mL Iopamiro 400; Bracco), which was started at the same time as the mask run via an 18G left or right cubital venous line.
Statistical Analysis

Normal distribution was tested using graphic distribution and the Shapiro-Wilk test. Data are displayed as number (percentage) and median (interquartile range) if not otherwise specified. No data of the examined variables were missing.

The ICC was used to calculate interrater reliability because it is fit to handle ordinal data.19 ICC estimates and their 95% confidence intervals were calculated on the basis of a single rating, absolute agreement, and the 2-way random effects model. Interpretation was as follows: 

- <0.5, poor;
- 0.5–0.75, moderate;
- 0.75–0.9, good; and
- >0.9, excellent reliability.19 As proposed by Koo et al,19 categories of agreement were determined on the basis of 95% confidence intervals, and if confidence intervals included 2 categories, agreement was described as transition (eg, moderate-to-good).

For correlation analysis, the consensus ratings for ASITN/SIR DSA scores and Calgary/Menon mFDCTA scores were used. Correlations were calculated using the Spearman correlation because the Spearman correlation can handle ordinal and non-normally distributed data. Spearman correlation coefficients were interpreted as follows: 

- ρ < 0.3, weak relationship;
- 0.3 ≤ ρ ≤ 0.5, moderate relationship;
- ρ > 0.5, strong relationship.20

In boxplot analyses, overall differences were compared using the Kruskal-Wallis test.

All statistical analyses were conducted using R (Version 4.0.2; http://www.r-project.org/).21 A 2-tailed P value < .05 was considered statistically significant.

RESULTS

Population

Of 36 patients, we excluded 6 patients due to bad FDCTP quality caused by delayed bolus arrival (n = 5) or a dispersed bolus (n = 1), leaving a final population of 30 patients for the final analysis (Online Supplemental Data). The median age was 76.5 years, 40% were women, and 21 patients presented with M1 occlusions. Baseline characteristics and distribution of patients according to the ASITN/SIR DSA score and the Calgary/Menon mFDCTA score are shown in the Online Supplemental Data.

Interrater Reliability

Interrater reliability was moderate-to-good for the ASITN/SIR DSA score (ICC estimate, 0.68; 95% CI, 0.50–0.82) and poor-to-moderate for the Calgary/Menon mFDCTA score (ICC estimate, 0.53; 95% CI, 0.29–0.72).

When considering only M1 occlusions, interrater reliability improved for the ASITN/SIR DSA score (ICC estimate, 0.75; 95% CI, 0.56–0.88) and for the Calgary/Menon mFDCTA score (ICC estimate, 0.66; 95% CI, 0.43–0.83).

Correlation of Collateral Scores

The Online Supplemental Data show the distribution of ASITN/SIR DSA versus Calgary/Menon mFDCTA consensus scores for each case.

We found strong correlations between ASITN/SIR DSA score and Calgary/Menon mFDCTA score (r = 0.54, P = .002) and between the HIR and the Calgary/Menon mFDCTA score (r = -0.57, P < .001), and moderate correlation between the HIR and ASITN/SIR DSA score (r = -0.49, P = .006). Again, when we considered only M1 occlusions, correlations among all scores were strong: between the ASITN/SIR DSA score and Calgary/Menon mFDCTA score (r = 0.65, P = .001), between the HIR and Calgary/Menon mFDCTA score (r = -0.56, P = .008), and between HIR and ASITN/SIR DSA score (r = -0.62, P = .003).

Comparing the HIR for distinct Calgary/Menon mFDCTA degrees revealed a trend for lower HIR values in increasing Calgary/Menon mFDCTA scores (overall difference, P = .006; Fig 1A). The same trend was present for the different ASITN/SIR DSA scores (overall difference, P = .035; Fig 1B).

Illustrative cases are shown in Fig 2.

Correlation of Collateral Scores and Infarct Core

We also found a trend of decreasing infarct volumes with better collateral scores (Fig 3). This trend was present for the Calgary/Menon mFDCTA score (overall difference, P = .002; Fig 3A) as well as for the ASITN/SIR DSA score (overall difference, P = .03; Fig 3B). Correlation with rCBF of <45% was moderate for the ASITN/SIR DSA score (r = -0.46, P = .01), strong for the Calgary/Menon (r = -0.66, P < .001), and strong for the HIR (r = 0.76, P < .001; Fig 3C).

DISCUSSION

This exploratory study has the following main findings: 1) Interrater reliability was moderate for the ASITN/SIR DSA score and the Calgary/Menon mFDCTA score, 2) collateral grading derived from FDCTP (mFDCTA, HIR) correlated with collateral grading derived from DSA as the gold-standard, and 3) collateral scores correlated with the size of infarct core.

Similar to previous studies, interrater reliability was only moderate for the ASITN/SIR DSA collateral score and the Calgary/Menon score for mFDCTA. Interrater reliability for the Calgary/Menon score of conventionally acquired mCTA was also moderate in the study of Kauw et al22 but excellent in other studies.6,23 A reason for our lower interrater reliability could be the inclusion of M2 occlusions in our study because it was not the case in the study of Lyndon et al23 and was not clear in the study of Menon et al.6 Additionally, our interrater reliability improved in both modalities.
when only considering M1 occlusions. Interrater reliability for the ASITN/SIR DSA collateral score for 19 readers was only poor in another study (generalized $\kappa = 0.16$).24

In a study including 24 patients, Maier et al9 found a strong correlation between the Calgary/Menon mFDCTA collateral score and the ASITN/SIR DSA collateral score (Pearson correlation coefficient, 0.86). However, collaterals were not graded by consensus but by a single rater. For trichotomized (poor, intermediate, excellent) mCTA and DSA scores, a Spearman correlation coefficient of 0.827 was reported.25 One explanation for our lower correlation of the Calgary/Menon mFDCTA score and the ASITN/SIR DSA score could be that we included a considerably higher proportion of M2 occlusions (30% in our study versus 18.5%25 and 4.2%,9 respectively). Another reason could be some incomplete pre-interventional DSA runs in which the selected DSA of the nonoccluded cervical and intracranial vessels were not performed, and consequently, the examination of collaterals and cross-flow was limited. This point, on the other hand, highlights an important advantage of mFDCTA, in which imaging of collaterals can be performed immediately pre-intervention with a single injection of contrast agent instead of selective angiographies of different vessels with the potential to cause complications as for example dissections or emboli.

Guenego et al26 found a significant correlation of the HIR derived from conventional CTP maps and DSA collaterals (Pearson correlation coefficient, $-0.327$; $P = .01$). Our correlation was substantially better, likely because we calculated the HIR from FDCTP in the angio suite, which was performed only a few minutes before the pre-interventional DSA. The correlation of the HIR and mFDCTA
reached similar correlation as HIR and mCTA derived from CT (Pearson correlation coefficient, −0.55; P < .001),23 highlighting again the clinical comparability of FDCT and CT. Imperfect interrater reliability is certainly a limitation of visual collateral assessment, and the particular strength of the HIR derived from FDCTP is that it provides an objective surrogate of collateral status that is also relatively easy to interpret.

The association of good collaterals and small infarct core is well-known.27 We could confirm these findings because the Calgary/Menon mFDCTA collateral score showed a strong correlation with the infarct core (rCBF <45%), similar to previous findings examining conventional CTP.28 Corroborating these results, we also found a strong correlation between the HIR and infarct core. Last, correlation of the ASITN/SIR DSA score and infarct core was moderate but nonetheless significant.

Our results show that measures of collateral status derived from FDCTP, namely mFDCTA and HIR, are clinically reliable and reached similar results compared with collateral scoring derived from CT in other studies. FDCTP collateral imaging provides some advantages over conventional CT/MR collateral imaging. First, it is acquired in the angio suite and, therefore, omits the delay between imaging and intervention caused by transfer of the patient. Second, mFDCTA makes selective DSA of nonoccluded vessels dispensable, potentially reducing the amount of contrast agent required and reducing the time to recanalization. Third, it allows the acquisition of 8 angiographic phases instead of 3 phases in the mCTA, providing more detailed information with better resolution in time of collateral flows.

Another important advantage of FDCTP is that it allows acquisition of nonenhanced brain CT, mFDCTA, and qualitative and quantitative perfusion maps simultaneously instead of the separately acquired sequences of CT/MR imaging.

Motion artifacts can have a severe negative impact on FDCTP imaging. Because it is our institutional guideline to perform all mechanical thrombectomies with the patient under general anesthesia, we were able to prevent the occurrence of motion artifacts and case exclusion was restricted to problems with the application of the contrast agent. Performing FDCTP without general anesthesia could compromise image quality and is a problem that remains to be resolved.

However, if technically adequate, pre-interventional FDCTP allows ruling out intracranial hemorrhage, determination of vessel occlusions, and, as we showed, assessing the collateral situation and estimating infarct core size. Our findings encourage the direct-to-the-angio approach, in which the patient is transported directly to the angio suite bypassing conventional CT or MR imaging. This approach can optimize in-hospital workflows, reduce time to treatment, and may ultimately improve clinical outcome.11–16 Furthermore, FDCTP imaging after incomplete recanalization could add significant value, for example, in deciding whether to extend thrombectomy or to stop.

Limitations

This study is limited by its retrospective and single-center study design. Furthermore, we did not include patients consecutively and present results of a relatively small and highly selected sample size. Due to our small sample size, we also did not cover all degrees of the ASITN/SIR DSA and Calgary/Menon mFDCTA collateral scores. However, other studies also reported only very few patients with either very high or very low collateral scores, representing a regular distribution with most patients with moderate-to-good collaterals. Last, we included only patients with large-vessel occlusions of the anterior circulation, and validation of FDCTP-derived collateral assessment in vessel occlusions of the posterior circulation is still needed. In summary, larger and prospective studies would be needed to overcome these limitations.

CONCLUSIONS

In our cohort, the Calgary/Menon mFDCTA collateral score and the HIR derived from FDCTP have good correlation with the ASITN/SIR DSA collateral score as gold-standard and with each other. Collateral scoring derived from FDCTP, especially the HIR as an objective measurement, is a promising tool to evaluate collateral status, but larger studies are needed to confirm our findings. In addition, our results support the implementation of the direct-to-the-angio approach, potentially reducing time to recanalization.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


Successful Reperfusion is Associated with Favorable Functional Outcome despite Vessel Perforation during Thrombectomy: A Case Series and Systematic Review


ABSTRACT

BACKGROUND: Arterial perforation is a potentially serious complication during endovascular thrombectomy.

PURPOSE: Our aim was to describe interventional approaches after arterial perforation during endovascular thrombectomy and to determine whether reperfusion remains associated with favorable outcome despite this complication.

DATA SOURCES: Data from consecutive patients with acute stroke undergoing endovascular thrombectomy were retrospectively collected between 2015 to 2020 from a single-center cohort, and a systematic review was performed using PubMed, EMBASE, and Ovid MEDLINE up to June 2020.

STUDY SELECTION: Articles reporting functional outcome after arterial perforation during endovascular thrombectomy were selected.

DATA ANALYSIS: Functional outcomes of patients achieving successful reperfusion (TICI 2b/3) were compared with outcomes of those with unsuccessful reperfusion in our single-center cohort. We then summarized the literature review to describe interventional approaches and outcomes after arterial perforation during endovascular thrombectomy.

DATA SYNTHESIS: In our single-center cohort, 1419 patients underwent endovascular thrombectomy, among whom 32 (2.3%) had vessel perforation and were included in the analysis. The most common hemostatic strategy was watchful waiting (71% of cases). Patients with successful reperfusion had a higher proportion of favorable 90-day mRS scores (60% versus 12.5%; \( P = .006 \)) and a lower mortality rate (13.3% versus 56.3%, \( P = .01 \)) than patients without successful reperfusion. Thirteen articles were included in the systematic review. Successful reperfusion also appeared to be associated with better outcomes.

LIMITATIONS: Given the low number of published reports, we performed only a descriptive analysis.

CONCLUSIONS: Arterial perforation during endovascular thrombectomy is rare but is associated with high mortality rates and poor outcome. However, successful reperfusion remains correlated with favorable outcome in these patients.

ABBREVIATIONS: EVT = endovascular thrombectomy; IQR = interquartile range; mTICI = modified TICI; sICH = symptomatic intracerebral hemorrhage

Endovascular therapy (EVT) is the standard of care for the treatment of patients with acute ischemic stroke due to large-vessel occlusion. Technologic advances have allowed development of new devices that have greatly improved the efficacy and safety of EVT compared with older-generation tools. Despite these improvements, as well as greater comfort and expertise among interventionalists across time, the procedure is still not exempt from severe complications. Arterial perforation, defined as contrast extravasation noticed during a procedural angiographic run, is one of the most serious and feared complications during EVT because it has been associated with poor functional outcomes and death. In large EVT trials, the rate of procedural arterial perforations varied between 0.6% and 4.9%.
When a vessel perforation occurs, some operators might be tempted to abort the procedure, with the risk of leaving the culprit occlusion untreated. Others may decide to pursue EVT once hemostasis is achieved, risking further arterial wall damage. However, little is known regarding the best approach when facing an arterial perforation during EVT and whether reperfusion still represents a reasonable goal in the context of such a complication.5

Therefore, we aimed to describe rescue therapies, management, and clinical outcomes after intraprocedural arterial perforation during EVT, and we sought to determine whether reperfusion is still associated with favorable outcome in this setting.

MATERIALS AND METHODS
This single-center observational study retrospectively analyzed clinical and imaging data prospectively gathered from a quality-improvement stroke database: the Montreal Neurovascular and STrokE Repository (MONSTER), maintained by a high-volume comprehensive stroke center in Montreal, Canada (Center Hospitalier de l’Université de Montréal).

Patient Population
All consecutive adult patients (18 years of age or older) treated with EVT for a large-vessel occlusion between March 1, 2015, and December 31, 2020, in whom arterial perforation occurred during EVT were included. Patients were included when an arterial perforation, defined as contrast extravasation noticed during a procedural angiographic run, was reported in radiology reports or clinical notes. Baseline demographics, stroke characteristics, and procedural details were collected, including information regarding the procedural technique, location of arterial occlusion, type of devices used (stent retriever, contact aspiration, and combined technique), number of passes, procedural duration, and the adopted rescue therapy after vessel perforation. All angiograms were reviewed by 2 interventional neuroradiologists (D.R. and B.M.). We then performed a descriptive analysis of the main steps undertaken after arterial perforation was observed.

Outcomes
Patients were divided in 2 groups with either successful reperfusion or unsuccessful reperfusion to correlate the angiographic results with functional outcomes. Successful reperfusion was defined as a modified TICI (mTICI) \(\geq 2b\) on the final intracranial run. Favorable functional outcome was defined as an mRS score of 0–2, as determined by a certified assessor at 90-day telephone or in-person follow-up. Proportions of hemorrhagic transformation, symptomatic intracerebral hemorrhage (sICH, defined as any hemorrhagic transformation associated with a 4-point increase in the baseline NIHSS score), and death at 90 days were also collected. All patients had immediate brain imaging following the end of their procedure (plain CT or DynaCT [Siemens] in the angio suite) and a 24-hour follow-up CT. The 24-hour CT was used to identify hemorrhagic transformation to better distinguish true hemorrhagic transformation from contrast staining.

Systematic Review of the Literature
We also performed a systematic review to identify articles reporting on outcomes of patients with acute ischemic stroke with arterial perforation during EVT. With the help of a medical librarian having expertise in systematic reviews (B.N.), we searched the PubMed database, EMBASE database, and Ovid MEDLINE with search terms including "perforation," "complication," "stent retriever," "contact aspiration," "thrombectomy," and "stroke" (see the Online Supplemental Data for the full search strategy). We included any study published between January 1, 2015, and June 30, 2020, specifically describing functional outcomes of patients who had arterial perforation observed during EVT. This date range was used to capture studies primarily completed in the modern EVT era. We selected only the references that met all of the following criteria: full-text articles in French or English, studies reporting 3-month clinical outcomes using the mRS score, and studies of patients with stroke undergoing EVT with a procedural arterial perforation. Using a free Web-based application,7 two reviewers (C.D., G.J.) independently screened all titles and abstracts. Full texts were obtained for any article considered relevant for the research question. Disagreements about eligibility were resolved by consensus. Data collection was completed by one author (C.D.) and reviewed by a second (G.J.). Collected data for each study included, when available, the following: baseline NIHSS score, thrombus location, ASPECTS, intravenous thrombolysis, type of anesthesia, EVT technique (stent retriever, contact aspiration, and a combined technique), mTICI score, causes of perforation, sICH, mRS score, and death at 90-day follow-up. The review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.8

Statistics
Differences between groups were tested using the \(\chi^2\) test of independence or the Fisher exact test for categoric variables and the Mann-Whitney \(U\) test for continuous variables. We described the population according to reperfusion status. Reperfusion status was dichotomized as either successful reperfusion (mTICI \(\geq 2b\)) or unsuccessful reperfusion (mTICI < 2b). The statistical level of significance was set at \(P < .05\). Data were analyzed using SPSS (Version 26.0.0.1; IBM). Given the expected low number of previously published reports, we did not plan to perform a statistical meta-analysis of the systematic review results and only performed a descriptive analysis.

The study was approved by our local institutional ethics board for retrospective data collection and review (project No. 20.028). The data supporting the findings of this study are available on reasonable request by a qualified investigator to the corresponding author.

RESULTS
From March 1, 2015, to December 31, 2020, a total of 1419 patients underwent EVT for acute ischemic stroke in our comprehensive stroke center, among whom 32 (2.3%) experienced a vessel perforation during EVT and were included in the study. The annual proportion of EVT procedures complicated by a perforation appeared to decrease during the study period (Online Supplemental Data). Follow-up at 90 days was unavailable for 1 (3%) patient. Baseline demographics and stroke characteristics are shown in the Online Supplemental Data.
Procedural Details
We extracted data from radiology reports and review of source angiographic images, though only 29 complete angiographic studies were available for analysis.

Endovascular thrombectomy was performed with the patient under general anesthesia in 5 patients (15.6%) (including 2 cases with conversion to general anesthesia after arterial perforation), under conscious sedation in 12 patients (37.5%), and under local anesthesia only in the remaining 15 patients (46.9%). The median number of device passes was 1 (interquartile range [IQR], 0–1.75). Vessel perforation occurred more often with the use of a microwire (n = 14, 43.8%) than with a microcatheter (n = 9, 28.1%). The cause of vessel perforation was unknown in the remaining 9 patients (28.1%) (Online Supplemental Data.). Patients with perforation due to a microwire had numerically better 3-month outcomes than patients with microcatheter perforation (6/14 patients, 46.2%, versus 3/9 patients, 33.3%, respectively).

After review of available angiograms, we found that 16 patients had a perforation identified only on microcatheter injection (16/29; 55.2%), 13 patients (44.8%) had a perforation noticed after ICA injection, and 13 patients (44.8%) had a perforation viewed on multiple runs. Outcomes of these patients were similar regardless of how perforation was identified or the number of runs on which the perforation was viewed (Online Supplemental Data).

Most intraprocedural vessel perforations occurred at a distal location: the MCA M2 in 18 patients (56.3%) and the anterior cerebral artery in 3 patients (9.4%). The remainder occurred proximally: the MCA M1 in 7 patients (21.9%) and the ICA in 2 patients (6.3%). Among patients with proximal perforation (ICA and M1), rescue therapy was performed in 4/9 patients (intermittent balloon inflation in 2 patients and parent vessel occlusion in 1 patient). In the last case, the microcatheter was left in place and cut and sewn at the groin in an attempt to seal the intracranial arterial perforation point. Contrast extravasation stopped spontaneously in the 5 remaining cases (Fig 2). Among patients with distal perforation, contrast extravasation was self-resolving in most (17/22 patients), parent vessel occlusion was performed in 4 cases, and intermittent balloon inflation was performed in the last case. “Self-resolving” is defined as contrast extravasation stopping without a specific intervention. The median number of runs before concluding that a bleed was self-resolving was 1 (IQR, 1–2).

Outcomes and Association with Reperfusion
Of 31 patients with an available 90-day mRS, 11 (34.4%) patients had favorable outcomes and 11 (34.4%) patients died (5 sICH, 3 cases of malignant edema, 2 cases of aspiration pneumonia, and 1 from multiple causes). Reperfusion (mTICI 2b/3) was successful in 16 (50%) patients and unsuccessful in 16 (50%) others, with baseline characteristics being similar in these 2 groups (Online Supplemental Data).

As shown in Fig 1, patients with successful reperfusion had a higher proportion of favorable functional outcomes at 90 days than patients without successful reperfusion (60% versus 12.5%, P = .006) as well significantly lower mortality rates (13.3% versus 56.3%, P = .01) (Table).

Among patients with successful reperfusion, vessel perforation occurred before achieving reperfusion in 13 cases (13/16, 81.3%) and after achieving reperfusion in 3 cases (18.7%). In these last 3 cases, a secondary medium vessel occlusion (A2 and M3) was targeted and recanalized, despite a reperfusion status of ≥TICI 2b.

Among patients with unsuccessful reperfusion, the procedure was aborted after vessel perforation in 5 patients, while in the remaining 11 cases, the procedure was stopped because of failure to achieve successful recanalization. Among these patients, 9 had unsuccessful thrombectomy despite several passes and 2 patients had persistent distal emboli.

Patients with self-resolving bleeding did not have a greater proportion of favorable outcomes than patients needing hemostatic intervention (14/23 patients [60.9%] versus 6/9 patients [66.7%]).

Intracerebral Hemorrhage
The median delay between the groin puncture and control imaging was 18 hours (IQR, 13–24 hours). One patient died within 24 hours before any follow-up imaging was performed. All patients had an SAH on their 24-hour CT. Intraparenchymal hemorrhage of any type occurred in 14 patients (37.5%), of whom 6 (18.8%) had sICH (Table). Among patients with sICH, 4 patients had a distal perforation (distal M2, M3, or A2) and 2 patients had a proximal perforation (M1 segment).

Systematic Review
The initial literature search yielded 6052 articles. After all titles and abstracts were screened by C.D. and G.J., 5969 articles were considered irrelevant. Of the remaining 83 articles, 70 were excluded for
incorrect outcome assessments, wrong population, wrong study design, and wrong publication type (abstract only, language other than French or English), leaving a total of 13 studies eligible for analysis ($n = 37$ patients; Online Supplemental Data: PRISMA diagram). Eight studies were cohort studies, and 5 were case reports (Online Supplemental Data). The median baseline NIHSS score was 14.5 (IQR, 11.75–19). A stent retriever was used in most cases (28/37 cases); contact aspiration, in 13/37 cases; and combined therapy, in 1 case. Nine patients had multiples passes using different techniques. Vessel perforation occurred more often in distal branches (16/37 cases; 43%), while 14 patients (38%) had proximal vessel perforation, and the exact location was not detailed in the remainder.

In most cases (23/37, 62%), the cause of vessel perforation was not described. For those in whom the cause was mentioned, 9 patients (24%) had vessel perforation due to a microwire; 4 patients (11%), due to a microcatheter; and 1 patient (0.03%), due to a strong contrast injection. Different hemostatic strategies were described for 26 patients: 1) procedural abandonment without any additional maneuver despite a persistent intracranial occlusion (7 cases); 2) inflation of an intracranial balloon (8 cases); 3) parent vessel occlusion using coils or glue (6 cases); or 4) watchful waiting (no intervention performed because of spontaneous regression of bleeding) in 2 cases. In 1 case, despite inflation of an intracranial balloon catheter, bleeding persisted, and therapeutic occlusion using coils was performed.

In all studies included in this literature review, the functional outcome at 3 months was available for 35 of 37 patients. The outcomes were poor (median mRS, 6 [IQR, 4–8]; only 9 patients [9/35, 26%] had a favorable outcome (mRS, 0–2) at 3 months, and mortality was high (20/35 cases, 57%). Both reperfusion status and outcome at 3 months were available for 34 patients. Although formal statistical analysis was not possible due to an overall paucity of data in the published reports, the median mRS appeared slightly better in patients with successful reperfusion

<table>
<thead>
<tr>
<th>Follow-up</th>
<th>All Patients ($n = 32$)</th>
<th>mTICI &lt; 2b ($n = 16$)</th>
<th>mTICI ≥ 2b ($n = 16$)</th>
<th>P Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIHSS day 1</td>
<td>18 (9–24)</td>
<td>22 (219–24)</td>
<td>13 (59–21)</td>
<td>.04</td>
</tr>
<tr>
<td>mRS at 3 months$^b$</td>
<td>4 (29–6)</td>
<td>6 (49–6)</td>
<td>2 (159–5)</td>
<td>.01</td>
</tr>
<tr>
<td>Favorable outcome (mRS, 0–2)</td>
<td>11 (34.4)</td>
<td>2 (12.5)</td>
<td>9 (60.0)</td>
<td>.006</td>
</tr>
<tr>
<td>Death at 3 mo</td>
<td>11 (34.4)</td>
<td>9 (56.3)</td>
<td>2 (13.3)</td>
<td>.01</td>
</tr>
<tr>
<td>Safety outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any hemorrhagic transformation</td>
<td>15 (46.9)</td>
<td>6 (40.0)</td>
<td>9 (56.3)</td>
<td>.4</td>
</tr>
<tr>
<td>sICH</td>
<td>6 (18.8)</td>
<td>3 (20.0)</td>
<td>3 (18.8)</td>
<td>.7</td>
</tr>
<tr>
<td>SAH</td>
<td>28 (87.5)</td>
<td>14 (93)</td>
<td>14 (87.5)</td>
<td>.6</td>
</tr>
</tbody>
</table>

$^a$Values are presented as No. (%), mean (SD), or median (IQR).

$^b$Follow-up at 3 months was unavailable for 1 patient in the unsuccessful reperfusion group.
DISCUSSION

Our findings demonstrate that vessel perforation in the context of EVT for acute stroke is infrequent but may result in a high rate of mortality and poor functional outcome. In our series, the proportion of patients having this complication was similar to that reported in recent EVT randomized trials (0.6%–4%), registries, and a previous cohort study by Mokin et al (1%). However, our results suggest that patients might, nevertheless, do better despite perforation if successful reperfusion is achieved.

Vessel perforation is arguably one of the most serious and feared complications during EVT and is associated with high rates of mortality. The risk of vessel perforation is increased during “blind maneuvering” while trying to gain access to occluded intracranial vessels with a microwire or microcatheter and while withdrawing a stent retriever. Vessel perforation tends to involve more distal vessel segments: 65% of cases in our study and 61% in our literature review. This finding is particularly relevant because the field is moving toward more aggressive recanalization of distal vessel occlusions, with upcoming trials evaluating the role of EVT in such patients (NCT05029414). However, the clinical impact of distal perforation might be less severe than that of proximal perforation (ICA or M1). In our cohort, rescue therapy was performed more often in patients with proximal perforation, but outcomes were similar regardless of perforation site.

It is usually thought that iniprocedural vessel perforation requires immediate action to achieve hemostatic control, such as blood pressure reduction and/or the interruption or reversal of any ongoing thrombolytic agent or blood thinners, temporary intracranial balloon occlusion, or parent vessel occlusion by injection of either liquid embolic agents or detachable coils. These maneuvers were used in most patients found in our systematic review, other than cases in which the procedure was simply aborted prematurely. However, in our cohort, most cases of contrast extravasation resolved spontaneously (71.9%) after the device or microcatheter was withdrawn. In some cases, the offending thrombus itself may provide effective hemostasis when a perforation occurs in the vasculature distal to the occlusion. On the other hand, parent vessel occlusion may potentially result in major stroke with severe disability and could increase the risk of poor clinical outcome and mortality.

In our series, as well as in previously published reports, procedural perforations during EVT were associated with overall high mortality rates and low rates of good clinical outcome. Compared with outcomes found in the major EVT trials and in most large EVT registries, functional outcomes of patients with vessel perforation remain relatively poor. However, such poor clinical outcomes might be due to the absence of reperfusion rather than cerebral hemorrhage. The decision to resume or abort EVT should be based on stroke severity, hemostatic control, technical difficulty, and the safety of pursuing thrombectomy, while always being aware that successful reperfusion appears to be associated with better outcomes and lower mortality in this population.

There are several suspected risk factors for vessel perforation, notably a distal occlusion, the presence of arterial tortuosity, and intracranial atherosclerosis. Moreover, some clot types can be more difficult to cross with a microcatheter and microwire, thus increasing the risk of traumatic vessel injury and perforation. Contact aspiration does not always require crossing the clot with a microcatheter and might intuitively seem safer than stent retrievers in this regard. However, a randomized trial comparing both techniques did not show a significant difference in vessel perforation. Some authors have suggested that crossing the clot with a wireless microcatheter may reduce the risk of vessel perforation.

In our cohort, functional outcome and mortality at 3 months were better than in the literature review. Most studies reporting procedural complications, including vessel perforation, described only severe cases with poor outcomes. Conversely, in our study, we reported all cases of perforation, which could be more representative of real life than smaller series or case reports. Since the widespread adoption of EVT following the major randomized trials, the tools and techniques available have continuously improved, and in our center, the rate of vessel perforation decreased from 3% in 2015 to 1.6% in 2020.

Despite being a larger cohort than those in previously published reports, our study has several limitations, including its single-center, retrospective design, a relatively small sample size, and the heterogeneity in the management of complications. This last limitation reflects the known variety of practices among neurointerventionalists and stroke physicians regarding the management of vessel perforation during EVT. Because this complication is, fortunately, rare, the limited number of cases precluded the use of statistical analysis to reliably determine which clinical or technical variables were associated with favorable outcome. We did not assign degrees of severity to the perforations, given the lack of a standardized angiographic definition and because procedural imaging of the perforation varied widely among cases. Finally, the 90-day mRS was assessed by raters who were not necessarily blinded to perforation status, and although performed by certified assessors, the mRS is known to have only fair-to-moderate interobserver reliability.

CONCLUSIONS

Procedural vessel perforation during EVT is a rare-but-serious complication, associated with high mortality and poor clinical outcome. However, successful reperfusion remains correlated with favorable outcome in these patients and can be pursued when technically safe and feasible.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


24. Haussen DC, Ferreira IM, Barreira C, et al. Active reperfusion hemorrhage during thrombectomy: angiographic findings and real-time correlation with the CT ”spot sign.” *Interv Neuroradiol* 2018;24:77–82 CrossRef Medline


MR Imaging Findings of Carcinoma Ex Pleomorphic Adenoma Related to Extracapsular Invasion and Prognosis


ABSTRACT

BACKGROUND AND PURPOSE: MR imaging can reflect the pathologic progression of carcinoma ex pleomorphic adenoma (CXPA). This study aimed to identify the imaging findings related to extracapsular invasion of CXPA. Additionally, the pathologic background of these findings was investigated.

MATERIALS AND METHODS: This retrospective study included 37 patients with histologically confirmed CXPA. Three radiologists independently evaluated whether the CXPA showed the following characteristic MR imaging findings: border, capsule, the corona sign on fat-saturated T2WI and contrast-enhanced fat-saturated TIWI, and the black ring sign. The corona sign appeared larger on fat-saturated and/or contrast-enhanced fat-saturated TIWI than on TIWI. The black ring sign was defined as an intratumoral nodule with a thick low-intensity rim on T2WI. Interreader agreement of the visual assessment was performed using k analysis, and MR imaging and histopathologic findings were also correlated. Kaplan-Meier survival and the log-rank test were used to estimate the 3-year disease-free survival.

RESULTS: MR imaging findings, especially peritumoral findings, showed a significant difference between invasive and noninvasive CXPA. The reliability was poor for the border and capsule. In contrast, it was good for the corona sign on fat-saturated and contrast-enhanced fat-saturated TIWI and the black ring sign. Pathologically, the corona sign reflected the invasiveness of the tumor and inflammatory cells, while the black ring sign reflected hyalinization or fibrosis. The corona sign also showed a significant difference in the 3-year disease-free survival.

CONCLUSIONS: MR imaging findings, including the corona and black ring signs, reliably differentiated invasive and noninvasive CXPA. The corona sign can be used as a prognostic factor for CXPA.

ABBREVIATIONS: CE = contrast-enhanced; CXPA = carcinoma ex pleomorphic adenoma; FS = fat-saturated; PA = pleomorphic adenoma

Carcinoma ex pleomorphic adenoma (CXPA) arises from a pre-existing pleomorphic adenoma (PA). It is more likely to occur in cases of PA with multiple recurrences or requiring long-term follow-ups. CXPA comprises 3.6% and 11.6% of all salivary gland tumors and malignancies, respectively, and is most often found in the parotid gland.1,2

Carcinoma in PA develops in the luminal cells of the tubular structures, and the malignant cells then destroy the pre-existing PA structure.3-5 CXPA is classified by the World Health Organization as noninvasive, minimally invasive, or frankly invasive.6 In CXPA, the carcinoma is considered noninvasive if the malignant cells are confined within the pre-existing PA capsule and invasive if the malignant cells cross over the capsule.6,7 Noninvasive and minimally invasive CXPAs have a better prognosis and can be treated with localized resection. In contrast, frankly invasive CXPAs have a poor prognosis and require widespread resection, including the margins around the tumor.6-8

We hypothesized that MR imaging findings could reflect this pathologic spectrum of CXPA. CXPA may initially resemble PA, and the imaging findings are likely to change according to the pathologic changes that occur with carcinomatous invasion. The internal components of CXPA can show various imaging findings, depending on the proportions of the mucinous stroma and hyalinization/fibrosis proportions in the pre-existing PA and the histologic diversity of the carcinoma component.9,10 Hence, we predicted that the imaging features of CXPA could be captured by focusing on the tumor margins rather than on its internal morphology.
FIG 1. Corona sign on FS-T2WI and CE-FS-T1WI. Invasive CXPA (salivary duct carcinoma) of the right parotid gland in a 77-year-old man. MRI shows a homogeneous low-intensity tumor on axial TIWI (A), mixed high- and low-intensity signals on axial FS-T2WI (B), and irregularly enhanced signal on axial CE-FS-T1WI (C). The tumor size on FS-T2WI and CE-FS-T1WI (solid line) was larger than that on TIWI (dotted line). We defined these MRI findings as corona signs on FS-T2WI and CE-FS-T1WI.

FIG 2. Black ring sign. Invasive CXPA (high-grade mucoepidermoid carcinoma) of the right submandibular gland in a 76-year-old man. MRI shows a nodule with a thick low-intensity rim (A and B, arrows) and an intra-ring component with mixed high- and low-intensity signals on axial and coronal T2WI (A and B). We defined this MRI finding as the black ring sign.

Only a few case reports describing the radiologic features of CXPA have been published. A previous review showed encapsulated components with a hypointense rim on T2WI and fat-saturated (FS) T2WI in some CXPA cases, which may be a characteristic finding.3 However, the clinical significance of this finding has not been fully investigated.

Thus, we aimed to reveal the imaging spectrum of CXPA, specifically focusing on the imaging findings reflecting invasion beyond the PA capsule. In addition, we correlated the imaging findings with the pathologic background and subsequently evaluated the contribution of the imaging findings to prognosis.

MATERIALS AND METHODS

Study Participants

This retrospective study was approved by Chiba University Hospital review board, and the need for written informed consent was waived.

We found 41 potentially relevant cases via a computer search of the pathologic records between August 2007 and April 2020 at Chiba University Hospital. The following keyword phrase was used during the search: “carcinoma ex pleomorphic adenoma.”

Patients were excluded for the following reasons: 1) absent or inaccessible MR images because the MR imaging was performed about 15 years ago (n = 1), 2) no head and neck MR imaging because of CXPA metastasis to the vertebral body (n = 1), 3) nonstandard MR imaging protocol (only intracranial MR imaging) (n = 1), and 4) lack of surgical-pathologic confirmation (n = 1). Of the 41 potential cases that were reviewed, only 37 patients who underwent an operation and had histopathologically proved CXPA were included. Five patients were aware of the mass for about 10 years but had neglected it. Six were under observation because of benign or suspected PA on fine-needle aspiration and imaging tests, and in 1 patient the tumor was surgically removed in the past. The patients underwent multiple preoperative imaging studies at various time points as part of their standard care.

In our institution, all patients underwent an initial CT examination approximately 3 months after the operation, followed by CT evaluations every 6 months. If recurrence was suspected, additional imaging studies, such as MR imaging and FDG-PET/CT or biopsies were performed. Patients who were pathologically positive or those with close surgical margins and who were histologically identified as having a high-grade malignancy also underwent postoperative radiation (60 Gy/30 fractions).

MR Imaging Protocol

MR images were obtained using a 1.5T scanner (Signa HDxt; GE Healthcare). The imaging protocol included axial T1WI, T2WI, FS-T2WI, and coronal T2WI sequences. Dynamic MR imaging, contrast-enhanced (CE)-FS-T1WI, and DWI/ADC mapping were also performed.

Image and Data Analysis

Clinical and prognostic data were extracted from the medical records, and MR imaging findings were independently evaluated by 3 radiologists with 6, 10, and 18 years of imaging experience, respectively. In cases involving initial disagreement, the final evaluation was decided by consensus among the 3 raters. Visual assessment of the tumor margins included the border and capsule. The border was evaluated using only conventional T1WI and T2WI, and the capsule was defined as the low-signal area and/or the contrast-effect area of the margin, in consideration of the chemical shift artifacts. The border was evaluated first, followed by the capsule. The border was assessed as well-defined, partially ill-defined, or totally ill-defined, and the capsule was assessed as complete, incomplete, or absent on a 3-point scale.

In addition, the corona signs on FS-T2WI and CE-FS-T1WI and the black ring sign were evaluated. The corona sign was considered if the tumor size on FS-T2WI or CE-FS-T1WI was larger than that on T1WI (Fig 1 and Online Supplemental Data). We defined the presence of a component encapsulated with a hypointense rim on T2WI or FS-T2WI as the black ring sign, as reported by Kashiwagi et al1 (Fig 2). In this study, a lesion with a hypointense rim, which was noticeably thicker than the pre-existing PA capsule, was defined as the black ring sign. Intra-ring signals were not

This study was approved by Chiba University Hospital. The following keyword phrase was used during the search: “carcinoma ex pleomorphic adenoma.”

Patients were excluded for the following reasons: 1) absent or inaccessible MR images because the MR imaging was performed about 15 years ago (n = 1), 2) no head and neck MR imaging because of CXPA metastasis to the vertebral body (n = 1), 3) nonstandard MR imaging protocol (only intracranial MR imaging) (n = 1), and 4) lack of surgical-pathologic confirmation (n = 1). Of the 41 potential cases that were reviewed, only 37 patients who underwent an operation and had histopathologically proved CXPA were included. Five patients were aware of the mass for about 10 years but had neglected it. Six were under observation because of benign or suspected PA on fine-needle aspiration and imaging tests, and in 1 patient the tumor was surgically removed in the past. The patients underwent multiple preoperative imaging studies at various time points as part of their standard care.
considered. Because the thickness of the PA capsule ranged from 15 to 1750 μm, we defined lesions with >2 mm thickness as having the black ring sign.

Radiology-Pathology Correlation
Radiology-pathology correlation was assessed by 2 of the 3 radiologists who performed the imaging evaluations and a pathologist. The review was done with a consensus among these 3 individuals. In particular, we focused on peritumoral findings and the region corresponding to the black ring sign.

Statistical Analyses
We sorted the raters’ findings into 2 groups for statistical analyses. Specifically, noninvasive and minimally invasive CXPAs were categorized into the noninvasive group, and frankly invasive CXPAs were categorized into the invasive group. For each imaging assessment, the Fisher exact probability test was performed in both the invasive and noninvasive groups. Intereader agreement of the visual assessment was performed using κ analysis. κ values were interpreted as follows: <0.40, poor to fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80, substantial agreement; and 0.81–1.00, almost perfect agreement. Kaplan-Meier survival and the log-rank test were used to estimate the 3-year disease-free survival. All statistical analyses were performed using R (Version 3.6.3; http://www.r-project.org/), and statistical significance was set at P < .05.

RESULTS

Clinical Findings
Two of the 37 patients were excluded from the CE image analysis because they had not undergone CE MR imaging. Twelve patients had noninvasive tumors, 25 with frankly invasive and 0 with minimally invasive tumors. The clinical characteristics of the patients are summarized in Table 1. Clinical information, such as age, sex, location, laterality, swelling, pain, infection, immobility, nerve palsy, and skin infiltration, showed no significant difference in relation to extracapsular invasion.

Pathologic Findings
The pathologic characteristics of the patients are summarized in Table 2. No significant difference was observed in the extracapsular invasion based on the histologic subtypes of the carcinoma.

MR Imaging Findings
The MR imaging findings of the border, capsule, corona sign on FS-T2WI and CE-FS-T1WI, and the black ring sign were significantly different in the 2 groups (Table 3). In the noninvasive group, the black ring sign was not observed in 11 of the 12 patients (91.7%). The black ring sign was observed with massive calcification of the left buccal region on CT in 1 case of maxillary CXPAs; the calcification showed no signal on MR imaging and was mistakenly judged as the black ring sign.

Intereader Reliability
The κ values among the 3 raters are summarized in Table 4 and Online Supplemental Data. The border and capsule assessments showed poor agreement; in contrast, assessments of the corona signs on FS-T2WI and CE-FS-T1WI showed substantial agreement. Assessments of the black ring sign showed near-perfect agreement.

Radiology-Pathology Correlation
In the noninvasive group, the malignant component was completely surrounded by the fibrous capsule of the PA. Additionally, there was no infiltrating tumor or inflammatory cell infiltration into the normal salivary gland tissue beyond the lesion margins in this group (Fig 3).

In the invasive group, the corona signs on FS-T2WI and CE-FS-T1WI reflected tumor and/or inflammatory cells. The tumor

<table>
<thead>
<tr>
<th>Table 1: Clinical characteristics of CXPAs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathology</strong></td>
</tr>
<tr>
<td>--------------</td>
</tr>
<tr>
<td>Age (mean) (yr)</td>
</tr>
<tr>
<td>Sex</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Location</td>
</tr>
<tr>
<td>Parotid gland</td>
</tr>
<tr>
<td>Submandibular</td>
</tr>
<tr>
<td>Minor salivary</td>
</tr>
<tr>
<td>Laterality</td>
</tr>
<tr>
<td>Left</td>
</tr>
<tr>
<td>Right</td>
</tr>
<tr>
<td>Swelling</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Pain</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Infection</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Immobility</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Nerve palsy</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Skin infiltration</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2: Pathologic characteristics of CXPAs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathology</strong></td>
</tr>
<tr>
<td>--------------</td>
</tr>
<tr>
<td>Salivary duct</td>
</tr>
<tr>
<td>Myoepithelial</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>Squamous</td>
</tr>
<tr>
<td>Mucoepidermoid</td>
</tr>
<tr>
<td>Undifferentiated</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
</tbody>
</table>
The current study yielded 3 main findings: First, the imaging findings (the border, capsule, corona signs on FS-T2WI and CE-FS-T1WI, and black ring sign) were significantly different between the invasive and noninvasive groups. These differences were useful for distinguishing invasiveness beyond the ex-PA capsule. Second, the corona signs on FS-T2WI and CE-FS-T1WI reflected the presence of an extracapsular tumor and/or inflammatory cells. For the black ring sign, the hypointense rim on T2WI or FS-T2WI indicated hyalinization/fibrosis, and the intra-ring components reflected various cells and tissues pathologically. Third, a significant difference in disease-free survival was observed between the invasive and noninvasive groups, and pathologic extracapsular invasion was confirmed to be a prognostic factor. In addition, the imaging findings of the corona signs on FS-T2WI and CE-FS-T1WI were also prognostic factors.

To the best of our knowledge, this study included the largest number of CXPAs and is the first to compare the imaging findings of CXPAs based on the World Health Organization’s classification of invasiveness. Surgical resection is the first choice of treatment for CXPAs. Partial lobectomy is indicated for noninvasive or minimally invasive CXPAs localized in the superficial lobe of the parotid gland, and total parotidectomy is indicated for frankly invasive CXPAs. Preoperative MR imaging may facilitate surgical planning and prognosis when one is seeking to manage CXPAs.

Marginal information could be used to differentiate invasive and noninvasive CXPAs. We considered that a fibrous capsule usually surrounds a PA and that the appearance of invasion beyond the capsule affects the morphology of the capsule and border. However, the interrater reliability was poor for border and capsule findings. This poor reliability might be due to variations in the pre-existing PA. PA can present with a lobulated morphology, and even a normal PA can have an incomplete capsule or no capsule. In PA of minor salivary glands, the capsule and capsule findings. This poor reliability might be due to variations in the pre-existing PA. PA can present with a lobulated morphology, and even a normal PA can have an incomplete capsule or no capsule. In PA of minor salivary glands, the capsule surrounding the lobules could be unclear or missing. In addition, chemical shift artifacts make it difficult to assess thin capsules. Conversely, the corona signs on FS-T2WI and CE-FS-T1WI and the black ring sign showed good interrater reliability (Table 4). These findings may be useful for assessing marginal findings.

The corona signs on FS-T2WI and CE-FS-T1WI reflected pathologically extracapsular tumor and/or inflammatory cells, which could indicate invasion. The black ring sign was a highly specific finding (Table 3; specificity, 91.7% [11 of 12 patients]) for invasive CXPAs, with 1 case in which massive calcification was mistaken for a black ring sign. Calcification can be easily recognized on CT images, and its specificity may increase further. In the pathologic evaluation, severe hyalinization and fibrosis were observed, which manifested as a hypointense rim of the black ring sign on T2WI or FS-T2WI. On MR imaging, the intra-ring components of the black ring sign showed various signals.

### Table 3: Imaging findings of CXPA

<table>
<thead>
<tr>
<th>Total</th>
<th>Invasive</th>
<th>Noninvasive</th>
<th>P Value</th>
<th>OR 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Border</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Totally ill-defined | 2 | 2 | 0 | .002 | 14.41 (2.23–171.2)
| Partially ill-defined | 19 | 17 | 2 |    |         |
| Well-defined | 16 | 6 | 10 |    |         |
| Capsule |          |             |         |           |
| None | 9 | 9 | 0 | <.001 | 38.18 (4.06–1956.7)
| Partial | 12 | 11 | 1 |    |         |
| Total | 16 | 5 | 11 |    |         |
| Corona sign on FS-T2WI |          |             |         |           |
| Present | 21 | 19 | 2 | .001 | 14.40 (2.23–171.2)
| Absent | 16 | 6 | 10 |    |         |
| Corona sign on CE-FS-T1WI |          |             |         |           |
| Present | 22 | 19 | 3 | .007 | 9.31 (1.55–76.4)
| Absent | 13 | 5 | 8 |    |         |
| Black ring sign |          |             |         |           |
| Present | 15 | 14 | 1 | .011 | 13.11 (1.49–642.2)
| Absent | 22 | 11 | 11 |    |         |

*These ORs and 95% CIs were calculated between the 2 groups as well-defined versus totally ill-defined. These ORs and 95% CIs were calculated between the 2 groups as none and partial versus total. Two cases lacked contrast-enhanced images.

### Table 4: Interrater reliability of visual assessment (κ value)*

<table>
<thead>
<tr>
<th>Rater 1 vs 2</th>
<th>Rater 1 vs 3</th>
<th>Rater 2 vs 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Border</td>
<td>0.12</td>
<td>0.10</td>
</tr>
<tr>
<td>Capsule</td>
<td>0.19</td>
<td>0.38</td>
</tr>
<tr>
<td>Corona sign on FS-T2WI</td>
<td>0.78</td>
<td>0.79</td>
</tr>
<tr>
<td>Corona sign on CE-FS-T1WI</td>
<td>0.65</td>
<td>0.78</td>
</tr>
<tr>
<td>Black ring sign</td>
<td>0.89</td>
<td>0.84</td>
</tr>
</tbody>
</table>

*Raters 1, 2, and 3 had 6, 10, and 18 years of experience, respectively.

or inflammatory cells or both showed infiltration into the surrounding fatty tissue or salivary gland tissue. The black ring sign reflected hyalinization/fibrosis. Intra-ring components showed various cells and tissues (eg, carcinoma cells; hyalinization/fibrosis; comedonecrosis; and epithelial, myoepithelial, and mesenchymal components) containing mucoid, myxoid, and chondroid stroma, depending on the individual case and surrounding the lobules could be unclear or missing. In addi-

### Prognosis

Significant differences were observed in the disease-free survival for invasiveness (Fig 5A, P = .002). Imaging findings showed significant differences in the corona signs on FS-T2WI and CE-T1WI. However, no difference was observed in the black ring sign (Fig 5B, -D, corona signs on FS-T2WI and CE-FS-T1WI [P < .001 and P = .001, respectively] and black ring sign [P = .31]).

### Discussion

The current study yielded 3 main findings: First, the imaging findings (the border, capsule, corona signs on FS-T2WI and CE-FS-T1WI, and black ring sign) were significantly different between the invasive and noninvasive groups. These differences were useful for distinguishing invasiveness beyond the ex-PA capsule. Second, the corona signs on FS-T2WI and CE-FS-T1WI reflected the presence of an extracapsular tumor and/or inflammatory cells. For the black ring sign, the hypointense rim on T2WI or FS-T2WI indicated hyalinization/fibrosis, and the intra-ring components reflected various cells and tissues pathologically. Third, a significant difference in disease-free survival was observed between the invasive and noninvasive groups, and pathologic extracapsular invasion was confirmed to be a prognostic factor. In addition, the imaging findings of the corona signs on FS-T2WI and CE-FS-T1WI were also prognostic factors.

To the best of our knowledge, this study included the largest number of CXPAs and is the first to compare the imaging findings of CXPAs based on the World Health Organization’s classification of invasiveness. Surgical resection is the first choice of treatment for CXPAs. Partial lobectomy is indicated for noninvasive or minimally invasive CXPAs localized in the superficial lobe of the parotid gland, and total parotidectomy is indicated for frankly invasive CXPAs. Preoperative MR imaging may facilitate surgical planning and prognosis when one is seeking to manage CXPAs.

Marginal information could be used to differentiate invasive and noninvasive CXPAs. We considered that a fibrous capsule usually surrounds a PA and that the appearance of invasion beyond the capsule affects the morphology of the capsule and border. However, the interrater reliability was poor for border and capsule findings. This poor reliability might be due to variations in the pre-existing PA. PA can present with a lobulated morphology, and even a normal PA can have an incomplete capsule or no capsule. In PA of minor salivary glands, the capsule surrounding the lobules could be unclear or missing. In addition, chemical shift artifacts make it difficult to assess thin capsules. Conversely, the corona signs on FS-T2WI and CE-FS-T1WI and the black ring sign showed good interrater reliability (Table 4). These findings may be useful for assessing marginal findings.

The corona signs on FS-T2WI and CE-FS-T1WI reflected pathologically extracapsular tumor and/or inflammatory cells, which could indicate invasion. The black ring sign was a highly specific finding (Table 3; specificity, 91.7% [11 of 12 patients]) for invasive CXPAs, with 1 case in which massive calcification was mistaken for a black ring sign. Calcification can be easily recognized on CT images, and its specificity may increase further. In the pathologic evaluation, severe hyalinization and fibrosis were observed, which manifested as a hypointense rim of the black ring sign on T2WI or FS-T2WI. On MR imaging, the intra-ring components of the black ring sign showed various signals.
Pathologically, various components, such as hyaline, mucoid, myxoid, and chondroid stroma, were present, and the proportions of these components varied in each case. The organization of PA shows various patterns and a wide range of morphologic and structural diversity. The black ring sign is suggested to reflect a pre-existing PA or a part of the existing PA. Extensive hyalinization or fibrosis has been identified as an important predictor of malignant transformation in PAs in several pathologic studies. This finding supports our hypothesis and we observed that the black ring sign effectively assessed invasiveness. If the black ring sign reflects a pre-existing PA, it could be a sign of invasive CXPA.

In the survival curve, pathologic invasion beyond the pre-existing PA capsule was associated with recurrence. This result was consistent with previous reports, and CXPA without extracapsular infiltration showed benign behavior. Our results showing no recurrence in noninvasive cases were similar to those reported by Mariano et al and Zhao et al. Therefore, noninvasive CXPA may be managed surgically, similar to benign PAs.

Information on the tumor margins, such as the corona signs on FS-T2WI and CE-FS-T1WI, was a prognostic finding. The black ring sign did not show a significant difference in prognosis. This finding is because the black ring sign had high specificity but low sensitivity to extracapsular infiltration of the CXPA (Table 3; sensitivity, 56% [14 of 25 patients]).

This study had some limitations. First, the histologic types of the carcinomas in the CXPA varied in our study, and this variation may have affected the imaging findings. Second, only CXPA—and no other type of salivary gland tumor—was studied. Third, although CXPA has been classified into 3 types based on the degree of invasiveness, this study did not include cases of minimally invasive CXPA. Minimally invasive CXPA may be overlooked because it requires pathologic evaluation of all tumor margins. However, none of the cases that were actually considered noninvasive showed recurrence, and the prognosis was clearly divided between invasive and noninvasive cases. These findings indicate that a proper pathologic classification was performed.

**CONCLUSIONS**

MR imaging is useful for differentiating invasive and noninvasive CXPAs. The corona signs on FS-T2WI and CE-FS-T1WI were reliable predictors of the invasiveness of CXPA and overall prognosis. The black ring sign was also a characteristic feature of invasive CXPA. Distinction between invasive
and noninvasive CXPAs using preoperative MR imaging may contribute to surgical planning and prediction of the prognosis of CXPA.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES

11. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74 CrossRef Medline


The Cochlea in Branchio-Oto-Renal Syndrome: An Objective Method for the Diagnosis of Offset Cochlear Turns

A.F. Juliano, F. D’Arco, J. Pao, S. Picariello, E. Clement, G. Moonis, and C.D. Robson

ABSTRACT

BACKGROUND AND PURPOSE: An “unwound” or “offset” cochlea has been described as a characteristic imaging feature in patients with branchio-oto-renal syndrome, and recently recognized to be associated in particular to those with EYA1 gene mutations. Determination of this feature has traditionally relied on subjective visual assessment. Our aim was to establish an objective assessment method for cochlear offset (the cochlear turn alignment ratio) and determine an optimal cutoff turn alignment ratio value that separates individuals with EYA1-branchio-oto-renal syndrome from those with SIX1-branchio-oto-renal syndrome and healthy controls.

MATERIALS AND METHODS: Temporal bone CT or MR imaging from 40 individuals with branchio-oto-renal syndrome and 40 controls was retrospectively reviewed. Cochlear offset was determined visually by 2 independent blinded readers and then quantitatively via a standardized technique yielding the cochlear turn alignment ratio. The turn alignment ratio values were compared between cochleae qualitatively assessed as “not offset” and “offset.” Receiver operating characteristic analysis was used to determine the ability of the turn alignment ratio to differentiate between these populations and an optimal cutoff turn alignment ratio value. Cochlear offset and turn alignment ratio values were analyzed for each branchio-oto-renal syndrome genotype subpopulation and for controls.

RESULTS: The turn alignment ratio can accurately differentiate between cochleae with and without an offset (P < .001). The optimal cutoff value separating these populations was 0.476 (sensitivity = 0.986, specificity = 0.986). All except 1 cochlea among the EYA1-branchio-oto-renal syndrome subset and all with unknown genotype branchio-oto-renal syndrome had a cochlear offset and a turn alignment ratio of <0.476. All except 1 cochlea among the SIX1-branchio-oto-renal syndrome subset and all controls had no offset and a turn alignment ratio of >0.476.

CONCLUSIONS: There is a statistically significant difference in turn alignment ratios between offset and nonoffset cochleae, with an optimal cutoff of 0.476. This cutoff value allows excellent separation of EYA1-branchio-oto-renal syndrome from SIX1-branchio-oto-renal syndrome and from individuals without branchio-oto-renal syndrome or sensorineural hearing loss. The turn alignment ratio is a reliable and objective metric that can aid in the imaging evaluation of branchio-oto-renal syndrome.

ABBREVIATIONS: BOR = branchio-oto-renal syndrome; ROC = receiver operating characteristic; TAR = turn alignment ratio

Branchio-oto-renal syndrome (BOR) is a cause of hearing loss with autosomal dominant inheritance, first described in 1975 in a family with hearing loss, cup-shaped antverted pinnae, preauricular pits, branchial fistulas, and renal dysplasia.\(^1\) Cochlear hypoplasia was later noted on tomography.\(^2\) Since then, with the advent of CT and MR imaging, much more has been described in the literature of characteristic features of the temporal bone among patients with BOR, most notably an “unwound” or “offset” appearance of the cochlea,\(^3,4\) in which small middle and apical turns are anteriorly offset and appear separated from the basal turn. Most recently, it was shown that the offset appearance of cochlear middle and apical turns is indeed a distinctive finding among patients with BOR, but only among those with EYA1 gene mutations having the EYA1 genotype-phenotype; patients with SIX1 mutations have different phenotypes without cochlear offset.

Please address correspondence to Amy F. Juliano, MD, Department of Radiology, Massachusetts Eye and Ear, 243 Charles St, Boston, MA 02114; e-mail: amy.juliano@meei.harvard.edu; @amyfjuliano

http://dx.doi.org/10.3174/ajnr.A7653
but the apical turns have a protuberant “thorny” appearance. The differing genotype-phenotype correlation could be related to different functions of the SIX1 and EYA1 genes, and the different sites of expression and roles of the resultant proteins in the cochlea during the embryologic development of the inner ear. Recognition of these distinct phenotypes on imaging and knowledge of the respective genotype-phenotype correlation offers a powerful tool to radiologists, who can then suggest a genetic diagnosis in the context of a potential syndromic presentation compatible with BOR.

With regard to the offset cochleae seen among patients with EYA1-BOR, prior description and determination of this feature in the literature has been based on visual assessment. This presumes familiarity with normal cochlear morphology, in order to recognize when the middle and upper turns of the cochlea are anteromedially displaced by a degree that is more than expected for the typical normal cochlea. However, this recognition may be challenging for radiologists who do not regularly interpret temporal bone imaging, and there may be other conditions in which the cochlear turns are not aligned normally or where the turns may not be sufficiently offset to raise the suspicion for EYA1-BOR syndrome or another anomaly.

The aim of this study was to define and quantify the cochlear turn alignment ratio (TAR), to analyze the TAR among both cochleae with offset and cochleae without offset as visually assessed by expert head and neck radiologists (the traditional/usual method of assessment), and to determine whether there is a distinct TAR cutoff value that distinguishes the 2 groups. We then examined the cochleae of patients with EYA1-BOR, those with SIX1-BOR, patients with BOR of unknown genetic association, and controls without evidence of sensorineural hearing loss to determine whether there are quantitative TAR cutoff values that can distinguish patients with BOR from healthy controls and patients with EYA1-BOR from those with SIX1-BOR. The goal was to establish objective metrics that can separate these populations from each other. The resultant TAR measurement method and criteria can aid any radiologist in the determination of “how offset is too offset” with objectivity and establish normative TAR values for the normal cochlea.

**MATERIALS AND METHODS**

**Participants**

This was a multicenter retrospective review of temporal bone imaging studies among individuals with clinically diagnosed BOR (from the same database we previously used for qualitative comparison of BOR cochlear phenotypes) and controls without BOR or sensorineural hearing loss. For the BOR group, 40 individuals from 4 participating institutions were included; inclusion criteria were a clinical diagnosis of BOR syndrome and diagnostic temporal bone CT and/or MR imaging available for review. Among these 40 patients, 16 had known underlying causative EYA1 genetic mutations, 4 had known SIX1 genetic mutations, and 20 had not undergone genetic testing. For the control group, consecutive multidetector row CT scans of 40 patients without clinical or audiometric evidence of sensorineural hearing loss who underwent temporal bone CT for symptoms unrelated to hearing loss (eg, otalgia, otitis media, dizziness, facial palsy) were included. Imaging among the BOR group occurred between April 2001 and April 2021. Imaging among the control group occurred between January 2019 and December 2020. This study was approved by the institutional review board/ethics committee of each institution.

**Image Acquisition**

**BOR Group.** Of the 40 patients, 33 had undergone CT, 6 had undergone MR imaging, and 1 had undergone both CT and MR imaging. All CT scanners across the participating institutions were helical multidetector row scanners (Discovery 750 HD, LightSpeed Pro 16 SYS, HiSpeed CT/i SYS, or HiSpeed RP SYS; GE Healthcare; SOMATOM Sensation 40 or SOMATOM Force SYS; Siemens) with parameters ranging as follows: 120 kV (peak), 100–200 mA, section thickness = 0.6–0.625 mm, some with an overlap of 0.2 mm. All MR imaging scanners across the participating institutions were 3T units, with assessment conducted on the heavily T2-weighted sequence such as 3D driven equilibrium radiofrequency reset pulse (DRIVE; Philips Healthcare), constructive interference in steady state (CISS; Siemens), and T2 sampling perfection with application-optimized contrasts by using different flip angle evolution (T2 SPACE; Siemens). All temporal bone images were uploaded onto the PACS, with axial reformats created in a plane parallel to the plane of the lateral semicircular canal (or estimated to be so in cases when the lateral semicircular canal was anomalous), and coronals perpendicular to these reformatted axial reformats, before image analyses.

**Control Group.** Multidetector row CT scanning (Discovery 750 HD) of the temporal bone was performed with 120 kV(p), 240 mA, 0.6-mm section thickness, and 0.2-mm overlap. Axial reformats of the temporal bones were created in a plane parallel to the lateral semicircular canal, and coronals perpendicular to these reformatted axial reformats before image analyses.

**Image Review**

Two neuroradiologists with 5 (J.P.) and 15 (A.F.J.) years of experience with subspecialty head and neck expertise reviewed all cases and controls. The reviewers were blinded to the original reports, patient demographics, clinical diagnoses including whether there was BOR syndrome, underlying genetic abnormality, and the other reviewer’s findings.

**Qualitative Assessment.** The cochlea of all enrolled individuals (patients with BOR and controls) were assessed qualitatively on standardized reformatted axial images in the plane of the lateral semicircular canal. Each cochlea was designated as “with offset” or “without offset” by consensus. Any thorny appearance of the apical turn of the cochlea was also noted as present or absent.

**Quantitative Assessment.** For each ear, the TAR of the cochlea was assessed quantitatively on standardized reformatted axial images in the plane of the lateral semicircular canal, with the following methodology (Fig 1):

- A line was drawn parallel to the long axis of the basal turn, extending from the round window to the medial bend (line a).
- The midpoint of the last complete uppermost turn/apex was identified (point b).
TAR is defined as the distance from the anterior border of the round window to the point of intersection, which is propagated across all axial images. The midpoint of the uppermost turn is identified on the image that best displays it (black arrows in C and F). The point of intersection is measured (distance a, line e/d); this point can also be propagated across all axial images. TAR is e/d. As can be seen in these images, TAR in the patient with EYA1-BOR (F) is smaller than in the patient without BOR (C).

- A perpendicular line was drawn from point b to intersect line a at a right angle (line c), using the “angle” function on PACS to ensure that the angle of intersection measured 90°.
- The distance from the anterior border of the round window to the point of intersection was recorded (distance d).
- The distance from the point of intersection to the medial bend of the basal turn was recorded (distance e).
- TAR is defined as e/d.

These lines and points were usually not all appreciated on 1 single axial plane; thus, care was taken to scroll through consecutive images while keeping the electronic caliper fixed at 1 point from the initial index image before reaching the end point on another image, or lines were propagated across images with identical orientation. When there was need for confirmation, minimum-intensity projections were made to view structures in a stack.

To accurately and reproducibly quantify the cochlear offset, we carefully determined cochlear turns by considering the cochlea in fifths as mentioned by Fitch et al and Chen et al. The basal turn constitutes the first and second fifths (from the round window to the medial bend, then the medial bend back to the lateral edge), the middle turn constitutes the third and fourth fifths (from the lateral edge to the medial bend, then the medial bend back to the lateral edge), and the apical turn is the last fifth (from the lateral edge at the end of the middle turn going medially toward the end of the tip) (Fig 2). The very short segment of the cochlea that is relatively linear, extending from the round window to the point when the cochlea begins to coil, has been referred to as the “hook region” of the cochlea. For this study, we followed the methodology of a previously published article, in which the hook region of the cochlea is grouped with the spiraling main portion of the basal turn to be collectively considered as the first fifth, ensuring a standardized lateral boundary of the basal turn at the round window membrane and thus ensuring measurement consistency.

### Statistical Analysis

On the basis of qualitative assessment, the cochleae of all enrolled individuals were divided into 2 groups: with offset and without offset. The number of individuals with EYA1-BOR, SIX1-BOR and unknown-mutation BOR and healthy controls (non-BOR and without hearing loss) in each group was noted.

On the basis of quantitative assessment that yielded TAR numeric values, interrater reliability was evaluated by the intraclass correlation coefficient. Due to excellent agreement, the average of the 2 readers was used for further analysis.

Continuous parametric variables are presented as mean (SD), whereas categoric data are presented as number and percentage. Normal distribution was determined using the Shapiro-Wilk test (P > .05) and histogram plots. A Student t test was performed to explore whether the offset ratio was different between cochleae qualitatively deemed to be with and without offset. Receiver operating characteristic (ROC) curve analysis was used to determine the diagnostic accuracy of the offset ratio. The optimal cutoff point was determined by the Youden index J. P values < .05 were considered statistically significant.

SPSS Statistics 22 software (IBM) was used to perform the analyses. GraphPad Prism 7 (GraphPad Software) was used for graphing.

### RESULTS

Eighty participants with a total of 160 cochleae were included in this study: 16 participants (32 cochleae) with EYA1 mutations, 4 (8 cochleae) with SIX1 mutations, 20 (40 cochleae) with BOR of unknown genotype, and 40 (80 cochleae) controls (Table 1).

There was excellent interrater reliability in the TAR measurements obtained by the 2 independent reviewers, with an intraclass correlation coefficient of 0.976. The values within each of the 2 groups (offset and not offset) followed normal distributions.

The cochleae deemed “not offset” by visual assessment had TAR values ranging from 0.492 to 0.741; the cochleae deemed “offset” by visual assessment had TAR values ranging from 0.189 to 0.460 with 1 outlier at 0.556 (Fig 3). The mean TAR value was significantly lower in cochleae with offset (0.338 [SD, 0.063]) compared with those without offset (0.492 [SD, 0.050]) (P < .001). ROC curve analysis showed that TAR can accurately distinguish between cochleae with anterior offset and those without, with an area under the curve (AUC) value of 0.997 (95% CI, 0.992–1) (P < .001) (Fig 4). Based on Youden index J, the optimal cutoff value was 0.476 (sensitivity = 1, specificity = 0.986, J = 0.986). TAR...
values above the cutoff were predictive of a lack of cochlear offset, whereas values below 0.476 were associated with cochlear offset.

Seventy-three cochleae showed anterior offset. Of these, 32 were among patients with EYA1-BOR, 1 was among patients with SIX1-BOR, and 40 were among patients with BOR of unknown genotype. Eighty-seven cochleae showed no offset. Of these, 7 were among patients with SIX1-BOR, and the remaining 80 were controls. Of note, all 80 controls showed no offset.

The mean TAR among patients with SIX1-BOR (0.577 [SD, 0.107]) was similar to that among controls (0.598 [SD, 0.051]), with none <0.476. The mean TAR among patients with EYA1-BOR (0.338 [SD, 0.071]) was much lower. The mean TAR among patients with BOR of unknown genotype (0.339 [SD, 0.057]) was similar to that among patients with EYA1-BOR, and all were <0.476. These are listed in Table 1 and depicted in Fig 5.

On qualitative assessment, all individuals with EYA1-BOR (32 cochleae of a total of 32) and BOR of unknown genotype (40 cochleae of a total of 40) had bilateral offset cochleae (Fig 6). None had a thorny apical turn (Table 2). On the contrary, cochlear offset was not seen in individuals with SIX1-BOR except in 1 cochlea; that cochlea appeared different from the typical unwound, offset cochlea but instead fit the description of cochlear hypoplasia type 4 (Fig 7) and lacked a thorny apical turn. The remainder of the SIX1-BOR cochleae had thorny tips (7 cochleae of 8). None of the controls had cochlear offset or a thorny apical turn.

**DISCUSSION**

The presence of a cochlear offset associated with EYA1-BOR has traditionally been determined qualitatively, whereby the radiologist visually estimates whether the alignment of the cochlear turns appears to be anomalous, with the upper turns anteriorly displaced and slightly tipped away relative to the basilar turn, outside the range of normal.

<table>
<thead>
<tr>
<th>Total No. of Cochleae</th>
<th>No. of Cochleae with Offset</th>
<th>No. of Cochleae without Offset</th>
<th>Mean TAR</th>
</tr>
</thead>
<tbody>
<tr>
<td>EYA1-BOR</td>
<td>32</td>
<td>32</td>
<td>0.338 (SD, 0.071)</td>
</tr>
<tr>
<td>SIX1-BOR</td>
<td>8</td>
<td>1</td>
<td>0.577 (SD, 0.107)</td>
</tr>
<tr>
<td>Unknown genotype</td>
<td>40</td>
<td>40</td>
<td>0.339 (SD, 0.057)</td>
</tr>
<tr>
<td>BOR</td>
<td>80</td>
<td>0</td>
<td>0.598 (SD, 0.051)</td>
</tr>
</tbody>
</table>

**FIG 2.** A, Fifths of a cochlea, as demonstrated on a 3D reconstruction of the inner ear from a heavily T2-weighted sequence (3D DRIVE). The first fifth is in red (including the hook region), the second fifth in orange, the third fifth in blue, the fourth fifth in green, and the fifth fifth in black. (B, C, and D). CT of the temporal bone in a bone algorithm in the Stenvers view (B) and axial (C and D) planes shows the fifths of the cochlea in the same color scheme as depicted on the 3D model in A.

**FIG 3.** Cochlear TAR among cochlea-deemed offset and not offset on visual assessment. EYA1-BOR: black round dots; SIX1-BOR: black square dots; unknown genotype: gray rhomboid dots; controls: gray triangle dots. The dashed line indicates the TAR cutoff (0.476) as determined by ROC curve analysis.
However, this estimation may be challenging for radiologists who do not routinely interpret temporal bone imaging studies. In this study, we explored an objective method to evaluate and quantify the presence of an anteriorly offset or unwound cochlea in patients with *EYA1*-BOR, to provide a reproducible and reliable diagnostic tool for all radiologists.

All of our patients with a clinical diagnosis of BOR and confirmed *EYA1* mutations (16 patients, 32 cochleae) had anteriorly offset cochlea on subjective visual analysis. We found that there was a statistically significant difference in TAR between individuals with *EYA1*-BOR and controls without a diagnosis of BOR or sensorineural hearing loss. The optimal cutoff value for the upper limit of TAR that produced the greatest sensitivity and specificity for the detection of cochlear offset suggestive of *EYA1*-BOR was 0.476. This implies that this TAR measurement method and cutoff value can be used to suggest *EYA1* mutations in patients with a clinical diagnosis of BOR.

Furthermore, except for 1 outlier, all cochleae among the patients with *SIX1*-BOR in our cohort did not have anterior offset, with a TAR of >0.476. In the 1 outlier that did demonstrate misaligned cochlear turns, it appeared to be due to an underlying cochlear hypoplasia (type 4) (Figs 7), distinct in morphology from the typical *EYA1*-BOR offset cochlea (Fig 1E, F). Thus, there is a good degree of quantitative difference in cochlear turn alignment between individuals with *EYA1*-BOR and those with *SIX1*-BOR. This is in addition to morphologic differences in the apical turn of the cochlea previously demonstrated, whereby the *EYA1*-BOR cochlea appears unwound with an anterior offset, while the *SIX1*-BOR cochlea has a thorny apical turn without the characteristic anterior offset (Fig 8).5

Notably, in our cohort, all the individuals with BOR of an unknown underlying causative genotype had offset cochleae, with a TAR of <0.476. In addition, they did not have thorny apical turns. On the basis of the strong phenotype-genotype correlation in patients with BOR and our current results, we speculate that all the patients with BOR in our cohort of an unknown genetic diagnosis may have *EYA1* mutations, given their anteriorly offset cochlea and lack of a thorny apical turn. This finding would be in keeping with the estimated substantially higher prevalence of *EYA1* compared with *SIX1* mutations among patients with BOR reported in the literature.16-19

Interestingly, all our patients with *EYA1*-BOR (TAR < 0.476) had moderate-to-severe conductive hearing loss and mild-to-moderate sensorineural hearing loss. All our patients with *SIX1*-BOR without obvious cochlear dysmorphology (TAR > 0.476) had mild conductive hearing loss (35–40 dB) and mild sensorineural hearing loss (25–35 dB). The 1 patient with *SIX1*-BOR with a hypoplastic cochlea had severe conductive hearing loss and profound sensorineural hearing loss. All except one of the patients with BOR of unknown genotype had moderate-to-severe conductive hearing loss and mild-to-moderate sensorineural hearing loss, showing that most of them had hearing ability similar to that of those with the *EYA1* mutation rather than the *SIX1* mutation; this finding would be in
keeping with the known estimated prevalence of these 2 genotypes among the overall BOR population.

The interactions between SIX1 and EYA1 protein expression during cochlear development are complex; however, we know from murine models that while SIX1 expression is dependent on EYA1, EYA1 expression is not impacted by SIX1. Moreover, SIX1 is mainly expressed in the apical part of the cochlea.\(^{20}\) This location may explain the milder alteration in cochlear phenotype associated with SIX1 mutations compared with EYA1 mutations. It is unclear why one of our patients with a SIX1 mutation had the characteristic thorny cochlea on only 1 side and an anterior offset and hypoplastic cochlea on the other; it is possible that this feature is due to the particular locus of the mutated base pairs in the gene leading to different resultant disturbances in the complex SIX1/EYA1 interactions.\(^{21}\) Furthermore, the SIX1 variant in this case (Cys16Tyr) is located closer toward the N-terminal (SD domain) within an α-helix critical for EYA interaction. More studies with larger cohorts of patients with SIX1-mutated BOR would be helpful to clarify whether specific mutations within the same gene can create varying and potentially characteristic phenotypes.

As expected, none of the control patients had anteriorly offset cochleae, corroborating the high sensitivity of this radiologic sign. However, there are other genetic causes of malformed cochleae with hypoplastic middle and apical turns reported in literature, such as Walker-Warburg syndrome, where the “hook” of the basal turn is the only well-preserved portion of the cochlea and the upper parts are anteriorly placed and markedly hypoplastic, resembling an extreme anteriorly offset cochlea.\(^{22}\) This appearance may relate to an arrest in embryonic development before the end of the seventh week of gestation, when only the first half of the basal turn is formed and the second half of the basal turn and the middle/upper turns have yet to develop and fold on themselves to create the final cochlear structure. To the best of our knowledge, at the current time, the anterior offset unwound cochlea fitting the original radiologic description\(^{3,5}\) has been described only in EYA1-BOR and Walker-Warburg syndrome. However, as knowledge in genetics increases with time, it might be discovered that this offset appearance of the cochlea may be a part of the phenotypic constellation in other, rare causes and genotypes related to cochlear dysplasia.\(^{23}\)

Some limitations of this study are its retrospective design, different CT and MR imaging protocols among the participating institutions, and its relatively small sample size. In the future, we would benefit by prospective enrollment of patients with BOR to achieve a larger population size, preferably with known underlying genotypes, and to perform qualitative and quantitative TAR assessment in a large BOR population.

CONCLUSIONS

This study shows that there is a statistically significant difference in TAR between offset and nonoffset cochleae, with an optimal cutoff at 0.476. This is also the optimal TAR threshold value that allows excellent separation of the EYA1-BOR population from the SIX1-BOR population, and separation of patients with EYA1-BOR from individuals without sensorineural hearing loss. The proposed TAR measurement method and threshold value can aid any radiologist in the determination of “how offset is too...
The thorny apical turn in a patient with SIX1-BOR. Notice the normal size and morphology of the basal turn first half (short arrow), while the distal basal, middle, and apical turns are hypoplastic (arrowhead).

**FIG 7.** CT image of the patient with SIX1-BOR in whom the right cochlea does not demonstrate any offset [long arrow], while the left cochlea has an offset but with an appearance akin to cochlear hypoplasia type 4 rather than the typical unwound and offset cochlea of EYA1-BOR. Notice the normal size and morphology of the basal turn (short arrow), while the distal basal, middle, and apical turns are hypoplastic (arrowhead).

**FIG 8.** A thorny apical turn in a patient with SIX1-BOR. The apical turn of the cochlea appears as a short, protuberant, thorny tip, as seen on CT (A) and MR imaging (B).

offset", to decide objectively whether there are anomalous offset cochlea compatible with the EYA1-BOR genotype-phenotype.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

**REFERENCES**

11. Atturo F, Barbara M, Rask-Andersen H. On the anatomy of the “hook” region of the human cochlea and how it relates to cochlear hypoplasia type 4 rather than the typical unwound and offset cochlea of EYA1-BOR. Notice the normal size and morphology of the basal turn (short arrow), while the distal basal, middle, and apical turns are hypoplastic (arrowhead).

**FIG 7.** CT image of the patient with SIX1-BOR in whom the right cochlea does not demonstrate any offset [long arrow], while the left cochlea has an offset but with an appearance akin to cochlear hypoplasia type 4 rather than the typical unwound and offset cochlea of EYA1-BOR. Notice the normal size and morphology of the basal turn (short arrow), while the distal basal, middle, and apical turns are hypoplastic (arrowhead).

**FIG 8.** A thorny apical turn in a patient with SIX1-BOR. The apical turn of the cochlea appears as a short, protuberant, thorny tip, as seen on CT (A) and MR imaging (B).
Accelerated Synthetic MRI with Deep Learning–Based Reconstruction for Pediatric Neuroimaging


ABSTRACT

BACKGROUND AND PURPOSE: Synthetic MR imaging is a time-efficient technique. However, its rather long scan time can be challenging for children. This study aimed to evaluate the clinical feasibility of accelerated synthetic MR imaging with deep learning–based reconstruction in pediatric neuroimaging and to investigate the impact of deep learning–based reconstruction on image quality and quantitative values in synthetic MR imaging.

MATERIALS AND METHODS: This study included 47 children 2.3–14.7 years of age who underwent both standard and accelerated synthetic MR imaging at 3T. The accelerated synthetic MR imaging was reconstructed using a deep learning pipeline. The image quality, lesion detectability, tissue values, and brain volumetry were compared among accelerated deep learning and accelerated and standard synthetic data sets.

RESULTS: The use of deep learning–based reconstruction in the accelerated synthetic scans significantly improved image quality for all contrast weightings (P < .001), resulting in image quality comparable with or superior to that of standard scans. There was no significant difference in lesion detectability between the accelerated deep learning and standard scans (P > .05). The tissue values and brain tissue volumes obtained with accelerated deep learning and the other 2 scans showed excellent agreement and a strong linear relationship (all, R² > 0.9). The difference in quantitative values of accelerated scans versus accelerated deep learning scans was very small (tissue values, <0.5%; volumetry, −1.46%–0.83%).

CONCLUSIONS: The use of deep learning–based reconstruction in synthetic MR imaging can reduce scan time by 42% while maintaining image quality and lesion detectability and providing consistent quantitative values. The accelerated deep learning synthetic MR imaging can replace standard synthetic MR imaging in both contrast-weighted and quantitative imaging.

ABBREVIATIONS: DIFF = percentage difference; DLR = deep learning–based reconstruction; FAST-SyMRI = accelerated synthetic MRI without DLR; FAST-SyMRI+DLR = accelerated synthetic MRI with DLR; ICC = intraclass correlation coefficient; PD = proton density; PSIR = phase-sensitive inversion recovery; ST-SyMRI = standard synthetic MRI

Synthetic MR imaging using a multidynamic, multiecho sequence is a well-known time-efficient technique that simultaneously provides quantitative MR imaging and multiple contrast-weighted images in a single scan. Therefore, the availability of synthetic MR imaging for clinical practice and research purposes has increased, and this technique has been extensively validated for diagnostic value in neuroimaging in both children and adults.1–8 However, its rather long single-scan time of 6–7 minutes, despite being clinically acceptable, can be a practical challenge for pediatric neuroimaging because of the possibility of motion increase; therefore, the application of acceleration techniques to synthetic MR imaging is essential to overcome this limitation. Established methods for reducing the scan time include parallel imaging, compressed sensing, and adjusting MR imaging acquisition...
parameters such as the receiver bandwidth, number of excitations, and in-plane/through-plane resolution.\textsuperscript{9–11} However, accelerated techniques generally reduce the SNR and/or spatial resolution, resulting in degradation of image quality. Recently, deep learning–based reconstruction (DLR) techniques have been proposed to address the trade-off between the image quality and scan time. DLR techniques can mitigate image noise induced by acceleration techniques and improve SNR/spatial resolution, enabling a previously unattainable level of fast imaging.\textsuperscript{12,13}

We hypothesized that the application of DLR to an accelerated synthetic MR imaging protocol can reduce the scan time while maintaining image quality, facilitating the use of synthetic MR imaging in pediatric neuroimaging.\textsuperscript{12,13} For this study, we created an accelerated synthetic MR imaging protocol by increasing both the bandwidth and parallel imaging acceleration factor and then applied a vendor-supplied DLR (AIR Recon DL; GE Healthcare) to the accelerated synthetic protocol. Although several previous studies have investigated the impact of this DLR technique on the image quality and diagnostic performance of conventional MR imaging,\textsuperscript{13–15} no study has investigated the impact of DLR on synthetic MR imaging in terms of the image quality and quantitative value measurements. When one applies the synthetic MR imaging protocol with DLR in clinical practice, in addition to validating its image quality, it is important to determine whether this MR imaging protocol provides less biased and consistent quantitative data.

This study aimed to evaluate the clinical feasibility of accelerated synthetic MR imaging with DLR in pediatric neuroimaging and to investigate the impact of DLR on image quality and quantitative values (tissue values and brain tissue volume measurements) in synthetic MR imaging. To achieve our goals, we compared the accelerated synthetic MR imaging with DLR with the accelerated synthetic MR imaging without DLR and the standard synthetic MR imaging (ST-SyMRI) protocol previously validated in a large prospective study.\textsuperscript{6}

### MATERIALS AND METHODS

#### Subjects

This study was approved by the institutional review board of Kyungpook National University Chilgok Hospital. The requirement for informed consent was waived due to the retrospective nature of the study. We retrospectively reviewed the database of our institution. The inclusion criteria for this study were as follows: 1) younger than 19 years of age, and 2) patients who underwent brain MR imaging, including both standard and accelerated (with and without DLR) synthetic MR imaging protocols between October 2021 and December 2021. A total of 52 consecutive patients were identified, and we excluded 5 subjects after reviewing for quality control (the details are provided in Online Supplemental Data). Finally, 47 patients (male/female ratio, 30:17; mean age, 7.2 (SD, 3.7) years; age range, 2.3–14.7 years) were included in this study.

#### Image Acquisition and Technical Details

All 2D synthetic MR images were acquired using a 3T scanner (Signa Architect; GE Healthcare) with a 48-channel head coil at a single institution. The synthetic MR images were acquired using a multidynamic, multiecho sequence.\textsuperscript{1,16,17} All included patients underwent 2 sets of synthetic MRIs as follows: 1) a standard protocol (manufacturer’s suggested protocol, ST-SyMRI),\textsuperscript{6} and 2) an accelerated protocol without DLR (FAST-SyMRI). After acquiring 2 sets of synthetic MR images, a prototype version of DLR (AIR Recon DL) was used to reconstruct the FAST-SyMRI (accelerated synthetic MRI with DLR [FAST-SyMRI + DLR]). The DLR accepts a user-specified denoising level between 0 and 1, and we chose a denoising level of 0.5 when applying the DLR to balance noise reduction with minimizing artificial image textures. Detailed methods for DLR have been described previously.\textsuperscript{13–15,18} Thus, 3 sets of synthetic MR images were acquired for each patient. The detailed imaging parameters are listed in the Table. All MR imaging acquisition parameters and scan times were identical for FAST-SyMRI and FAST-SyMRI + DLR.

#### Image Quality and Lesion Detectability

Synthetic T1WIs and T2WIs, T2 FLAIR, and phase-sensitive inversion recovery (PSIR) images were automatically generated using synthetic MR imaging software (Version 11.3.3; SyntheticMR; https://www.syntheticmr.com/). We used the default settings of TR, TE, and TI to create synthetic contrast-weighted images, except for T1WI (Online Supplemental Data).\textsuperscript{19} All anonymized images were independently reviewed on the PACS workstation by 2 radiologists (S.M.L. and H.H.C.) with 10 years of pediatric radiology experience. Both readers were blinded to the type of MR imaging protocol, clinical information, and the results of the available conventional MR imaging examinations. All MR imaging protocol data sets were

---

**Synthetic MR imaging—acquisition parameters**

<table>
<thead>
<tr>
<th></th>
<th>ST-SyMRI</th>
<th>FAST-SyMRI with/without DLR$^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>TR (ms)</td>
<td>4000–4743</td>
<td>4000</td>
</tr>
<tr>
<td>TE (ms)</td>
<td>21.2/84.8</td>
<td>17.5/87.4</td>
</tr>
<tr>
<td>TI (ms)</td>
<td>4 Automatically calculated</td>
<td>12</td>
</tr>
<tr>
<td>Echo-train length$^b$</td>
<td>22.73</td>
<td>31.25</td>
</tr>
<tr>
<td>Bandwidth (kHz)</td>
<td>12</td>
<td>31.25</td>
</tr>
<tr>
<td>Acceleration factor (ASSET)</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Section thickness (mm)$^b$</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Spacing (mm)$^b$</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>FOV (cm)$^b$</td>
<td>23</td>
<td>23</td>
</tr>
<tr>
<td>Phase FOV$^b$</td>
<td>0.8</td>
<td>0.8</td>
</tr>
<tr>
<td>Frequency matrix (m × n)$^b$</td>
<td>308</td>
<td>308</td>
</tr>
<tr>
<td>No of sections$^b$</td>
<td>24–32</td>
<td>24–32</td>
</tr>
<tr>
<td>NEX$^b$</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Scan time (min:sec)</td>
<td>5:04–6:01</td>
<td>3:28</td>
</tr>
</tbody>
</table>

**Note:** $m × n$ indicates slices of m by n dimensions; ASSET, array spatial sensitivity encoding technique; NEX, number of excitations.

$^a$ All MR imaging acquisition parameters and scan times were identical for FAST-SyMRI and FAST-SyMRI + DLR.

$^b$ The same parameters were used in all 3 MR imaging protocols.
randomly ordered, and image analysis was performed in 3 sessions, with a memory-washout period of at least 2 weeks.

The overall image quality, gray-white matter differentiation (GM-WM), and visibility of anatomic structures were assessed on a 5-point Likert scale (1 = nondiagnostic, 2 = poor, 3 = sufficient, 4 = good, and 5 = excellent). The anatomic structures included the central sulcus, head of the caudate nucleus, lentiform nucleus, posterior limb of the internal capsule, cerebral peduncle, and middle cerebellar peduncle. The severity of artifacts was rated on a similar 5-point Likert scale (1 = severe, 2 = moderate to severe, 3 = moderate, 4 = mild, and 5 = none), and we evaluated the following artifacts: motion artifacts, low SNR, truncation artifacts, blurring, regional low-SNR artifacts, aliasing artifacts, parenchymal-CSF interface hyperintensities, and pulsation artifacts. The confidence in the presence of brain lesions was rated on a 5-point scale. The detailed criteria for image assessment are presented in the Online Supplemental Data. After completing the qualitative image analysis, an experienced pediatric radiologist (S.M.L.) confirmed the presence of lesions based on the available conventional MR images, original radiology reports, and clinical diagnoses.

**Tissue Value Measurement and Brain Volume Estimation**

Quantitative tissue maps (T1, T2, and proton density [PD] maps) and tissue fraction maps were generated using the synthetic MR imaging software (Version 11.3.3). Tissue values of aggregate GM and WM and the brain tissue volumes were automatically obtained using the latest version of the synthetic MR imaging software. To determine the topologic differences in tissue values between the FAST-SyMRI + DLR and the other 2 MR imaging protocols, we first spatially normalized quantitative tissue maps on the basis of the synthetic T1WIs using SPM 12 (https://www.fil.ion.ucl.ac.uk/spm/software/spm12/). Next, the voxelwise differences in tissue values were analyzed by calculating the percentage difference at the group level.

**Statistical Analysis**

To compare the overall image quality, GM-WM, visibility of anatomic structures, and artifacts between FAST-SyMRI + DLR and the other 2 synthetic protocols, we performed the Wilcoxon signed-rank test and the McNemar test. Because MR images classified as having "good/excellent" image quality and "mild/none" artifacts are generally preferred in routine clinical practice, we dichotomized the readers’ ratings before performing the McNemar test (4 or 5 versus ≤3 on a 5-point Likert scale). For lesion detectability, readers’ ratings of 4 and 5 were assigned for the presence of brain lesions, and the McNemar test was also used.

The quantitative values were compared using the paired t test. The percentage difference (DIFF) was calculated. The intraclass correlation coefficient (ICC) and Pearson correlation coefficient (r) were computed to assess the agreement and correlation among quantitative data. Linear regression analysis and Bland-Altman analysis were performed. SPSS software, Version 28.0 (IBM) and MedCalc, Version 19.2 (MedCalc software) were used for analysis. A P value < .05 was considered statistically significant.

**RESULTS**

**Scan Time**

The scan times for ST-SyMRI and FAST-SyMRI with and without DLR were 5 minutes 4 seconds - 6 minutes 1 second and 3 minutes 28 seconds, respectively (the details are provided in the Online Supplemental Data).

**Image Quality and Lesion Conspicuity**

The results of the 2 readers’ ratings were pooled for analysis because there were no significant differences in the overall image-quality scores between the 2 readers (P > .05, 2-tailed t test). The results of the qualitative image analysis performed by the 2 radiologists and pair-wise comparison results between FAST-SyMRI + DLR and the other 2 MR imaging protocols are summarized in the Online Supplemental Data. Representative examples of contrast-weighted images acquired using 3 synthetic MR imaging protocols are shown in Fig 1 and the Online Supplemental Data.

For FAST-SyMRI + DLR versus ST-SyMRI, PSIR derived from FAST-SyMRI + DLR showed superior overall image quality compared with the corresponding sequence of ST-SyMRI (P < .001),
and there was no significant difference in overall image quality for other sequences (P values for T2WI, T2-FLAIR, and T1WI were .56, .22, and .47, respectively). When we considered all contrast-weighted images, 93.6% (352/376) of FAST-SyMRI images and 87.8% (330/376) of ST-SyMRI images were rated as good or excellent for overall image quality (Fig 2). Although visibility of some anatomic structures was inferior on FAST-SyMRI+DLR images compared with that on ST-SyMRI images (P < .05), when we applied a dichotomous classification, only the visibility of the cerebral peduncle on T1WI (P = .02) showed a statistical difference (Online Supplemental Data). No significant difference was found in the GM-WM between the 2 MR imaging protocols for all contrast weightings (P > .05). Scores for low SNR, truncation artifacts, and pulsation artifacts were higher on FAST-SyMRI+DLR than in ST-SyMRI for all contrast weightings (P < .05), suggesting a lesser degree of artifacts on FAST-SyMRI+DLR than on ST-SyMRI.

Meanwhile, the overall image quality of FAST-SyMRI+DLR was significantly superior to that of FAST-SyMRI for all contrast weightings (P < .001). The visibility of anatomic structures (eg, the lentiform nucleus, posterior limb of the internal capsule, cerebral peduncle, and middle cerebellar peduncle) was mostly more superior on FAST-SyMRI+DLR than on FAST-SyMRI (P < .05) (Online Supplemental Data). The low SNR and truncation artifacts were significantly reduced after the application of DLR for all contrast weightings (P < .001). The pulsation artifact was not significantly different (T2 FLAIR, P = .41; PSIR, P = .59) or was slightly emphasized after DLR application (T1WI, P = .046; T2WI, P < .001).

This study included 7 cases of abnormal findings on MR imaging based on radiology reports, available conventional MR images, and clinical diagnoses: necrosis (n = 3), cerebellar heterotopia (n = 1), brain abscess (n = 1), and chemotherapy-induced leukoencephalopathy (n = 2) (Online Supplemental Data). All pathologies were rated 4 or 5 on synthetic contrast-weighted images acquired using 3 MR imaging protocols by 2 radiologists, and there were no false-positive cases. Therefore, there was no significant difference in lesion detectability between FAST-SyMRI+DLR and the other 2 MR imaging protocols (P > .05).

**Tissue-Value Measurement**

The Online Supplemental Data summarize the comparison of tissue values of the GM and WM between FAST-SyMRI+DLR and the other 2 MR imaging protocols. The tissue values of GM and WM were significantly different between FAST-SyMRI+DLR and ST-SyMRI (WM-PD, P = .02; others, P < .001). GM T1 showed the highest values of DIFF (~4.76%) across all tissue values of GM and WM in FAST-SyMRI+DLR versus ST-SyMRI (Fig 3). In the WM, the mean DIFF of T2 values was the highest (3.6%), but this finding may be attributable to the relatively low T2 values rather than the absolutely large differences between the 2 protocols (81.0 [SD, 4.0] ms [FAST-SyMRI+DLR] versus 78.2 [SD, 3.7] ms [ST-SyMRI]). Except for GM T1 and WM T2, the mean DIFFs were small, ranging from −1.5% to 1.86%. Regarding topologic differences, higher DIFFs were noted in the cerebral/cerebellar cortices for T1 values and in the CSF space for T2 values. The interface between different tissue types, such as ventricle walls and brain surfaces, showed a higher DIFF for both T1 and T2 values (Online Supplemental Data). Despite these differences in tissue value measurements between FAST-SyMRI+DLR and ST-SyMRI, the agreement and correlation between the tissue values were excellent (ICC = 0.94–0.99) and strong (r = 0.89–0.98) for all tissue values of GM and WM. Linear regression analysis also showed a strong linear relationship with a robust fit (R² = 0.96–0.998), indicating good consistency between the tissue values derived from the 2 MR imaging protocols (Fig 3).

For FAST-SyMRI+DLR versus FAST-SyMRI, there were no significant differences in the tissue values, except for GM T1 (GM T1, P < .001; others, P > .05). Additionally, the differences in tissue values between the 2 MR imaging protocols were very small or negligible (mean DIFFs = −0.34%–0.09%). Regarding the topologic differences in tissue values, all tissue values showed little difference in the brain parenchyma; only small differences at the brain surface and ventricle walls were observed in the T2
FIG 3. Scatterplots and Bland-Altman plot results for FAST-SyMRI + DLR versus ST-SyMRI (A) and FAST-SyMRI + DLR versus FAST-SyMRI (B). The linear regression lines fit to the data of 47 patients (solid blue line), which are shown along with 95% confidence intervals (dotted blue lines), represent a strong linear relationship with a robust fit between the tissue value measurements of GM and WM obtained from the 2 MR imaging protocols. Bland-Altman plots show mean differences (solid red line) and the mean difference (SD, 1.96) of the differences (dotted black line).
values. The tissue values derived from FAST-SyMRI+DLR and FAST-SyMRI yielded excellent agreement (ICC = 0.993–0.999), strong correlations (r = 0.987–0.998), and strong linear relationships in the linear regression analysis (R^2 > 0.999 for all) (Fig 3).

### Brain Volume Estimation

A comparison of the brain tissue volume estimates between FAST-SyMRI+DLR and the other 2 MR imaging protocols is summarized in the Online Supplemental Data. In FAST-SyMRI+DLR versus ST-SyMRI, all brain-tissue volumes were significantly different between the 2 MR imaging protocols (CSF volume, P = .02; others, P < .001). All volume measurements of GM and voxels not classified as GM/WM/CSF (hereafter referred to as “non-WM/GM/CSF”) obtained with FAST-SyMRI+DLR were smaller (mean DIFF = −8.46%) and larger (mean DIFF = 50.73%) compared with ST-SyMRI-derived volume estimates, respectively (Online Supplemental Data). However, the mean DIFFs for brain parenchymal volume and intracranial volume between the 2 MR imaging protocols were minimal (−0.59%, −0.77%, respectively), and the Bland–Altman plot also showed minimal spread. Despite this systematic bias, excellent agreement and strong correlation between volume measurements derived from the 2 MR imaging protocols were found for all brain tissues (ICC = 0.98–1.0, r = 0.96–0.999). Linear regression analysis also demonstrated a strong linear relationship with a robust fit (R^2 = 0.92–0.998) (Online Supplemental Data).

For FAST-SyMRI+DLR versus FAST-SyMRI, the differences in the brain tissue volumes between the 2 MR imaging protocols were very small (mean DIFFs = −1.46%–0.83%). Additionally, the agreement (ICC = 0.98–1.0) and correlation (r = 0.97–1.0) between the brain tissue volumes derived from the 2 MR imaging protocols were very high, and the linear regression analysis exhibited a strong linear relationship (R^2 = 0.99–1.0).

### DISCUSSION

In this study, we applied DLR to a FAST-SyMRI protocol that reduced the scan time by up to 42% by adjusting both the receiver bandwidth and the parallel imaging acceleration factor. We found that the use of DLR in the FAST-SyMRI protocol improved image quality by effectively mitigating the noise generated using accelerated techniques. After applying DLR to FAST-SyMRI, the low SNR and truncation artifacts, which were the main image-quality issues in FAST-SyMRI, were noticeably improved for all contrast weightings, and the visibility of anatomic structures was mostly enhanced. This result was consistent with the findings of previous studies in which DLR reduced image noise and truncation artifacts without noticeable loss of anatomic structure visibility compared with ST-SyMRI images for all contrast weightings; thus, in this study, FAST-SyMRI+DLR yielded image quality comparable with or superior to that in ST-SyMRI, validated in a large prospective study. Additionally, pulsation artifacts were less pronounced on FAST-SyMRI+DLR than on ST-SyMRI for all contrast weightings. However, this finding is likely attributed to the use of different MR imaging acquisition parameters rather than the artifact-reduction effect of DLR; indeed, when we compared FAST-SyMRI+DLR and FAST-SyMRI, the pulsation artifact was not significantly different or was slightly emphasized after DLR application. Our findings are in line with those reported by van der Velde et al., who demonstrated that ghosting artifacts became more pronounced when late gadolinium-enhancement images of the myocardium were reconstructed with DLR.

When one applies DLR in conjunction with accelerated techniques, there is a concern about whether the pathology is less visible. A previous study reported that accelerated conventional shoulder MR imaging using this DLR pipeline showed diagnostic performance comparable with that of standard conventional MR imaging. Our study also showed no significant difference in lesion detectability between FAST-SyMRI+DLR and ST-SyMRI. This result shows the potential of FAST-SyMRI+DLR for application in clinical practice. However, because only a small number of lesions were analyzed and subjects with very small lesions such as intracranial metastases and multiple sclerosis were not included in our study, its diagnostic value should be validated in future studies with large cohorts. We expect that further research on the impact of postcontrast FAST-SyMRI+DLR on lesion diagnosis may reveal additional clinical utility of this protocol.

Tissue values obtained from FAST-SyMRI+DLR and ST-SyMRI showed excellent agreement and strong correlation, indicating good consistency between the MR imaging protocols, thus supporting the clinical use of FAST-SyMRI+DLR in synthetic MR imaging-based quantitative imaging. In addition, there was a small systematic bias between FAST-SyMRI+DLR and ST-SyMRI (mean DIFFs = −4.76%–3.6%). We speculated that the main source of the systematic bias is different MR imaging acquisition parameters between the MR imaging protocols, because there was no significant difference in tissue values between FAST-SyMRI+DLR and FAST-SyMRI, indicating that the impact of DLR on quantitative tissue values was negligible (mean DIFF, −0.34%–0.09%). It is important to preserve quantitative tissue values when DLR is applied in identical synthetic MR imaging protocols. These results allow DLR to be used for the optimization of synthetic MR imaging protocols without concern about whether quantitative tissue values change remarkably after DLR application.

The brain tissue volumes obtained with FAST-SyMRI+DLR and ST-SyMRI also showed excellent agreement and a strong correlation for all brain-tissue volumes, suggesting the applicability of FAST-SyMRI+DLR in brain volumetry. However, in FAST-SyMRI+DLR versus ST-SyMRI, systematic over- and underestimations were observed. In particular, the difference in GM volume was relatively larger than that in the other brain-tissue volumes; our finding that differences in GM T1 between these 2 MR imaging protocols were noticeable supports this volumetric result because tissue values deviating from the narrow range of the predefined tissue cluster in the R1-R2-PD space can affect the segmentation and volume measurements. More specifically, differences in T1 values occurred mainly in the cerebral/cerebellar cortices, and higher differences in both T1 and T2 values were found in the brain surfaces.
These brain regions are mostly partial volume voxels containing a mixture of GM and CSF. In these brain regions, the substantial deviations of tissue values from a predefined tissue cluster in the R1-R2-PD space can lead to misclassification of the GM volume fraction within partial volume voxels as non-WM/GM/CSF volume.

Obtained with FAST-SyMRI.

The use of DLR in synthetic MR imaging can reduce scan time, which will facilitate the clinical application of synthetic MR imaging in pediatric neuroimaging. Furthermore, the quantitative value estimation using quantitative MRI.


Distinctive Brain Malformations in Zhu-Tokita-Takenouchi-Kim Syndrome


ABSTRACT

BACKGROUND AND PURPOSE: Zhu-Tokita-Takenouchi-Kim syndrome is a severe multisystem malformation disorder characterized by developmental delay and a diverse array of congenital abnormalities. However, these currently identified phenotypic components provide limited guidance in diagnostic situations, due to both the nonspecificity and variability of these features. Here we report a case series of 7 individuals with a molecular diagnosis of Zhu-Tokita-Takenouchi-Kim syndrome, 5 ascertained by their presentation with the neuronal migration disorder, periventricular nodular heterotopia.

MATERIALS AND METHODS: Individuals with a molecular diagnosis of Zhu-Tokita-Takenouchi-Kim syndrome were recruited from 2 sources, a high-throughput sequencing study of individuals with periventricular nodular heterotopia or from clinical diagnostic sequencing studies. We analyzed available brain MR images of recruited individuals to characterize periventricular nodular heterotopia distribution and to identify the presence of any additional brain abnormalities.

RESULTS: Pathogenic variants in SON, causative of Zhu-Tokita-Takenouchi-Kim syndrome, were identified in 7 individuals. Brain MR images from these individuals were re-analyzed. A characteristic set of imaging anomalies in addition to periventricular nodular heterotopia was identified, including the elongation of the pituitary stalk, cerebellar enlargement with an abnormally shaped posterior fossa, rounding of the caudate nuclei, hippocampal malformations, and cortical anomalies including polymicrogyria or dysgyria.

CONCLUSIONS: The recurrent neuroradiologic changes identified here represent an opportunity to guide diagnostic formulation of Zhu-Tokita-Takenouchi-Kim syndrome on the basis of brain MR imaging evaluation.

ABBREVIATIONS: PVNH = periventricular nodular heterotopia; VUS = variant of uncertain significance; WES = whole-exome sequencing; WGS = whole-genome sequencing; ZTTK syndrome = Zhu-Tokita-Takenouchi-Kim syndrome

Understanding of the distinctive phenotypic features of a rare syndromic disorder facilitates earlier diagnosis. This is particularly evident when genomic sequencing studies yield ambiguous findings, such as variants of uncertain significance (VUSs) in syndromic genes. Moreover, characteristic phenotypic features, or “phenotypic handles,” often guide focused investigations. Rare phenotypically heterogeneous disorders present a considerable challenge in this respect due to prior ascertainment biases and limited cohort sizes.

Zhu-Tokita-Takenouchi-Kim (ZTTK) syndrome (OMIM #617140) is a rare phenotypically heterogeneous disorder characterized by developmental delay and a wide array of congenital multisystem anomalies. Haploinsufficiency of SON, mediated by either truncating variants or whole-gene deletions, has been identified as the underlying cause of ZTTK syndrome. SON encodes the RNA-binding protein SON and is constitutively expressed, though expression is enriched during early brain development.
Table 1: Molecular findings identified in a cohort of 7 unrelated individuals with ZTTK syndrome

<table>
<thead>
<tr>
<th>Individuals</th>
<th>cDNA (NM_138927.2)</th>
<th>Protein (NP_620305.2)</th>
<th>Inheritance</th>
<th>Sequencing method</th>
<th>Capture platform</th>
<th>Note: WGD indicates whole-genome deletion; CMA, chromosomal microarray.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>c.575_57 del</td>
<td>p.Val1918</td>
<td>De novo WES</td>
<td>SureSelect V5 (Agilent)</td>
<td>No capture</td>
<td>WGD</td>
</tr>
<tr>
<td>2</td>
<td>c.2357_23 del</td>
<td>p.Ala87*</td>
<td>De novo WES</td>
<td>SeqCap EZ V2 (Roche)</td>
<td>No capture</td>
<td>Unknown CMA</td>
</tr>
<tr>
<td>3</td>
<td>c.457del</td>
<td>p.Asp153I</td>
<td>De novo WES</td>
<td>SureSelect V5+UTRs (Agilent)</td>
<td>No capture</td>
<td>De novo WGS</td>
</tr>
<tr>
<td>4</td>
<td>c.1881_18 del</td>
<td>p.Val629</td>
<td>Unknown WGS</td>
<td>No capture</td>
<td>No capture</td>
<td>Unknown CMA</td>
</tr>
<tr>
<td>5</td>
<td>c.573_57 del</td>
<td>p.Val1918</td>
<td>Unknown WES</td>
<td>No capture</td>
<td>SureSelect V5 (Agilent)</td>
<td>De novo WGS</td>
</tr>
<tr>
<td>6</td>
<td>c.385_38 del</td>
<td>p.Val629</td>
<td>Unknown WES</td>
<td>SureSelect V5+UTRs (Agilent)</td>
<td>QXT CRE</td>
<td>De novo CMA</td>
</tr>
<tr>
<td>7</td>
<td>c.573_57 del</td>
<td>p.Val629</td>
<td>De novo WES</td>
<td>SureSelect V5+UTRs (Agilent)</td>
<td>CGH ISCA</td>
<td>WGD</td>
</tr>
</tbody>
</table>

Note: WGD indicates whole-genome deletion; CMA, chromosomal microarray.

**MATERIALS AND METHODS**

**Cohort Recruitment and Ethics**

A cohort of 7 unrelated individuals with pathogenic variants in SON was assembled by 2 approaches. Individuals 1–5 were ascertained through a physician-initiated referral into a high-throughput sequencing study of individuals with PVNH. This cohort was pre-emptively screened for pathogenic variants in FLNA. Individuals 6 and 7 were identified through diagnostic sequencing studies and were included after demonstration of a pathogenic SON variant. Individuals 1–3 were previously analyzed by Heinzen et al., however, the pathogenic SON variants described here failed validation but are now confirmed as true-positives. Individuals 3 and 4 were reported in brief by Dingemans et al. This study was approved by the Health and Disability Ethics Committee of New Zealand (13-STH/56).

**Sequence Analysis**

Genomic DNA from probands and parents was extracted from peripheral blood for either whole-exome sequencing (WES) or whole-genome sequencing (WGS), summarized in Table 1. WES libraries were constructed for individuals 1–3 by Orogenetics (Atlanta) and sequenced using a HiSeq 2500. WGS libraries were prepared for individuals 4 and 5 using a TruSeq DNA Nano v2.5 kit and sequenced using a HiSeq X Ten at the Kinghorn Center for Clinical Genomics (Sydney). Paired-end FASTQ reads were aligned to the human reference GRCh37 using BWA MEM (Version 0.7.17; https://github.com/bwa-mem2/bwa-mem2) and outputted in BAM format.

Single sample variant calls were produced using GATK HaplotypeCaller (Version 3.8; https://github.com/broadinstitute/gatk), in genomic VCF format. Genomic VCFs were then jointly genotyped using GATK GenotypeGVCFs producing a multisample VCF. Annotation with gene context information was performed using SnpEff (Version 4.3S; https://github.com/pcingola/SnpEff), and additional information from the gnomAD project (Version 2.1.1; https://gnomad.broadinstitute.org) was added using BCFtools annotate (Version 1.9; https://github.com/samtools/bcftools).

**Variant Prioritization**

Sequence data from individuals 1–5 were filtered under a monogenic disease model. Variants were required to have a read depth of >7 and an alternative allele percentage of >20%. Missense and
predicted loss-of-function variants were selected. Common variants with a gnomAD allele frequency of >0.001 were removed.

For individuals 1–4, parental sequence data were available, permitting identification of de novo variants. For individual 5, parental data were unavailable, so a restrictive disease-gene filtering model was implemented. Variants in genes with a dominant disease phenotype were retained based on data from the Developmental Disorder Genotype-Phenotype database. Remaining variants for all 5 individuals were interpreted on the basis of the American College of Medical Genetics and Genomics guidelines.

Neuroradiologic Evaluation

Brain MR images were systematically reviewed by a pediatric neuroradiologist (S.M.) with >20 years of experience in the imaging of brain dysmorphism. Normative data for the corpus callosum and cerebellum were used to test abnormalities of these structures.

Data Availability

Individual genomic data sets are not freely available due to restrictions imposed by the consenting process and privacy concerns.

RESULTS

Molecular Findings

De novo loss-of-function SON variants were identified for individuals 1–4, consistent with pathogenic class 5 variants causative of ZTTK syndrome. For individual 5, a heterozygous SON frameshift variant (NM_138927.2:c.5753_5756del) of unknown inheritance was identified, which was classified as a class 5 pathogenic variant based on recurrence in other published cases of ZTTK syndrome. Identified SON variants for individuals 1–5 were validated using polymerase chain reaction and Sanger sequencing.

Class 5 pathogenic SON variants were identified for individuals 6 and 7 before recruitment into this study. A recurrent heterozygous frameshift variant (NM_138927.2:c.3852_3856del) of unknown inheritance was identified for individual 6 and a de novo heterozygous whole-gene deletion (NC_000021.8:g.(34849772_34911445)_(35109752_35171289del) was identified for individual 7. Sequencing results are summarized in Table 1.

Clinical Descriptions

Individual 1. Individual 1 is a female who presented with hypotonia and mild global developmental delay at 10 months of age. Intrauterine growth restriction occurred during pregnancy. Delivery was by cesarean delivery, and her weight and height were both below the 3rd centile. Poor feeding and febrile seizures were noted, with hemiplegic migraine attacks occurring from 6 years of age. She was diagnosed with mild intellectual disability in childhood. She had a ridged, sagittal suture, broad nasal bridge, anteverted nares, a small chin, and cupped posteriorly rotated ears.

Recurrent respiratory and middle ear infections occurred throughout childhood. At 13 years of age, she developed end-stage polyuric renal disease, requiring renal transplantation. When last examined at 17 years of age, her weight and head circumference were in the 50th centile, with height below the 3rd centile. She had hearing loss, hypermetropia, and convergent strabismus. Echocardiogram findings were normal.

Individual 2. Individual 2 is a female who presented in early childhood with global developmental delay with severe intellectual disability and hypotonia. She had an irregular whole-body tremor from birth. Poor feeding occurred from early infancy, requiring the insertion of a gastrostomy tube at 6 years of age. Myoclonic seizures with fever began at 6 years of age, developing into multifocal myoclonic and clonic seizures by 11 years of age. At 13 years of age, she had an episode of status epilepticus. Dysmorphic features included a flat nasal bridge, broad nose, and anteverted nares. Divergent strabismus and nonsensorineural deafness were also noted.

When last examined at 28 years of age, her height was below the 1st centile, her weight was below the 3rd centile, and her head circumference was between the 2nd and 50th centile. She could walk with assistance but was nonverbal and displayed self-harm behaviors. Partial second- and third-digit syndactyly was noted. She had bilateral hypoplastic kidneys and osteopenia. She developed heart failure after an episode of sepsis.

Individual 3. Individual 3 is a male who presented with global developmental delay with moderate intellectual disability. He had asthma and recurrent respiratory infections throughout infancy. Through childhood, he developed selective mutism and disrupted sleep patterns, as well as epilepsy with mixed seizure types. Major feeding difficulties occurred throughout his life, and he is now predominantly fed by gastrostomy.

During childhood, his height tracked below the 2nd centile, and his weight, between the 9th and 25th centiles. His dysmorphic features included down-slanting palpebral fissures and epicanthal folds. Craniosynostosis of the left coronal suture was observed. Other congenital anomalies included astigmatism, joint hypermobility, and a unilateral multicystic kidney.

Individual 4. Individual 4 is a female who presented with moderate developmental delay and hypotonia. When last examined at 4 years of age, her height and weight were below the 1st and 3rd centiles, respectively. Dysmorphic features included down-slanting palpebral fissures, epicanthal folds, and a flat philtrum. Feeding difficulties were pronounced during infancy. Additional anomalies included fourth and fifth digit campodactyly, sensorineural hearing loss, hypermetropia and astigmatism, strabismus, and a horseshoe kidney. She developed coronal craniosynostosis, requiring surgical intervention. After the operation, she developed seizures, well-controlled with levetiracetam.

Individual 5. Individual 5 is a female who presented with moderate developmental delay with intellectual disability and hypotonia in early childhood. Notable facial features included frontal bossing and epicanthal folds. Conductive hearing impairment and strabismus were noted. She required surgical intervention for right-hip dysplasia. When last examined at 5 years 8 months of age, her height was at the 25th centile, her weight, in the 3rd centile, and her head circumference, in the 90th centile.
Individual 6. Individual 6 is a male who presented with suspected seizures after several episodes of confusion, later diagnosed as a concussion. He was delivered at term after an uneventful pregnancy. Early childhood developmental milestones were normal, but he was diagnosed with mild intellectual disability during his early school years. When examined at 14 years of age, his height and weight were between the 10th and 25th centiles. Dysmorphic facial features were noted, but he had fifth finger and toe clinodactyly as well as elbow extension limitation. A ventricular septal defect was noted on an echocardiogram.

Individual 7. Individual 7 is a female who presented prenatally with intrauterine growth restriction, breech presentation, and oligohydramnios. She was delivered at 37 weeks by cesarean delivery, with an 11th centile birth weight. During infancy she had central hypotonia with a peripheral increase in tone. At 4 years of age, she had onset of seizures, with an episode of status epilepticus. Her development was globally delayed, with suspected moderate intellectual disability and autism spectrum disorder.

During early childhood, her height and weight were between the 10th and 25th centiles, with a head circumference at the 73rd centile. She had down-slanting and short palpebral fissures, epicranial folds, smooth philtrum, small mouth with thin lips, and low-set ears with diagonally creased earlobes. Additional anomalies included developmental hip dysplasia and a ventricular septal defect.

**Neuroradiologic Findings**

A prior diagnosis of PVNH was available for individuals 1–5 before recruitment into this study. The initial goal of neuroradiologic re-evaluation was to categorize the PVNH of these individuals and assess whether it demonstrates characteristics distinctive to ZTTK syndrome. However, after re-evaluation of MR images, PVNH was also identified for individuals 6 and 7, who were recruited solely on the basis of their molecular diagnosis of ZTTK syndrome.

Heterotopic nodules were sparse, small, and predominantly frontal in all 7 individuals. They were bilateral in 5 of 7 cases. Similarly, sparse and small nodules were identified in the posterior infrasylvian regions in 3 of 7 cases. MR images depicting the PVNH distribution for each individual are presented in Fig 1. No nodules were observed in the occipital horns.

In addition to PVNH, consistent involvement of abnormalities in specific structures were identified in all 7 individuals, summarized in Table 2. These included malformations of the corpus callosum, cerebellum, pituitary stalk, caudate nuclei, hippocampi, and cortex.

Corpus callosum abnormalities were frequently observed and included short anterior-posterior diameter (<3 centiles, 3 of 7) and thinning of the corpus callosum, particularly at the genu (<3 centiles, 5 of 7). Dysmorphic corpora callosa were observed in 2 individuals, depicted in Fig 2C–F. Abnormalities of the pituitary gland and stalk were also seen, with glands appearing small (5 of 7), with a markedly elongated pituitary stalk (5 of 7). The pituitary stalk elongation observed in individuals may relate to platybasia or a similar anomaly at the base of the skull; however, this was not assessed in the current study. Examples of identified corpus callosum and pituitary abnormalities are depicted in Fig 2A–C.
The cerebellum was large in all individuals, with 4 individuals above the 97th centile for cranio-caudal vermis height and 6 individuals above the 97th centile for anterior-posterior vermis diameter. The cerebellar tonsils were herniated through the foramen magnum in 2 of 7 individuals (≥3 mm below the level of the foramen magnum). For individual 4, MR images were available at 2 time points, revealing a normal-sized cerebellum at 16 days of age. However, by 16 months of age, the cerebellum was overgrown with tonsillar herniation. Appearances most consistent with posterior fossa was grown with tonsillar herniation. Appearances most consistent with posterior fossa was grown with tonsillar herniation. Appearances most consistent with posterior fossa was grown with tonsillar herniation. Appearances most consistent with posterior fossa was grown with tonsillar herniation. Appearances most consistent with posterior fossa was grown with tonsillar herniation. Appearances most consistent with posterior fossa was grown with tonsillar herniation. Appearances most consistent with posterior fossa was grown with tonsillar herniation.

The lateral ventricles were dysmorphic in all individuals, with caudate heads appearing malrotated and globular in 5 individuals, depicted in Fig 2L-M. Abnormalities in the lentiform nucleus were frequently observed, restricted to the globus pallidus in 3 individuals and generalized in an additional case. Abnormal hippocampi were seen in all individuals, appearing small and malrotated in 4 individuals (Fig 2E). The hippocampi of the remaining 3 individuals showed a lack of internal architecture (Fig 2D). The thalami were normal in all individuals.

The lateral ventricles were dysmorphic and dilated in all individuals, affecting both the frontal (6 of 7) and occipital (3 of 7) horns. Further abnormalities of the ventricular system were also observed, with a small fourth ventricle in all individuals, likely secondary to enlargement of the cerebellum. A generalized decrease in WM volume was seen in 4 individuals, with delays in age-appropriate myelination in 3 individuals.

Malformations in cerebral cortical gyriﬁcation and sulcation were seen in all individuals. Examples are depicted in Fig 2I, J-L, N, O. These cortical malformations included bilateral perisylvian polymicrogyria (3 of 7), bilateral perisylvian dysgyria or polymicrogyria-like cortical dysplasia (2 of 7), and perisylvian cortex thickening (3 of 7). Disorganized sulcation was also observed in 2 individuals, appearing to be especially localized to the temporal lobe in individual 1.

**DISCUSSION**

ZTTK syndrome is a rare disorder with a wide phenotypic spectrum, posing diagnostic challenges in the absence of genomic testing. Instead, high-throughput sequence screening of SON has been suggested as the only practical way of diagnosing ZTTK syndrome. The cohort described here manifests the core phenotypic features of ZTTK syndrome, including developmental delay, seizures, and dysmorphic features. However, this core presentation remains both nonspecific and highly variable, offering limited utility for recognition in a clinical setting.

We identified PVNH as an imaging feature that may aid clinical recognition of ZTTK syndrome and analyzed a cohort of 7 cases with this phenotypic feature. The distribution of FLNA-associated PVNH overlaps that seen with the frontal predominant distribution of ZTTK syndrome. However, FLNA-associated nodules are typically larger and more contiguous and do not frequently

| Table 2: Neuroradiologic findings identified in a cohort of 7 unrelated individuals with ZTTK syndrome |

<table>
<thead>
<tr>
<th>Individuals</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PVNH</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebellar tonsils</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Cerebellar vermis height (centile)</td>
<td>50–97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
</tr>
<tr>
<td>Cerebellar vermis diameter (centile)</td>
<td>&gt;97</td>
<td>50–97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
</tr>
<tr>
<td>Posterior fossa</td>
<td>Abnormal shape</td>
<td>Abnormal shape</td>
<td>Normal</td>
<td>Normal</td>
<td>Abnormal shape</td>
<td>Abnormal shape</td>
<td>Normal</td>
</tr>
<tr>
<td>Corpus callosum diameter (centile)</td>
<td>&lt;3</td>
<td>50–97</td>
<td>&lt;3</td>
<td>50–97</td>
<td>50–97</td>
<td>&lt;3</td>
<td>50–97</td>
</tr>
<tr>
<td>Genu diameter (centile)</td>
<td>3–50</td>
<td>&lt;3</td>
<td>&lt;3</td>
<td>&lt;3</td>
<td>50–97</td>
<td>&lt;3</td>
<td>&lt;3</td>
</tr>
<tr>
<td><strong>PVNH</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebellar vermis height (centile)</td>
<td>50–97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
</tr>
<tr>
<td>Cerebellar vermis diameter (centile)</td>
<td>&gt;97</td>
<td>50–97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
</tr>
<tr>
<td>Posterior fossa</td>
<td>Abnormal shape</td>
<td>Abnormal shape</td>
<td>Normal</td>
<td>Normal</td>
<td>Abnormal shape</td>
<td>Abnormal shape</td>
<td>Normal</td>
</tr>
<tr>
<td>Corpus callosum diameter (centile)</td>
<td>&lt;3</td>
<td>50–97</td>
<td>&lt;3</td>
<td>50–97</td>
<td>50–97</td>
<td>&lt;3</td>
<td>50–97</td>
</tr>
<tr>
<td>Genu diameter (centile)</td>
<td>3–50</td>
<td>&lt;3</td>
<td>&lt;3</td>
<td>&lt;3</td>
<td>50–97</td>
<td>&lt;3</td>
<td>&lt;3</td>
</tr>
</tbody>
</table>

**Note:** FH indicates frontal horns; TH, temporal horns; OH, occipital horns; PS, perisylvian; PMG, polymicrogyria; LIA, lack of internal architecture.
FIG 2. Brain MR images depicting additional brain anomalies in a cohort of 7 unrelated individuals with ZTTK syndrome. A, Sagittal midline T2-weighted MRI of the brain of individual 4 at 1 year 4 months of age showing a thin corpus callosum (white arrowheads), an elongated pituitary stalk (black arrowhead), and a small pituitary gland. B, Sagittal midline TI-weighted MRI of the brain of individual 5 at 1 year 8 months of age showing an elongated pituitary stalk (black arrowhead) and a small pituitary gland. C, Sagittal midline TI-weighted MRI of the brain of individual 6 at 15 years 2 months of age showing a shortened corpus callosum with a hypoplastic anterior and posterior body (white arrowheads), a normal-sized pituitary stalk, and a normal-sized pituitary gland. D, Coronal T2-weighted MRI of the brain of individual 5 at 1 year 8 months of age revealing normal-sized hippocampi with a lack of internal architecture (white arrowheads). E, Coronal T2-weighted MRI of the brain of individual 2 at 11 years 6 months of age revealing small malrotated hippocampi (white arrowheads). F, Sagittal midline TI-weighted MRI of the brain of individual 1 at 7 years 7 months of age showing a box-shaped posterior fossa (white dashed lines) and a shortened corpus callosum with a hypoplastic posterior body, isthmus, and splenium (black arrow). G, Sagittal midline T2-weighted MRI of the brain of individual 2 at 11 years 6 months of age showing a box-shaped posterior fossa (white dashed lines) with a posterior fossa cyst (black star) and dysmorphic cerebellar tonsils (white arrowhead). H, Sagittal midline TI-weighted MRI of the brain of individual 3 at 1 year of age showing a large cerebellum. I, Right parasagittal TI-weighted MRI of the brain of individual 2 at 11 years 6 months of age revealing perisylvian polymicrogyria with upswept Sylvian fissures (white arrowhead). J, Right parasagittal TI-weighted MRI of the brain of individual 6 at 15 years 2 months of age revealing a thick perisylvian cortex and dysgyria (white arrowheads). K, Axial TI-weighted MRI of the brain of a control individual depicting caudate nuclei with caudate heads (white arrowheads) that are less rounded than in L and M, L. Axial T2-weighted MRI of the brain of individual 2 at 11 years 6 months of age revealing a dysmorphic caudate nucleus with rounded and malrotated caudate heads (white arrowheads), large dysmorphic frontal and occipital horns, and a bilaterally thickened perisylvian cortex (black arrowheads). M, Axial TI-weighted MRI of the brain of individual 1 at 7 years 7 months of age revealing dysmorphic caudate nuclei with rounded and malrotated caudate heads (white arrowheads) and large dysmorphic frontal horns. N, Axial T2-weighted MRI of the brain of individual 4 at 1 year 4 months of age revealing bilateral perisylvian polymicrogyria (white arrowheads). O, Axial TI-weighted MRI of the brain of individual 3 at 1 year of age revealing a thick perisylvian cortex and dysgyria (white arrowheads).

Neuroradiologic assessment of MR imaging data led to the identification of a set of brain structures with recurrent abnormalities. These features may suggest the diagnosis of ZTTK syndrome in situations in which hypothesis-free high-throughput sequencing is not available. Additionally, these features may support the pathogenic nature of VUS identified in SON, such as the multiple missense variants that have now been reported in conjunction with ZTTK syndrome-like features. Interestingly, craniosynostosis was also noted in 2 patients, both involving the coronal sutures. Craniosynostosis has been previously reported in individuals with ZTTK syndrome and could represent another phenotypic feature overrepresented in this disorder.

Most individuals reported in this study were recruited based on the presence of PVNH with a subsequent molecular diagnosis, representing a potential recruitment bias. As a consequence, the...
neuroradiologic signature identified may be associated with PVNH, with no direct association with ZTTK syndrome. The frequency of these newly identified neuroradiologic features in ZTTK syndrome will be best assessed through studying individuals recruited purely on the basis of a molecular diagnosis. Re-assessing published ZTTK cohorts for these imaging features may validate the clinical utility of the observations made in this cohort.3,4,11,12

CONCLUSIONS
We identify a recurrent set of cortical malformations in a cohort of individuals with ZTTK syndrome. These imaging features have the potential to aid in the diagnosis of ZTTK syndrome in the absence of high-throughput sequencing.

ACKNOWLEDGMENTS
Patients and their families are thanked for their willing participation. The authors wish to acknowledge access to New Zealand eScience Infrastructure high-performance computing facilities for the processing of whole-exome and genome sequence data in this research.

Disclosure forms provided by the authors are available with the full text and this research.

REFERENCES
ABSTRACT

BACKGROUND AND PURPOSE: Juvenile xanthogranuloma is a rare clonal, myeloid, neoplastic disorder. Typically, juvenile xanthogranuloma is a self-limited disorder of infancy, often presenting as a solitary red-brown or yellow skin papule/nodule. A small subset of patients present with extracutaneous, systemic juvenile xanthogranuloma, which may include the CNS. The goal of this retrospective study was to evaluate and categorize the neuroimaging findings in a representative cohort of pediatric patients with CNS juvenile xanthogranuloma.

MATERIALS AND METHODS: The brain and/or spine MR imaging data of 14 pediatric patients with pathology-proven juvenile xanthogranuloma were categorized and evaluated for the location; the signal intensity of xanthogranulomas on T1WI, T2WI, DWI, and a matching ADC map for the pattern and degree of contrast enhancement; and the presence of perilesional edema, cysts, or necrosis.

RESULTS: Fourteen pediatric patients (8 girls, 6 boys; mean age, 84 months) were included in the study. Patients presented with a wide variety of different symptoms, including headache, seizure, ataxia, strabismus, hearing loss, facial paresis, and diabetes insipidus. Juvenile xanthogranuloma lesions were identified in a number of different sites, including supra- and infratentorial as well as intracranial and spinal leptomeningeal. Five patients were categorized into the neuroradiologic pattern unifocal CNS juvenile xanthogranuloma; 8, into multifocal CNS juvenile xanthogranuloma; and 1, into multifocal CNS juvenile xanthogranuloma with intracranial and spinal leptomeningeal disease. In most cases, xanthogranulomas were small-to-medium intra-axial masses with isointense signal on T1WI (compared with cortical GM), iso- or hyperintense signal on T2WI, had restricted diffusion and perilesional edema. Almost all xanthogranulomas showed avid contrast enhancement. However, we also identified less common patterns with large lesions, nonenhancing lesions, or leptomeningeal disease. Four cases had an additional CT available. On CT, all xanthogranulomas were homogeneously hyperdense (solid component) without evident calcifications.

CONCLUSIONS: CNS juvenile xanthogranuloma may demonstrate heterogeneous neuroimaging appearances potentially mimicking other diseases, such as primary brain neoplasms, metastatic disease, lymphoma and leukemia, other histiocytic disorders, infections, or granulomatous diseases.

ABBREVIATIONS: ALK = anaplastic lymphoma kinase; BRAF V600 = B-Raf proto-oncogene, serine/threonine kinase (V600E); CE = contrast-enhanced; ECD = Erdheim-Chester disease; GRE = gradient recalled-echo; HLH = hemophagocytic lymphohistiocytosis; JXG = juvenile xanthogranuloma; LCH = Langerhans cell histiocytosis; MAPK = mitogen-activated protein kinase; RDD = Rosai-Dorfman disease

Juvenile xanthogranuloma (JXG) is a rare, clonal, myeloid, neoplastic disorder traditionally belonging to the group of non-Langerhans cell histiocytosis. Typically, JXG is a self-limited condition in infancy with skin lesions often presenting as a solitary red-brown or yellow skin papule or nodule on the head, neck, or upper trunk. A small subset present with systemic JXG, which is commonly progressive without therapy and is potentially fatal. Extracutaneous systemic involvement may include the eyes, oral cavity, heart, lung, gastrointestinal tract, liver, spleen, kidneys, lymph nodes, bone marrow, soft tissue, and the CNS. Characteristic histopathologic features include vacuolated CD163, factor-XIIIa- and fascin-positive histiocytic cells, and multinucleated Touton giant cells (which may not be present in CNS lesions). Involvement of the CNS is seen in only up to 7% of cases with JXG. The clinical
presentation of CNS JXG is nonspecific and includes a wide range of symptoms, such as headache, seizures, ataxia, increased intracranial pressure, macrocrania, developmental delay, weakness, numbness, cranial nerve abnormalities, and diabetes insipidus.\(^1,2,5,10\) To date, there is no generally accepted consensus or standard-of-care treatment for CNS JXG. Successful outcomes have been reported in individual cases and case series, including chemotherapy (eg, clofarabine), anaplastic lymphoma kinase (ALK) inhibition (for ALK fusion events), or mitogen-activated protein kinase (MAPK) pathway blockade with B-Raf proto-oncogene, serine/threonine kinase (V600E) (BRAF V600E) or mitogen-activated protein kinase kinase (MAP2K) inhibitors.\(^3,11,12\) Only scarce literature on imaging in CNS JXG exists, and the imaging spectrum remains incompletely characterized.\(^1,6,7,13-15\) Accordingly, the goal of this article was to study and categorize the neuroimaging findings in a representative cohort of pediatric patients with confirmed CNS JXG.

MATERIALS AND METHODS

Following institutional review board approval, an electronic search of the pediatric histopathologic and pediatric neuroradiologic database covering January 1, 2010, to August 31, 2021, was performed using the following keywords: juvenile xanthogranuloma (JXG). Inclusion criteria for this retrospective study were the following: 1) pediatric patients (younger than 19 years of age) with pathology-proven JXG (from CNS and/or other lesions), and 2) brain and/or spine MR imaging data (indication: initial diagnostic work-up of newly emerged symptoms).

All MR imaging studies were performed at either 1.5T or 3T magnetic field strength. Images were obtained by different institutions, but protocols mostly included axial and/or sagittal T1WI and axial T2WI, axial FLAIR, axial contrast-enhanced T1-weighted (T1+CE) images, axial SWI or T2*-gradient recalled-echo (T2*-GRE) sequences, and axial DWI or DTI. Isotropic diffusion-weighted images were generated; and matching ADC maps were automatically calculated using vendor-specific software. The relevant clinical and histopathologic data, including the age at diagnosis/biopsy, age at initial imaging, sex, sites of disease involvement, presenting symptoms, histologic diagnosis, and clinical molecular data were extracted from the electronic medical charts.

MR imaging studies were independently reviewed and categorized on the PACS workstation by 2 board-certified pediatric neuroradiologists (N.K.D. and R.P.P.). The readers were not blinded to the patient’s medical history. The interrater reliability was assessed by the Cohen \(\kappa\) (for categoric variables) and the intra-class correlation coefficient (for interval and metric variables). The MR imaging studies were evaluated for the exact location (including an intra- versus extra-axial classification), the T1WI and T2WI signal intensity of xanthogranulomas (hypo-, iso-, or hyperintense compared with the cortical GM), the pattern of contrast enhancement (contrast enhancement versus no contrast enhancement; homogeneous contrast enhancement versus heterogeneous contrast enhancement), the degree of contrast enhancement (none, mild, moderate, marked), the percentage (proportion of the mass; visually estimated) of contrast enhancement of the lesion (0%–25%, 26%–50%, 51%–75%, and 76%–100%), the extent of perilesional T2-weighted hyperintensity suggestive of vasogenic edema (no, mild, moderate, marked), evidence of blood products or calcium on SWI or T2*-GRE (yes/no), the presence of cysts or necrosis (yes/no; “cyst” was defined as a well-defined collection, and “necrosis”, as a nonsolid irregular area), and the signal intensity on DWI and the matching ADC map (diffusion restriction or no diffusion restriction with reference to the brain). In addition, quantitative measurements of ADC values were performed. An ROI was manually placed within the xanthogranuloma on the ADC maps as follows: section with the largest expansion of the solid component of the xanthogranuloma using a 5-mm\(^2\) ROI. The mean ADC value and the standard deviation (SD) were determined.

Statistical analyses were performed using the software package SPSS Statistics, Version 28.0 (IBM).

RESULTS

Fourteen pediatric patients (8 girls, 6 boys; mean age, 84 months at imaging; median age, 65.5 months; age range, 1 month to 18 years 11 months) fulfilled the inclusion criteria. Patients were categorized into 3 primary neuroradiologic patterns: 1) unifocal, 2) multifocal, and 3) multifocal leptomeningeal. Five subjects had unifocal CNS JXG (Fig 1 and Online Supplemental Data), 8 patients had multifocal CNS JXG (Fig 2), and 1 child had multifocal CNS JXG with additional intracranial and spinal leptomeningeal disease (Fig 3).

Isolated CNS involvement was found in all 5 patients categorized into the unifocal neuroradiologic pattern. Of the 8 patients categorized into the multifocal neuroradiologic pattern, 2 had a single-system involvement of the CNS, while 6 patients showed involvement of ≥2 organ systems. From the latter, the skin was involved in all 6 patients, followed by bone involvement in 3 patients. Furthermore, 1 patient had, in addition to CNS and skin involvement, lesions in the conjunctiva and eye globe; 1 patient had, in addition to CNS and skin involvement, a lesion in the soft tissue (pharynx); and 1 patient had extensive systemic involvement with lesions in the CNS, skin, bone, lung, kidneys, and lymph nodes. The 1 patient categorized into the multifocal leptomeningeal neuroradiologic pattern had lesions in the CNS and peripheral nervous system. In total, 7 of 14 patients (50%) had isolated CNS involvement, and 7 patients (50%) had involvement of ≥2 organ systems. The involved organ systems of all 14 patients are summarized in the Online Supplemental Data.

Xanthogranulomas had an average maximum diameter at presentation of 2.2 (SD, 1.3) cm (range, 0.8–4.8 cm). Lesions were found in a number of different sites, including supra- and infratentorial, intra-axial or extra-axial (in the hypothalamic-pituitary region, the internal auditory canal, or the Meckel cave), as well as in spinal leptomeningeal locations. With the 5 subjects categorized into the neuroradiologic pattern, unifocal CNS JXG, lesions were located in the right frontal lobe (cortical/subcortical WM; Fig 1), in the left parietal lobe (cortical/subcortical WM; Online Supplemental Data), cerebellar vermis, pons, and infundibulum. With patients with multifocal CNS JXG, lesions were scattered supra- and infratentorially (Figs 2 and 3). Supratentorial lesions were mainly found in the cortex, subcortical WM, or central GM, followed by deep WM and periventricular WM. Infratentorial xanthogranulomas were located in the pons in 6 patients; in the
FIG 1. Brain images of a 6-year-old girl with pathology-proven unifocal JXG who presented with increased frequency of headaches, occasionally accompanied by vomiting. Brain MR imaging with an axial T1-weighted image (A), axial T1-weighted image (B), axial DWI (C), axial ADC map (D), axial T1+CE-weighted image (E), and axial noncontrast CT (F) shows a large, round, unfocal mass lesion located in the right frontal lobe (arrows in A–F) with central necrosis (arrowhead in A). Compared with cortical GM, the solid non-necrotic peripheral component of the lesion is T2-isointense (A) and T1-isointense (B) and shows contrast enhancement (E) and restricted diffusion (C and D). The axial CT image (F) demonstrates the hyperdense (solid portion) large mass lesion.

cerebellar GM in 5 patients; in the brachium pontis in 3 patients; in the cerebellar WM in 2 patients; in the midbrain in 2 patients; in the vermis in 1 patient; and in the medulla in 1 patient. Lesions were found in the infundibulum in 6 patients; in the corpus callosum, pituitary gland, and hypothalamus in 3 patients each; in the optic chiasm and septum pellucidum in 2 patients each; in the ventricles in 1 patient; and in the internal auditory canal and the Meckel cave on both sides in 1 patient. In 1 patient, the infundibulum was involved in isolation, and in 5 patients, the infundibulum was part of a multifocal manifestation. Two children were diagnosed with diabetes insipidus. In 1 patient, diabetes insipidus was an initial presenting symptom, and the other patient developed diabetes insipidus later in the disease course.

Images were obtained from different institutions. In 2 patients, no T1WI (12/14 with available T1WI); in 1 child, no T2WI (13/14 with available T2WI); in 4 subjects, no DWI (10/14 with available DWI); and in 3 patients no SWI/T2*-GRE (11/14 with available SWI/T2*-GRE) images were available. On T1WI, xanthogranulomas were isointense compared with cortical GM in 7 patients (7/12), hyperintense in 4 patients (4/12), and hypointense in 1 patient (1/12). In the 12 patients with available T1WI, the pituitary bright spot was lost in 3 subjects (3/12). The infundibulum was involved in all 3 patients in whom the pituitary bright spot was lost. On T2WI, xanthogranulomas were isointense compared with cortical GM in 5 patients (5/13), hyperintense in 4 patients (4/13), isointense in 3 patients (3/13), and hypointense in 1 patient (1/13), respectively. In 13 patients with available T2WI, perilesional edema was evident in 11 patients (11/13). The xanthogranulomas of 2 patients had no edema, and 4 patients had mild, 3 patients had moderate, and 4 patients had marked perilesional edema. Necrosis was seen in 6 patients (6/14), and 2 patients (2/14) had cystic components within the lesions. The xanthogranulomas of 13 patients (13/14) showed contrast enhancement on T1+CE-weighted images; the xanthogranulomas of 6 patients had homogeneous and the xanthogranulomas of 5 patients had heterogeneous contrast enhancement. In 2 patients with multifocal JXG, larger xanthogranulomas showed heterogeneous and smaller xanthogranulomas showed homogeneous contrast enhancement. One patient with multifocal xanthogranulomas had lesions with and without contrast enhancement on T1+CE-weighted images. All contrast-enhancing xanthogranulomas were characterized by marked contrast enhancement, comprising >50% of the lesion size, with 13 patients having 76%–100%, and 1 patient having 51%–75% of the lesion enhancing.

Seven of 10 patients with available DWI (7/10) showed restricted diffusion, and 3 had no restricted diffusion (equivalent values compared with normal brain on the ADC map; increased ADC values were not found). The mean ADC values and SD were determined on the available ADC maps. For 1 patient, no measurement could be obtained because the small size of the lesion prevented proper ROI positioning. The overall (n = 9) mean ADC value was 868.96 (SD, 179.24); the mean ADC value calculated for lesions with diffusion restriction (n = 7) was 823.97 (SD, 175.99); and without diffusion restriction (n = 2), it was 1026.42 (SD, 86.15).

Three of 11 patients with available SWI or T2*-GRE images demonstrated hypointense blood products or calcifications.

Due to an obstructive mass effect of the xanthogranulomas, hydrocephalus was found in 2 patients (2/14).

In 9 patients (9/14), additional spine MRIs were available. By means of these spine MRIs, spinal leptomeningeal disease
was found in 1 patient (neuroradiologic pattern: multifocal leptomeningeal).

In addition to MRIs, 4 patients had an additional CT available. Xanthogranulomas were homogeneously hyperdense (solid component) on all 4 CT scans without evident calcifications. Two demonstrated central necrosis; and 1, a marginal cyst.

The interrater reliability was assessed using the Cohen $\kappa$ (for categoric variables) and by the intraclass correlation coefficient (for interval and metric variables). The Cohen $\kappa$ and the intraclass correlation coefficient values ranged from 0.71 to 1.00. According to Field, values of $>0.7$ represent reliable ratings.

Detailed information comprising the demographics, imaging features, and clinical information including the clinical mutational data are shown as Online Supplemental Data. A summary focusing on the signal characteristics of CNS xanthogranulomas is presented in the Table.

DISCUSSION
In this cohort of pediatric patients with biopsy-proven CNS JXG (from the CNS site and/or from other locations), most JXG lesions were typified by small-to-medium masses with iso-intense signal on T1WI, iso- or hyper-intense signal on T2WI, restricted diffusion and perilesional edema. Almost all xanthogranulomas showed marked contrast enhancement. Cases were categorized into 3 primary neuroradiologic patterns: unifocal, multifocal, and multifocal leptomeningeal.

The category of histiocytosis includes Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), JXG, Rosai-Dorfman disease (RDD), hemophagocytic lymphohistiocytosis (HLH), and malignant histiocytosis. These entities are characterized by pathogenic myeloid cells that share histologic features with macrophages or dendritic cells. The lesional cells may originate from the embryonic yolk sac, fetal liver, or postnatal bone marrow. The term “histiocytic disorders” for LCH, ECD, JXG, RDD, and HLH has been proposed to differentiate them from hyperproliferative cancer-typical lesions such as Langerhans cell sarcoma and malignant histiocytosis. While LCH, ECD, JXG, and RDD have somatic mutations in MAPK pathway genes and show an accumulation of clonal, mononuclear phagocytes, HLH is a syndrome of immune dysregulation.

The Working Group of the Histiocyte Society published the first classification system of histiocytic diseases in 1987, which consisted of 3 categories, namely, Langerhans cell histiocytosis, histiocytosis of mononuclear phagocytes other than Langerhans cells, and malignant histiocytic disorders. In the past decades with the incorporation of molecular features, there have been several revisions, with the most recent revision in 2016. This updated contemporary classification consists of 5 groups (the Langerhans-related; cutaneous and mucocutaneous histiocytoses; malignant histiocytoses; RDD; and HLH and macrophage activation syndrome) and is based on histology, phenotype, molecular alterations, and clinical characteristics. The proposed Langerhans group includes LCH, ECD, and extracutaneous JXG.

Depending on the histiocytic entity, these diseases may be seen in both the pediatric and adult populations in various proportions and may show a broad variety of clinical presentations and outcomes. The intense inflammatory infiltrates in histiocytic disorders play a key role in the origination and maintenance of...
organ-specific lesions and contribute to the clinical symptoms. To date, very little is known concerning the underlying pathogenetic mechanisms of JXG. JXG cells share some common features with dermal macrophages, including expression of fascin, factor-XIIIa, CD163, and CD68 (Online Supplemental Data).

JXG is a rare entity; a frequency of approximately 1 per million children and a male/female ratio of 1.4:1 have been described in the Kiel Pediatric Tumor Registry. In our cohort, there was a 1.33:1 female predominance. With systemic JXG, a predominance of females of up to 3:1 has been reported in the literature. Most often, JXG presents in children (<4 years) as a solitary red-brown or yellow skin papule or nodule of 0.5–1 cm in diameter and may undergo spontaneous regression. Most skin lesions involve the head, neck, or upper trunk. Some patients have isolated or very few cutaneous lesions, while others may develop hundreds of lesions. A small subset present with systemic JXG. Besides the CNS (7%), extracutaneous JXG may involve the liver (22%), lungs (16%), soft tissue (16%), spleen (11%), eyes (9%), oral cavity (7%), adrenal glands (7%), gastrointestinal tract (7%), lymph nodes (7%), bone marrow (7%), and heart (4%). In this study, 7 of 14 patients (50%) had isolated CNS involvement. Seven patients (50%) had involvement of ≥2 organ systems, with involvement of functions such as vision or swallowing. In patients with systemic JXG including CNS lesions, there is evidence of successful treatment using chemotherapy (eg, clofarabine) or targeted therapies such as MAPK pathway blockade, or ALK inhibition (for ALK fusion events). Available treatment options for JXG include “wait and see/follow-up,” chemotherapy (eg, clofarabine), targeted therapies such as ALK inhibition (for ALK fusion events) and MAPK pathway blockade with BRAF V600E or MAP2K inhibitors, surgery, or a combination of these modalities. Most skin-limited JXG lesions show spontaneous involution, but surgical excision may be considered if lesions are cosmetically unacceptable or endanger or impair the skin and/or bones being most common (Online Supplemental Data).

The clinical presentation depends on the involved organ systems. For CNS JXG, clinical presentation is nonspecific and includes headache, seizures, ataxia, increased intracranial pressure, macrocrania, developmental delay, weakness, numbness, cranial nerve abnormalities, and diabetes insipidus. The findings are in line with the initial presentation of the patients in our study, which included headache, seizure, ataxia, strabismus, hearing loss, facial paresis, and diabetes insipidus, among others (Online Supplemental Data).

In general, JXG is a self-limiting disease. However, systemic JXG, especially with CNS involvement, may be associated with long-term problems such as structural damage by brain lesions or liver failure by large hepatic tumors or may even be fatal. Available treatment options for JXG include “wait and see/follow-up,” chemotherapy (eg, clofarabine), targeted therapies such as ALK inhibition (for ALK fusion events) and MAPK pathway blockade with BRAF V600E or MAP2K inhibitors, surgery, or a combination of these modalities. Most skin-limited JXG lesions show spontaneous involution, but surgical excision may be considered if lesions are cosmetically unacceptable or endanger or impair the skin and/or bones being most common (Online Supplemental Data).

FIG 3. MR images obtained in a 10-year-old boy with pathology-proven multifocal JXG with leptomeningeal brain and spine involvement. The patient presented with progressive right ear pain and erythema and decreased hearing and right-sided facial nerve palsy along with headaches. Axial (A, B, and D) and coronal (C) MR images of the brain. Sagittal T1+CE-weighted fat-suppressed MR image of the spine. For example, 2 centrally necrotic, peripherally contrast-enhancing lesions are noted within both cerebral hemispheres (arrows in A). In addition, nodular contrast enhancement involving the leptomeninges of the right temporal lobe (arrow in B) and contrast enhancement within both internal auditory canals (arrows in C and D) are shown. Sagittal T1+CE-weighted images of the spine depict increased contrast enhancement of the leptomeninges (“sugar coating”), partially with nodular components, most obvious at the C7 and T8 level (arrows in E).
positive histiocytosis demonstrates histopathologic features of classic JXG. Additionally, recurrent mutations in CSF1R have recently been described in JXG.

To date, data describing imaging features of CNS JXG are largely limited to case studies and reviews, including clinical and pathological aspects as well as a summary description of the imaging features. This article aims to present a large case series focusing on neuroimaging features of CNS JXG in children. Intracranial xanthogranulomas have been described variously as T1/T2-hypo-, iso-, or hyperintense lesions on MR imaging. In our cohort, on T1WI, xanthogranulomas were mainly isointense compared with cortical GM (7/12; Online Supplemental Data), several lesions were hyperintense (4/12; Fig 2), and 1 lesion was hypo- to isointense (1/12). On T2WI, xanthogranulomas were mainly isointense (5/13; Fig 1 and Online Supplemental Data) or hyperintense (4/13), followed by an iso- to hyperintense (3/13; Fig 2) or hypo- to isointense (1/13) appearance.

Ginat et al characterized the imaging features of head and neck xanthogranulomas of 10 patients, with 6 patients undergoing MR imaging. They reported that on T1WI, lesions were characterized by an iso- or hyperintensity, and on T2WI, by an iso- or hypointensity. Within our cohort, several lesions showed a high signal on T1WI and T2WI. This could be due to lipid components within these lesions because lipidized or xanthomatous cells may be found within xanthogranulomas. In general, CNS JXGs and head and neck JXGs are described as showing homogeneous contrast enhancement on T1+CE-weighted images. Marked contrast enhancement seems to be a reliable imaging feature of JXG because almost all xanthogranulomas showed avid contrast enhancement (Fig 1–3 and Online Supplemental Data), and only 1 patient (1/14) who had multifocal xanthogranulomas showed lesions with marked contrast enhancement as well as lesions without contrast enhancement on T1+CE-weighted images. Most lesions (7/10) demonstrated restricted diffusion (Figs 1 and Online Supplemental Data). This finding is in agreement with the literature describing decreased diffusion in such lesions. Ginat et al described decreased diffusivity as likely attributed to hypercellularity and/or a collagenous matrix.

Because there are heterogeneous, non-pathognomonic imaging appearances of CNS JXG with neuroradiologic patterns ranging from unifocal to multifocal leptomeningeal involvement, neuroradiology alone is not able to provide an accurate diagnosis. Accordingly, a wide array of differential diagnoses must be considered, including primary brain neoplasms, lymphoma and leukemia, other histiocytic disorders such as LCH or ECD, and infections. If multifocal lesions with leptomeningeal involvement are evident, metastatic and granulomatous diseases such as sarcoidosis and tuberculosis should be included in the differential diagnosis.

The range of intracranial CNS findings in LCH is better known and comprises a neurodegenerative pattern including infratentorial WM abnormalities more pronounced in the peridentate regions, abnormalities of the dentate nuclei and basal ganglia, and bilateral symmetric leukoencephalopathy-like abnormalities in the supratentorial white matter. In addition, CNS LCH may show mass lesions in the hypothalamic-pituitary region, seen as thickening and enhancement of the pituitary stalk with possibly loss of the posterior bright spot, and it is clinically frequently accompanied by diabetes insipidus. Rare neuroimaging manifestations include enlargement of the pineal gland, thickening and enhancement of the choroid plexus, and intraparenchymal masses. Hence, in contrast to CNS JXG, in CNS LCH, intra-axial parenchymal mass lesions are rather uncommon. However, involvement of the hypothalamic-pituitary region appears to be a common feature of both CNS JXG and LCH. In our cohort, infundibular involvement was seen in 6 patients, and pituitary gland or hypothalamic involvement was noted in 3 patients each. In addition, the posterior pituitary gland T1-hyperintense signal or bright spot was absent in 3 patients. In general, a loss of the posterior bright spot is thought to be a result of a lack of vasopressin-containing granules. We assume a similar mechanism as seen in LCH, in which an absent pituitary bright spot and involvement of the infundibulum are frequent but do not necessarily occur in all patients. In our cohort, we did not find changes suggestive of posterior fossa neurodegeneration. In addition to CNS LCH, neurodegeneration has also been described in the context of ECD. CNS JXG may not be prone to neurodegeneration, or neurodegeneration could potentially develop later in the course of the disease because neuroimaging in our cohort was performed for the initial diagnostic work-up of new symptoms.

We are aware of several limitations in our study. The imaging findings are based on a retrospective study design with a quite limited number of pediatric patients and MR imaging was performed as a diagnostic work-up of newly emerged symptoms on various scanners with somewhat different protocols. Subsequent studies with larger cohorts and standardized imaging protocols are needed to confirm the proposed imaging patterns presented in our study. In addition, future prospective studies should correlate histologic features to neuroimaging characteristics, and longitudinal follow-up

<table>
<thead>
<tr>
<th>No.</th>
<th>T1-Weighted</th>
<th>T2-Weighted</th>
<th>T1+CE</th>
<th>DWI/ADC</th>
</tr>
</thead>
<tbody>
<tr>
<td>4/12</td>
<td>← ←</td>
<td>← ←</td>
<td>← ←</td>
<td>← ←&lt;br&gt; 4 Marked contrast enhancement&lt;br&gt;4 Diffusion restriction</td>
</tr>
<tr>
<td>3/12</td>
<td>← ← ↑ or ↑</td>
<td>← ← ↑ or ↑</td>
<td>← ←</td>
<td>← ←&lt;br&gt; 3 Marked contrast enhancement&lt;br&gt;1 Diffusion restriction, 2 no diffusion restriction</td>
</tr>
<tr>
<td>2/12</td>
<td>↑ ↑</td>
<td>↑ ↑</td>
<td>↑ ↑</td>
<td>↑ ↑&lt;br&gt; 2 Marked contrast enhancement&lt;br&gt;1 Diffusion restriction, 1 NA</td>
</tr>
<tr>
<td>2/12</td>
<td>↑ ← or ← ↑</td>
<td>↑ ← or ← ↑</td>
<td>↑ ←</td>
<td>↑ ←&lt;br&gt; 1 Marked contrast enhancement&lt;br&gt;1 No diffusion restriction, 1 NA</td>
</tr>
<tr>
<td>1/12</td>
<td>↓ ← ←</td>
<td>↓ ← ←</td>
<td>↓ ←</td>
<td>↓ ←&lt;br&gt; 1 Marked contrast enhancement&lt;br&gt;1 Diffusion restriction</td>
</tr>
</tbody>
</table>

Note: ← ← indicates isointense; ↑, hyperintense; ← ↑, iso- to hyperintense; ↓ ←, hypo- to isointense; NA, not applicable.

*aCases were included only when both T1WI and T2WI were available.
studies may shed more light on the rate of progression, the response to therapy, and the possible changes in imaging characteristics.

CONCLUSIONS
In this study, pediatric patients with biopsy-proven CNS JXG were categorized into 3 primary neuroradiologic patterns: 1) unifocal, 2) multifocal, and 3) multifocal leptomeningeal. CNS JXG lesions were typified by small-to-medium masses with isointense signal on T1WI, iso- or hyperintense signal on T2WI, restricted diffusion, perilesional edema, and marked contrast enhancement. However, we also identified less common patterns with large lesions, nonenhancing lesions, or leptomeningeal disease. These findings demonstrate the heterogeneous neuroimaging appearances of JXG potentially mimicking other diseases, such as primary brain neoplasms, metastatic disease, lymphoma and leukemia, other histiocytic disorders, and infections or granulomatous diseases. Pediatric neuroradiologists should be familiar with this entity.

ACKNOWLEDGMENT
The authors thank M. Christiner for providing statistical support.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES
Volumetric Brain MRI Study in Fetuses with Intrauterine Growth Restriction Using a Semiautomated Method

R. Peretz, T. Halevy, M. Gafner, S. Fried, Y. Revesz, A. Mayer, and E. Katorza

ABSTRACT

BACKGROUND AND PURPOSE: According to the medical literature, it is known that intrauterine growth restriction is associated with abnormal fetal brain findings. The aim of this study was to assess the volume of fetal brain structures in fetuses with intrauterine growth restriction compared with the control group and to examine the effect of intrauterine growth restriction on birth weight in relation to the effect on the volumes of these structures.

MATERIALS AND METHODS: This historical cohort study included 26 fetuses diagnosed with intrauterine growth restriction due to placental insufficiency. The control group included 66 fetuses with MR imaging scans demonstrating normal brain structures. The volumes of the supratentorial brain, left and right hemispheres, and the cerebellum were measured using a semiautomatic method. In addition, the cerebellum and supratentorial brain ratio was calculated. The measurements of each brain structure were then converted to percentiles according to growth curves.

RESULTS: The absolute volumes and percentiles of all brain structures examined were smaller in the intrauterine growth restriction group. All examined brain structures showed results that were statistically significant (P < .015). There was no statistically significant difference in the cerebellum/supratentorial brain ratio (P > .39). The difference in brain volume percentiles was statistically smaller than the difference in birth weight and birth weight percentiles (Dolberg growth curves) between the groups.

CONCLUSIONS: Intrauterine growth restriction affects the volume of brain structures, as measured by quantitative MR imaging. Compared with healthy controls, the effect on birth weight was more prominent than the effect on brain structures, possibly due to the “brain-preserving” capability.

ABBREVIATIONS: CER = cerebellum; GA = gestational age; ICC = intraclass correlation coefficient; IUGR = intrauterine growth restriction; LH = left hemisphere; RH = right hemisphere; ST = supratentorial brain

Intrauterine growth restriction (IUGR) is a halt in growth or a change in the growth rate of the fetus. The American College of Obstetricians and Gynecologists has defined IUGR as a fetus with a birth weight below the 10th percentile for gestational age (GA). IUGR affects 5%–10% of all pregnancies and has many etiologies. Some etiologies are related to maternal factors (age, poor diet, hypertension, preeclampsia), some are related to fetal factors (chromosomal abnormalities, genetic syndromes, major congenital anomalies, multiple gestation, metabolic disorders), and some are related to the placenta. The diagnosis of IUGR is usually made with the help of a sonographic examination during pregnancy. Studies have shown that early detection of IUGR leads to better management of the pregnancy and thus to a better outcome for the neonate. Currently, a number of prenatal and long-term effects caused by IUGR are known. These effects include both prenatal and neonatal mortality and morbidity, growth retardation, hypertension, obesity, diabetes, neurodevelopmental impairment, impaired cognitive and motor function, as well as impaired attention and performance at school. Studies have shown a relationship between IUGR and abnormal findings in fetal brain tissue such as abnormal brain topology, reduced volume ratio between the cerebellum (CER) and supratentorial areas, metabolic changes, decreased size of the intracranial structures, decreased gray and white matter, and decreased diffusion in certain areas of the brain. Measuring the volume of the brain structures with manual and automatic...
methods presents various difficulties,\textsuperscript{18,19} and as a result, a Matlab-based method (MathWorks) has been developed to measure 3D brain volumes in a semiautomatic fashion.\textsuperscript{18} This study used a semiautomatic method to assess volume changes of in utero brain structures in fetuses with IUGR compared with controls and examined the association between IUGR and birth weight in relation to the association between IUGR and the volumes of these structures.

**MATERIALS AND METHODS**

This is a historical cohort study during which MR imaging scans were obtained between 2011 and 2017 at a tertiary medical center. Data regarding medical history, obstetric history, sonography and MR imaging, perinatal history, and medical follow-up were collected from patients’ medical records, and a database was constructed.

**Subjects**

The study population included 26 fetuses with IUGR due to placental insufficiency who underwent MR imaging. The only indication for fetal MR imaging was IUGR. The MR imaging examination was performed as part of a pilot study at our medical center. This pilot study aimed to assess the contribution of fetal brain MR imaging in the diagnosis and management of IUGR.

Subject selection criteria were as follows:

1. Women who underwent fetal MRI at Sheba Medical Center during 8 years.
2. Age of pregnancy at the time of fetal MRI between 25 and 38 weeks.
3. Pregnancies with IUGR below 10% according to Dolberg growth curves, intrauterine or at birth.
4. Pregnancies of a single fetus.
5. IUGR pregnancies caused by placental insufficiency were selected using an ultrasound examination with abnormal placental findings: notch in the umbilical arteries, high arterial resistance in the umbilical arteries, abnormal systolic-diastolic flow ratio in the umbilical arteries, increased diastolic flow in the umbilical arteries, abnormal MCA pulsatility index/pathologic or thickened placenta/low amniotic fluid.

Fetuses were excluded from the test group on the basis of the following criteria:

1. Clinical or laboratory findings that indicated nonplacental reasons for the presence of IUGR:
   - Fetal causes: intrauterine fetal infection, abnormal anatomic fetal findings, abnormal genetic test results, and pregnancies with multiple fetuses.
   - Maternal causes: uterine malformations, background diseases such as chronic cardiovascular disease and so forth and women with substance abuse disorder (including alcohol and drugs).
2. Significant imaging findings according to MRI or previous ultrasound examination; mild findings without prognostic significance were included (Online Supplemental Data).
3. Lack of sufficient data on the case.
4. Poor MRI scan quality, preventing the production of essential information.

The control group included 66 fetuses who underwent MR imaging examinations between 2011 and 2017, and their examination revealed no abnormal findings. The indications for fetal MR imaging in these women included a previous child with prenatal neurologic findings, a previous abnormal pregnancy, fetal ultrasound examination with abnormal findings that were later ruled out with an MR imaging examination, and suspicion of cytomegalovirus infection without confirmation by amnio-polymerase chain reaction.

**Measurements**

**MR Imaging and Semiautomated Algorithm.** Fetal MR imaging was performed in a 1.5T MR imaging system in T1 and T2 sequences. The performed protocol is consistent with the one described in Katorza et al.\textsuperscript{20}

Measurements were obtained using a semiautomated algorithm previously described by Ber et al.\textsuperscript{18} To evaluate the consistency of the semiautomated method, we examined interobserver reliability by comparing measurements of 20 fetuses (10 fetuses from the study group and 10 fetuses from the control group) made by 2 independent observers. Intraobserver reliability was assessed by 1 observer who measured a sample of 20 different fetuses twice.

**Anatomic Boundaries**

**Supratentorial Brain Volume.** External boundaries were determined by the parenchyma of the frontal, parietal, occipital, and temporal lobes. The measurement did not include the brainstem, supratentorial ventricular system, and CER. The lateral ventricles were measured separately and then reduced (Fig 1A).

**Left Hemisphere Volume and Right Hemisphere Volume.** The hemispheres were measured independently with a lateral boundary identical to the boundary set in the cerebral measurement. The medial border is determined by the longitudinal groove...
separating the hemispheres. The lateral ventricles were measured separately and then reduced.

Cerebellar Volume. External boundaries were determined by the cerebellar hemispheres. The measurement included the peduncles and vermis. The brainstem and the fourth ventricle were not included (Fig 1B).

Comparison among Subjects. To compare the subjects and overcome the differences in GA, we converted our data into percentiles. The measurements for each fetal brain structure were converted according to growth curves previously published by Ber et al.18 based on data from measurements of 94 healthy fetuses who ranged from $25 + 1$ to $39 + 0$ GA.

Statistics
The percentile of each brain structure in the study group and in the control group is presented as mean (SD). The quantitative variable between 2 independent groups was compared using an independent \( t \) test. Categoric variables were compared using the \( \chi^2 \) test or Fisher exact test. The intraclass correlation coefficient (ICC) was used to evaluate the inter- and intraobserver agreement. All statistical tests were 2-tailed, and \( P < .05 \) was considered statistically significant, as is customary in the literature. SPSS Statistical software for Windows, Version 25 (IBM, 2017), was used for all statistical analyses.

Ethics
The study was approved by the local institutional Helsinki Committee, with the following registration number: 0256–13-SMC. The medical information collected will be kept confidential and will not be passed on to those who do not belong to the study. The information is displayed anonymously without revealing the identities of the study participants.

RESULTS
Twenty-six fetuses were included in the study group. The characteristics of the study population are detailed in the Online Supplemental Data.

The mean GA in which the MR imaging was performed in the control group was 34.1 (SD, 2.58) weeks. The distribution of MR images according to GA in the study and control groups is shown in Fig 2.

Additional data relevant for comparison between the study and the control groups are presented in Table 1. No statistically significant difference was found between the study and the control groups in terms of maternal and pregnancy characteristics. In terms of neonatal characteristics, a statistically significant difference was found when comparing the type (\( P < .001 \)) and the week of birth (\( P < .001 \)).

3D MRI Measurements
The mean volume of the structures and the SD in the study and control groups as well as the significance are shown in Table 2. In all structures, the mean volume in the study group was smaller than that of the control group. All the structures had a statistically significant difference. The CER/supratentorial brain (ST) ratio was also smaller in the study group than in the control group, but this result was not statistically significant.

Comparison with Percentiles
The mean percentiles and SD of each brain structure as well as the level of significance difference between the groups are shown in Table 3. In all brain structures examined, the mean percentile in the IUGR group was smaller than the mean percentile in the control group. The difference was statistically significant. The CER/ST ratio was smaller in the study group compared with the control group; this result, however, was not statistically significant.

A comparison of the mean percentile of brain structures of the 2 groups is shown in Fig 3.

Comparison with Birth Weight and Birth Weight Percentile (Dolberg Growth Curves)
The mean birth weight (in grams) and birth weight percentile, SD in both

![FIG 2. Distribution of MR images according to GA in the study and control groups.](image)

### Table 1: Characteristics of the control population alongside the study population expressed as mean (SD) or frequency and percentage and level of significance

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Study Group (n = 26)</th>
<th>Control Group (n = 66)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mothers’ characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal age at pregnancy (yr)</td>
<td>32.38 (SD, 5.26)</td>
<td>33.03 (SD, 4.66)</td>
<td>.57</td>
</tr>
<tr>
<td>Thyroid disorders</td>
<td>3/26 (11.5%)</td>
<td>4/66 (6%)</td>
<td>.40</td>
</tr>
<tr>
<td>Anemia</td>
<td>1/26 (3.8%)</td>
<td>5/66 (7.5%)</td>
<td>.67</td>
</tr>
<tr>
<td>Blood clotting disorders</td>
<td>1/26 (3.8%)</td>
<td>7/66 (10.6%)</td>
<td>.43</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1/26 (3.8%)</td>
<td>2/66 (3%)</td>
<td>1</td>
</tr>
<tr>
<td>Pregestational diabetes</td>
<td>1/26 (3.8%)</td>
<td>0</td>
<td>.28</td>
</tr>
<tr>
<td>Pregnancy characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spontaneous conception</td>
<td>21/26 (80%)</td>
<td>57/65* (88%)</td>
<td>.51</td>
</tr>
<tr>
<td>Fetal sex</td>
<td>Male 15/26 (57%)</td>
<td>Male 32/66 (48%)</td>
<td>.43</td>
</tr>
<tr>
<td></td>
<td>Female 11/26 (42%)</td>
<td>Female 34/66 (52%)</td>
<td></td>
</tr>
<tr>
<td>GA at MR imaging examination</td>
<td>33.3 (SD, 2.79)</td>
<td>34.1 (SD, 2.58)</td>
<td>.20</td>
</tr>
<tr>
<td>Neonate characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of birth</td>
<td>Vaginal 4/25* (16%)</td>
<td>Vaginal 43/64* (67%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>Cesarean 21/25* (84%)</td>
<td>Cesarean 21/64* (33%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Week of birth</td>
<td>35.04 (SD, 2.66)</td>
<td>38.52 (SD, 1.27)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

*There are some cases in which the data are not documented in our records.
groups, and level of significance are shown in Table 4. The birth weight and percentile difference were significantly greater than the difference in brain volumes.

**Comparison among the Percentiles of Brain Structures within the Different Birth Weight Percentiles of the Study Group**

The mean percentile of the brain structures in each subgroup and its level of significance are shown in Table 5. All measured structures were above the 10th percentile. In all structures, excluding the CER, the mean percentile within the birth weight group of $\leq 3\%$, was smaller compared with the birth weight group of $3\%–10\%$. The results were not statistically significant.

### Table 2: Mean volume of brain structures (mL), ratio (CER/ST), and SD in the study group compared with the control group and level of significance

<table>
<thead>
<tr>
<th>Brain Area</th>
<th>Study Group</th>
<th>Control Group</th>
<th>$P$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ST</td>
<td>179.93 (SD, 45.71)</td>
<td>210.66 (SD, 48.99)</td>
<td>.006</td>
</tr>
<tr>
<td>RH</td>
<td>88.43 (SD, 22.02)</td>
<td>105.34 (SD, 24.59)</td>
<td>.003</td>
</tr>
<tr>
<td>LH</td>
<td>88.76 (SD, 22.68)</td>
<td>105.22 (SD, 24.82)</td>
<td>.004</td>
</tr>
<tr>
<td>CER</td>
<td>10.25 (SD, 3.5)</td>
<td>12.16 (SD, 3.27)</td>
<td>.015</td>
</tr>
<tr>
<td>CER/ST</td>
<td>0.056 (SD, 0.01)</td>
<td>0.058 (SD, 0.01)</td>
<td>.39</td>
</tr>
</tbody>
</table>

### Table 3: Mean percentile of the brain structures or ratio (CER/ST), and the SD in the research group compared with the control group, and the level of significance for the difference between them

<table>
<thead>
<tr>
<th>Brain Area</th>
<th>Study Group</th>
<th>Control Group</th>
<th>$P$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ST</td>
<td>15.57 (SD, 23.4)</td>
<td>40.78 (SD, 37.24)</td>
<td>$&lt;.001$</td>
</tr>
<tr>
<td>RH</td>
<td>15.25 (SD, 23.03)</td>
<td>41.76 (SD, 37.22)</td>
<td>$&lt;.001$</td>
</tr>
<tr>
<td>LH</td>
<td>14.52 (SD, 22.64)</td>
<td>41.86 (SD, 37.77)</td>
<td>$&lt;.001$</td>
</tr>
<tr>
<td>CER</td>
<td>30.82 (SD, 39.24)</td>
<td>46.62 (SD, 34.39)</td>
<td>.04</td>
</tr>
<tr>
<td>CER/ST</td>
<td>57.58 (SD, 34.04)</td>
<td>60.17 (SD, 31.72)</td>
<td>.73</td>
</tr>
</tbody>
</table>

A comparison of the mean percentile between the subgroups is shown in Fig 4.

**Inter- and Intraobserver Reliability**

The results of the inter- and intraobserver reliability were excellent in all measured structures (ICC > 0.996). The results are shown in Table 6.

### DISCUSSION

IUGR affects 5%–10% of all pregnancies. This pathologic fetal condition has been associated with abnormal findings in the brain. In all examined structures, the mean volume in the study group was smaller compared with the control group. The measurements in our study are consistent with previous studies. In a study by Polat et al., similar values were found when adjusting the measurements by GA. Furthermore, the cerebellar volume in normal-growing fetuses in our study is comparable with that in a study by Clouchoux et al., who examined fetuses at weeks 25–36 of pregnancy and found that cerebellar volumes ranged between 3.3 and 16 mL, and comparable with a study by Grossman et al., which found that the volume of the CER ranged from 5 to 15 mL for the same GA.

To neutralize the effect of the GA for the MR images, we converted the volumes of the structures to percentiles according to the normal curves. That the volumes of structures were significantly smaller in the IUGR group relative to the control group, both in terms of absolute size (milliliters) and percentiles, reinforces our hypothesis that IUGR affects brain volumes.

When comparing birth weight and birth weight percentile between the 2 groups, we found that the difference in these variables was statistically greater than the difference in brain structure percentiles. Furthermore, after creating an additional division within the study group according to the birth weight percentile, we discovered that in all structures, excluding the CER, the mean percentile within the birth weight group of $\leq 3\%$ was smaller compared with the birth weight group of $3\%–10\%$. The results were not statistically significant but suggest a correlation between the birth percentile of the fetus and the brain structure percentile. However, the percentile of the fetus did not represent the percentile of brain structures. Even fetuses with very low birth weight percentiles below 3 maintained brain volume percentiles above 10. The fetuses were not microcephalic, and the CER was only slightly abnormal in volume. These results would support the concept of a brain-preserving effect.

In the past, a number of studies have shown neurologic developmental outcomes in fetuses with IUGR. However, in a recent study that examined discordant twins, no statistical difference was found in neurodevelopment outcomes between the appropriate for gestational age twin and the small for gestational age twin. The results of our study may support the hypothesis that some degree of change in brain volume in IUGR might have no or only limited effect on neurologic developmental outcomes, potentially due to the brain-preserving effect. The long-term neurologic outcome seems not to be determined solely by weight assessment, and further research should be performed.

### Table 4: Mean birth weight and birth weight percentile and SD in the study group compared with the control group and level of significance

<table>
<thead>
<tr>
<th></th>
<th>Study Group $\ (n = 25)\text{*}$</th>
<th>Control Group $\ (n = 63)\text{*}$</th>
<th>$P$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth weight (g)</td>
<td>1639.16 (SD, 543.70)</td>
<td>3209.42 (SD, 456.93)</td>
<td>$&lt;.001$</td>
</tr>
<tr>
<td>Birth weight percentile</td>
<td>4.04 (SD, 3.29)</td>
<td>54.09 (SD, 26.76)</td>
<td>$&lt;.001$</td>
</tr>
</tbody>
</table>

*There are some cases in which the birth weight and birth weight percentile are not documented in our records.
We acknowledge some limitations of this study. First, despite a relatively high prevalence of IUGR in the population (5%-10%), it was rare to find fetuses diagnosed with IUGR due to placental insufficiency and who, therefore, underwent MR imaging at our institution as well as had their records collected. We were able to assemble a study group of 26 fetuses that met the inclusion criteria. Our study group is larger than groups collected in similar studies in the past;\textsuperscript{19,23} even so, it is still difficult to prove a correlation and reach statistically significant results. Another limitation was due to the control group not being composed of fetuses of random volunteers without any findings, as we would ideally like. Due to ethical limitations in our environment, it is not possible to perform MR imaging scans on healthy fetuses; therefore, research is limited to the use of existing scans that were necessary for the fetal examination. To best simulate the healthy fetus population, is large compared with previous studies that examined similar research questions. Second, it uses a semiautomatic method, which allows us to overcome the existing challenges in measuring fetal brain structure volumes. Another strength is that we analyzed the volume of brain structures both as absolute values and as percentiles. Converting the measurements to percentiles neutralizes the effect of GA, Thus allowing more accurate analysis.

CONCLUSIONS

IUGR affects the volume of structures in the brain (ST, right hemisphere [RH], left hemisphere [LH], and CER). However, the effect on the volume of brain structures is smaller than the effect on birth weight. Despite various studies on the subject, it is still unclear whether IUGR by itself has a negative neurologic implication. Our findings support the concept of brain-sparing, but further research is needed to correlate with neurodevelopmental outcomes.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES


Table 5: Mean percentile of brain structures by birth weight percentiles in the study group and level of significance for the difference between them\textsuperscript{*}

<table>
<thead>
<tr>
<th>Brain Area</th>
<th>&lt;3% (n = 16)</th>
<th>3%–10% (n = 9)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ST</td>
<td>12.84 (SD, 25.27)</td>
<td>22.11 (SD, 20.55)</td>
<td>.36</td>
</tr>
<tr>
<td>RH</td>
<td>13.53 (SD, 24.89)</td>
<td>19.89 (SD, 20.98)</td>
<td>.52</td>
</tr>
<tr>
<td>LH</td>
<td>12.81 (SD, 25.15)</td>
<td>19.11 (SD, 18.99)</td>
<td>.52</td>
</tr>
<tr>
<td>CER</td>
<td>35.68 (SD, 32.56)</td>
<td>25.56 (SD, 25.99)</td>
<td>.43</td>
</tr>
</tbody>
</table>

\textsuperscript{*}There is 1 case in which the weight percentile is not documented in our records.

Table 6: Intraobserver and interobserver reliability of measurements expressed as ICC and 95% CI

<table>
<thead>
<tr>
<th>Brain Area</th>
<th>Intraobserver</th>
<th>Interobserver</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ICC</td>
<td>95% CI</td>
</tr>
<tr>
<td>ST</td>
<td>1</td>
<td>0.999–1</td>
</tr>
<tr>
<td>RH</td>
<td>0.999</td>
<td>0.997–1</td>
</tr>
<tr>
<td>LH</td>
<td>0.997</td>
<td>0.988–0.999</td>
</tr>
<tr>
<td>CER</td>
<td>0.999</td>
<td>0.995–1</td>
</tr>
</tbody>
</table>


Peer Learning Program Metrics: A Pediatric Neuroradiology Example


ABSTRACT

BACKGROUND AND PURPOSE: The American College of Radiology is now offering an accreditation pathway for programs that use peer learning. Here, we share feasibility and outcome data from a pilot peer learning program in a pediatric neuroradiology section that, in its design, follows the American College of Radiology peer learning accreditation pathway criteria.

MATERIALS AND METHODS: We retrospectively reviewed metrics from a peer learning program with 5 participating full-time pediatric neuroradiologists during 1 year: 1) number of cases submitted, 2) percentage of radiologists meeting targets, 3) monthly attendance, 4) number of cases reviewed, 5) learning points, and 6) improvement actions. In addition, a faculty survey was conducted and is reported here.

RESULTS: Three hundred twenty-four cases were submitted (mean, 7 cases/faculty/month). The faculty never met the monthly submission target. Peer learning meeting attendance was 100%. One hundred seventy-nine cases were reviewed during the peer learning meetings. There were 22 learning points throughout the year and 30 documented improvement actions. The faculty survey yielded the highest ratings (4.8 of 5) for ease of meeting the 100% attendance requirement and for the learning value of the peer learning sessions. The lowest rating (4.2 of 5) was given for the effectiveness of improvements as a result of peer learning discussions.

CONCLUSIONS: Implementing a peer learning program that follows the American College of Radiology peer learning accreditation pathway criteria is feasible. Program metric documentation can be time-consuming. Participant feedback led to meaningful program improvement, such as improving trust, expanding case submission categories, and delegating tasks to administrative staff. Effort to make peer learning operations more efficient and more effective is underway.

ABBREVIATIONS: ACR = American College of Radiology; CME = Continuing Medical Education; PL = peer learning

The American College of Radiology (ACR) is now offering an accreditation pathway for programs that use peer learning (PL). To qualify, a PL program should have a PL policy, explicit program targets, and annual documentation of program metrics. Specifically, the annual report should include the total number of case submissions to the PL program, the number and percentage of radiologists meeting targets as defined in the facility practice policy, a determination of whether PL activities met the minimum standard as defined by the facility practice policy, and a summary of related quality-improvement effort and accomplishments.

Many radiology practices in the United States are adopting PL in lieu of or in addition to traditional score-based peer review. PL is an approach to performance improvement that is based on quality and safety concepts found in high-reliability organizations. PL builds a safety culture by creating a safe environment for error disclosure, it facilitates joint learning from mistakes, and it creates opportunities for improvement through group discussions that elucidate sources of errors. Higher case submission rates have been observed after switching from score-based peer review to PL, indicating higher engagement of radiologists. Here, we share feasibility and outcomes data from a pilot PL program in a pediatric neuroradiology section that, in its design, follows the ACR PL accreditation pathway criteria. Our program uses several PL metrics, including radiologist participation rates, number of cases submitted, number of cases reviewed, tangible lessons learned, and improvement projects completed.

Received June 27, 2022; accepted after revision September 12.
From the Department of Radiology and Imaging Sciences (N.K., K.M.R., G.K., S.F.S., J.W.A., M.E.H.), Emory University School of Medicine, Atlanta, Georgia; and Department of Radiology (N.K., K.M.R., G.K., S.F.S.), Children’s Healthcare of Atlanta, Atlanta, Georgia. Please address correspondence to Nadja Kadom, MD, Department of Radiology, 1405 Clifton Rd NE, Atlanta, GA 30322; e-mail: nkadom@emory.edu; @nkpiano

Indicates article with online supplemental data.
http://dx.doi.org/10.3174/ajnr.A7673

1680 Kadom Nov 2022 www.ajnr.org
MATERIALS AND METHODS

This quality-assurance study was exempt from institutional review board approval. The data were collected at Children’s Healthcare of Atlanta (CHOA), a freestanding academic pediatric hospital with nearly 300,000 examinations annually. Five full-time pediatric neuroradiologists participated in the PL program during the 1-year study period, January 1, 2021, through December 31, 2021. A total of 24,724 neuroradiology examination reports were issued during this time.

PL Program

In December 2020, we incorporated an additional pediatric site into our practice and added substantially to our pediatric neuroradiology faculty, resulting in a separation of pediatric from adult neuroradiology service lines. This created an opportunity for implementing a pilot PL program for the pediatric neuroradiologists who previously participated in score-based peer review.

Our PL program is informed by a written policy that incorporates the elements recommended by the ACR accreditation checklist for PL.1 Our section chief defined the program targets as follows: PL conferences to occur monthly, 100% faculty attendance, and 5 PL cases submitted each month per pediatric neuroradiologist. The annual documentation of our PL program metrics includes the following: a statement of commitment to sequestering PL from performance evaluations, the total number of case submissions to the PL program, the number and percentage of radiologists meeting targets as defined in the facility practice policy, the number of cases reviewed during the PL session, 5) the number and nature of learning points, and 6) the number and nature of improvement actions with assigned faculty volunteer and documented completion.1

PL conferences occur monthly throughout the calendar year and are recorded for asynchronous viewing. The meetings occur between 12:00 and 1:00 PM, when, in most instances, there is service coverage by a fellow, and they last for 1 hour. There are 2 dedicated faculty members who alternate monthly in selecting and presenting cases. During the study period, we reviewed not only discrepancies of perception, interpretation, or communication, but also interesting cases. Each month, cases submitted during the previous month were reviewed. Cases were presented as anonymized PowerPoint slides (Microsoft). The case discussion was documented for each case on a case-review form, along with any learning points and improvement actions. Each session was recorded (Teams; Microsoft) and saved in an online location outside the institution’s health records system, where it is protected under peer review state law. Recordings are shared only with faculty and PL staff and can be accessed for remote viewing by those who could not attend the in-person session. During the study period, any improvement actions were immediately assigned to a faculty volunteer who set a deadline; he or she was followed to the conclusion at the beginning of subsequent PL meetings.

Data Collection

We analyzed the following items that were collected monthly: 1) the number of cases submitted per faculty per month, 2) the percentage of radiologists meeting PL program targets for case submissions (5 per month per faculty), 3) monthly faculty PL attendance (target of 100% live attendance or asynchronous viewing of session recordings), 4) the number of cases reviewed during the PL session, 5) the number and nature of learning points, and 6) the number and nature of improvement actions with assigned faculty volunteer and documented completion.

Faculty Survey

An 11-item survey (Online Supplemental Data) was developed and face-validated by the radiology quality director (N.K.). Responses were collected anonymously in January 2022. There were 2 yes/no questions, 3 open-comment items, and 6 Likert items requesting a Likert star rating with the maximum rating of 5 stars.

Data Analysis

Descriptive statistics were performed in Excel (Microsoft).

RESULTS

PL Program Metrics

The number of monthly case submissions varied widely. During the year, 324 cases were submitted for the PL meetings, with an average of 7 case submissions per faculty per month, and monthly submissions ranging from 0 to 26 cases for a single faculty member (Online Supplemental Data and Fig 1).

There was no month during which >80% of the faculty met the monthly submission target of 5 cases (Fig 2). The low case-submission rate for review in January could be due to the program being new (it was started December 2020), and low submission rates in April correspond to high case volumes and diminished staffing in the same month (data not shown).

PL meeting attendance was 100% for each faculty member.
A total of 179 cases were reviewed throughout the year, which is about 50% of all case submissions (179/324). On average, we reviewed 14 cases per PL meeting, ranging from 6–24 case reviews per session. The session moderator documented any learning points and improvement actions during each PL meeting. There were 22 learning points throughout the year, which averages to 2 learning points per session. Lessons learned included recognizing the importance of accurate use of overnight agree/disagree statements, identifying potential pitfalls in image interpretation, importance of report proofreading, identifying instances when it is appropriate to reference normative values for measurements, and identifying imaging signs of rare diagnoses.

There were 30 documented improvement actions throughout the year, which average to 2.5 improvements identified per session. Improvements that resulted from the PL program thus far included changes to CT and MR imaging protocols, education of radiologists and technologists, changes to reporting templates, changes to EPIC workflows, and modifications of team communications.

**PL Faculty Survey**

All faculty members responded to the survey (response rate, 100%) (Online Supplemental Data). All section members had previously participated in randomized score-based peer review, and only 2 faculty members had experienced PL previously.

When asked to list any differences between random score-based review and PL, that favor random score-based review, respondents listed the following: faster, more objective, simple, easy metric, and mixed agree/disagree (versus only reporting disagreements) as giving a sense of accuracy. Respondents listed differences that favor PL as the following: more fun, learning, discovering improvement opportunities, group discussion, interactive and constructive feedback, and better experience overall.

The highest ratings (4.8 of 5) were given for ease of meeting the 100% attendance requirement and for the learning value of the PL sessions. A slightly lower rating (4.6 of 5) was given for feeling safe during case discussions, for the ease of submitting cases, and for the ability to gain Continuing Medical Education (CME) credit for session participation. The lowest rating (4.2 of 5) was given for effectiveness of improvements as a result of PL discussions.

Additional general comments included lowering the participation target to 80% to include good calls and not just discrepancies, having too many case-submission tools, and improvement actions being rushed and seeming reactive.

**DISCUSSION**

We were able to set up a PL program in pediatric neuroradiology that incorporates the checklist items for the new ACR accreditation pathway for PL, demonstrating feasibility in program design and implementation. However, we have not yet sought ACR accreditation through this pathway.

Most interesting, generating the data required for ACR reporting adds to the overall time commitment for running a PL program. While we did not measure this issue, we estimate that the annual time commitment for the physician leaders is 56 hours, which includes 4 hours/month to collate, select, prepare, and discuss cases for the monthly PL conference, 0.5 hour/month for transcribing PL program data and submitting CME materials, and 2 hours for writing the annual report. We have now trained an administrative assistant who reviews the PL session recording to track attendance, fill out the case-review forms, and handle any activities related to CME credit. While obtaining CME credit for PL was rated less important in our survey, we will continue to offer it because our administrative staff is now managing this aspect of the program. The more time-intensive effort for PL programs compared with score-based peer review has been acknowledged by others.

The monthly PL meeting attendance target was easily met when allowing our faculty who could not attend the live session to attest to viewing session recordings. Faculty rated the ease of compliance with this target very favorably. Similar to others, we used the virtual format due to coronavirus disease 2019 (COVID-19) conditions but realize now that it remains the best option for participating from various sites and practice locations within our system. Most interesting, we are not using any incentives or penalties to drive up our faculty participation rate.

There was not a single month when our entire faculty met the target for case submissions. Two faculty members (Fig 1, faculty D and E) disclosed not entirely trusting the separation of learning from performance assessment and, therefore, avoiding case submissions, which was also reflected in the survey by low ratings for the perceived safety during PL meetings. The other faculty member struggled with the multitude of reporting tools to be used, ie, RADPEER (https://www.acr.org/Clinical-Resources/RADPEER), EPIC, and e-mails. In response to these concerns, we have...
uninvited an external PL session participant who represented the system Peer Practice Evaluation Committee. We also informed our faculty about the educational nature of the PL program and its protection under state peer review legislation, and a reminder slide is now included in the introductory portion of the PL meeting slides. As another change in response to these concerns, we are now keeping case discussions completely anonymous, meaning that we no longer allow faculty to self-identify in any way during a case discussion. Regarding the case submission tools, we are currently still required to use the ACR RADPEER tool for ongoing professional practice evaluation. Unfortunately, our RADPEER is not set up to allow reviews for past faculty readers nor can we submit cases when the current and past reader is the same person. In those instances, we have configured a quality reporting tool in EPIC, but it can only be used as long the report has not been finalized. For all other cases, we notify the PL leaders by e-mail so that cases can be included. We are currently developing an alternate performance review system for ongoing professional practice evaluation so that we can abandon RADPEER and replace all current submission options with a single tool.

At the start of the PL program, we randomly determined the target for monthly case submission per faculty on the basis of what seemed “reasonable.” Because our faculty never met that target, we propose several changes. In our program we reviewed a maximum of 24 cases in a PL conference, which can help determine faculty case submissions per month. For example, for our general pediatric radiology section with currently 18 faculty, it was decided to maintain a minimum submission of 2 cases per month per faculty. This still yields a surplus of cases that allows the PL program to select cases with the highest yield for discussion and omit redundant/repetitive cases. If we continually fail to meet our monthly case-submission target in pediatric neuroradiology, we may lower the monthly target below 5 cases or set the target at our monthly case-submission target in pediatric neuroradiology, and omit redundant/repetitive cases. If we continually fail to meet this target for monthly case submission per faculty on the basis of what seemed “reasonable.” Because our faculty never met that target, we propose several changes. In our program we reviewed a maximum of 24 cases in a PL conference, which can help determine faculty case submissions per month. For example, for our general pediatric radiology section with currently 18 faculty, it was decided to maintain a minimum submission of 2 cases per month per faculty. This still yields a surplus of cases that allows the PL program to select cases with the highest yield for discussion and omit redundant/repetitive cases. If we continually fail to meet our monthly case-submission target in pediatric neuroradiology, we may lower the monthly target below 5 cases or set the target at the section rather than the individual level. Another option to consider, especially for smaller radiology subspecialties, could be to expand PL programs across multiple institutions to spread the shared learning experience and variety of cases.

On the basis of the collected data on learning points and survey responses highly rating the learning value, our program performs similar to those of others who reported higher rates of satisfaction and learning. On the basis of the feedback submitted in the survey, we have expanded the submission categories from only discrepancies to also include good calls, interesting cases, and cases for any type of group discussion (communication, protocols, imaging technique, and so forth). Sources for PL cases in our program include routine workflow, clinical conferences, consultations, as well as a provider feedback submission system. In the future, we may be able to integrate artificial intelligence applications that can identify cases with radiology–pathology correlations.

The lowest survey ratings from our faculty were issued for the improvement effectiveness of the PL program. On further inquiry, faculty members were concerned that improvement actions were decided too quickly without deeper reflection on root causes and balancing measures. We are now documenting any improvement ideas that are mentioned during PL conferences, but we hold off on initiating improvements until a subsequent discussion with the section director has occurred.

Of note, our PL process eliminates faculty “voting” on discrepancies of perception, interpretation, and communication. In our system, the radiologist who identifies a discrepancy is in charge of immediately addressing any patient care issues and notifying the original interpreting radiologist of the discrepancy. He or she can suggest that the original radiologist should act, eg, by issuing an addendum to a report. Whether the recommended action is implemented by the original radiologist, however, is left to that radiologist’s professional decision. Any concerns regarding a radiologist’s clinical practice or behaviors are to be submitted to our system’s Peer Practice Evaluation Committees, which review any physician practice or behavior concerns and determine possible actions.

This study has several limitations. While we assume that PL is more effective than score-based peer review when it comes to improved practice, we do not have any data to show this to be true. Some programs use addendum rates as a proxy for improvement effects and show higher addendum rates with PL compared with score-based peer review. Our survey supports the notion that PL is a valued activity for our faculty, and that at a minimum, it creates opportunities for teambuilding and collaboration. Some of the submitted discrepancies may be unproven, disputed, or clinically insignificant. We have not yet needed a system to address disputes. We currently have the person identifying a discrepancy notify the original reader and indicate that either no further action is needed on the basis of an existing follow-up report or an action would be helpful on the basis of a clinician request or patient care impact. It is then up to the radiologist receiving this feedback to act appropriately and responsibly.

**CONCLUSIONS**

We show the feasibility of a PL program in a pediatric neuroradiology section that follows the ACR PL accreditation pathway criteria. At our academic institution, PL is currently piloted in the pediatric radiology sections. Solicitation of feedback from PL program participants has been helpful in making changes to certain aspects of the program, such as improving trust in the PL program, including meaningful case submission types, and more thoughtful improvement actions. While radiologists favor PL over score-based review, the lack of tools and support to run PL meetings efficiently and effectively may present a barrier to a widespread replacement of score-based review with PL. We are currently developing a submission and data collection tool that supports semiautomated reporting for the ACR accreditation pathway, and we are exploring aspects of the PL process that can be handed off to administrative staff.

**ACKNOWLEDGMENTS**

Special thanks goes to Jennifer Broder, MD, who provided insight and support throughout the process of designing and implementing our peer learning program.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

**REFERENCES**

Celebrating 35 Years of the AJNR

November 1987 edition

MR of Neuronal Migration Anomalies

A. James Barkovich, M.D.*
Syracuse University, Syracuse, New York

The study protocol was approved by the Institutional Review Board of Syracuse University and the University of Rochester. The patients were informed of the risks and benefits of the procedure and gave informed consent. The study was performed on a 1.5-T magnet (Gyroscan ACS, Philips Medical Systems, Best, The Netherlands) using a 4-channel head coil. Axial, coronal, and sagittal T1-weighted (TR/TE 800/30, FOV 24 cm, 1.5 mm voxels) and T2-weighted (TR/TE 2500/100, FOV 24 cm, 1.5 mm voxels) spin-echo images were obtained. In addition, a 200/30 gradient-echo sequence (TR/TE 200/30, FOV 24 cm, 1.1 mm voxels) was used. The images were reviewed by a team of neuroradiologists and neuroradiology fellows.

Abnormalities of cell migration are characterized by the presence of abnormal neurons and glial cells in the white and gray matter. These abnormalities may be seen on T1- and T2-weighted images and may be associated with other findings such as lissencephaly, polymicrogyria, and schizencephaly. The abnormalities are usually more pronounced on T2-weighted images, where they appear as hyperintense lesions. The abnormalities may also be seen on T1-weighted images, where they appear as hypointense lesions. The abnormalities are often associated with other abnormalities such as microdysgenesis, macrodysgenesis, and microcephaaly.

Variable Appearances of Subacute Intracranial Hematomas on High-Field Spin-Echo MR

John M. Gomori, M.D.†
Robert Grossman, M.D.*
David F. Badley, M.D.*
Herbert J. Sheline, M.D.*
Robert A. Zimmerman, M.D.*
Larisa T. Galin, Ph.D.*

Subacute intracranial hematomas have various appearances in T1- and T2-weighted images. In the acute phase, subacute intracranial hematomas appear as hyperintense lesions on T1-weighted images and hypointense lesions on T2-weighted images. As the hematoma evolves, the signal intensity on T1-weighted images decreases, while the signal intensity on T2-weighted images increases. This is due to the presence of hemosiderin, which is a paramagnetic substance that causes T1 shortening and T2 prolongation. The hemosiderin is seen as a hypointense rim on T1-weighted images and a hyperintense rim on T2-weighted images.

Early experience with MR imaging of intracranial hematoma revealed three distinct signal patterns (1):

1. Acute hematoma (<1 week old): a hypointense signal on T1-weighted images and a hyperintense signal on T2-weighted images.
2. Subacute hematoma (1-8 weeks old): a hypointense signal on T1-weighted images and a hyperintense signal on T2-weighted images.
3. Chronic hematoma (>8 weeks old): a hypointense signal on T1-weighted images and a hypointense signal on T2-weighted images.

The signal intensity in the hematoma on T1-weighted images becomes stronger with time. The signal intensity in the hematoma on T2-weighted images becomes weaker with time. This is because the iron in the hemosiderin is converted to ferritin, which is a paramagnetic substance that causes T2 shortening and T1 prolongation. ferry.
Recalling the Usefulness of Conebeam CT in Temporal Bone Imaging: Higher Resolution with Lower Radiation Dose

We read with great interest the article by Benson et al on the potential clinical utility of photon-counting detector CT on temporal bone imaging. They prospectively recruited 13 patients who underwent clinically indicated temporal bone imaging on an energy-integrating detector CT (ie, conventional CT) and performed an additional temporal bone scan using an investigational photon-counting detector CT system. Reconstructed images from both examinations were then compared side-by-side by 2 blinded neuroradiologists using a 5-point Likert scale, and 2 important results were obtained: 1) significant preference for images from the photon-counting detector CT scanner; and 2) images obtained with this technique rated superior for the evaluation of all individual anatomic structures, with particularly higher scores on the oval window and incudostapedial joint. These results were mainly due to higher spatial resolution (0.2 mm image thickness versus 0.4 mm for conventional CT), with the additional advantage of performing the examinations with a 31% decrease in the total radiation dose (compared with conventional CT).

After reading these interesting results, we immediately recalled the role of conebeam CT (CBCT) in temporal bone imaging; thus, with the hope of adding to the aforementioned results, we would like to share some thoughts on this topic. CBCT systems operate using an x-ray beam with a conical geometry between the source and the detector; this is in contrast to the fan-beam geometry of conventional CT, in which the collimator restricts the x-ray beam to a 2D geometry. This difference explains why, in CBCT systems using a 2D flat panel detector, a volumetric data set can be acquired with a single rotation of the gantry, a fact that enables a spatial resolution of ≤0.1 mm with some systems, using low radiation protocols of about 10–100 μSv.

Although initially used almost exclusively to perform dental radiology, such as implant placement-planning, temporal bone imaging applications became relatively frequent throughout some centers, obtaining a spatial resolution in the order of 0.075–0.15 mm with a much lower radiation dose than conventional CT scanners (in some cases down to 14% of the total dose obtained with a conventional CT). This high spatial resolution leads to better capability of evaluating chronic otitis media complications (lysis of the long process or lenticular process of the incus, subtle tympanosclerosis, and/or incudostapedial subluxation), discrete fractures of the ossicles, dehiscence of the facial nerve canal or superior semicircular canal, and discrete foci of otosclerosis. One should remember that the latter can manifest solely as thickening and hypodensity of the stapes footplate (type Ia of the Veillon classification), which is much more easily detected on CBCT due to its higher resolution. However, this technique has a few limitations: 1) the high resolution comes with the expense of a long acquisition time (up to 40 seconds), a problem for patients who are not able to cooperate enough (ie, pediatric and very elderly patients), leading to motion artifacts that degrade image quality; 2) the need for more powerful x-ray tubes to study the dense temporal bone, which can lead to image degradation by increased scatter, especially in patients with large heads. There are, however, multiple approaches to scatter reduction, such as the use of a bowtie filter and an antiscatter grid.

Nevertheless, many centers still rely on conventional CT for temporal bone imaging, possibly due to the reluctance to invest in a scanner that lacks soft-tissue contrast resolution (limiting its use in general diagnostic imaging), with conventional CT having much broader general application. Due to the apparently similar diagnostic capabilities of CBCT and photon-counting detector CT (eg, higher resolution and lower radiation dose), we wonder if there could be an important difference in the diagnostic capability of the latter that could prevail over the somewhat clinically established CBCT. Moreover, it would be interesting for future studies to compare both of these techniques.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES

http://dx.doi.org/10.3174/ajnr.A7564
We thank the authors for their interest and commentary on our study1 published in American Journal of Neuroradiology. We agree with the authors that studies comparing the diagnostic capabilities of conebeam CT (CBCT) and photon-counting detector (PCD) CT are of potential interest. However, there are key advantages of multidetector CT (MDCT) over CBCT that led to its widespread adoption in clinical practice for temporal bone imaging. Here, we will highlight the benefits offered by both MDCT in general and specifically PCDs, which may further enhance the utility of MDCT for temporal bone imaging.

First, modern MDCT systems offer considerable speed benefits. Such systems use conebeam geometry2 (versus true fan-beam geometry used in older CT systems), multiple detector rows (eg, 120 detector rows, 0.2 mm/row3) in a helical configuration, and fast gantry rotation times (0.5–1.0 seconds). These result in a typical temporal bone scan time of ≤5 seconds, with little-to-no motion artifacts and minimal patient discomfort. CBCT, in comparison, requires a scan time of up to 40 seconds.3 Second, radiation dose comparisons between CBCT and MDCT have been historically challenging due to the lack of standardized dose metrics and reliable measurement techniques for CBCT. The absorbed doses in CBCT and MDCT are reportedly similar if the scan FOV and image-quality parameters are approximately matched.4,5 The radiation dose in MDCT has continued to decrease with technical advancements in detector technology and reconstruction software (eg, iterative reconstruction). For instance, Leng et al6 reported a volume CT dose index (CTDIvol) of 82 mGy for ultra-high-resolution temporal bone imaging and a further 50% potential dose reduction using z-deconvolution and iterative reconstruction algorithms in a second-generation MDCT system without sacrificing diagnostic image quality.

A recent MDCT temporal bone imaging study7 reported a CTDIvol of 30 mGy and dose-length product (DLP) of 119 mGy × cm. For CBCT, a DLP of 134 mGy × cm for unilateral temporal bone imaging with a small in-plane FOV (8 × 8 cm) has been reported in a cadaveric study.8 Our study1 used a mean CTDIvol of 35 mGy and a DLP of 250 mGy × cm without a tin filter for bilateral imaging. By means of PCD-CT with a tin filter, the CTDIvol can be further reduced to ≤10 mGy,9 and the DLP, to ≤150 mGy × cm, without sacrificing diagnostic image quality. Therefore, the substantial improvement in PCD-CT in spatial resolution relative to non-PCD MDCT could be achieved at doses comparable with those of CBCT for bilateral temporal bone imaging.

Next, the utility of spectral images (such as virtual monenergetic images) that are routinely available on PCD-CT is yet to be fully explored for temporal bone evaluation. Finally, CBCT has poor CT number uniformity and accuracy, poor soft-tissue contrast, and image artifacts compared with MDCT. Scatter-correction techniques such as anticounter grids could help reduce artifacts at the cost of increased noise, which consequently warrants an increase in the radiation dose or a reduction in spatial resolution.5 Unlike MDCT with fixed-source-detector geometry, CBCT uses an open gantry setup with flexible source-to-detector distance configurations, which requires robust and frequent geometric calibrations; residual calibration errors may degrade the spatial resolution in CBCT.

Spatial resolution and radiation dose are 2 of several factors contributing to the diagnostic utility of an x-ray imaging technique, and the limitations of CBCT may hinder its widespread adoption in large medical centers for temporal bone imaging as an alternative to MDCT. Current academic centers using conventional MDCT for temporal bone examinations may find the transition to PCD-based MDCT practical and reliable, with minimal changes to the imaging workflow. As with any technology, CBCT is likely to evolve beyond its current limitations and challenges, and we anticipate that research studies comparing CBCT with PCD-based MDCT for temporal bone imaging may provide insight regarding the strengths and weaknesses of each imaging technique.

REFERENCES

Editorial expression of concern:
In the May 2021 edition, the American Journal of Neuroradiology published the article “MRI-Based Deep-Learning Method for Determining Glioma MGMT Promoter Methylation Status” by Yogananda CGB, et al.1

On August 22, 2022, the authors self-reported data errors related to the computer code and the training and testing data sets. The authors are now in the process of re-evaluating the accuracies using the correct test set.

This notice of concern is to inform readers about these possible issues related to this articles results. After additional tests from the authors on the correct data set are available, we will determine what additional action is warranted, such as an erratum.

REFERENCE

http://dx.doi.org/10.3174/ajnr.A7029_ERR
In Planning for Brain Metastases Treatment, Imaging may be the Missing Link in Cost Containment

When faced with a patient presenting with metastatic brain cancer, determining whether to use up-front stereotactic radiosurgery (SRS) vs. first treating with whole brain radiotherapy (WBRT) is a significant clinical decision.

WBRT: The whole story on cognitive impairment
While whole brain radiotherapy (WBRT) has been the main treatment option for many years, experts agree that it often results in cognitive deterioration and a negative impact on quality of life. This mental decline has a devastating impact on patients and their families and adds ongoing costs for the healthcare systems managing these symptoms.

Using WBRT instead of SRS in some patients is estimated to decrease the total costs of brain metastasis management, though with increased toxicity.

SRS: Fewer side effects but greater risk of missed tumors
The cost of upfront SRS is the greatest contributor to cost of brain metastasis management. SRS is often more expensive than WBRT. What’s more, multiple applications of SRS can increase the cost of treatment greatly.

Stereotactic radiosurgery (SRS) has far fewer side effects, but upfront use of SRS is expensive and can carry the risk of missed tumors, requiring repeat procedures such as salvage SRS.

Number of lesions and lesion size are key factors to be considered when determining the treatment plan for these patients. It follows that increased diagnostic information and accuracy could be beneficial in directing the proper therapy and improving overall long-term patient outcomes and containing costs. Getting the diagnosis right the first time is crucial to ensure proper treatment begins quickly, and high cost/high stakes procedures such as SRS need precise surgical planning.

What does optimal visualization mean for outcomes and cost?
For surgical planning with SRS, radiologists need the best visualization achievable to accurately count the number and size of the lesions. These metrics are the key predictors of the need for SRS, WBRT, or a combination of both.

By selecting the ideal contrast agent and equipment protocols, neuroradiologists can identify the proximate numbers of metastases for upfront treatment and reduced salvage treatment occurrences.

The role of radiology
As medical care for oncology patients continues to evolve, it will be increasingly important to assess the cost of various interventions given the often-limited life expectancy of cancer patients, the rising costs of cancer therapy, and the increasing prevalence of cancer in an aging population.

Through seeing all the tumors and tumor borders as clearly as technology allows, radiology can play a part in ensuring that proper treatment can begin quickly, while containing costs through optimized patient care. Efforts to carefully manage treatment approaches require improvements in protocol design, contrast administration in imaging, and utilizing multimodal imaging approaches.

In this era of precision medicine, radiology departments’ contribution to this improved standard of care will have significant short and long-term implications by reducing cost of care, providing a more proximate diagnosis, and ensuring optimal patient outcomes.


For more information on MRI contrast agents, precision medicine, and reducing cost of care please visit braccomr.com
© 2022 Bracco Diagnostics Inc.
THE ONLY FLOW-DEPENDENT MICROCATHERETER SERIES